



US 20190300926A1

(19) **United States**(12) **Patent Application Publication****Hull et al.**(10) **Pub. No.: US 2019/0300926 A1**(43) **Pub. Date:****Oct. 3, 2019**

(54) **METHOD TO SCREEN COMPOUNDS FOR ANTIFUNGAL ACTIVITY AND PHARMACEUTICAL COMPOSITIONS AND METHODS TO TREAT FUNGAL DISEASES BY INHIBITING SPORE GERMINATION**

(71) Applicant: **WISCONSIN ALUMNI RESEARCH FOUNDATION**, Madison, WI (US)

(72) Inventors: **Christina Marie Hull**, Middleton, WI (US); **Mingwei Huang**, Madison, WI (US); **Sebastien Claude Ortiz**, Madison, WI (US)

(21) Appl. No.: **16/369,939**

(22) Filed: **Mar. 29, 2019**

Related U.S. Application Data

(60) Provisional application No. 62/649,802, filed on Mar. 29, 2018.

Publication Classification








(51) **Int. Cl.**
C12Q 1/18 (2006.01)
C12Q 1/66 (2006.01)
A01N 41/12 (2006.01)
A01N 47/40 (2006.01)
A01N 37/44 (2006.01)
A01N 33/10 (2006.01)
A61K 31/145 (2006.01)
A61K 31/155 (2006.01)
A61K 31/24 (2006.01)

A61K 31/137 (2006.01)
A61P 31/10 (2006.01)
 (52) **U.S. Cl.**
 CPC *C12Q 1/18* (2013.01); *C12Q 1/66* (2013.01); *A01N 41/12* (2013.01); *A01N 47/40* (2013.01); *A01N 37/44* (2013.01); *A61P 31/10* (2018.01); *A61K 31/145* (2013.01); *A61K 31/155* (2013.01); *A61K 31/24* (2013.01); *A61K 31/137* (2013.01); *A01N 33/10* (2013.01)

(57) **ABSTRACT**

A method of testing compounds for activity to inhibit germination of spores. The method includes the steps of providing bacterial, fungal, or plant spores transformed to contain and express a detectable marker, wherein the marker when expressed, is operationally linked to a spore-specific or yeast-specific protein, in a medium and under environmental conditions in which the spores will germinate, and measuring a first signal output generated by the marker prior to the spores initiating germination; contacting the spores of step (a) with a compound whose activity to inhibit germination of spores is to be measured; incubating the spores of step (b) under environmental conditions and for a time wherein spores not treated with the compound will germinate; and determining extent of germination of the spores by measuring a second signal output generated by the marker, wherein a difference between the first signal output and the second signal output is proportional to the extent of germination of the spores. Also described are compositions of matter for inhibiting spore germination in vitro and in vivo.

Specification includes a Sequence Listing.






FIG. 1











FIG. 2A

FIG. 2B




FIG. 3A




FIG. 3B




FIG. 3C




FIG. 3D




FIG. 4




FIG. 5B

FIG. 5A




FIG. 6




FIG. 7A




FIG. 7B




FIG. 8A




FIG. 8B




FIG. 9

**METHOD TO SCREEN COMPOUNDS FOR
ANTIFUNGAL ACTIVITY AND
PHARMACEUTICAL COMPOSITIONS AND
METHODS TO TREAT FUNGAL DISEASES
BY INHIBITING SPORE GERMINATION**

**CROSS-REFERENCE TO RELATED
APPLICATIONS**

[0001] Priority is hereby claimed to provisional application Ser. No. 62/649,802, filed Mar. 29, 2018, which is incorporated herein by reference.

FEDERAL FUNDING STATEMENT

[0002] This invention was made with government support under AI089370 awarded by the National Institutes of Health. The government has certain rights in the invention.

BACKGROUND

[0003] Spores are an essential cell type required for long-term survival across diverse organisms and are a hallmark of fungal reproduction, persistence, and dispersal. Among human fungal pathogens, spores are presumed infectious particles, but relatively little is known about this robust cell type. Sporulation enables a relative quiescence—a type of hibernation—that contributes to the survival of fungi. However, sporulation also requires a transition back into a vegetative form so that the fungi can replicate—i.e., germination. Germination, despite its central importance in fungal reproduction and pathology in plants and animals, is not well understood.

[0004] Spores are a particularly successful cell type used by many microorganisms, including bacteria, fungi, and protozoa to survive unsuitable growth conditions and/or to disperse to new environments. Among eukaryotes, some of the most environmentally resistant spores are those of fungi, and much of our current understanding of spores comes from studies in model fungi such as *Saccharomyces cerevisiae* and *Aspergillus nidulans*. There are two general categories of fungal spores—sexual and asexual, and both forms occur across diverse fungal species via myriad developmental strategies. For example, in the budding yeast *S. cerevisiae* sexual spores are formed when yeast diploids are subject to nitrogen starvation and a non-fermentable carbon source, resulting in four haploid ascospores; *S. cerevisiae* does not produce asexual spores. In contrast, the filamentous fungus *Aspergillus nidulans* produces both asexual and sexual spores via the development of multicellular fruiting structures with thousands of spores per structure. In all instances, however, spores are adapted for general survivability.

[0005] As a consequence, fungal spores share three basic characteristics: First, mature spores are relatively metabolically quiescent, allowing them to remain dormant for long periods of time under sub-optimal growth conditions (e.g. in the absence of nutrients). Second, spores are resistant to environmental stresses, such as high temperatures, desiccation, and UV radiation, thus facilitating long-term survival and/or dispersal across great distances. Third, upon encountering growth-promoting environments, spores rapidly escape quiescence and germinate to resume vegetative growth. As a result, fungi are ubiquitous across all ecosystems on earth.

[0006] Spore-producing fungi commonly generate spores with thick, protective coats and robust stress resistance. Spores respond to different environmental signals to initiate germination, depending on their adapted niches. For example, spores of *S. cerevisiae* germinate readily in response to the presence of a fermentable carbon source. In contrast, spores of *Talaromyces marssonii* require nutrients and a rigorous external trigger of very high temperature or pressure. These triggers generally result in responses such as water uptake, cell wall remodeling, and activation of nutrient metabolism and protein synthesis, leading to active fungal growth.

[0007] The transition from dormant particle to actively growing cell is particularly important because fungal survival cannot occur in the absence of the ability to germinate when (and only when) appropriate for vegetative growth. Environmental fungi are well adapted to their niches, and interestingly, these adaptations have led to a handful of fungi with the ability to cause life-threatening diseases in humans. *Histoplasma capsulatum*, *Blastomyces dermatitidis*, *Aspergillus fumigatus*, *Coccidioides immitis*, *Sporothrix schenckii*, *Penicillium marneffei*, and *Cryptococcus neoformans* are the most common environmental fungi that can cause disease in humans. The general route of infection is by inhaling cells from environmental sources. Spores (sexual or asexual, depending on the fungus) are the most likely infectious particles for all of these pathogens; however, very little is known about their basic spore biology, making the development of disease prevention and treatment strategies challenging.

[0008] Among human fungal pathogens, the most common cause of fatal fungal disease (and a well-developed model for study) is *Cryptococcus neoformans*, a primarily opportunistic pathogenic yeast that causes meningoencephalitis. People with AIDS are particularly susceptible, and there are an over 200,000 cases and nearly as many deaths annually worldwide from cryptococcosis. Rajasingam R, Smith R M, Park B J, Jarvis J M, Govender N, Chiller T M, Denning D W, Loyse A, Boulware D R (2017) “Global burden of disease of HIV-associated cryptococcal meningitis: and updated analysis” *Lancet Infectious Disease* 17: 873-881 (pmid:2848341). *C. neoformans* is ubiquitous in the environment, and inhalation of aerosolized spores and/or yeast is the most common route of infection of humans. Under laboratory conditions, spores are produced through sexual development between haploid yeast of opposite mating types (a and α) or by α fruiting. In response to specific environmental conditions, cells form filaments and fruiting bodies (basidia) from which haploid, recombinant spores bud in chains.

[0009] Spores of *C. neoformans* exhibit the fundamental properties of most fungal spores, such as stability in the absence of nutrients and resistance to a variety of environmental stresses, including high temperature, desiccation, and oxidative stress. These spores have also been shown to germinate efficiently and synchronously in response to nutrients, and they germinate and cause disease in a mouse inhalation model of infection. See Velagapudi R, Hsueh Y-P, Geunes-Boyer S, Wright J R, Heitman J (2009) “Spores as infectious propagules of *Cryptococcus neoformans*,” *Infect Immun*. 77:4345-4355 (pmid:19620339) and Giles S S, Dagenais T R T, Botts M R, Keller N P, Hull C M (2009) “Elucidating the pathogenesis of spores from the human fungal pathogen *Cryptococcus neoformans*,” *Infect Immun*

77:3491-3500 (pmid:19451235). These findings indicate that *C. neoformans* spores harbor intrinsic properties that facilitate survival in the environment, maintain spore viability and stability, and initiate germination in response to external signals, including those of a mammalian host.

[0010] Current antifungal therapeutics are relatively limited because of high toxicity or insufficient efficacy. These issues arise because, unlike bacteria, fungi are eukaryotes. Thus, fungi are far more similar (metabolically and biochemically) to plants and animals than are bacteria. In short, compounds that interfere with fungal biology or are toxic to fungi, tend also to interfere with or be toxic to humans and animals.

[0011] A comparatively small number of antifungal compounds are approved for human, veterinary, and agricultural use in the United States. Focusing on antifungal drugs approved for use in humans, the gold standard by which all other antifungal pharmaceuticals are measured in terms of systemic antifungal activity is the polyene amphotericin B, first marketed in 1955. It is widely used to treat life-threatening fungal infections such as invasive mucormycosis, cryptococcal meningitis, aspergillosis, and candidiasis. While highly effective against fungi, amphotericin B itself has a slew of well-known and potentially life-threatening side effects. When administered intravenously, amphotericin B typically induces a debilitating set of symptoms, including high fever, shaking chills, hypotension, anorexia, nausea, vomiting, headache, dyspnea and tachypnea, drowsiness, and generalized weakness. Kidney damage is a commonly reported side effect. As a result, amphotericin B is administered with very close monitoring of the patient by health-care professionals.

[0012] Other antifungal compounds approved for use in humans include imidazoles (e.g., miconazole), triazoles (e.g., fluconazole), and thiazole antifungals (e.g., abafungin). Most of these types of antifungal compounds, however, are used topically, rather than systemically. They are much less toxic than amphotericin B, but not as efficacious.

[0013] Echinocandins are a much newer class of systemic antifungal compounds approved for use in humans. The echinocandins are macrocyclic lipopeptides. Their structure is characterized by (typically) a 6-mer macrocyclic peptoid moiety bonded to a long (e.g., >C10) hydrocarbon tail. Echinocandins inhibit the synthesis of glucan in the cell wall of fungi via noncompetitive inhibition of the enzyme 1,3- β glucan synthase. In this sense, they exert a pharmacological activity against fungi that is analogous to the pharmacological activity of beta-lactam antibiotics against bacteria. Echinocandins are also far less toxic than amphotericin B, but again, not as effective.

[0014] Thus, there remains a long-felt and unmet need for a method to test new and existing compounds for their ability to inhibit fungal growth.

SUMMARY

[0015] While vegetative fungi are similar metabolically and biochemically to other eukaryotic cells, fungi also sporulate and germinate. Thus, chemical inhibitors of fungal germination are potentially highly useful compounds in antifungal compositions (i.e., human and veterinary pharmaceuticals, topical and systemic pharmaceuticals, and agricultural and industrial fungicides). Thus, disclosed herein is a fluorescence-based quantitative germination assay suitable

for high throughput screening. Using the subject germination assay, a screening of a 75,000-compound library yielded 108 germination-inhibiting compounds. Some of these compounds exhibited specific activity to inhibit germination of *Cryptococcus* spores (as contrasted to inhibiting vegetative cell growth). This indicates that germination itself is an effective target in developing antifungal drugs for prophylactic use in at-risk patients.


[0016] Thus, disclosed hererin is a method of testing compounds for activity to inhibit germination of spores. The method comprises providing bacterial, fungal, or plant spores transformed to contain and express a detectable marker, wherein the marker is operationally linked to a spore-specific or yeast-specific protein, in a medium and under environmental conditions in which the spores will germinate, and measuring a first signal output generated by the marker prior to the spores initiating germination. The spores are then contacted with a compound whose activity to inhibit germination of spores is to be measured. The spores are then incubated under environmental conditions and for a time wherein spores not treated with the compound will germinate. The extent of germination of the spores is determined by measuring a second signal output generated by the marker, wherein a difference between the first signal output and the second signal output is proportional to the extent of germination of the spores.

[0017] In certain versions of the method, the marker is operationally linked to a spore-specific protein selected from the group consisting of XP_567740.1 (SEQ. ID. NO: 2), XP_566791.1 (SEQ. ID. NO: 4), XP_570303.1 (SEQ. ID. NO: 6), XP_571089.1 (SEQ. ID. NO: 8), XP_571997.1 (SEQ. ID. NO: 10), XP_569295.1 (SEQ. ID. NO: 12), XP_569173.1 (SEQ. ID. NO: 14), XP_569068.1 (SEQ. ID. NO: 16), XP_569336.1 (SEQ. ID. NO: 18), XP_567136.1 (SEQ. ID. NO: 20), XP_568990.1 (SEQ. ID. NO: 22), XP_570610.1 (SEQ. ID. NO: 24), XP_571921.1 (SEQ. ID. NO: 26), XP_572925.1 (SEQ. ID. NO: 28), XP_570796.1 (SEQ. ID. NO: 30), XP_571548.1 (SEQ. ID. NO: 32), XP_570447.1 (SEQ. ID. NO: 34), and XP_571343.1 (SEQ. ID. NO: 36).

[0018] Another version of the method comprises the steps described previously, and further comprising plotting the area and aspect ratio of the spores and any germinated cells after the incubation of step (c). Because spores tend to be smaller and have a more oblong aspect ratio than do germinated, vegetative cells, the extent of germination can be determined by measuring the distribution of the cells' area versus aspect ratio. Again, in this version of the method, the marker, if present, is operationally linked to a spore-specific protein selected from the group consisting of XP_567740.1 (SEQ. ID. NO: 2), XP_566791.1 (SEQ. ID. NO: 4), XP_570303.1 (SEQ. ID. NO: 6), XP_571089.1 (SEQ. ID. NO: 8), XP_571997.1 (SEQ. ID. NO: 10), XP_569295.1 (SEQ. ID. NO: 12), XP_569173.1 (SEQ. ID. NO: 14), XP_569068.1 (SEQ. ID. NO: 16), XP_569336.1 (SEQ. ID. NO: 18), XP_567136.1 (SEQ. ID. NO: 20), XP_568990.1 (SEQ. ID. NO: 22), XP_570610.1 (SEQ. ID. NO: 24), XP_571921.1 (SEQ. ID. NO: 26), XP_572925.1 (SEQ. ID. NO: 28), XP_570796.1 (SEQ. ID. NO: 30), XP_571548.1 (SEQ. ID. NO: 32), XP_570447.1 (SEQ. ID. NO: 34), and XP_571343.1 (SEQ. ID. NO: 36).


[0019] Also disclosed herein are antifungal compositions and method of using them as topical and systemic fungicides for industrial, agricultural, and pharmaceutical uses. Dis-

closed herein is a composition of matter for inhibiting germination of fungal spores, the composition comprising a spore germination-inhibiting concentration of a compound selected from the group consisting of




and salts thereof, in combination with a vehicle.

[0020] Also disclosed herein is a pharmaceutical composition for inhibiting fungal infection in mammals (as well as the corresponding method of inhibiting topical or systemic fungal infections in mammals, including humans), the composition comprising a spore germination-inhibiting amount of a compound selected from the group consisting of:



-continued



[0021] wherein R is linear or branched C_{1-12} alkyl and “x” is an integer of from 1 to 12, and salts thereof, in combination with a pharmaceutically suitable vehicle.

BRIEF DESCRIPTION OF THE DRAWINGS

[0022] FIG. 1 is a graph showing that *C. neoformans* var. *grubii* spores are pathogenic in a murine model of cryptococcosis. Groups of eight AJ/Cr mice were infected with *C. neoformans* var. *grubii* spores (10^5) or yeast (10^5) via intranasal inhalation. See Giles et al. *Infect. Immun.* 2009, 77(8):3491. Time post-infection (in days) is shown in the X-axis; percent of surviving mice is shown on the Y-axis.

[0023] FIG. 2A is a series of scanning electron micrographs showing morphological transitions during germination. The germinating spore is false-colored green; the emerging yeast wall is false-colored yellow, and the resulting daughter cell is false-colored orange. Bar=1 μ m for 0, 4, and 8 Hr; bar=2 μ m for 12 Hr.

[0024] FIG. 2B is a series of micrographs analogous to those in FIG. 2A using transmission electron microscopy rather than scanning electron microscopy. Bars=500 nm.

[0025] FIG. 3A is a schematic diagram of a screening assay for an uninhibited germination reporter strain as it undergoes germination (left-hand panel) and graphs depicting germination as reported by NanoLuciferase (NL) activity (top right, NanoLuc®-brand luciferase, Promega Corporation, Madison, Wis.), and as measured by optical density (OD) (bottom right). The schematic pictures below show the morphology and number of cells over time. This example depicts a yeast-specific protein.

[0026] FIG. 3B is a schematic diagram showing the workflow for the screening assay.

[0027] FIG. 3C shows representative plates from the screening assay described in FIGS. 3A and 3B, showing wells that contain germination-inhibiting compounds in red.

[0028] FIG. 3D is a schematic diagram of the transformation construct containing a marker, in this case a gene encoding luciferase (“Nano-Luc”).

[0029] FIG. 4 is a flow chart showing the workflow of a high-throughput screening assay according to the present disclosure.

[0030] FIG. 5A shows schematic views of a microliter-scale well device and how it operates. The microfluidic device includes an input port connected to a culture well connected to an output port. Each microfluidic chamber is built upon a transparent support, such as a glass microscope slide. The microfluidic device is dimensioned and configured to culture and image non-adherent cells, such as spores and germinated fungi, yeast, and the like. The top panel of FIG. 5A shows a perspective view of a single microfluidic

culturing device. The middle panel of FIG. 5A shows six (6) such devices disposed on a glass slide. Each of the six devices shown is filled with 10 μ L of blue dye. The bottom panel of FIG. 5A shows a front elevation cutaway of the device shown in the top panel.

[0031] FIG. 5B depicts representative raw images of the fungal cells (spores and germinated cells) in the device shown in FIG. 5A. Image processing steps are then applied to the raw images to discriminate between spores and germinated cells. These process steps may include, without limitation, applying a density threshold to the raw images and then automatically detecting and measuring the cells 2-D area and aspect ratio.

[0032] FIG. 6 depicts how photos of germinating spores in the micro-device depicted in FIG. 5A were analyzed for the size and shape of the cells and the aspect ratio calculated. This was done using modified algorithms of ImageJ, a public domain, open-source, Java-based image processing program, which was developed originally by Wayne Rasband at the Research Services Branch of the National Institutes of Health. ImageJ can be downloaded free of charge at <https://imagej.nih.gov/ij/download.html>. The images of the cells are then plotted based on their 2-D area (X-axis) versus their aspect ratio (Y-axis) as shown in the right-hand panels of FIG. 6. Spores, because they are more oblong and smaller in area, plot to the bottom left-hand side of the histogram; germinated cells, because they are more spherical and larger in area, plot to the upper right quadrant of the plots.

[0033] FIG. 7A depicts a series of photographic analyses showing that germination in microscale devices as described herein can be determined by cell area versus aspect ratio. Thus, each panel in FIG. 7A depicts the germination dynamics of spores visualized by 2D histograms of cell area vs. aspect ratio. Data are also shown as a stacked bar plot of the population composition over time (at lower right). Colors are normalized on each plot such that yellow represents the area and aspect ratio combination with the most cells observed and dark blue represents area and aspect ratio combinations that were not observed. Cells in the lower left quadrant are defined as spores; cells in the upper right quadrant as yeast; all remaining cells are classified as intermediates.

[0034] FIG. 7B shows 2D histograms as in FIG. 7A, but for a 16-hour germination of *Cryptococcus* spores using PBS as a control (no germination), synthetic dextrose growth medium (SD) alone (full germination in the absence of compounds), and fluconazole (16 mg/mL) in the presence of growth medium.

[0035] FIGS. 8A and 8B show that pentamidine treatment lowers fungal burden in mouse lung. FIG. 8A is a graph showing lung colony-forming units quantified for each mouse infected with JEC20xJEC21 yeast. The test group of mice were treated with 4 mg/kg/day pentamidine; the control group of mice were treated with 1xPBS; * $p < 0.05$ for two-tailed paired t-test.

[0036] FIG. 8B is a graph depicting lung colony-forming units quantified for each mouse infected with JEC20x

JEC21. Again, the test mice were treated with 4 mg/kg/day pentamidine; the control mice were given 1xPBS; ** $p < 0.01$ for two-tailed paired t-test.

[0037] FIG. 9 is a graph showing that pentamidine prophylactically inhibits fungal spore germination in vivo. FIG. 9 depicts lung colony-forming units quantified for each mouse infected with JEC20xJEC21 spores. The test group of mice were treated with 4 mg/kg/day pentamidine; the control group of mice were treated with 1xPBS. ** $p < 0.01$ for two-tailed paired t-test. See Examples for complete details.

DETAILED DESCRIPTION

Abbreviations and Definitions:

[0038] The term “pharmaceutically-suitable salt” refers to any acid or base addition salt whose counter-ions are non-toxic to the patient in pharmaceutical doses of the salts, so that the beneficial inhibitory effects inherent in the free base or free acid are not vitiated by side effects ascribable to the counter-ions. A host of pharmaceutically-suitable salts are well known in the art. For basic active ingredients, all acid addition salts are useful as sources of the free base form even if the particular salt, per se, is desired only as an intermediate product as, for example, when the salt is formed only for purposes of purification, and identification, or when it is used as intermediate in preparing a pharmaceutically-suitable salt by ion exchange procedures. Pharmaceutically-suitable salts include, without limitation, those derived from mineral acids and organic acids, explicitly including hydrohalides, e.g., hydrochlorides and hydrobromides, sulphates, phosphates, nitrates, sulphonates, acetates, citrates, lactates, tartrates, malonates, oxalates, salicylates, propionates, succinates, fumarates, maleates, gentisates, isethionates, di-p-toluoxytartrates, methane sulphonates, ethanesulphonates, benzenesulphonates, p-toluenesulphonates, cyclohexylsulphonates, quaternates, and the like. Base addition salts include those derived from alkali or alkaline earth metal bases or conventional organic bases, such as triethylamine, pyridine, piperidine, morpholine, N-methylmorpholine, and the like. See, for example, “Handbook of Pharmaceutical Salts, Properties, Selection, and Use,” P. H. Stahl and C. G. Wermuch, Eds., © 2008, Wiley-VCH (Zurich, Switzerland), ISBN: 978-3-90639-058-1.

[0039] “Spore-specific molecule” refers to any molecule, moiety, or protein that is highly overrepresented in abundance in spores relative to yeast. Conversely, “Yeast-specific molecule” refers to any molecule, moiety, or protein that is highly overrepresented in abundance in yeast relative to spore. Specifically included in the terms are the proteins identified in Huang M, Hebert A S, Coon J J, Hull C M (2015) “Protein Composition of Infectious Spores Reveals Novel Sexual Development and Germination Factors in *Cryptococcus*,” PLoS Genet 11(8): e1005490 (<https://doi.org/10.1371/journal.pgen.1005490>). These spore-specific proteins were repeatedly identified by mass spectrometry in spore samples and never in yeast samples and are encoded by the following genes:

TABLE 1

Genes encoding spore-specific proteins.			
Gene	JEC21 ID	Predicted functions/domains	Deletion phenotype(s)
Group 1: Replication and Chromosome Biology			
TOP1	CNI03280	topoisomerase1	sporulation defects
IRR1	CNA07890	nuclear cohesion complex component	inviable
Group 2: Transcription and Splicing			
RSC9	CNB00580	chromatin remodeling complex component	cell fusion defect
DST1	CNF01160	general transcription elongation factor TFIIS	sporulation defect
PRP31	CNB05520	U4/U6-U5 snRNP complex component	inviable
PRP11	CND02290	SF3a splicing factor complex component	inviable
Group 3: Cellular Transport			
BCH1	CNG02530	specialized cargo export from Golgi	filamentation defect
SFH5	CNE04320	non-classical phosphatidylinositol transfer protein	no phenotype
DDI1	CNC00460	vSNARE binding protein	sporulation defect
EMC3	CNF02470	protein folding in the ER	decreased spore yield
Group 4: Carbohydrate Metabolism			
GRE202	CNG01830	D-lactaldehyde dehydrogenase	decreased spore yield
ISP1 ^a	CNB02490	conserved in fungi/short chain dehydrogenase	filamentation defect
ISP3	CND04560	conserved in fungi/mannose-6-phosphate isomerase	no phenotype
ISP4	CNK01510	conserved in fungi/glycosyl hydrolase	no phenotype
Group 5: Proteins of Unknown Function			
ISP2	CNE01730	<i>Cryptococcus</i> -specific/no conserved domains	increased sporulation; slow germination
ISP5	CNB04980	conserved in fungi/ferritin-like superfamily domain	no phenotype
ISP6	CNA04360	<i>Cryptococcus</i> -specific/transmembrane domain	no phenotype
ISP7	CND00650	<i>Cryptococcus</i> -specific/no conserved domains	no phenotype

^aGenes encoding proteins with no obvious homologs were named ISP for identified Spore Protein.
dDoi: 10.1371/journal.pgen.1005490.t003

[0040] The spore-specific genes and proteins identified in the above table have the nucleotide and amino acid sequences and protein ID's shown in the Sequence Listing at SEQ. ID. NOS. 1-36.

[0041] Yeast-specific proteins include, but are not limited to, CND06170, XP_570090.1 (SEQ. ID. NOS. 37 and 38); CND01050, XP_570422.1 (SEQ. ID. NOS. 39 and 40); CNH01340, XP_572322.1 (SEQ. ID. NOS. 41 and 42); CNN02360, XP_568723.1 (SEQ. ID. NOS. 43 and 44); CNB01440, XP_568816.1 (SEQ. ID. NOS. 45 and 46); CNG00410, XP_571739.1 (SEQ. ID. NOS. 47 and 48); CNH02740, XP_572447.1 (SEQ. ID. NOS. 49 and 50); CNJ01750, XP_567350.1 (SEQ. ID. NOS. 51 and 52); CNI02030, XP_572658.1 (SEQ. ID. NOS. 53 and 54); CNB05750, XP_569316.1 (SEQ. ID. NOS. 55 and 56); CNI03560, XP_572607.1 (SEQ. ID. NOS. 57 and 58); CNK01820, XP_567661.1 (SEQ. ID. NOS. 59 and 60); CNI00900, XP_572819.1 (SEQ. ID. NOS. 61 and 62); CNK02880, XP_567883.1 (SEQ. ID. NOS. 63 and 64); CNF00610, XP_571239.1 (SEQ. ID. NOS. 65 and 66); and CNI00870, XP_572850.1 (SEQ. ID. NOS. 66 and 67). These yeast-specific proteins, which are shown in the Sequence Listing, can be utilized as markers of germination.

[0042] The gene and encoded protein encoded by CNK01510 (SEQ. ID. NOS. 1 and 2, respectively) is the preferred spore-specific molecule to be labeled in accordance with the assay disclosed herein.

[0043] The terms "label," "marker," "probe," "reporter," and "tag" are used interchangeable and mean a molecular

moiety or probe of any structure or configuration, that can be detected by any means, now known or developed in the future, by which a vegetative cell, spore, or molecule bearing such a "label," "marker," "probe," "reporter," or "tag" can be distinguished from cells, spores, or molecules not bearing such a "label," "marker," "probe," "reporter," or "tag." The terms include, without limitation, radioactive labels, fluorescent labels, chromophoric labels, affinity-based labels (such as antibody-type markers), chemiluminescent labels, and the like. Conventional radioactive isotopes used for detection include, without limitation, ³²P, ³H and many others. A huge number of fluorescent and chromophoric probes are known in the art and commercially available from numerous worldwide suppliers, including Life Technologies (Carlsbad, Calif., USA), Enzo Life Sciences (Farmingdale, N.Y., USA), and Sigma-Aldrich (St. Louis, Mo., USA). Luciferase is the preferred marker. Complete kits for accomplishing luciferase labeling to a desired substrate are commercially available from several suppliers, including Promega Corporation, Madison, Wis. (e.g., Promega's NanoLuc®-brand vectors and NanoGlo®-brand luciferase assay systems).

[0044] The term "operationally linked" or "operationally connected" when referring to joined polynucleotide sequences denotes that the sequences are in the same reading frame and upstream regulatory sequences will perform as such in relation to downstream structural sequences. Polynucleotide sequences which are operationally linked are not necessarily physically linked directly to one another but may

be separated by intervening nucleotides which do not interfere with the operational relationship of the linked sequences. Similarly, when referring to joined polypeptide sequences, operationally linked means that the functionality of the individual joined segments are substantially identical as compared to their functionality prior to being operationally linked. For example, a fluorescent protein or chemiluminescent protein can be fused to a polypeptide of interest and in the fused state retain its fluorescence or chemiluminescence, while the fused polypeptide of interest also retains its original biological activity.

[0045] All strains used in the working examples were of the serotype D background (*Cryptococcus neoformans* var. *neoformans* strains JEC20 (ATCC 96909) and JEC21 (ATCC 96910 and ATCC MYA-565). See Kwon-Chung K J, Edman J C, Wickes B L (1992) "Genetic association of mating types and virulence in *Cryptococcus neoformans*," *Infect Immun.* 60:602-605 (pmid:1730495) and Moore T D, Edman J C (1993) "The alpha-mating type locus of *Cryptococcus neoformans* contains a peptide pheromone gene," *Mol Cell Biol.* 13:1962-1970 (pmid:8441425). All were handled using standard techniques and media as described in Sherman F. (2002) "Getting started with yeast," *Methods Enzymol.* 350:3-41 (pmid:12073320) and Alspaugh J A, Perfect J R, Heitman J. (1998) "Signal transduction pathways regulating differentiation and pathogenicity of *Cryptococcus neoformans*," *Fungal Genet Biol.* 25:1-14 (pmid:9806801).

[0046] Numerical ranges as used herein are intended to include every number and subset of numbers contained within that range, whether specifically disclosed or not. Further, these numerical ranges should be construed as providing support for a claim directed to any number or subset of numbers in that range. For example, a disclosure of from 1 to 10 should be construed as supporting a range of from 2 to 8, from 3 to 7, from 1 to 9, from 3.6 to 4.6, from 3.5 to 9.9, and so forth.

[0047] All references to singular characteristics or limitations of the present invention shall include the corresponding plural characteristic or limitation, and vice-versa, unless otherwise specified or clearly implied to the contrary by the context in which the reference is made. The indefinite articles "a" and "an" mean "one or more" unless explicitly stated otherwise.

[0048] All combinations of method or process steps as used herein can be performed in any order, unless otherwise specified or clearly implied to the contrary by the context in which the referenced combination is made.

[0049] The methods disclosed herein can comprise, consist of, or consist essentially of the essential elements and limitations of the method described, as well as any additional or optional ingredients, components, or limitations described herein or otherwise useful in microbiology, biochemistry, and/or mycology.

The Method:

[0050] At the core of the present invention is the realization that targeting a cellular process that is specific to organisms that sporulate—namely, spore germination—is likely to yield highly effective antifungal compositions that exhibit fewer side-effects than conventional antifungal drugs when used in humans. (Organisms that produce spores include fungi, bacteria, protists, plant seeds, ferns, and the like.) What then is needed then is a high-throughput assay that can evaluate compounds for their ability to inhibit

fungal spore germination. As shown in FIG. 1, it is known that spores are infectious agents. FIG. 1 is a graph showing survivability in a widely accepted mouse model of cryptococcosis. See Giles et al. *Infect. Immun.* 2009, 77(8):3491. Here, mice were infected with spores or yeast of *C. neoformans* var. *grubii*. Spores (10^5) or yeast (10^5) were administered to the test animals via intranasal inhalation. Mice infected with spores are shown in black circles; mice infected with yeast are shown in white circles. As can be seen in FIG. 1, the mice died at virtually identical rates. In other words, *Cryptococcus* spores are just as virulent as the yeast form.

[0051] The method functions on two principles. The first principle is that the vegetative form of organisms, especially fungi, are very different, morphologically than their corresponding spores. This is shown quite convincingly in FIGS. 2A and 2B. FIG. 2A is a series of scanning electron micrographs showing the morphological transitions that take place during germination of *C. neoformans* spores. A *C. neoformans* spore is shown in the far left photo. The germinating spore is false-colored green. The emerging yeast wall is false-colored yellow. This can be seen initially in the photo second from the left and then in a much more pronounced fashion in the third photo of the series. The daughter cell is false-colored orange and is seen clearly in the far right photo. A simple visual comparison between the far left and far right photos in FIG. 2A illustrates the significant morphological differences between a spore of *C. neoformans* (on the left) and a yeast (vegetative form, on the right). As can be seen from FIG. 2A, the spore is roughly cylindrical and clearly has a major axis that is much longer than its minor axis. The vegetative yeast form, in contrast is more nearly spherical or globular. Its major and minor axes are much closer in physical length. FIG. 2B shows the same phenomenon using transmission electron microscopy rather than scanning electron microscopy. Spores are quantitatively smaller and more oblong than yeast.

[0052] The second principle is that the inventors have identified 18 proteins that are expressed at far greater levels in the spore form as contrasted to the yeast form. Thus, by affixing a marker to one or more of these spore-specific proteins, the extent of germination can be tracked by following changes in the signal generated by the marker as the spore-specific protein is degraded during the germination process.

[0053] The first step of the method is to provide bacterial, fungal, or plant spores transformed to contain and express a detectable marker, wherein the marker is operationally linked to a spore-specific or a yeast-specific protein. The marker is preferably a protein fluorophore or protein chemiluminescent marker, such as luciferase, fluorescent protein A, green fluorescent protein, etc. The marker protein is incorporated into spores or yeast by fusing the gene encoding the marker protein to a spore-specific or yeast-specific target gene. The spore then produces the spore-specific protein with the marker attached. (Or the yeast then produces the yeast-specific protein with the marker attached.) The marker will thus generate a first signal associated with the spores. That first signal remains unchanged for as long as the spores remain intact. However, when the spore germinates, the spore-specific protein and its attached marker are degraded, which then alters the signal generated by the attached marker (or the yeast-specific marker is

increased). A second signal measurement taken after germination is thus proportional to the extent of germination.

[0054] This process is shown schematically in FIG. 3A. As shown in the left-hand side of the figure, the yeast form of the organism (in this case *C. neoformans*) was transformed to contain a fusion construct comprising a spore-specific protein fused to a luciferase gene. The transformed yeast were cultured to yield a population of propagating yeast that include the fusion construct. The yeast were then induced to sporulate. A first measure of the signal generated by the luciferase marker generated by the fusion construct is taken. This is shown at Time=0 in the two right-hand graphs depicted in FIG. 3A. The upper graph shows the signal generated by the reporter as the spore germinate. The lower graph shows the optical density of the culture solution at 600 nm (OD₆₀₀) over the same time period. As can be seen from the two graphs, as the spore germinate and multiply, the optical density increases (as the number of cells increases). In a corresponding fashion, the signal generated by the marker displays a proportional rise. The schematic pictures below show the morphology and number of cells over time.

[0055] The assay can be implemented in a massively redundant, massively high-throughput format that is easily automated using conventional multiwell plates and robotic equipment. (Laboratory robotics for handling multiwell culture plates are available from a host of international commercial suppliers, including Agilent Technologies (Santa Clara, Calif.), Beckman Coulter (Grants Pass, Oreg.), Hudson Robotics (Springfield, N.J.), and many others.) For a non-limiting example, see FIG. 3B, which is a schematic diagram showing the workflow for a high-throughput screening assay according to the present disclosure. As shown in FIG. 3B, the method can be implemented using conventional 384-well incubation plates. Spores to be studied are modified to contain a suitable marker, as described earlier. The spores are then incubated in a multiwell plate in a suitable germination medium. For many fungi, yeast extract-peptone-dextrose growth medium (YPD or YEPD) is suitable. (YPD is a well known medium for fungal germination and contains roughly 2% w/v bacto-peptone, 1% w/v yeast extract, and 2% w/v dextrose. A 1 L batch is made by combining 20 g bacto-peptone, 10 g yeast extract, and 20 g dextrose, adding water to 1 L and then autoclaving before use.)

[0056] A first signal from each well of the multiwell plate is then taken at the start of the incubation period. The contents of each well can be arranged in any suitably logical fashion, with positive and negative control wells, and wells containing compounds to be tested for their ability to inhibit germination of the spores, perhaps in appropriate serial dilutions of the compounds. The entire multiwell plate is then cultured for a time, temperature, humidity, etc. that is conducive to germination of the spores. After a set time, and OD600 measurement may optionally be taken to confirm that in the control wells the spores responded appropriately. The cells are then lysed, luciferase substrate is added, and a second measurement of the signal generated by the marker is taken. The extent of germination can then be determined by comparing the first signal to the second.

[0057] FIG. 3C shows a representative multiwell plate from the resulting from the method just described. Positive and negative control wells are in columns 23 and 24, respectively. Wells that contain germination-inhibiting compounds in various shades of pink/red, with the darker red

hues indicating great inhibitory activity. The signals can be gathered, digitized, recorded, and compared using a photomultiplier tube, in conventional fashion. Thus, wells H11, K11, C15, M16, and C21 all appear to contain very effective germination-inhibiting compounds.

[0058] FIG. 3D shows a schematic diagram of a vector used to transform a spore so that it includes a marker responsive to germination

[0059] An exemplary protocol, using luciferase as the marker, can be accomplished using commercial kits and largely following the manufacture's instructions on how to use the kit. A preferred kit for is Promega's Nano-Luc®-brand vectors and Nano-Glo®-brand luciferase assay system.

[0060] Briefly, homologous recombination is utilized to tag spore proteins with luciferase under their endogenous promoters. See FIG. 3D. In this fashion, their expression levels in the spores will remain undisturbed by tagging. As illustrated in FIG. 3D, the transformation construct contains three parts (A, B, and, C). Part A includes the sequence that encodes ISP4 but without a stop codon. Part B includes NanoLuc sequence (GeneBank sequence number KM359770) and *C. neoformans* URAS gene (GenBank sequence number AE017347.1), the latter of which serves as a selection marker for cell transformation. Part C includes the 3' UTR of ISP4, so that together with Part A, the transformation construct will be more favorably integrated into the genome through homologous recombination. Individual parts were generated by regular PCR and the full-length transformation construct was created using fusion PCR. See Davidson R C, Blankenship J R, Kraus P R, de J Berrios M, Hull C M, D'Souza C, et al. A PCR-based strategy to generate integrative targeting alleles with large regions of homology. *Microbiology*. 2002; 148: 2607-2615. PMID: 12177355. The construct was transformed into cells by biolistic transformation before selection. See Toffaletti D L, Rude T H, Johnston S A, Durack D T, Perfect J R. Gene transfer in *Cryptococcus neoformans* by use of biolistic delivery of DNA. *J Bacteriol*. 1993; 175: 1405-1411. PMID: 8444802.

[0061] The present inventors have identified a significant number of proteins in *C. neoformans* that were detected in spores only. Thus, these proteins are all candidates for labelling in the present invention. In *C. neoformans* and in other fungi where the corresponding genes are conserved, one or more of the following proteins can be labelled with the marker: XP_567740.1 (SEQ. ID. NO: 2), XP_566791.1 (SEQ. ID. NO: 4), XP_570303.1 (SEQ. ID. NO: 6), XP_571089.1 (SEQ. ID. NO: 8), XP_571997.1 (SEQ. ID. NO: 10), XP_569295.1 (SEQ. ID. NO: 12), XP_569173.1 (SEQ. ID. NO: 14), XP_569068.1 (SEQ. ID. NO: 16), XP_569336.1 (SEQ. ID. NO: 18), XP_567136.1 (SEQ. ID. NO: 20), XP_568990.1 (SEQ. ID. NO: 22), XP_570610.1 (SEQ. ID. NO: 24), XP_571921.1 (SEQ. ID. NO: 26), XP_572925.1 (SEQ. ID. NO: 28), XP_570796.1 (SEQ. ID. NO: 30), XP_571548.1 (SEQ. ID. NO: 32), XP_570447.1 (SEQ. ID. NO: 34), XP_571343.1 (SEQ. ID. NO: 36).

[0062] FIG. 4 is a flow chart showing the workflow of a high-throughput screening assay according to the present disclosure. Here, the figure shows how a large library of 75,000 compounds was screened using the present method set up in high-throughput format. As shown on the left-hand side of the figure, the full library was first subjected to a primary screening comprising a 10-hour germination, fol-

lowed by evaluating which compounds showed initial interest as germination inhibitors. This yielded 2,100 putative “hits,” i.e., compounds that at least initially showed promise as germination inhibitors. These 2,100 hits were then re-screened and the upper 900 best performing inhibitors were tested further. These 900 compounds were then re-screened using longer germination and yeast growth incubation times. This resulted in 270 compounds being advanced for further study. This group of 270 compounds was then studied using the method described herein to determine if any of the compounds inhibited spore germination and/or fungal growth in a dose-dependent fashion. This final screen yielded 108 compounds from the original 75,000 compounds that inhibited fungal spore germination and/or yeast growth in a dose-dependent fashion.

[0063] As shown in the middle panel of FIG. 4, the 108 compounds that were “hits” were then clustered by structural similarity and further tested to see if their anti-fungal properties were germination specific (i.e., primarily germination inhibitory), non-specific, or primarily growth specific. As shown in the right-hand graphs of FIG. 4, 37 of the compounds specifically inhibited germination in a dose-dependent manner; 52 of the compounds were non-specific, dose-dependent inhibitors; and 19 of the compounds specifically inhibited vegetative fungal growth in a dose-dependent manner.

[0064] As shown in FIGS. 5A and 5B, the method described herein can also be formatted for continuous studies using a microfluidic test bed. The test bed, depicted schematically in FIG. 5A, comprises a microliter-scale culture well having an input port and an output port. That is, the device includes an input port operationally linked in fluid connection to a culture well which is operationally linked in fluid connection to an output port. Each microfluidic chamber is built upon a transparent support, such as a glass microscope slide. The microfluidic device is dimensioned and configured to culture and image non-adherent cells, such as spores and germinated fungi, yeast, and the like. The top panel of FIG. 5A shows a perspective view of a single microfluidic culturing device. The middle panel of FIG. 5A shows six (6) such devices disposed on a glass slide. These six devices held 10 μ L blue dye. The bottom panel of FIG. 5A shows a front elevation cutaway of the device shown in the top panel. In this bottom panel, fluid flow is depicted as moving from left-to-right. Non-adherent cells are retained within the culture well, while the medium gently flows above them. Compounds to be tested are introduced through the input port, where they then flow to the culture well to interact with the cells therein. When built on an optically transparent substrate, the cells can be visualized and photographed in real time, as shown in the photos in FIG. 5B.

[0065] FIG. 5B depicts representative raw images of the fungal cells (spores, germinating cells, and yeast) in the device shown in FIG. 5A. Various imaging processing steps, described in detail below, are then applied to the raw images to discriminate among spores, germinating cells, and yeast. These process steps may include, without limitation, applying a density threshold to the raw images and then automatically detecting and measuring the cells’ 2-D area and aspect ratio.

[0066] FIG. 6 shows how computer processing can be brought to bear to automatically discriminate between ungerminated spores and vegetative yeast after a culture period has been completed. The left-hand side of FIG. 6

shows the three raw photographs from FIG. 5B. These are raw photographs of the germinating spores in the microfluidic device shown in FIG. 5A. The photos are digitized from the outset. The digitized images were analyzed for the size and shape of each cell in each image. The area of each cell, as well as its aspect ratio can be determined using a public domain, open-source, Java-based image processing program called ImageJ. Several other commercial image processing software packages can also accomplish this task. For example, Stream-brand image analysis software from Olympus Corporation (Waltham, Mass.) and PAX-it brand image analysis software from MIS, Inc. (Villa Park, Ill.). The images of the cells are then plotted based on their 2-D area (X-axis) versus their aspect ratio (Y-axis) as shown in the right-hand panels of FIG. 6. As can be seen from the plots in FIG. 6, the spores (upper plot) cluster in a distinctly different location and with a distinctly different distribution as compared to the vegetative yeast (lower plot). This is because spores, being more oblong and smaller in area, plot to the left-hand side of the histogram—indicating smaller average area and ovoid nature in the photographs. Spores tend toward a wider distribution of their aspect ratios and areas. This may be due to the fact that the spores settle in the device at many angles. When photographed, spore aspect ratios and sizes are more variable than in reality. Yeast, because they are more spherical and larger in area regardless of the position from which they are photographed, plot in a tight cluster in the upper right quadrant of the histograms.

[0067] Further examples of how spores, germinating cells, and yeast can be compared is shown in FIGS. 7A and 7B. FIG. 7A depicts a series of photographic analyses further demonstrating that germination in microscale devices as described herein can be determined by cell area versus aspect ratio. Each panel in FIG. 7A depicts the germination dynamics of spores visualized by 2D histograms of cell area vs aspect ratio, as well as a stacked bar plot of the population composition over time (at lower right). Colors are normalized on each plot such that yellow represents the area and aspect ratio combination with the most cells observed and dark blue represents area and aspect ratio combinations that were not observed. Cells in the lower left quadrant are defined as spores; cells in the upper right quadrant as yeast; all remaining cells are classified as intermediates undergoing germination. FIG. 7B shows 2D histograms as in FIG. 7A, but for a 16-hour germination of *Cryptococcus* spores using PBS as a control (no germination), synthetic dextrose growth medium (SD) alone (full germination in the absence of compounds), and the antifungal compound fluconazole (16 mg/mL) in the presence of growth medium. In this study, we demonstrate that spore germination is a viable target for antifungal development by identifying and characterizing FDA approved drugs able to inhibit both spore germination and yeast replication. These inhibitors have the potential of becoming tools to probe the essential fungal process of spore germination, or repurposed into antifungal therapies. Importantly, we determined that one of the drugs, Pentamidine, was effective at lowering fungal burden in vivo and could be repurposed as a prophylactic treatment against *Cryptococcus* pathogens.

Germination Provides a Suitable Target for the Development of Novel Antifungals:

[0068] Limited therapies exist to combat fungal disease. Humans and fungi share many biological processes due to

their eukaryotic nature. Because fungi-specific drug targets are difficult to find, potent antifungal agents often have toxic side-effects in humans. In the quest to find novel fungal-specific targets, the field has mainly focused on the cell membrane processes (ergosterol biosynthesis), and the fungal cell wall ($\beta(1,3)$ -glucan synthesis). While these targets have been effective in the discovery of antifungals in the past; the lack of novel antifungal therapies is an indication that these targets currently have limited success. It is critical that novel fungi-specific targets are identified for the development of new antifungals. This requires identifying new cell processes to probe that are unique to fungi. Fungal spore germination provides one of these novel targets.

[0069] Fungal spore germination has been previously suggested to be a modified cell cycle. Recently discovered evidence suggests otherwise. In previous studies we identified and characterized spore-enriched proteins. One of these proteins (Isp2) was found to stall germination for two hours prior to initiating vegetative growth. Isp2 showed no apparent phenotype in vegetatively growing yeast. Isp2, along with other spore germination-specific results, indicate that it is unlikely that germination is simply a modified cell cycle. Spore germination is not only a unique fungal process but is also unlike any process defined in humans. The uniqueness of fungal spore germination makes it a prime process to probe in the effort to develop novel antifungals. The examples below show that using germination inhibition as a signal can identify drugs that could be repurposed in the treatment of invasive fungal diseases.

Targeting Hermination Provides a Mechanism for Prevention:

[0070] In addition to providing a fungal-specific drug targets, targeting germination provides a unique opportunity for preventing fungal disease. Spores are stress-resistant cell types that are known infectious particles of many fungal pathogens, and have distinct phenotypes compared to yeast when interacting with hosts. Developing antifungals that target all potential infectious particles could be used to protect against fungal pathogens through prophylaxis treatment. If a low toxicity antifungal is found, prophylactic treatment could be administered to immunocompromised individuals, the population most at risk of developing invasive fungal infections.

Screening Characterized Drugs Allows for the Potential Development of Tools:

[0071] The screening of already approved FDA drugs provides a unique opportunity to screen drugs that often have known targets. By screening compounds with known inhibition targets, pathways can be identified that could be potentially important to fungal spore germination. These compounds can be used to probe fungal spore germination to help understand this critical fungal differentiation process. One of the clearest examples of a potential tool in this study was alexidine hydrochloride, which had strong antifungal activity and was a potent inhibitor of fungal spore germination. See the Examples section. This drug has previously been reported to inhibit phospholipases of *Cryptococcus* (Ganendren et al., 2004). This may suggest that phospholipases are important for viability of fungal spores. The ability of alexidine to inhibit other fungal processes, however, is

unclear. In the future, we will use alexidine as a tool to probe the molecular events of phospholipid biosynthesis in fungal spore germination.

Pentamidine, a Potential Antifungal Prophylactic Against *Cryptococcus* Infection:


[0072] Screening FDA-approved drugs has the benefit of potential repurposing as these drugs could reach patients in need sooner than novel compounds. The Examples section shows that pentamidine has huge promise in repurposing for a variety of reasons. Pentamidine, an antiparasitic, is only approved for use against one fungal pathogen, *Pneumocystis*. Pentamidine is approved for use in immunocompromised individuals, which is the primary group of individuals infected by *Cryptococcus* pathogens. Pentamidine already exists in an aerosolized formulation which allows for the drug to build up in the lung, which is the main site where *Cryptococcus* pathogens establish infections. Finally, this drug is already approved for use prophylactically against *Pneumocystis*, which would suggest that pentamidine could be used to protect immunocompromised individuals from cryptococcosis.


[0073] The Examples section shows that pentamidine was able to inhibit *Cryptococcus* infectious particles in vitro, was effective at lowering fungal burden in a mouse model of infection and, when used prophylactically, was able to inhibit spore germination in vivo, suggesting that pentamidine can build up in the lung sufficiently to inhibit this stress resistant cell type. The ability to inhibit both cell types, and the nature of this drug, suggest that it could make an ideal prophylactic against *Cryptococcus* pathogens which cause hundreds of thousands of deaths per year in immunocompromised individuals. While pentamidine is often not the first choice for prophylaxis against *Pneumocystis*, the data presented herein shows that pentamidine can be used to protect patients against other fungal pathogens generally and *Cryptococcus* spp. specifically.

Pharmaceutical Compositions:

[0074] Using the method disclosed herein, the inventors identified four (4) FDA-approved compounds with germination-inhibiting properties that are effective antifungal therapeutics. These four compounds are disulfiram, pentamidine, otilonium bromide, and benzethonium chloride.

[0075] Thus, also disclosed herein are pharmaceutical compositions for inhibiting topical and systemic fungal infection in mammals. The compositions comprise a spore germination-inhibiting amount of a compound selected from the group consisting of:





[0076] wherein R is linear or branched C_{1-12} alkyl and “x” is an integer of from 1 to 12, and pharmaceutically suitable salts thereof, in combination with a pharmaceutically suitable vehicle.

[0077] The active ingredients may be used in combination with a standard, well-known, non-toxic pharmaceutically suitable carrier, adjuvant or vehicle such as, for example, phosphate buffered saline, water, ethanol, polyols, vegetable oils, a wetting agent or an emulsion such as a water/oil emulsion. The composition may be in either a liquid, solid or semi-solid form. For example, the composition may be in the form of a tablet, capsule, ingestible liquid or powder, injectible, suppository, or topical ointment or cream. Proper fluidity can be maintained, for example, by maintaining appropriate particle size in the case of dispersions and by the use of surfactants. It may also be desirable to include isotonic agents, for example, sugars, sodium chloride, and the like. Besides such inert diluents, the composition may also include adjuvants, such as wetting agents, emulsifying and suspending agents, for example, by maintaining appropriate particle size in the case of dispersions and by the use of surfactants. It may also be desirable to include isotonic agents, for example, sugars, sodium chloride, and the like. Besides such inert diluents, the composition may also include adjuvants, such as wetting agents, emulsifying and suspending agents, sweetening agents, flavoring agents, perfuming agents, and the like.

[0078] Suspensions, in addition to the active compounds, may comprise suspending agents such as, for example, ethoxylated isostearyl alcohols, polyoxyethylene sorbitol and sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar and tragacanth or mixtures of these substances.

[0079] Solid dosage forms such as tablets and capsules can be prepared using techniques well known in the art of pharmacy. For example, compounds as described herein can be tableted with conventional tablet bases such as lactose, sucrose, and cornstarch in combination with binders such as acacia, cornstarch or gelatin, disintegrating agents such as potato starch or alginic acid, and a lubricant such as stearic acid or magnesium stearate. Capsules can be prepared by incorporating these excipients into a gelatin capsule along with antioxidants and the relevant active agent.

[0080] For intravenous administration, the compounds may be incorporated into commercial formulations such as Intralipid®-brand fat emulsions for intravenous injection. (“Intralipid” is a registered trademark of Fresenius Kabi AB, Uppsalla, Sweden.) Where desired, the individual components of the formulations may be provided individually, in kit form, for single or multiple use. A typical intravenous dosage of a representative compound as described herein is from about 0.1 mg to 100 mg daily and is preferably from 0.5 mg to 3.0 mg daily. Dosages above and below these stated ranges are specifically within the scope of the claims.

[0081] Possible routes of administration of the pharmaceutical compositions include, for example, enteral (e.g., oral and rectal) and parenteral. For example, a liquid preparation may be administered, for example, orally or rectally. Additionally, a homogenous mixture can be completely dispersed in water, admixed under sterile conditions with physiologically acceptable diluents, preservatives, buffers or propellants in order to form a spray or inhalant. The route of administration will, of course, depend upon the desired effect and the medical state of the subject being treated. The dosage of the composition to be administered to the patient may be determined by one of ordinary skill in the art and depends upon various factors such as weight of the patient, age of the patient, immune status of the patient, etc., and is ultimately at the discretion of the medical professional administering the treatment.

[0082] With respect to form, the composition may be, for example, a solution, a dispersion, a suspension, an emulsion or a sterile powder which is then reconstituted. The composition may be administered in a single daily dose or multiple doses.

[0083] The present disclosure also includes treating fungal infections (topical and systemic) in mammals, including humans, by administering a spore germination-inhibiting amount of one or more compounds described herein. In particular, the compositions of the present invention may be used to treat fungal infections of any and all description.

[0084] The above-described pharmaceutical compositions may be utilized in connection with non-human animals, both domestic and non-domestic, as well as humans.

EXAMPLES

[0085] The following examples are included to provide a more complete description of the methods and compositions disclosed and claimed herein. The examples are not intended to limit the scope of the claims in any fashion.

Strain Manipulation, Media and Spore Isolation:

[0086] The following strains were used and handled using standard techniques and media as previously described. (Sherman et al., 1987). *Cryptococcus neoformans* serotype D: JEC20, JEC21, JEC20-GFP, JEC21-GFP (Walsh et al. 2018), serotype A: H99, *Candida albicans*: SC5314 and *Aspergillus fumigatus*: AF293. Spores were isolated from cultures as previously described. (Botts et al., 2009). Briefly, yeast of both mating types (JEC20 and JEC21) were grown on YPD for 2 days at 30° C. combined in phosphate buffered saline (PBS) mixed to a 1:1 ratio and spotted onto V8 pH 7 agar plates. Plates were incubated for 5 days at 25° C. and spots were resuspended in 70% Percoll in 1×PBS. Spores were counted using a hemocytometer.

MIC/MFC Experiments:

[0087] All minimum inhibitory concentration (MIC) experiments were based on EUCAST methodology. (European Committee on Antimicrobial Susceptibility Testing, a standards-setting committee of the European Society of Clinical Microbiology and Infectious Diseases; EUCAST Development Laboratory for fungi, Statens Serum Institut, Building 211, Artillerivej 5, DK-2300 Copenhagen, Denmark; www.eucast.org.) Yeast cells were grown overnight in liquid YPD and used to inoculate fresh YPD. After 6-hour incubation, yeast cells were washed in 1×PBS and quantified

using a hemocytometer. For each drug, 1.25×10^5 yeast cells were incubated in RPMI, and 0.33M MOPS, pH 7 at varying concentrations of inhibitors, with a final volume of 200 μ L. *Cryptococcus neoformans* cells were incubated for 2 days at 30° C. while *Candida albicans* strains were incubated for 2 days at 35° C. OD₆₀₀ readings were used to assess the MIC values for each drug. To determine minimum fungicidal concentrations (MFC) values, 3 μ L per well were plated on YPD and allowed to grow for 2 days. Spinning down of 96-well plates and washing did not alter the read outs of the MFC experiment.

[0088] For *Aspergillus fumigatus* MIC, conidia were collected using 0.01% Tween 80 in PBS after 3 days of growth on glucose medium media plates. Conidia at a final concentration of 2×10^4 cells were incubated in RPMI, 0.33 M MOPS, and 2% glucose at pH 7 at varying concentrations of inhibitors, with a final volume of 200 μ L. MIC values were assessed based on the lowest concentration of drug that had complete absence of germ tubes or hyphae.

Quantitative Germination Assay:

[0089] All germination assays are based on Barkal et al., 2016. Briefly, microfluidic devices were loaded with 1×10^5 spores, and at 0 hours, SD media with drug of interest, were added to the sample. Spores were allowed to germinate at 30° C. in a humidified chamber and cells were monitored every two (2) hours for 16 hours. Each assay was performed in two (2) individual wells with three (3) field of views acquired from each well. All images were analyzed as previously described based on cell shape and size. Population ratio of spores, intermediate, and yeast cells were determined. Error bars in plots are based on variation between all fields of view acquired. All experiments were able to be reproduced independently. After the 16-hour experiment, samples were plated on YPD and allowed to grow at 30° C. to determine if drugs were completely germicidal or not based on lack of growth. If assays were unable to be performed in microfluidic devices, the 2×10^5 spores were incubated in identical conditions outside of PDMS devices and only loaded into devices for image acquisition.

Fungal Burden Animal Studies:

[0090] All yeast cells were cultured overnight in YPD, washed and diluted to 5×10^6 cells. For JEC20 and JEC21, 2.5×10^6 cells of each were combined. Spores were cultured as previously described and diluted to 2×10^6 cells. All experiments were performed on 8- to 10-week old C57BL/6J (Jackson Laboratory, Bar Harbor, Me., USA) female mice (5 mice per group). All mice were infected intranasally with a total of 50 μ L. All dosing was performed with 4 mg/kg/day or 1xPBS for three (3) days either prior to infection or 1-day post-infection. Mice were sacked day-4 post-infection and lungs were collected, processed, and fungal burden was assessed.

In Vivo Germination:

[0091] Female mice, 8- to 10-week-old C57BL/6J (Jackson Laboratory) female mice (3 mice per group) were used. Mice were dosed with either 4mg/kg/day or 1xPBS (50 μ L) for three (3) consecutive days. Mice were intranasally infected with 2×10^6 JEC20-GFPxJEC21-GFP spores, strains described in Walsh et al., 2018. After 8 hours post-infection,

mice were sacked and lavaged with 0.05% TirtionX in 1xPBS. Lavage suspension underwent a series of treatments and washes, in order: red blood cell lysis (ACK lysing buffer, 2 mL, 5 minutes), formaldehyde fixation (4%, 500 μ L, 30 minutes) and calcofluor white staining (25 μ g/mL, 20 μ L for 1 minute). Cells (50-100 per mouse) were imaged, and identified as *Cryptococcus neoformans* cells based on green fluorescent signal or cyan staining from calcofluor staining. Cells surface area and aspect ratio were measured in ImageJ and cells were classified as spores, intermediates, or yeast based on size and shapes parameters used in the quantitative germination assay.

Identifying Inhibitors of Germination and Growth

[0092] To identify inhibitors of *Cryptococcus neoformans* spore germination, a high throughput screen was developed that utilizes a nanoluciferase construct to monitor whether spores germinate in the presence of inhibitor. Briefly a protein luciferase construct was created resulting in a low luciferase signal for non-germinated spores and a high signal from germinated and replicating cells. The screen was coupled with OD₆₀₀ readings to monitor the ability of compounds to inhibit yeast replication. The examples focused on FDA-approved drugs, as these drugs have the potential of being repurposed into antifungal therapeutics. To determine whether any FDA-approved drugs were able to inhibit *Cryptococcus neoformans* spore germination and yeast replication, the aforementioned high throughput screen was performed on the L1300 Selleck FDA-Approved Drug Library containing an array of 1108 compounds. This library of compounds is available commercially from Selleck Chemicals, 14408 W Sylvanfield Drive, Houston, Tex. 77014, USA.

[0093] The screening was successful at identifying known antifungal drugs as inhibitors of yeast replication as indicated by an OD₆₀₀ signal of less than 75% of the negative control (Table 2). For the purpose of these examples, antifungal drugs were defined as any FDA-approved drug used in the treatment of fungal infections. Of these 23 known antifungal drugs, only six (6) were identified as inhibitors of spore germination, indicated by a luciferase signal of less than 30% of the negative control. These germination inhibitors demonstrated normal nanoluciferase signal dose response curves (data not shown).

TABLE 2

Antifungal drugs used to treat fungal infections and their ability to inhibit <i>Cryptococcus neoformans</i> spore germination (based on luciferase signal) and yeast replication (based on OD ₆₀₀).			
	Drugs	Germination Percent Luciferase Signal	Replication Percent OD ₆₀₀
Inhibitors of	Pentamidine HCl	6.5	38.3
Germination (6)	Bifonazole	13.6	33.4
Less than 30%	Econazole nitrate	16.1	33.1
Luciferase Signal	Isoconazole nitrate	16.8	37.0
	Tioconazoie	25.0	36.8
	Miconazole nitrate	25.5	38.2
Non-inhibitors of	Butoconazole	41.5	33.4
Germination (17)	nitrate		
	Fenticonazole	49.1	36.4
	nitrate		
	Naftifine HCl	55.5	34.5
	Sulconazole nitrate	57.8	40.9

TABLE 2-continued

Antifungal drugs used to treat fungal infections and their ability to inhibit <i>Cryptococcus neoformans</i> spore germination (based on luciferase signal) and yeast replication (based on OD ₆₀₀).		
Drugs	Germination Percent Luciferase Signal	Replication Percent OD ₆₀₀
Butenafine HCl	57.5	32.9
Tolnaftate	60.2	47.3
Liranaftate	64.8	37.6
Clotrimazole	65.9	34.1
Fluconazole	84.0	72.2
Amphotericin B	84.6	45.7
Amorolfine HCl	88.6	41.4
Casopfungin acetate	89.7	48.5
Climbazole	151.5	38.9
Ketoconazole	154.8	35.4
Itraconazole	159.6	58.9

[0094] In addition to the antifungal drugs from the screen, 60 other inhibitors of yeast replication were identified, 16 of which were also inhibitors of spore germination (Table 3). These inhibitors have a wide range of clinical functions, including quaternary ammonium compounds (“QACs”) and mammalian target of rapamycin (“mTOR” inhibitors (i.e.,) which are known to have broad effects on eukaryotic processes. Some drugs used in treating neurological diseases were also identified. Finally, antimicrobial and antihelminth drugs were also identified to inhibit germination. All compounds, with the exception of doxercalciferol, demonstrated appropriate nanoluciferase dose response curves (data not shown). Only a handful of compounds were pursued further in the examples due to limited availability of certain drugs. Representatives from each group, however, were selected for further characterization. Finally, five inhibitors of only germination were identified (see below).

TABLE 3

FDA-approved drugs able to inhibit spore germination and yeast replication. List of drugs, their ability to inhibit <i>Cryptococcus neoformans</i> spore germination (based on luciferase signal) and yeast replication (based on OD ₆₀₀), as well as their function as listed by L1300 Selleck FDA Approved Drug Library.				
		Germination Percent Luciferase Signal	Replication Percent OD ₆₀₀	Function
Germination and Growth Inhibitors	Cetylpyridinium chloride	4.2	31.9	Infection
	Domiphen bromide	4.4	63.9	Infection
	Cetrimonium bromide	4.4	63.2	Infection
	Alexidine HCl	4.6	29.6	
	Otilonium bromide	6.9	29.0	Cardiovascular Disease
	Benzethonium chloride	6.9	30.3	Neurological Disease
	Niclosamide	7.8	43.4	
	PCI-32765	10.6	70.3	Neurological Disease
	Everolimus	15.7	67.7	Cancer
	Doxercalciferol	17.1	55.2	Endocrinology
	Rapamycin	18.5	61.8	Immunology
	Temsirolimus	21.3	59.2	Cancer
	Ezetimibe	22.0	51.3	Cardiovascular Disease
	Dequalinium chloride	22.3	47.9	
	Disulfiram	22.7	65.6	Neurological Disease
	Biperiden HCl	23.4	56.6	Neurological Disease

TABLE 2-continued

Antifungal drugs used to treat fungal infections and their ability to inhibit <i>Cryptococcus neoformans</i> spore germination (based on luciferase signal) and yeast replication (based on OD ₆₀₀).		
Drugs	Germination Percent Luciferase Signal	Replication Percent OD ₆₀₀
Posaconazole	167.2	46.7
Voriconazole	173.9	35.8

[0095] Together these results give a set of compounds that are germination inhibitors and replication inhibitors that can be further investigated as potential targets for repurposing or to elucidate germination processes. Inhibitors of both germination and yeast replication were prioritized for further study.

Antifungal Drugs are Inhibitors of Fungal Pathogen Vegetative Growth:

[0096] To confirm the ability of the known antifungals to inhibit yeast replication, minimum inhibitory concentration (MIC) and minimum fungicidal concentration (MFC) testing was performed on the top three germination inhibition

hits. All three antifungal compounds inhibited replication of *Cryptococcus neoformans* yeast of both serotype A and D, while being less potent against *Candida albicans* (Table 4). All of the antifungal drugs were fungicidal with the exception of bifonazole against H99.

TABLE 4

Ability to inhibit fungal pathogens of antifungal drug germination-inhibitor hits. MIC/MFC values of top three germination inhibitors against prominent human fungal pathogens.				
	<i>Cryptococcus neoformans</i> (JEC21)		<i>Cryptococcus neoformans</i> (H99)	
	MIC (μg/mL)	MFC (μg/mL)	MIC (μg/mL)	MFC (μg/mL)
Pentamidine isethionate	1.56	3.13	6.25	6.25
Bifonazole	6.25	6.25	6.25	>100
Econazole nitrate	<0.78	6.25	<0.78	6.25

	<i>Candida albicans</i> (SC5314)		<i>Aspergillus fumigatus</i> (AF293)
	MIC (μg/mL)	MFC (μg/mL)	MIC (μg/mL)
Pentamidine isethionate	50	50	>100
Bifonazole	>100	>100	>100
Econazole nitrate	6.25	12.5	3.13

[0097] Pentamidine and bifonazole were unable to inhibit *Aspergillus fumigatus* while econazole nitrate was able to inhibit its growth. It is important to note the *Aspergillus fumigatus* inhibition testing is performed on conidia, their asexual spore (Table 4). Together these results confirm the ability of these antifungals to inhibit fungal growth in a fungicidal manner.

[0098] Antifungal Drugs are Inhibitors of Fungal Spore Germination:

[0099] Once yeast replication inhibition was confirmed, the ability of the drugs to inhibit spore germination was characterized using a quantified microfluidics-based germination assay where the changes in size and morphology are monitored as small ovoid spores germinate into large circular yeast.

[0100] Pentamidine isethionate was able to successfully inhibit spore germination as seen by a decrease in morphology transition (data not shown). While germination is not completely halted, the spores were only able to circularize partially and unable to transition into the yeast state. It is important to note that all of the spores were inhibited, indicating that none of the ~10,000 spores showed inherent resistance and escape from inhibition. Due to the hydrophobic nature of bifonazole and econazole nitrate, the PDMS devices resulted in sequestration of the compounds and the assays could not be performed in the microfluidic devices. To determine if these compounds had an effect on spore germination, the assay was performed outside of the microfluidic device and imaged at 0 and 16 hours. Both econazole nitrate and bifonazole were able to inhibit spore germination effectively with spore escape apparent in bifonazole-treated spores as determined by a yeast population increase. None of these drugs were fully germicidal at these concentrations. These assays confirm that the high throughput screen identified antifungal drugs that are potent inhibitors of spore germination.

FDA Drug Hits are Inhibitors of Fungal Pathogen Vegetative Growth:

[0101] To determine the ability of the 16 non-antifungal drugs to inhibit yeast growth, MIC and MFC testing was performed on nine of the 16 drugs. The nine drugs were selected based on dose response curves, drug availability and ensuring that all classes of inhibitors were tested. Seven inhibitors were able to inhibit yeast replication to varying degrees (Table 5) while biperiden HCl and ezetimibe, were unable to inhibit yeast growth (data not shown). All drugs were tested against *Aspergillus fumigatus* with varying degrees of success. Notably alexidine was extremely potent against *A. fumigatus*. Additionally, cetylpyridinium bromide, otilonium bromide, benzethonium chloride and disulfiram were all able to inhibit *A. fumigatus*. (Table 5)

TABLE 5

Ability to inhibit fungal pathogens of FDA drugs germination-inhibitor hits. MIC/MFC values of germination inhibitors against prominent human fungal pathogens.				
	<i>Cryptococcus neoformans</i> (JEC21)		<i>Cryptococcus neoformans</i> (H99)	
	MIC (μg/mL)	MFC (μg/mL)	MIC (μg/mL)	MFC (μg/mL)
Cetylpyridinium chloride	<0.78	<0.78	<0.78	<0.78
Alexidine HCl	<0.78	<0.78	<0.78	<0.78
Otilonium bromide	3.13	3.13	3.13	3.13
Benzethonium chloride	3.13	3.13	3.13	3.13
Niclosamide	<0.78	1.56	1.56	>100
Temsirolimus	6.25	6.25	6.25	6.25
Disulfiram	3.13	3.13	6.25	6.25

	<i>Fumigatus Candida albicans</i> (SC5314)		<i>Aspergillus</i> (AF293)
	MIC (μg/mL)	MFC (μg/mL)	MIC (μg/mL)
Cetylpyridinium chloride	1.56	3.13	1.56
Alexidine HCl	<0.78	<0.78	<0.78
Otilonium bromide	3.13	3.13	6.25
Benzethonium chloride	6.25	12.5	12.5
Niclosamide	>100	>100	>100
Temsirolimus	1.56	1.56	>100
Disulfiram	6.25	12.5	25

[0102] These results indicate that these FDA-approved drugs have the ability to inhibit fungal pathogen vegetative growth and kill fungal cells. While some of these drugs have previously been shown to have antifungal activities, some have not. **[text missing or illegible when filed]**

FDA Drug Hits are Inhibitors of Fungal Spore Germination:

[0103] To determine the ability of these seven drugs, which inhibit fungal vegetative growth, to inhibit spore germination; germination assays were performed on the drugs at a concentration of 25 μg/mL. All seven of these drugs were able to inhibit germination to different extents (data not shown).

[0104] Five of the seven drugs were tested in microfluidic devices. Alexidine hydrochloride, an antimicrobial, and otilonium bromide, an antimuscarinic used to treat irritable

bowel syndrome, were both able to completely inhibit spore germination, as seen by the lack of change in morphology. Both of these drugs were fully germicidal. Niclosamide, an antihelminth that inhibits oxidative phosphorylation, was also able to completely inhibit germination, but was not fully germicidal. Temsirolimus, an mTOR inhibitor used in some cancer treatments, was able to partially inhibit germination and appeared to stall germination strongly between 6 and 8 hours. When spores were exposed to temsirolimus they were able to circularize but appeared to have difficulty growing in size. Finally, disulfiram, an alcohol dehydrogenase inhibitor used in the treatment of alcoholism, was a weak inhibitor of germination leading to about a 2-hour stall in germination overall at this concentration. At higher concentrations, a similar stall to that observed with temsirolimus was observed (data not shown). Neither temsirolimus nor disulfiram were germicidal.

[0105] Cetylpyridinium chloride and benzethonium chloride, both quaternary ammonium salts, were unable to be tested in the microfluidic devices due to their viscosity and were therefore tested in outside the devices and imaged at 0 and 16 hours. Both drugs were able to inhibit spore germination completely and were fully germicidal at this concentration. These assays confirm that the method disclosed herein has utility to identify a variety of non-antifungal, FDA-approved drugs that are able to inhibit fungal spore germination to varying degrees. These results also start to elucidate potential molecular processes crucial for fungal spore germination.

Pentamidine Ubiquitously Slows Germination:

[0106] Pentamidine was selected for further study due to many factors that make it a good candidate for repurposing. A range of concentrations of pentamidine isethionate was tested in a germination assay. As concentrations of pentamidine increased, spore germination became slower. However, no individual spores were able to escape inhibition, as seen by the lack of spores in the yeast state at higher concentrations. While pentamidine was not germicidal at lower concentration, at 50 µg/mL pentamidine showed germicidal activity. These results suggest that pentamidine slows the germination of spores ubiquitously and at high enough concentrations is sporicidal.

Pentamidine Treatment Lowers Fungal Burden in Mouse Lung:

[0107] Pentamidine is a successful inhibitor of *Cryptococcus neoformans* yeast replication in vitro. For repurposing

potential, it is important to determine drug efficacy in vivo. For this purpose, the ability of pentamidine to lower the fungal burden in mouse lungs infected by both spores and yeast was determined. One-day post-infection intranasal dosing was begun at 4 mg/kg/day and the mice were treated for three consecutive days. On the fourth day post-infection, lungs were collected and fungal burden was determined. Pentamidine-treated mice had significantly lower fungal burdens in the lung than PBS-treated mice, in both yeast- and spore-infected mice. See FIG. 8A and FIG. 8B, respectively. These results indicate that pentamidine is able to inhibit yeast replication in vivo.

Prophylactic Pentamidine Inhibits Spore Germination In Vivo:

[0108] Pentamidine is a successful inhibitor of spore germination in vitro. It is important, though, to determine drug efficacy in vivo. Therefore, the ability of pentamidine to inhibit germination of spores in mouse lungs was determined. To determine if prophylactic pentamidine had an effect on fungal lung burden, mice were treated with 4 mg/kg/day of pentamidine or 1xPBS for three consecutive days. After three days of infection, mice were infected with JEC20xJEC21 spores and 4-days post infection, mouse lungs were collected and lung fungal burden was determined. The results are shown in FIG. 9. As evidenced by data in FIG. 9, pentamidine prophylaxis was successful in decreasing spore-mediated lung burden. These results indicate that spore germination was inhibited in vivo.

[0109] In vivo spore germination has never been characterized mainly due to technical hurdles. Using a novel assay, *Cryptococcus neoformans* cells were recovered from prophylactically treated, spore-infected mouse lungs 8 hours post infection. This was an early enough time point where no budding yeast were recovered from mouse lungs, ensuring that all cells were spore derived and not budding derived. Based on size and shape of the cells, the level of in vivo spore germination was quantified. Prophylactic pentamidine was able to inhibit spore germination as indicated by a higher spore percent and a lower yeast percent in pentamidine-treated mice. Together these results demonstrate that prophylactic pentamidine has in vivo activity against *Cryptococcus neoformans* spores, indicating it is useful to prophylactically treat (i.e., prevent) fungal infection.

SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 68

<210> SEQ ID NO 1

<211> LENGTH: 804

<212> TYPE: DNA

<213> ORGANISM: *Cryptococcus neoformans*

<220> FEATURE:

<221> NAME/KEY: CDS

<222> LOCATION: (1)..(804)

<400> SEQUENCE: 1

atg tct gac gac gga caa gta caa agg gga aag gcc gcc att agc tgg
Met Ser Asp Asp Gly Gln Val Gln Arg Gly Lys Ala Gly Ile Ser Trp

48

-continued

1	5	10	15	
ccg gct caa gaa cta acc tcg gat ccc att gcc aaa ttc ttc cag tac				96
Pro Ala Gln Glu Leu Thr Ser Asp Pro Ile Ala Lys Phe Phe Gln Tyr	20	25	30	
ggc tct aaa ctc tca tgg cac tgg aac tgg acc aag cat tgg aag ggc				144
Gly Ser Lys Leu Ser Trp His Trp Asn Trp Thr Lys His Trp Lys Gly	35	40	45	
cct ctg gtg ccg gag acc tct gac gac ctt gag att gac gca gaa ttt				192
Pro Leu Val Pro Glu Thr Ser Asp Asp Leu Glu Ile Asp Ala Glu Phe	50	55	60	
gtg ccc atg atc tgg tca ccc caa tct tta gat gat ggt tgc gac ttg				240
Val Pro Met Ile Trp Ser Pro Gln Ser Leu Asp Asp Gly Cys Asp Leu	65	70	75	80
caa gaa gga tgg aat ctt ctc ttg ggt ttc aac gag cct gac ctc gac				288
Gln Glu Gly Trp Asn Leu Leu Leu Gly Phe Asn Glu Pro Asp Leu Asp	85	90	95	
aac gaa gct gtt gca agc cat cgc tct ccg cag gaa gct gca gac gcg				336
Asn Glu Ala Val Ala Ser His Arg Ser Pro Gln Glu Ala Ala Asp Ala	100	105	110	
tgg atc cag ctg gca caa ctc cgt acc gat cca gac aac cag cac ctc				384
Trp Ile Gln Leu Ala Gln Leu Arg Thr Asp Pro Asp Asn Gln His Leu	115	120	125	
gtt tcc ccc gct gta gca tcc aac gtg gaa tgg ctt aaa gag ttc ctc				432
Val Ser Pro Ala Val Ala Ser Asn Val Glu Trp Leu Lys Glu Phe Leu	130	135	140	
tcc ctg att cca gaa gac act tat ccc gcc tac ttg gct gtg cac ctc				480
Ser Leu Ile Pro Glu Asp Thr Tyr Pro Ala Tyr Leu Ala Val His Leu	145	150	155	160
tac aca acc act ttt gat gat ttt gtc ggc aag atg gag atg tac cac				528
Tyr Thr Thr Thr Phe Asp Asp Phe Val Gly Lys Met Glu Met Tyr His	165	170	175	
aac gag ttt gga ttg cct att atc ttg act gaa ttc tgc atg cag agt				576
Asn Glu Phe Gly Leu Pro Ile Ile Leu Thr Glu Phe Cys Met Gln Ser	180	185	190	
tgg gac gaa ggt gtt cca ggc cca gag gac cag cag caa gtc cat gat				624
Trp Asp Glu Gly Val Pro Gly Pro Glu Asp Gln Gln Gln Val His Asp	195	200	205	
tac atg ggc caa aca aca aaa tgg ctt gat gaa act gac tat gtt att				672
Tyr Met Gly Gln Thr Thr Lys Trp Leu Asp Glu Thr Asp Tyr Val Ile	210	215	220	
aag tac tgt tgg ttt ggc gct gtt cgt gat acg gcg aac ttg cac gac				720
Lys Tyr Cys Trp Phe Gly Ala Val Arg Asp Thr Ala Asn Leu His Asp	225	230	235	240
gtc cac ccc ttc aac cga ctc atg gat gaa aac ggc gag att acc cca				768
Val His Pro Phe Asn Arg Leu Met Asp Glu Asn Gly Glu Ile Thr Pro	245	250	255	
ttg ggt ttc caa tac atg tat ggt ggg cat gag taa				804
Leu Gly Phe Gln Tyr Met Tyr Gly Gly His Glu	260	265		

<210> SEQ ID NO 2

<211> LENGTH: 267

<212> TYPE: PRT

<213> ORGANISM: *Cryptococcus neoformans*

<400> SEQUENCE: 2

Met Ser Asp Asp Gly Gln Val Gln Arg Gly Lys Ala Gly Ile Ser Trp
1 5 10 15

-continued

Pro Ala Gln Glu Leu Thr Ser Asp Pro Ile Ala Lys Phe Phe Gln Tyr
 20 25 30
 Gly Ser Lys Leu Ser Trp His Trp Asn Trp Thr Lys His Trp Lys Gly
 35 40 45
 Pro Leu Val Pro Glu Thr Ser Asp Asp Leu Glu Ile Asp Ala Glu Phe
 50 55 60
 Val Pro Met Ile Trp Ser Pro Gln Ser Leu Asp Asp Gly Cys Asp Leu
 65 70 75 80
 Gln Glu Gly Trp Asn Leu Leu Leu Gly Phe Asn Glu Pro Asp Leu Asp
 85 90 95
 Asn Glu Ala Val Ala Ser His Arg Ser Pro Gln Glu Ala Ala Asp Ala
 100 105 110
 Trp Ile Gln Leu Ala Gln Leu Arg Thr Asp Pro Asp Asn Gln His Leu
 115 120 125
 Val Ser Pro Ala Val Ala Ser Asn Val Glu Trp Leu Lys Glu Phe Leu
 130 135 140
 Ser Leu Ile Pro Glu Asp Thr Tyr Pro Ala Tyr Leu Ala Val His Leu
 145 150 155 160
 Tyr Thr Thr Thr Phe Asp Asp Phe Val Gly Lys Met Glu Met Tyr His
 165 170 175
 Asn Glu Phe Gly Leu Pro Ile Ile Leu Thr Glu Phe Cys Met Gln Ser
 180 185 190
 Trp Asp Glu Gly Val Pro Gly Pro Glu Asp Gln Gln Gln Val His Asp
 195 200 205
 Tyr Met Gly Gln Thr Thr Lys Trp Leu Asp Glu Thr Asp Tyr Val Ile
 210 215 220
 Lys Tyr Cys Trp Phe Gly Ala Val Arg Asp Thr Ala Asn Leu His Asp
 225 230 235 240
 Val His Pro Phe Asn Arg Leu Met Asp Glu Asn Gly Glu Ile Thr Pro
 245 250 255
 Leu Gly Phe Gln Tyr Met Tyr Gly Gly His Glu
 260 265

<210> SEQ ID NO 3
 <211> LENGTH: 1821
 <212> TYPE: DNA
 <213> ORGANISM: *Cryptococcus neoformans*
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1)..(1821)

<400> SEQUENCE: 3

atg tcg acc ctt ccc att tat cac ccc gtt cca acg gac gag aaa cac	48
Met Ser Thr Leu Pro Ile Tyr His Pro Val Pro Thr Asp Glu Lys His	
1 5 10 15	
cca ata tct gcc act ttg gta gac ggc gag ttt gac cct cgc tac att	96
Pro Ile Ser Ala Thr Leu Val Asp Gly Glu Phe Asp Pro Arg Tyr Ile	
20 25 30	
cat ccc gcc gca atc ggc tct caa tac ctt tat att ggc ggt ccc cgc	144
His Pro Ala Ala Ile Gly Ser Gln Tyr Leu Tyr Ile Gly Gly Pro Arg	
35 40 45	
agc gcc tat cag gcc gcg aag gac aag tac gct ggc ttg tcc aaa gtc	192
Ser Ala Tyr Gln Ala Ala Lys Asp Lys Tyr Ala Gly Leu Ser Lys Val	
50 55 60	

-continued

aag Lys 65	aaa Lys	ggt Gly	ctc Leu	ctc Leu	gct Ala	ctt Leu	gcc Ala	gtt Val	gtt Val	tgg Trp	ttc Phe	ggt Gly	ctt Leu	gtc Val	gtt Val	240
ggc Gly	cat His	cag Gln	gct Ala	gcg Ala	cgt Arg	ctt Leu	gct Ala	ggc Gly	ggc Gly	aaa Lys	tgc Cys	cac His	cag Gln	gac Asp	gct Ala	288
cat His	cat His	gct Ala	ccc Pro	gcc Ala	gaa Glu	ttt Phe	ggc Gly	gtg Val	aag Lys	cag Gln	tgg Trp	aga Arg	gac Asp	cac His	tca Ser	336
tct Ser	cat His	cga Arg	ttt Phe	ggt Gly	ggc Gly	cct Pro	atc Ile	ttc Phe	ctc Leu	gag Glu	gat Asp	ggt Gly	cca Pro	ctt Leu	gac Asp	384
tgt Cys	cat His	ggt Gly	ggc Gly	cgt Arg	aaa Lys	gac Asp	cgt Arg	gct Ala	cct Pro	gag Glu	gag Glu	ctt Leu	tct Ser	tcc Ser	gtt Val	432
gcc Ala	act Thr	gtc Val	tac Tyr	gag Glu	tcc Ser	atc Ile	aac Asn	gtt Val	gtc Val	ggg Gly	agc Ser	aac Asn	gat Asp	gct Ala	acc Thr	480
gac Asp	att Ile	ctc Leu	tcc Ser	gcc Ala	aac Asn	gcc Ala	tct Ser	ttc Phe	cct Pro	ctc Leu	aaa Lys	ctt Leu	ggc Gly	cgt Arg	ggc Gly	528
aag Lys	cac His	ttt Phe	gat Asp	ctc Leu	acc Thr	ttc Phe	caa Gln	ggt Gly	gag Glu	ggt Gly	aac Asn	gtc Val	atc Ile	atc Ile	tcg Ser	576
agg Arg	gct Ala	gag Glu	gag Glu	gag Ser	tct Glu	gaa Glu	gac Asp	tct Ser	act Thr	gtc Val	aac Asn	gtt Val	ttt Phe	gtt Val	gag Glu	624
tct Ser	act Thr	tgg Trp	tcc Ser	ggt Gly	gag Glu	gag Glu	gct Ala	gaa Glu	ggg Gly	gtc Val	aag Lys	atg Met	ttg Leu	tct Ser	gga Gly	672
aaa Lys	cac His	tct Ser	cac His	gct Ala	ctc Leu	tct Ser	gtt Val	gct Ala	tct Ser	tct Ser	caa Gln	tcc Ser	tcg Ser	tct Ser	cat His	720
att Ile	gtc Val	cac His	ctt Leu	gtt Val	ctt Leu	cct Pro	gcc Ala	aac Asn	aag Lys	aag Lys	cgt Arg	ctt Leu	cct Pro	tcc Ser	atc Ile	768
tct Ser	atc Ile	ttt Phe	tct Ser	acc Thr	aag Lys	gac Asp	ctt Leu	act Thr	ctt Leu	gat Asp	atc Ile	cat His	cca Pro	tct Ser	gtt Val	816
cag Gln	gac Asp	atc Ile	cac His	gtg Val	gga Gly	aag Lys	ctc Leu	tcc Ser	ctc Leu	aag Lys	tct Ser	gag Glu	agc Ser	ggt Gly	gat Asp	864
atc Ile	aag Lys	ctt Leu	cct Pro	acc Thr	ctc Leu	gct Ala	gtc Val	aac Asn	aag Lys	ctc Leu	gtg Val	gct Ala	gag Glu	acc Thr	gta Val	912
acc Thr	ggt Gly	gac Asp	gtc Val	ggc Gly	ggt Gly	aac Asn	ttc Phe	aac Asn	gtc Val	agc Ser	aac Asn	tct Ser	ttc Phe	gtt Val	gtc Val	960
aag Lys	aca Thr	gtc Val	aca Thr	ggt Gly	aac Asn	att Ile	aac Asn	gcc Ala	att Ile	gtt Val	aac Asn	gtt Val	gtt Val	cct Pro	cac His	1008
tcc Ser	cca Pro	cct Pro	aag Lys	gac Asp	aag Lys	ctt Leu	aac Asn	ctt Leu	cat His	aac Asn	gtt Val	gat Asp	gcc Ala	aag Lys	cac His	1056
gag Glu	cac His	aag Lys	aag Lys	ttt Phe	gac Asp	agc Ser	cgt Arg	cac His	gga Gly	gaa Glu	cac His	aat Asn	cac His	gag Glu	aag Lys	1104

-continued

aag cac ttc gga ggg cgt ttc cac tct gaa gaa gag cga cct tcc aag	1152
Lys His Phe Gly Gly Arg Phe His Ser Glu Glu Arg Pro Ser Lys	
370 375 380	
tggt tct ctc aat att ttc aag tct aag aaa gag gat gag cct gaa cac	1200
Trp Ser Leu Asn Ile Phe Lys Ser Lys Lys Glu Asp Glu Pro Glu His	
385 390 395 400	
cct ccc ccc cct ccg gtc ttt atc ggc gct ttc tcc acc tct ggc aac	1248
Pro Pro Pro Pro Val Phe Ile Gly Ala Phe Ser Thr Ser Gly Asn	
405 410 415	
att ctt ctc aag gtc ttc ggt tct ccc aac gtc tct act gat act aat	1296
Ile Leu Leu Lys Val Phe Gly Ser Pro Asn Val Ser Thr Asp Thr Asn	
420 425 430	
gtc ttc tcc cat acc ggt gac gtc gac gtt acc cat gac aag tca ttc	1344
Val Phe Ser His Thr Gly Asp Val Asp Val Thr His Asp Lys Ser Phe	
435 440 445	
cac ggt ttg tac gag gtc ggc agc tta aag ggc acc tat gat gtt gtc	1392
His Gly Leu Tyr Glu Val Gly Ser Leu Lys Gly Thr Tyr Asp Val Val	
450 455 460	
gtg agg gac ggc aag gtg cat cga gtc ctg gag gaa tac gtc act gag	1440
Val Arg Asp Gly Lys Val His Arg Val Leu Glu Glu Tyr Val Thr Glu	
465 470 475 480	
gag gga ggc aag cag aag ggc ctt gcc ttc gtt ccc aag aac aga aag	1488
Glu Gly Gly Lys Gln Lys Gly Leu Ala Phe Val Pro Lys Asn Arg Lys	
485 490 495	
act gag ggc tcc cac gag aag agg cac ttc cgc aat gct gaa agc gtt	1536
Thr Glu Gly Ser His Glu Lys Arg His Phe Arg Asn Ala Glu Ser Val	
500 505 510	
gat ggc gag ctt ccc cct ccc cct cct ggt aag ggc cac ggt cct gat	1584
Asp Gly Glu Leu Pro Pro Pro Pro Gly Lys Gly His Gly Pro Asp	
515 520 525	
ggt ccc gat ggt cct gat ggt cct gga ggt cct agt ggt cct gga ggt	1632
Gly Pro Asp Gly Pro Asp Gly Pro Gly Gly Pro Ser Gly Pro Gly Gly	
530 535 540	
cct ggt ggt cct gat ggt cct ggt ggt cct ggt ggt cct ggt ggc cct	1680
Pro Gly Gly Pro Asp Gly Pro Gly Gly Pro Gly Gly Pro Gly Gly Pro	
545 550 555 560	
gga ggt ccc ggt ggt ccc ggt ggt ccc ggt ggt ccc ggc ccc gac cac	1728
Gly Gly Pro Gly Gly Pro Gly Gly Pro Gly Gly Pro Gly Pro Asp His	
565 570 575	
ccc cgt ggt cct cct cct tgg gtt gtc ttc ccc ccc ggt cac tca gaa	1776
Pro Arg Gly Pro Pro Pro Trp Val Val Phe Pro Pro Gly His Ser Glu	
580 585 590	
gtc ttc gtc cac act gaa gtt ggc aac gcc aag att gtc ctc taa	1821
Val Phe Val His Thr Glu Val Gly Asn Ala Lys Ile Val Leu	
595 600 605	

<210> SEQ ID NO 4

<211> LENGTH: 606

<212> TYPE: PRT

<213> ORGANISM: Cryptococcus neoformans

<400> SEQUENCE: 4

Met Ser Thr Leu Pro Ile Tyr His Pro Val Pro Thr Asp Glu Lys His
1 5 10 15

Pro Ile Ser Ala Thr Leu Val Asp Gly Glu Phe Asp Pro Arg Tyr Ile
20 25 30

His Pro Ala Ala Ile Gly Ser Gln Tyr Leu Tyr Ile Gly Gly Pro Arg
35 40 45

-continued

Ser	Ala	Tyr	Gln	Ala	Ala	Lys	Asp	Lys	Tyr	Ala	Gly	Leu	Ser	Lys	Val	50	55	60
Lys	Lys	Gly	Leu	Leu	Ala	Leu	Ala	Val	Val	Trp	Phe	Gly	Leu	Val	Val	65	70	75
Gly	His	Gln	Ala	Ala	Arg	Leu	Ala	Gly	Gly	Lys	Cys	His	Gln	Asp	Ala	85	90	95
His	His	Ala	Pro	Ala	Glu	Phe	Gly	Val	Lys	Gln	Trp	Arg	Asp	His	Ser	100	105	110
Ser	His	Arg	Phe	Gly	Gly	Pro	Ile	Phe	Leu	Glu	Asp	Gly	Pro	Leu	Asp	115	120	125
Cys	His	Gly	Gly	Arg	Lys	Asp	Arg	Ala	Pro	Glu	Glu	Leu	Ser	Ser	Val	130	135	140
Ala	Thr	Val	Tyr	Glu	Ser	Ile	Asn	Val	Val	Gly	Ser	Asn	Asp	Ala	Thr	145	150	155
Asp	Ile	Leu	Ser	Ala	Asn	Ala	Ser	Phe	Pro	Leu	Lys	Leu	Gly	Arg	Gly	165	170	175
Lys	His	Phe	Asp	Leu	Thr	Phe	Gln	Gly	Glu	Gly	Asn	Val	Ile	Ile	Ser	180	185	190
Arg	Ala	Glu	Glu	Glu	Ser	Glu	Asp	Ser	Thr	Val	Asn	Val	Phe	Val	Glu	195	200	205
Ser	Thr	Trp	Ser	Gly	Glu	Glu	Ala	Glu	Gly	Val	Lys	Met	Leu	Ser	Gly	210	215	220
Lys	His	Ser	His	Ala	Leu	Ser	Val	Ala	Ser	Ser	Gln	Ser	Ser	Ser	His	225	230	235
Ile	Val	His	Leu	Val	Leu	Pro	Ala	Asn	Lys	Lys	Arg	Leu	Pro	Ser	Ile	245	250	255
Ser	Ile	Phe	Ser	Thr	Lys	Asp	Leu	Thr	Leu	Asp	Ile	His	Pro	Ser	Val	260	265	270
Gln	Asp	Ile	His	Val	Gly	Lys	Leu	Ser	Leu	Lys	Ser	Glu	Ser	Gly	Asp	275	280	285
Ile	Lys	Leu	Pro	Thr	Leu	Ala	Val	Asn	Lys	Leu	Val	Ala	Glu	Thr	Val	290	295	300
Thr	Gly	Asp	Val	Gly	Gly	Asn	Phe	Asn	Val	Ser	Asn	Ser	Phe	Val	Val	305	310	315
Lys	Thr	Val	Thr	Gly	Asn	Ile	Asn	Ala	Ile	Val	Asn	Val	Val	Pro	His	325	330	335
Ser	Pro	Pro	Lys	Asp	Lys	Leu	Asn	Leu	His	Asn	Val	Asp	Ala	Lys	His	340	345	350
Glu	His	Lys	Lys	Phe	Asp	Ser	Arg	His	Gly	Glu	His	Asn	His	Glu	Lys	355	360	365
Lys	His	Phe	Gly	Gly	Arg	Phe	His	Ser	Glu	Glu	Glu	Arg	Pro	Ser	Lys	370	375	380
Trp	Ser	Leu	Asn	Ile	Phe	Lys	Ser	Lys	Lys	Glu	Asp	Glu	Pro	Glu	His	385	390	395
Pro	Pro	Pro	Pro	Pro	Val	Phe	Ile	Gly	Ala	Phe	Ser	Thr	Ser	Gly	Asn	405	410	415
Ile	Leu	Leu	Lys	Val	Phe	Gly	Ser	Pro	Asn	Val	Ser	Thr	Asp	Thr	Asn	420	425	430
Val	Phe	Ser	His	Thr	Gly	Asp	Val	Asp	Val	Thr	His	Asp	Lys	Ser	Phe	435	440	445

-continued

His	Gly	Leu	Tyr	Glu	Val	Gly	Ser	Leu	Lys	Gly	Thr	Tyr	Asp	Val	Val
450						455					460				
Val	Arg	Asp	Gly	Lys	Val	His	Arg	Val	Leu	Glu	Glu	Tyr	Val	Thr	Glu
465					470					475					480
Glu	Gly	Gly	Lys	Gln	Lys	Gly	Leu	Ala	Phe	Val	Pro	Lys	Asn	Arg	Lys
			485						490					495	
Thr	Glu	Gly	Ser	His	Glu	Lys	Arg	His	Phe	Arg	Asn	Ala	Glu	Ser	Val
			500					505					510		
Asp	Gly	Glu	Leu	Pro	Pro	Pro	Pro	Pro	Gly	Lys	Gly	His	Gly	Pro	Asp
		515						520				525			
Gly	Pro	Asp	Gly	Pro	Asp	Gly	Pro	Gly	Gly	Pro	Ser	Gly	Pro	Gly	Gly
	530					535					540				
Pro	Gly	Gly	Pro	Asp	Gly	Pro	Gly	Gly	Pro	Gly	Gly	Pro	Gly	Gly	Pro
545					550					555					560
Gly	Gly	Pro	Gly	Gly	Pro	Gly	Gly	Pro	Gly	Gly	Pro	Gly	Pro	Asp	His
			565						570					575	
Pro	Arg	Gly	Pro	Pro	Pro	Trp	Val	Val	Phe	Pro	Pro	Gly	His	Ser	Glu
			580					585					590		
Val	Phe	Val	His	Thr	Glu	Val	Gly	Asn	Ala	Lys	Ile	Val	Leu		
		595					600					605			

<210> SEQ ID NO 5

<211> LENGTH: 594

<212> TYPE: DNA

<213> ORGANISM: Cryptococcus neoformans

<220> FEATURE:

<221> NAME/KEY: CDS

<222> LOCATION: (1) .. (594)

<400> SEQUENCE: 5

atg	cgt	ttt	act	tct	atc	atc	gtt	gcc	gct	ctt	cgc	ctt	gtc	ggc	tct	48
Met	Arg	Phe	Thr	Ser	Ile	Ile	Val	Ala	Ala	Leu	Pro	Leu	Val	Gly	Ser	
1			5				10						15			
gtc	ttc	gct	gcc	ccc	ttc	gct	gag	aag	gat	tct	atc	gct	tct	tcc	ccc	96
Val	Phe	Ala	Ala	Pro	Phe	Ala	Glu	Lys	Asp	Ser	Ile	Ala	Ser	Ser	Pro	
		20					25					30				
gac	ttg	gtc	aag	aag	gag	gtt	aac	gtc	ctc	tct	gtc	gtc	aat	gaa	gtc	144
Asp	Leu	Val	Lys	Lys	Glu	Val	Asn	Val	Leu	Ser	Val	Val	Asn	Glu	Val	
		35				40					45					
cag	tct	agg	gtt	aat	gct	gct	gcc	gcc	atg	ccc	cgc	cag	tct	caa	gcg	192
Gln	Ser	Arg	Val	Asn	Ala	Ala	Ala	Ala	Met	Pro	Arg	Gln	Ser	Gln	Ala	
		50			55					60						
gat	gtt	gag	gcc	tgt	ctc	aac	act	gtc	att	gat	gcc	ttt	aac	tggt	tggt	240
Asp	Val	Glu	Ala	Cys	Leu	Asn	Thr	Val	Ile	Asp	Ala	Phe	Asn	Trp	Cys	
	65				70				75					80		
ggg	ggc	cag	ctc	ggg	att	gac	gtt	tcc	gcc	agc	gcc	agc	gcc	aat	gcc	288
Gly	Gly	Gln	Leu	Gly	Ile	Asp	Val	Ser	Ala	Ser	Ala	Ser	Ala	Asn	Ala	
			85				90						95			
ggg	gct	agc	atc	cat	tac	ttg	cgt	cgt	gag	att	att	gcc	cgt	gat	gac	336
Gly	Ala	Ser	Ile	His	Tyr	Leu	Arg	Arg	Glu	Ile	Ile	Ala	Arg	Asp	Asp	
		100					105					110				
gac	aag	gag	gct	gtt	gct	cag	gca	ctc	tct	agc	gtt	gtt	cag	acc	gtt	384
Asp	Lys	Glu	Ala	Val	Ala	Gln	Ala	Leu	Ser	Ser	Val	Val	Gln	Thr	Val	
		115				120					125					
aat	gtc	ggc	atc	gtc	cag	cag	atc	ccc	agc	caa	ttc	atc	aac	atc	cct	432
Asn	Val	Gly	Ile	Val	Gln	Gln	Ile	Pro	Ser	Gln	Phe	Ile	Asn	Ile	Pro	
	130					135					140					

-continued

```

ggc gtc tcc aac ctt gtt aac cag ctt gac att gct ctc agt ctc atc      480
Gly Val Ser Asn Leu Val Asn Gln Leu Asp Ile Ala Leu Ser Leu Ile
145          150          155          160

```

```

ctt aag ggt gtt gac gct att ctc gcc ggt gtc ctc tac ctc gtc aag      528
Leu Lys Gly Val Asp Ala Ile Leu Ala Gly Val Leu Tyr Leu Val Lys
          165          170          175

```

```

gcc ctt ctc atc gat gtt ggc atc atc ctc gac tcg ctt ctc gcc ggt      576
Ala Leu Leu Ile Asp Val Gly Ile Ile Leu Asp Ser Leu Leu Gly Gly
          180          185          190

```

```

ctc ctt tcc atc ctt taa      594
Leu Leu Ser Ile Leu
          195

```

```

<210> SEQ ID NO 6
<211> LENGTH: 197
<212> TYPE: PRT
<213> ORGANISM: Cryptococcus neoformans

```

```

<400> SEQUENCE: 6

```

```

Met Arg Phe Thr Ser Ile Ile Val Ala Ala Leu Pro Leu Val Gly Ser
1          5          10          15

```

```

Val Phe Ala Ala Pro Phe Ala Glu Lys Asp Ser Ile Ala Ser Ser Pro
          20          25          30

```

```

Asp Leu Val Lys Lys Glu Val Asn Val Leu Ser Val Val Asn Glu Val
          35          40          45

```

```

Gln Ser Arg Val Asn Ala Ala Ala Ala Met Pro Arg Gln Ser Gln Ala
          50          55          60

```

```

Asp Val Glu Ala Cys Leu Asn Thr Val Ile Asp Ala Phe Asn Trp Cys
          65          70          75          80

```

```

Gly Gly Gln Leu Gly Ile Asp Val Ser Ala Ser Ala Ser Ala Asn Ala
          85          90          95

```

```

Gly Ala Ser Ile His Tyr Leu Arg Arg Glu Ile Ile Ala Arg Asp Asp
          100          105          110

```

```

Asp Lys Glu Ala Val Ala Gln Ala Leu Ser Ser Val Val Gln Thr Val
          115          120          125

```

```

Asn Val Gly Ile Val Gln Gln Ile Pro Ser Gln Phe Ile Asn Ile Pro
          130          135          140

```

```

Gly Val Ser Asn Leu Val Asn Gln Leu Asp Ile Ala Leu Ser Leu Ile
          145          150          155          160

```

```

Leu Lys Gly Val Asp Ala Ile Leu Ala Gly Val Leu Tyr Leu Val Lys
          165          170          175

```

```

Ala Leu Leu Ile Asp Val Gly Ile Ile Leu Asp Ser Leu Leu Gly Gly
          180          185          190

```

```

Leu Leu Ser Ile Leu
          195

```

```

<210> SEQ ID NO 7
<211> LENGTH: 894
<212> TYPE: DNA
<213> ORGANISM: Cryptococcus neoformans
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(894)

```

```

<400> SEQUENCE: 7

```

```

atg tct gcc gtc gaa gca ccc tcc gcc tcg cag gcc atc tgg ccc gag      48

```

Met 1	Ser	Ala	Val	Glu 5	Ala	Pro	Ser	Ala	Ser 10	Gln	Ala	Ile	Trp	Pro 15	Glu	
ctc Leu	act Thr	gaa Glu	gac Asp	cac His	ccc Pro	ctt Leu	tcg Ser	cag Gln	ctc Leu	aac Asn	tct Ser	cgc Arg	ctc Leu	cct Pro	act Thr	96
atc Ile	ctt Leu	tca Ser	gag Glu	gct Ala	ggc Gly	cac His	tcc Ser	caa Gln	atc Ile	tgg Trp	ggc Gly	gtt Val	act Thr	ctt Leu	act Thr	144
tac Tyr	tcc Ser	act Thr	ccc Pro	cca Pro	acc Thr	ttc Phe	agc Ser	ctt Ser	att Leu	att Ile	ile Ile	ctg Leu	caa Gln	aaa Lys	ttc Phe	192
ctt Leu	cgt Arg	tcc Ser	gtg Val	gat Asp	aat Asn	aac Asn	gtg Val	gat Asp	gag Glu	gct Ala	gcc Ala	acg Thr	gct Ala	cta Leu	ggc Gly	240
aag Lys	aca Thr	ctc Leu	aag Lys	tgg Trp	cgg Arg	aag Lys	gac Asp	tgg Trp	gga Gly	tgg Leu	gac Asp	cgc Ala	cgg Arg	gcg Ala	gac Asp	288
aaa Lys	aaa Lys	gag Glu	aag Lys	gaa Glu	aac Asn	ttt Phe	ggg Gly	ccc Pro	gat Asp	ttt Phe	gaa Glu	ggc Gly	tta Leu	gga Gly	tat Tyr	336
gtg Val	acc Thr	aag Lys	atc Ile	aag Lys	aaa Lys	aat Asn	gat Asp	ggc Gly	gga Gly	gat Asp	gag Glu	atc Ile	gtg Val	act Thr	tgg Trp	384
aac Asn	gtt Val	tat Tyr	gga Gly	gct Ala	gtg Val	aag Lys	gat Asp	tgg Leu	aaa Lys	tcg Ser	acc Thr	ttt Phe	ggg Gly	gat Asp	ctt Leu	432
gac Asp	cga Arg	ttc Phe	ctt Leu	cga Arg	tgg Trp	cgt Arg	gtc Val	aat Asn	ctt Leu	atg Met	gag Glu	gag Glu	gct Ala	atc Ile	gcc Ala	480
cat His	ctt Leu	cat His	ctc Leu	gct Ala	acc Thr	acc Thr	tct Ser	act Thr	ccc Pro	atc Ile	cca Pro	gac Asp	ttt Phe	aac Asn	gcc Ala	528
ggc Gly	att Ile	gat Asp	ccc Pro	cat His	cgc Arg	atg Met	gca Ala	caa Gln	gtc Val	cat His	cta Leu	tat Tyr	gaa Glu	ggc Gly	gtc Val	576
tca Ser	ttc Phe	ctt Leu	cgc Arg	atg Met	gat Asp	cct Pro	cat His	gtg Val	aaa Lys	gct Ala	gcc Ala	tcc Ser	aag Lys	gca Ala	acc Thr	624
att Ile	gag Glu	ctt Leu	atg Met	cgc Ala	gcc Ala	aac Asn	tat Tyr	ccc Pro	gaa Glu	ctt Leu	ctt Leu	tct Ser	cgc Arg	aaa Lys	ttc Phe	672
ttt Phe	gtg Val	ggc Gly	gtg Val	cct Pro	ttg Leu	ata Ile	atg Met	agc Ser	tgg Trp	atg Met	ttt Phe	cag Gln	gcc Ala	gtg Val	cga Arg	720
atg Met	ttc Phe	gtt Val	tcc Ser	gct Ala	gag Glu	act Thr	gcc Ala	aag Lys	aag Lys	ttt Phe	gtg Val	gtc Val	att Ile	agc Ser	tac Tyr	768
aag Lys	gag Glu	aat Asn	ctg Leu	cgc Ala	aat Asn	gag Glu	ctg Leu	gga Gly	gaa Glu	ctt Leu	gaa Glu	ggc Gly	gtg Val	ccc Pro	aag Lys	816
gag Glu	tat Tyr	ggc Gly	gga Gly	aag Lys	ggc Gly	ctc Leu	agt Ser	ttg Leu	ggc Gly	gaa Glu	ctt Leu	cag Gln	aac Asn	cag Gln	ctg Leu	864
cga Arg	ggg Gly	gag Glu	gac Asp	cgc Ala	gtg Val	act Thr	tct Ser	tcg Ser	taa							894

-continued

```

<210> SEQ ID NO 8
<211> LENGTH: 297
<212> TYPE: PRT
<213> ORGANISM: Cryptococcus neoformans

<400> SEQUENCE: 8

Met Ser Ala Val Glu Ala Pro Ser Ala Ser Gln Ala Ile Trp Pro Glu
1          5          10          15

Leu Thr Glu Asp His Pro Leu Ser Gln Leu Asn Ser Arg Leu Pro Thr
          20          25          30

Ile Leu Ser Glu Ala Gly His Ser Gln Ile Trp Gly Val Thr Leu Thr
          35          40          45

Tyr Ser Thr Pro Pro Thr Phe Ser Ser Leu Ile Ile Leu Gln Lys Phe
          50          55          60

Leu Arg Ser Val Asp Asn Asn Val Asp Glu Ala Ala Thr Ala Leu Gly
          65          70          75          80

Lys Thr Leu Lys Trp Arg Lys Asp Trp Gly Leu Asp Ala Arg Ala Asp
          85          90          95

Lys Lys Glu Lys Glu Asn Phe Gly Pro Asp Phe Glu Gly Leu Gly Tyr
          100         105         110

Val Thr Lys Ile Lys Lys Asn Asp Gly Gly Asp Glu Ile Val Thr Trp
          115         120         125

Asn Val Tyr Gly Ala Val Lys Asp Leu Lys Ser Thr Phe Gly Asp Leu
          130         135         140

Asp Arg Phe Leu Arg Trp Arg Val Asn Leu Met Glu Glu Ala Ile Ala
          145         150         155         160

His Leu His Leu Ala Thr Thr Ser Thr Pro Ile Pro Asp Phe Asn Ala
          165         170         175

Gly Ile Asp Pro His Arg Met Ala Gln Val His Leu Tyr Glu Gly Val
          180         185         190

Ser Phe Leu Arg Met Asp Pro His Val Lys Ala Ala Ser Lys Ala Thr
          195         200         205

Ile Glu Leu Met Ala Ala Asn Tyr Pro Glu Leu Leu Ser Arg Lys Phe
          210         215         220

Phe Val Gly Val Pro Leu Ile Met Ser Trp Met Phe Gln Ala Val Arg
          225         230         235         240

Met Phe Val Ser Ala Glu Thr Ala Lys Lys Phe Val Val Ile Ser Tyr
          245         250         255

Lys Glu Asn Leu Ala Asn Glu Leu Gly Glu Leu Glu Gly Val Pro Lys
          260         265         270

Glu Tyr Gly Gly Lys Gly Leu Ser Leu Gly Glu Leu Gln Asn Gln Leu
          275         280         285

Arg Gly Glu Asp Ala Val Thr Ser Ser
          290         295

```

```

<210> SEQ ID NO 9
<211> LENGTH: 2094
<212> TYPE: DNA
<213> ORGANISM: Cryptococcus neoformans
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(2094)

<400> SEQUENCE: 9

```

```

atg tca gag cta ttc aag gac atc cca gag ttt gta gag acc gac atc

```

-continued

Met	Ser	Glu	Leu	Phe	Lys	Asp	Ile	Pro	Glu	Phe	Val	Glu	Thr	Asp	Ile	
1				5					10					15		
gga	gag	agc	ctt	gca	gcc	aga	acg	gaa	acc	ctt	ggc	tcc	ttc	aga	gaa	96
Gly	Glu	Ser	Leu	Ala	Ala	Arg	Thr	Glu	Thr	Leu	Gly	Ser	Phe	Arg	Glu	
			20					25					30			
cta	ggc	cct	cca	gac	ctc	tgc	cat	ggt	atg	aaa	ggt	tat	ggg	aaa	ccg	144
Leu	Gly	Pro	Pro	Asp	Leu	Cys	His	Val	Met	Lys	Val	Tyr	Gly	Lys	Pro	
		35				40						45				
ccg	act	caa	cga	gag	atc	ggg	tcc	tat	cac	tac	tgc	tct	gga	ata	gag	192
Pro	Thr	Gln	Arg	Glu	Ile	Gly	Ser	Tyr	His	Tyr	Cys	Ser	Gly	Ile	Glu	
	50					55					60					
gct	tcg	tcc	tct	gcg	tca	ctc	gct	gcc	tat	ctc	aac	tct	ttg	cag	ttt	240
Ala	Ser	Ser	Ser	Ala	Ser	Leu	Ala	Ala	Tyr	Leu	Asn	Ser	Leu	Gln	Phe	
65				70						75				80		
tca	gtg	gaa	gat	tcg	tct	gca	tgg	ttt	ggc	aag	ggg	tcg	gca	tgg	aaa	288
Ser	Val	Glu	Asp	Ser	Ser	Ala	Trp	Phe	Gly	Lys	Gly	Ser	Ala	Trp	Lys	
			85						90					95		
gtt	cga	agc	ggg	acg	tat	tgc	tgc	ttc	aat	gcc	ttt	tca	cgg	gta	gat	336
Val	Arg	Ser	Gly	Thr	Tyr	Cys	Cys	Phe	Asn	Ala	Phe	Ser	Arg	Val	Asp	
		100					105						110			
atg	cgg	gtg	gaa	gcc	aat	att	ccc	ggc	ggt	gtc	gac	gct	ttt	gtg	gtt	384
Met	Arg	Val	Glu	Ala	Asn	Ile	Pro	Gly	Gly	Val	Asp	Ala	Phe	Val	Val	
		115				120						125				
gat	ctt	cac	ggt	caa	aga	cac	cct	gcg	acc	ccc	gag	ctc	tgg	caa	gag	432
Asp	Leu	His	Gly	Gln	Arg	His	Pro	Ala	Thr	Pro	Glu	Leu	Trp	Gln	Glu	
	130					135					140					
acg	tac	ctg	tct	gcg	atc	ctg	cgt	gct	att	aga	tat	gcg	gac	gat	gcc	480
Thr	Tyr	Leu	Ser	Ala	Ile	Leu	Arg	Ala	Ile	Arg	Tyr	Ala	Asp	Asp	Ala	
145				150						155				160		
tcc	tat	agg	ttg	gca	ggg	tat	aga	aag	ctg	gat	ccg	atc	aca	acg	cca	528
Ser	Tyr	Arg	Leu	Ala	Gly	Tyr	Arg	Lys	Leu	Asp	Pro	Ile	Thr	Thr	Pro	
			165					170						175		
gaa	gca	gag	gaa	aga	ttc	ctc	aaa	gcc	gcc	gaa	gcg	ctg	ttc	ttc	aag	576
Glu	Ala	Glu	Glu	Arg	Phe	Leu	Lys	Ala	Ala	Glu	Ala	Leu	Phe	Phe	Lys	
			180				185						190			
ggc	tgg	cag	ctt	ggc	tca	gat	ccc	gaa	ata	cag	gtc	gcc	aca	ggt	gtc	624
Gly	Trp	Gln	Leu	Gly	Ser	Asp	Pro	Glu	Ile	Gln	Val	Ala	Thr	Val	Val	
		195				200						205				
acc	aac	cac	ctg	acc	tct	gcc	att	ctt	aaa	tac	ttt	tcc	gac	tct	ttc	672
Thr	Asn	His	Leu	Thr	Ser	Ala	Ile	Leu	Lys	Tyr	Phe	Ser	Asp	Ser	Phe	
	210					215					220					
aga	ctt	cat	cga	gcc	gcc	aac	ctt	ttc	gaa	agg	atg	atg	gac	aag	gag	720
Arg	Leu	His	Arg	Ala	Ala	Asn	Leu	Phe	Glu	Arg	Met	Met	Asp	Lys	Glu	
225				230						235				240		
cca	gag	gta	gcc	gct	cta	gtg	gcg	aag	agt	tac	atc	ggc	atg	aac	gag	768
Pro	Glu	Val	Ala	Ala	Leu	Val	Ala	Lys	Ser	Tyr	Ile	Gly	Met	Asn	Glu	
			245					250					255			
gag	atc	aaa	gct	gtc	aag	atc	atg	aac	gct	gcc	ctt	gcc	gcc	aat	cct	816
Glu	Ile	Lys	Ala	Val	Lys	Ile	Met	Asn	Ala	Ala	Leu	Ala	Ala	Asn	Pro	
		260					265					270				
caa	tcc	tat	ccc	atc	ctt	cat	gcc	caa	gtc	gat	ttc	ctc	ctt	tcc	aag	864
Gln	Ser	Tyr	Pro	Ile	Leu	His	Ala	Gln	Val	Asp	Phe	Leu	Leu	Ser	Lys	
		275					280					285				
cac	aaa	tac	gaa	tgg	gcc	cag	caa	gtc	gcc	cag	cag	gcg	gtc	aat	tct	912
His	Lys	Tyr	Glu	Trp	Ala	Gln	Gln	Val	Ala	Gln	Gln	Ala	Val	Asn	Ser	
	290					295				300						
gca	ccc	agc	gag	ttc	acg	act	tgg	gcc	aaa	ctc	acg	gag	acg	tac	atc	960

-continued

Ala	Pro	Ser	Glu	Phe	Thr	Thr	Trp	Ala	Lys	Leu	Thr	Glu	Thr	Tyr	Ile	
305					310					315					320	
gag	ttg	ggg	caa	ctc	gac	cag	gct	ttg	ttg	aca	ctc	aac	tca	tgt	cca	1008
Glu	Leu	Gly	Gln	Leu	Asp	Gln	Ala	Leu	Leu	Thr	Leu	Asn	Ser	Cys	Pro	
			325					330						335		
atg	ttt	act	tat	aac	gaa	aga	gat	ctc	cat	cgg	atg	cct	acc	cct	gca	1056
Met	Phe	Thr	Tyr	Asn	Glu	Arg	Asp	Leu	His	Arg	Met	Pro	Thr	Pro	Ala	
			340					345						350		
aag	tcc	aat	atg	cca	gtc	aag	aag	ttt	atc	gca	gac	tcc	aat	ttg	gtg	1104
Lys	Ser	Asn	Met	Pro	Val	Lys	Lys	Phe	Ile	Ala	Asp	Ser	Asn	Leu	Val	
		355					360					365				
gat	gaa	gat	tcg	tca	cga	gag	aac	gag	gcc	gat	atc	gct	ctc	ctc	cgt	1152
Asp	Glu	Asp	Ser	Ser	Arg	Glu	Asn	Glu	Ala	Asp	Ile	Ala	Leu	Leu	Arg	
	370					375					380					
ctc	ccc	gct	ccc	aac	ctc	cgc	ggc	aca	ttc	gcc	aaa	gcg	tac	tcc	ctc	1200
Leu	Pro	Ala	Pro	Asn	Leu	Arg	Gly	Thr	Phe	Ala	Lys	Ala	Tyr	Ser	Leu	
385				390						395					400	
ctc	act	ctc	ctt	gtc	tct	aag	att	ggg	tgg	gat	gag	ctt	ctc	aaa	att	1248
Leu	Thr	Leu	Leu	Val	Ser	Lys	Ile	Gly	Trp	Asp	Glu	Leu	Leu	Lys	Ile	
			405					410						415		
aga	tcc	tcc	gtc	ttc	gtc	atg	gaa	gag	gaa	tat	cgg	ctg	cat	aaa	acg	1296
Arg	Ser	Ser	Val	Phe	Val	Met	Glu	Glu	Glu	Tyr	Arg	Leu	His	Lys	Thr	
			420					425					430			
aac	gtt	tct	gtt	gat	atg	aat	ggc	gaa	gcg	ggg	gac	ggc	gcg	tcc	att	1344
Asn	Val	Ser	Val	Asp	Met	Asn	Gly	Glu	Ala	Gly	Asp	Gly	Ala	Ser	Ile	
	435						440					445				
gcg	ggc	ttg	aag	agg	acc	tcg	tcc	gaa	gag	gtc	aac	act	ccc	agc	gat	1392
Ala	Gly	Leu	Lys	Arg	Thr	Ser	Ser	Glu	Glu	Val	Asn	Thr	Pro	Ser	Asp	
	450					455					460					
ata	cct	acc	atc	agg	ata	tca	agc	gag	tcg	atg	cgc	act	cct	aat	acg	1440
Ile	Pro	Thr	Ile	Arg	Ile	Ser	Ser	Glu	Ser	Met	Arg	Thr	Pro	Asn	Thr	
465					470					475					480	
gct	cca	gga	cca	ggg	ttc	agc	gaa	aag	gca	agt	act	cac	aag	ccc	gct	1488
Ala	Pro	Gly	Pro	Gly	Phe	Ser	Glu	Lys	Ala	Ser	Thr	His	Lys	Pro	Ala	
			485						490					495		
ctg	gag	aag	ccc	gag	aca	gca	caa	gcg	aat	gaa	gat	ccc	aat	tcg	cct	1536
Leu	Glu	Lys	Pro	Glu	Thr	Ala	Gln	Ala	Asn	Glu	Asp	Pro	Asn	Ser	Pro	
			500					505					510			
ttg	ggg	atg	aag	agt	gaa	ggg	gaa	cag	ccg	gtt	tcg	gcg	ttt	tct	cat	1584
Leu	Gly	Met	Lys	Ser	Glu	Gly	Glu	Gln	Pro	Val	Ser	Ala	Phe	Ser	His	
	515						520					525				
aag	cga	tta	tgt	gag	aga	tgg	tta	gat	aac	ctc	ttt	tta	gtt	ctg	tat	1632
Lys	Arg	Leu	Cys	Glu	Arg	Trp	Leu	Asp	Asn	Leu	Phe	Leu	Val	Leu	Tyr	
	530					535					540					
gaa	gac	ttg	aga	gtc	tac	acc	att	tgg	aga	gca	gag	ata	tct	cat	ttc	1680
Glu	Asp	Leu	Arg	Val	Thr	Thr	Ile	Trp	Arg	Ala	Glu	Ile	Ser	His	Phe	
	545				550					555					560	
aaa	acc	cag	cac	atg	tca	tac	cga	aag	act	ggg	acc	gag	tgg	gag	atc	1728
Lys	Thr	Gln	His	Met	Ser	Tyr	Arg	Lys	Thr	Gly	Thr	Glu	Trp	Glu	Ile	
			565						570					575		
ctt	ggg	gaa	ctt	gcc	aca	cgt	ttg	cat	cac	aaa	gaa	gaa	gcc	aag	gac	1776
Leu	Gly	Glu	Leu	Ala	Thr	Arg	Leu	His	His	Lys	Glu	Glu	Ala	Lys	Asp	
			580					585					590			
gcg	tac	caa	cgc	tgt	ctc	gac	tcc	aaa	ttc	agc	gca	aaa	gca	ctt	atg	1824
Ala	Tyr	Gln	Arg	Cys	Leu	Asp	Ser	Lys	Phe	Ser	Ala	Lys	Ala	Leu	Met	
	595					600						605				
aag	ctt	ctt	gaa	acg	tat	gcg	aat	gag	ggc	gat	ctt	caa	aag	acc	ttg	1872

-continued

Lys	Leu	Leu	Glu	Thr	Tyr	Ala	Asn	Glu	Gly	Asp	Leu	Gln	Lys	Thr	Leu		
610						615					620						
acg	gcg	gct	gtg	agg	ctg	aca	acc	tat	cac	cat	cga	tgg	tat	atg	gac	1920	
Thr	Ala	Ala	Val	Arg	Leu	Thr	Thr	Tyr	His	His	Arg	Trp	Tyr	Met	Asp		
625					630					635				640			
gcg	tca	tac	ccg	tcc	atg	gtc	gcg	cat	tat	ttg	tac	aag	gtc	gga	ctc	1968	
Ala	Ser	Tyr	Pro	Ser	Met	Val	Ala	His	Tyr	Leu	Tyr	Lys	Val	Gly	Leu		
				645					650					655			
ata	cat	gga	cat	gcc	aaa	tta	caa	tac	aca	atg	ctc	agt	atg	aac	ctg	2016	
Ile	His	Gly	His	Ala	Lys	Leu	Gln	Tyr	Thr	Met	Leu	Ser	Met	Asn	Leu		
				660				665						670			
ccg	gtc	ggg	atc	ttt	gaa	ata	atg	caa	ggc	tat	atg	aaa	tac	ggg	gcg	2064	
Pro	Val	Gly	Ile	Phe	Glu	Ile	Met	Gln	Gly	Tyr	Met	Lys	Tyr	Gly	Ala		
		675					680					685					
acg	ttc	aac	gtc	gaa	ggg	tca	gaa	ttc	tag							2094	
Thr	Phe	Asn	Val	Glu	Gly	Ser	Glu	Phe									
		690					695										

<210> SEQ ID NO 10

<211> LENGTH: 697

<212> TYPE: PRT

<213> ORGANISM: Cryptococcus neoformans

<400> SEQUENCE: 10

Met	Ser	Glu	Leu	Phe	Lys	Asp	Ile	Pro	Glu	Phe	Val	Glu	Thr	Asp	Ile		
1				5				10						15			
Gly	Glu	Ser	Leu	Ala	Ala	Arg	Thr	Glu	Thr	Leu	Gly	Ser	Phe	Arg	Glu		
			20				25						30				
Leu	Gly	Pro	Pro	Asp	Leu	Cys	His	Val	Met	Lys	Val	Tyr	Gly	Lys	Pro		
		35				40					45						
Pro	Thr	Gln	Arg	Glu	Ile	Gly	Ser	Tyr	His	Tyr	Cys	Ser	Gly	Ile	Glu		
		50				55					60						
Ala	Ser	Ser	Ser	Ala	Ser	Leu	Ala	Ala	Tyr	Leu	Asn	Ser	Leu	Gln	Phe		
				70						75				80			
Ser	Val	Glu	Asp	Ser	Ser	Ala	Trp	Phe	Gly	Lys	Gly	Ser	Ala	Trp	Lys		
			85					90						95			
Val	Arg	Ser	Gly	Thr	Tyr	Cys	Cys	Phe	Asn	Ala	Phe	Ser	Arg	Val	Asp		
			100					105						110			
Met	Arg	Val	Glu	Ala	Asn	Ile	Pro	Gly	Gly	Val	Asp	Ala	Phe	Val	Val		
		115				120					125						
Asp	Leu	His	Gly	Gln	Arg	His	Pro	Ala	Thr	Pro	Glu	Leu	Trp	Gln	Glu		
		130			135						140						
Thr	Tyr	Leu	Ser	Ala	Ile	Leu	Arg	Ala	Ile	Arg	Tyr	Ala	Asp	Asp	Ala		
				150					155					160			
Ser	Tyr	Arg	Leu	Ala	Gly	Tyr	Arg	Lys	Leu	Asp	Pro	Ile	Thr	Thr	Pro		
			165					170						175			
Glu	Ala	Glu	Glu	Arg	Phe	Leu	Lys	Ala	Ala	Glu	Ala	Leu	Phe	Phe	Lys		
			180					185						190			
Gly	Trp	Gln	Leu	Gly	Ser	Asp	Pro	Glu	Ile	Gln	Val	Ala	Thr	Val	Val		
		195				200						205					
Thr	Asn	His	Leu	Thr	Ser	Ala	Ile	Leu	Lys	Tyr	Phe	Ser	Asp	Ser	Phe		
	210					215					220						
Arg	Leu	His	Arg	Ala	Ala	Asn	Leu	Phe	Glu	Arg	Met	Met	Asp	Lys	Glu		
	225				230					235					240		

Pro	Glu	Val	Ala	Ala	Leu	Val	Ala	Lys	Ser	Tyr	Ile	Gly	Met	Asn	Glu	
				245					250					255		
Glu	Ile	Lys	Ala	Val	Lys	Ile	Met	Asn	Ala	Ala	Leu	Ala	Ala	Asn	Pro	
				260					265					270		
Gln	Ser	Tyr	Pro	Ile	Leu	His	Ala	Gln	Val	Asp	Phe	Leu	Leu	Ser	Lys	
				275					280					285		
His	Lys	Tyr	Glu	Trp	Ala	Gln	Gln	Val	Ala	Gln	Gln	Ala	Val	Asn	Ser	
				290					295					300		
Ala	Pro	Ser	Glu	Phe	Thr	Thr	Trp	Ala	Lys	Leu	Thr	Glu	Thr	Tyr	Ile	
				305					310					320		
Glu	Leu	Gly	Gln	Leu	Asp	Gln	Ala	Leu	Leu	Thr	Leu	Asn	Ser	Cys	Pro	
				325					330					335		
Met	Phe	Thr	Tyr	Asn	Glu	Arg	Asp	Leu	His	Arg	Met	Pro	Thr	Pro	Ala	
				340					345					350		
Lys	Ser	Asn	Met	Pro	Val	Lys	Lys	Phe	Ile	Ala	Asp	Ser	Asn	Leu	Val	
				355					360					365		
Asp	Glu	Asp	Ser	Ser	Arg	Glu	Asn	Glu	Ala	Asp	Ile	Ala	Leu	Leu	Arg	
				370					375					380		
Leu	Pro	Ala	Pro	Asn	Leu	Arg	Gly	Thr	Phe	Ala	Lys	Ala	Tyr	Ser	Leu	
				385					390					400		
Leu	Thr	Leu	Leu	Val	Ser	Lys	Ile	Gly	Trp	Asp	Glu	Leu	Leu	Lys	Ile	
				405					410					415		
Arg	Ser	Ser	Val	Phe	Val	Met	Glu	Glu	Glu	Tyr	Arg	Leu	His	Lys	Thr	
				420					425					430		
Asn	Val	Ser	Val	Asp	Met	Asn	Gly	Glu	Ala	Gly	Asp	Gly	Ala	Ser	Ile	
				435					440					445		
Ala	Gly	Leu	Lys	Arg	Thr	Ser	Ser	Glu	Glu	Val	Asn	Thr	Pro	Ser	Asp	
				450					455					460		
Ile	Pro	Thr	Ile	Arg	Ile	Ser	Ser	Glu	Ser	Met	Arg	Thr	Pro	Asn	Thr	
				465					470					480		
Ala	Pro	Gly	Pro	Gly	Phe	Ser	Glu	Lys	Ala	Ser	Thr	His	Lys	Pro	Ala	
				485					490					495		
Leu	Glu	Lys	Pro	Glu	Thr	Ala	Gln	Ala	Asn	Glu	Asp	Pro	Asn	Ser	Pro	
				500					505					510		
Leu	Gly	Met	Lys	Ser	Glu	Gly	Glu	Gln	Pro	Val	Ser	Ala	Phe	Ser	His	
				515					520					525		
Lys	Arg	Leu	Cys	Glu	Arg	Trp	Leu	Asp	Asn	Leu	Phe	Leu	Val	Leu	Tyr	
				530					535					540		
Glu	Asp	Leu	Arg	Val	Tyr	Thr	Ile	Trp	Arg	Ala	Glu	Ile	Ser	His	Phe	
				545					550					555		
Lys	Thr	Gln	His	Met	Ser	Tyr	Arg	Lys	Thr	Gly	Thr	Glu	Trp	Glu	Ile	
				565					570					575		
Leu	Gly	Glu	Leu	Ala	Thr	Arg	Leu	His	His	Lys	Glu	Glu	Ala	Lys	Asp	
				580					585					590		
Ala	Tyr	Gln	Arg	Cys	Leu	Asp	Ser	Lys	Phe	Ser	Ala	Lys	Ala	Leu	Met	
				595					600					605		
Lys	Leu	Leu	Glu	Thr	Tyr	Ala	Asn	Glu	Gly	Asp	Leu	Gln	Lys	Thr	Leu	
				610					615					620		
Thr	Ala	Ala	Val	Arg	Leu	Thr	Thr	Tyr	His	His	Arg	Trp	Tyr	Met	Asp	
				625					630					635		
Ala	Ser	Tyr	Pro	Ser	Met	Val	Ala	His	Tyr	Leu	Tyr	Lys	Val	Gly	Leu	
				640					645					650		

-continued

645	650	655	
Ile His Gly His Ala Lys Leu Gln Tyr Thr Met Leu Ser Met Asn Leu			
660	665	670	
Pro Val Gly Ile Phe Glu Ile Met Gln Gly Tyr Met Lys Tyr Gly Ala			
675	680	685	
Thr Phe Asn Val Glu Gly Ser Glu Phe			
690	695		
 <210> SEQ ID NO 11			
<211> LENGTH: 1662			
<212> TYPE: DNA			
<213> ORGANISM: Cryptococcus neoformans			
<220> FEATURE:			
<221> NAME/KEY: CDS			
<222> LOCATION: (1) .. (1662)			
 <400> SEQUENCE: 11			
atg tcg tta gcg gac gcc ctt ctg gca gac ctt gat ggt ctc tcg gat			48
Met Ser Leu Ala Asp Ala Leu Leu Ala Asp Leu Asp Gly Leu Ser Asp			
1	5	10	15
gac gaa gct cga tct cct tct cct ggc ccc gag gcc tcc tcc tcg tca			96
Asp Glu Ala Arg Ser Pro Ser Pro Gly Pro Glu Ala Ser Ser Ser Ser			
20	25	30	
atg ccg cct cct ggt ttg ccc aac aaa gga aaa cgt ccc gcc agc gct			144
Met Pro Pro Pro Gly Leu Pro Asn Lys Gly Lys Arg Pro Ala Ser Ala			
35	40	45	
atg gaa gtc gat gat ggc gaa gga ggt gcg aat gaa gat gag gga gac			192
Met Glu Val Asp Asp Gly Glu Gly Gly Ala Asn Glu Asp Glu Gly Asp			
50	55	60	
gat atg aag ctg gaa gac ggg acg agt gct gtg gga ttt gta cct gaa			240
Asp Met Lys Leu Glu Asp Gly Thr Ser Ala Val Gly Phe Val Pro Glu			
65	70	75	80
gga ggt gta agg cct gca gat gag ctg gac aag gag gaa gtg gaa aaa			288
Gly Gly Val Arg Pro Ala Asp Glu Leu Asp Lys Glu Glu Val Glu Lys			
85	90	95	
acc gat atg aag ggt gtc gag gat gtg aag aaa gta gcc agg ttg gca			336
Thr Asp Met Lys Gly Val Glu Asp Val Lys Lys Val Ala Arg Leu Ala			
100	105	110	
gga agc cag aag ctt cga gat gtt ctg gca gat atc ata aaa tac acc			384
Gly Ser Gln Lys Leu Arg Asp Val Leu Ala Asp Ile Ile Lys Tyr Thr			
115	120	125	
gag tct ccc acc gat atg tct tcg tct gcc ggt ccc ctc gag gag aat			432
Glu Ser Pro Thr Asp Met Ser Ser Ser Ala Gly Pro Leu Glu Glu Asn			
130	135	140	
cca gag tac cat ctt gtt gtc act gcg aac aac atg tcc gtc gag gtt			480
Pro Glu Tyr His Leu Val Val Thr Ala Asn Asn Met Ser Val Glu Val			
145	150	155	160
gac aac gag att ctc atc gtg cac aaa ttc att cgt gac cac tat gct			528
Asp Asn Glu Ile Leu Ile Val His Lys Phe Ile Arg Asp His Tyr Ala			
165	170	175	
cct cga ttt ccg gaa ctc gaa cag ctc att gcc gaa cct tgg aca tac			576
Pro Arg Phe Pro Glu Leu Glu Gln Leu Ile Ala Glu Pro Trp Thr Tyr			
180	185	190	
att gcc gcc gtt aat gcc atc ggt cag tct gaa gat cta acg aag gtc			624
Ile Ala Ala Val Asn Ala Ile Gly Gln Ser Glu Asp Leu Thr Lys Val			
195	200	205	
aca ttc ccc aac acc ctc cct gcg gct act gta ctc tct atc act ctt			672
Thr Phe Pro Asn Thr Leu Pro Ala Ala Thr Val Leu Ser Ile Thr Leu			

-continued

210	215	220	
act gct acg act tcc cgt ggt cgg ccg ctc acg cct gca gag tgg gaa			720
Thr Ala Thr Thr Ser Arg Gly Arg Pro Leu Thr Pro Ala Glu Trp Glu			
225	230	235	240
aca att cag cgc gcc atc gct gtc gcc caa aat ctc cgt tcg gcg cga			768
Thr Ile Gln Arg Ala Ile Ala Val Ala Gln Asn Leu Arg Ser Ala Arg			
	245	250	255
gaa caa att ttt tcc tac gtc gag tcc cgt atg gct gct gta gca cct			816
Glu Gln Ile Phe Ser Tyr Val Glu Ser Arg Met Ala Ala Val Ala Pro			
	260	265	270
aat ttg tct gct att gtg ggc acc ggt atc gct gcc aaa tta ctt ggt			864
Asn Leu Ser Ala Ile Val Gly Thr Gly Ile Ala Ala Lys Leu Leu Gly			
	275	280	285
tta gca ggt ggt ctc cat gcg ttt agt cga cag ccg agt tgt aat gtg			912
Leu Ala Gly Gly Leu His Ala Phe Ser Arg Gln Pro Ser Cys Asn Val			
	290	295	300
atg ctt ttt ggc gcg atg aag aag act ttg gcc acc tct cat ctt tct			960
Met Leu Phe Gly Ala Met Lys Lys Thr Leu Ala Thr Ser His Leu Ser			
	305	310	315
gct gcc tct cag caa cga cat acc ggc ttt atc ttc caa agc tct ata			1008
Ala Ala Ser Gln Gln Arg His Thr Gly Phe Ile Phe Gln Ser Ser Ile			
	325	330	335
gta cag agt gcc cag cct gaa gat cga aga aga gct cag cga gcg gtg			1056
Val Gln Ser Ala Gln Pro Glu Asp Arg Arg Arg Ala Gln Arg Ala Val			
	340	345	350
tct gcc aag tgt gct ctt gcg gcc agg atc gat gca gga aag ggg tct			1104
Ser Ala Lys Cys Ala Leu Ala Ala Arg Ile Asp Ala Gly Lys Gly Ser			
	355	360	365
agg gac gga tct tat gga aga aag tgt ttg gcg gat ttg caa aag agg			1152
Arg Asp Gly Ser Tyr Gly Arg Lys Cys Leu Ala Asp Leu Gln Lys Arg			
	370	375	380
att gaa aag atg gcg gaa cct cct ccc aac aag atg atc aag gcg ttg			1200
Ile Glu Lys Met Ala Glu Pro Pro Pro Asn Lys Met Ile Lys Ala Leu			
	385	390	395
cct atc cct cag gag act aac agg aag aag cgt ggt ggt aag aga gct			1248
Pro Ile Pro Gln Glu Thr Asn Arg Lys Lys Arg Gly Gly Lys Arg Ala			
	405	410	415
cga aaa gcc aag gaa gcg tac gcc cag acc gaa ttg aga aag tta caa			1296
Arg Lys Ala Lys Glu Ala Tyr Ala Gln Thr Glu Leu Arg Lys Leu Gln			
	420	425	430
aac cga atg gag ttt ggc aag gcg gaa gaa gag atc ggg gtg gac gac			1344
Asn Arg Met Glu Phe Gly Lys Ala Glu Glu Glu Ile Gly Val Asp Asp			
	435	440	445
gag act gtt ggt ttg ggt atg atc ggt tcc gcc gga agg gtc cga ggc			1392
Glu Thr Val Gly Leu Gly Met Ile Gly Ser Ala Gly Arg Val Arg Gly			
	450	455	460
gag atg gca gat gcg agg agt aaa gct aaa ctt tct cga gcc aac aaa			1440
Glu Met Ala Asp Ala Arg Ser Lys Ala Lys Leu Ser Arg Ala Asn Lys			
	465	470	475
ctt cga act cag ctc ctt ggt cgc tca gtc aca tcc aac gac gct gcc			1488
Leu Arg Thr Gln Leu Leu Gly Arg Ser Val Thr Ser Asn Asp Ala Ala			
	485	490	495
agc ggt atg gcc acc tcc tta tca ttc acg cct gtc caa ggt ctt gaa			1536
Ser Gly Met Ala Thr Ser Leu Ser Phe Thr Pro Val Gln Gly Leu Glu			
	500	505	510
ata gtt aca ccc tcc ctc tct gca gcc cag aaa gta cag gct gcg aat			1584
Ile Val Thr Pro Ser Leu Ser Ala Ala Gln Lys Val Gln Ala Ala Asn			

-continued

515	520	525	
gac aga tgg ttc tcc ggg ggt	aca ttt acg cat	gta agg aag ggg gga	1632
Asp Arg Trp Phe Ser Gly Gly Thr Phe Thr His Val Arg Lys Gly Gly			
530	535	540	
agc agt att ccg gga cag gaa cag aaa tag			1662
Ser Ser Ile Pro Gly Gln Glu Gln Lys			
545	550		
<210> SEQ ID NO 12			
<211> LENGTH: 553			
<212> TYPE: PRT			
<213> ORGANISM: Cryptococcus neoformans			
<400> SEQUENCE: 12			
Met Ser Leu Ala Asp Ala Leu Leu Ala Asp Leu Asp Gly Leu Ser Asp			
1	5	10	15
Asp Glu Ala Arg Ser Pro Ser Pro Gly Pro Glu Ala Ser Ser Ser Ser			
20	25	30	
Met Pro Pro Pro Gly Leu Pro Asn Lys Gly Lys Arg Pro Ala Ser Ala			
35	40	45	
Met Glu Val Asp Asp Gly Glu Gly Gly Ala Asn Glu Asp Glu Gly Asp			
50	55	60	
Asp Met Lys Leu Glu Asp Gly Thr Ser Ala Val Gly Phe Val Pro Glu			
65	70	75	80
Gly Gly Val Arg Pro Ala Asp Glu Leu Asp Lys Glu Glu Val Glu Lys			
85	90	95	
Thr Asp Met Lys Gly Val Glu Asp Val Lys Lys Val Ala Arg Leu Ala			
100	105	110	
Gly Ser Gln Lys Leu Arg Asp Val Leu Ala Asp Ile Ile Lys Tyr Thr			
115	120	125	
Glu Ser Pro Thr Asp Met Ser Ser Ser Ala Gly Pro Leu Glu Glu Asn			
130	135	140	
Pro Glu Tyr His Leu Val Val Thr Ala Asn Asn Met Ser Val Glu Val			
145	150	155	160
Asp Asn Glu Ile Leu Ile Val His Lys Phe Ile Arg Asp His Tyr Ala			
165	170	175	
Pro Arg Phe Pro Glu Leu Glu Gln Leu Ile Ala Glu Pro Trp Thr Tyr			
180	185	190	
Ile Ala Ala Val Asn Ala Ile Gly Gln Ser Glu Asp Leu Thr Lys Val			
195	200	205	
Thr Phe Pro Asn Thr Leu Pro Ala Ala Thr Val Leu Ser Ile Thr Leu			
210	215	220	
Thr Ala Thr Thr Ser Arg Gly Arg Pro Leu Thr Pro Ala Glu Trp Glu			
225	230	235	240
Thr Ile Gln Arg Ala Ile Ala Val Ala Gln Asn Leu Arg Ser Ala Arg			
245	250	255	
Glu Gln Ile Phe Ser Tyr Val Glu Ser Arg Met Ala Ala Val Ala Pro			
260	265	270	
Asn Leu Ser Ala Ile Val Gly Thr Gly Ile Ala Ala Lys Leu Leu Gly			
275	280	285	
Leu Ala Gly Gly Leu His Ala Phe Ser Arg Gln Pro Ser Cys Asn Val			
290	295	300	
Met Leu Phe Gly Ala Met Lys Lys Thr Leu Ala Thr Ser His Leu Ser			

-continued

305	310	315	320
Ala Ala Ser Gln Gln Arg His Thr Gly Phe Ile Phe Gln Ser Ser Ile			
	325	330	335
Val Gln Ser Ala Gln Pro Glu Asp Arg Arg Arg Ala Gln Arg Ala Val			
	340	345	350
Ser Ala Lys Cys Ala Leu Ala Ala Arg Ile Asp Ala Gly Lys Gly Ser			
	355	360	365
Arg Asp Gly Ser Tyr Gly Arg Lys Cys Leu Ala Asp Leu Gln Lys Arg			
	370	375	380
Ile Glu Lys Met Ala Glu Pro Pro Pro Asn Lys Met Ile Lys Ala Leu			
	385	390	395
Pro Ile Pro Gln Glu Thr Asn Arg Lys Lys Arg Gly Gly Lys Arg Ala			
	405	410	415
Arg Lys Ala Lys Glu Ala Tyr Ala Gln Thr Glu Leu Arg Lys Leu Gln			
	420	425	430
Asn Arg Met Glu Phe Gly Lys Ala Glu Glu Glu Ile Gly Val Asp Asp			
	435	440	445
Glu Thr Val Gly Leu Gly Met Ile Gly Ser Ala Gly Arg Val Arg Gly			
	450	455	460
Glu Met Ala Asp Ala Arg Ser Lys Ala Lys Leu Ser Arg Ala Asn Lys			
	465	470	475
Leu Arg Thr Gln Leu Leu Gly Arg Ser Val Thr Ser Asn Asp Ala Ala			
	485	490	495
Ser Gly Met Ala Thr Ser Leu Ser Phe Thr Pro Val Gln Gly Leu Glu			
	500	505	510
Ile Val Thr Pro Ser Leu Ser Ala Ala Gln Lys Val Gln Ala Ala Asn			
	515	520	525
Asp Arg Trp Phe Ser Gly Gly Thr Phe Thr His Val Arg Lys Gly Gly			
	530	535	540
Ser Ser Ile Pro Gly Gln Glu Gln Lys			
	545	550	

<210> SEQ ID NO 13

<211> LENGTH: 759

<212> TYPE: DNA

<213> ORGANISM: Cryptococcus neoformans

<220> FEATURE:

<221> NAME/KEY: CDS

<222> LOCATION: (1)..(759)

<400> SEQUENCE: 13

atg tca tca act gat ctc gga ggc caa gct gcc gtc atc act ggc ggt	48
Met Ser Ser Thr Asp Leu Gly Gly Gln Ala Ala Val Ile Thr Gly Gly	
1 5 10 15	
ggg aag aat ctt ggt gct ttg att gcg aag act ctc gcc aag cag gga	96
Gly Lys Asn Leu Gly Ala Leu Ile Ala Lys Thr Leu Ala Lys Gln Gly	
20 25 30	
gtc aac gtt gcg atc cat tac aac tcg gcc agt tcc aag tcc gag aca	144
Val Asn Val Ala Ile His Tyr Asn Ser Ala Ser Ser Lys Ser Glu Thr	
35 40 45	
gaa gct aca ttg aag aca ctc gga tcg tat ggg gtc aaa gcc gct gct	192
Glu Ala Thr Leu Lys Thr Leu Gly Ser Tyr Gly Val Lys Ala Ala Ala	
50 55 60	
ttc cag gcc aat ctt acc act gag gca tca gtt gag aaa ctc ttc tca	240
Phe Gln Ala Asn Leu Thr Thr Glu Ala Ser Val Glu Lys Leu Phe Ser	

-continued

65	70	75	80	
gac gca gca gct gct ctt gga gtg tcc aag ttc gat atc gcc atc aat				288
Asp Ala Ala Ala Ala Leu Gly Val Ser Lys Phe Asp Ile Ala Ile Asn	85	90	95	
acg gtc ggt aag gtt ctt aaa aag cct atc gtt gaa aca aca gag caa				336
Thr Val Gly Lys Val Leu Lys Lys Pro Ile Val Glu Thr Thr Glu Gln	100	105	110	
gga ttc gac gac atg ttc cta gtc aac tca aag tgt gcc ttc ttt ttt				384
Gly Phe Asp Asp Met Phe Leu Val Asn Ser Lys Cys Ala Phe Phe Phe	115	120	125	
atc aag cat gcg gcc aag aat ctc aac gag ggg ggc acg att ata tca				432
Ile Lys His Ala Ala Lys Asn Leu Asn Glu Gly Gly Thr Ile Ile Ser	130	135	140	
ctc gtg act tca ctc ctt gga gca ttt gcg cct ggt tat tca act tat				480
Leu Val Thr Ser Leu Leu Gly Ala Phe Ala Pro Gly Tyr Ser Thr Tyr	145	150	155	160
caa ggc agt aaa gct cct gta gag tgg ttc act aag tcg gct gcc aag				528
Gln Gly Ser Lys Ala Pro Val Glu Trp Phe Thr Lys Ser Ala Ala Lys	165	170	175	
gag ctt cag cct aag aat att agg gtc aac tgt gtg gct ccg ggg cca				576
Glu Leu Gln Pro Lys Asn Ile Arg Val Asn Cys Val Ala Pro Gly Pro	180	185	190	
atg gac act ccc ttc ttt tac ggg caa gag act gaa gat gcc gtt gct				624
Met Asp Thr Pro Phe Phe Tyr Gly Gln Glu Thr Glu Asp Ala Val Ala	195	200	205	
ttc cat aaa agc cag gcg ctc aca gga cgg ctc aca gat att aaa gat				672
Phe His Lys Ser Gln Ala Leu Thr Gly Arg Leu Thr Asp Ile Lys Asp	210	215	220	
att gca cca ttg gtg gag ttc ctt tgc aag gat aag tgg att acc gga				720
Ile Ala Pro Leu Val Glu Phe Leu Cys Lys Asp Lys Trp Ile Thr Gly	225	230	235	240
caa gtc atc ttc tca aat gga ggt tac acg act cgc tga				759
Gln Val Ile Phe Ser Asn Gly Gly Tyr Thr Thr Arg	245	250		

<210> SEQ ID NO 14

<211> LENGTH: 252

<212> TYPE: PRT

<213> ORGANISM: Cryptococcus neoformans

<400> SEQUENCE: 14

Met Ser Ser Thr Asp Leu Gly Gly Gln Ala Ala Val Ile Thr Gly Gly
1 5 10 15

Gly Lys Asn Leu Gly Ala Leu Ile Ala Lys Thr Leu Ala Lys Gln Gly
20 25 30

Val Asn Val Ala Ile His Tyr Asn Ser Ala Ser Ser Lys Ser Glu Thr
35 40 45

Glu Ala Thr Leu Lys Thr Leu Gly Ser Tyr Gly Val Lys Ala Ala Ala
50 55 60

Phe Gln Ala Asn Leu Thr Thr Glu Ala Ser Val Glu Lys Leu Phe Ser
65 70 75 80

Asp Ala Ala Ala Ala Leu Gly Val Ser Lys Phe Asp Ile Ala Ile Asn
85 90 95

Thr Val Gly Lys Val Leu Lys Lys Pro Ile Val Glu Thr Thr Glu Gln
100 105 110

Gly Phe Asp Asp Met Phe Leu Val Asn Ser Lys Cys Ala Phe Phe Phe

-continued

115				120				125								
Ile	Lys	His	Ala	Ala	Lys	Asn	Leu	Asn	Glu	Gly	Gly	Thr	Ile	Ile	Ser	
130						135					140					
Leu	Val	Thr	Ser	Leu	Leu	Gly	Ala	Phe	Ala	Pro	Gly	Tyr	Ser	Thr	Tyr	
145					150					155					160	
Gln	Gly	Ser	Lys	Ala	Pro	Val	Glu	Trp	Phe	Thr	Lys	Ser	Ala	Ala	Lys	
				165					170					175		
Glu	Leu	Gln	Pro	Lys	Asn	Ile	Arg	Val	Asn	Cys	Val	Ala	Pro	Gly	Pro	
			180					185					190			
Met	Asp	Thr	Pro	Phe	Phe	Tyr	Gly	Gln	Glu	Thr	Glu	Asp	Ala	Val	Ala	
	195						200					205				
Phe	His	Lys	Ser	Gln	Ala	Leu	Thr	Gly	Arg	Leu	Thr	Asp	Ile	Lys	Asp	
210						215					220					
Ile	Ala	Pro	Leu	Val	Glu	Phe	Leu	Cys	Lys	Asp	Lys	Trp	Ile	Thr	Gly	
225					230					235					240	
Gln	Val	Ile	Phe	Ser	Asn	Gly	Gly	Tyr	Thr	Thr	Arg					
				245					250							
<210> SEQ ID NO 15																
<211> LENGTH: 2199																
<212> TYPE: DNA																
<213> ORGANISM: Cryptococcus neoformans																
<220> FEATURE:																
<221> NAME/KEY: CDS																
<222> LOCATION: (1)..(2199)																
<400> SEQUENCE: 15																
atg	cag	cac	cac	ccc	gcg	gta	gca	gca	cag	ccg	ggc	cgc	act	att	gcc	48
Met	Gln	His	His	Pro	Ala	Val	Ala	Ala	Gln	Pro	Gly	Arg	Thr	Ile	Ala	
1				5					10					15		
cct	atc	ccg	cac	cac	cgc	cca	cag	caa	ccc	cgg	atc	act	cct	tac	aca	96
Pro	Ile	Pro	His	His	Arg	Pro	Gln	Gln	Pro	Arg	Ile	Thr	Pro	Tyr	Thr	
			20				25						30			
cca	aac	gta	cgc	gac	ctc	aac	cca	gga	cct	aag	aac	aga	ctc	atc	ctc	144
Pro	Asn	Val	Arg	Asp	Leu	Asn	Pro	Gly	Pro	Lys	Asn	Arg	Leu	Ile	Leu	
			35			40						45				
gcc	ctc	cgc	tcc	aac	atc	ccc	ttt	gaa	gtc	gac	tgg	gcg	cta	ccg	cag	192
Ala	Leu	Arg	Ser	Asn	Ile	Pro	Phe	Glu	Val	Asp	Trp	Ala	Leu	Pro	Gln	
	50				55					60						
ctt	gtt	gtc	gca	agt	ttc	gac	cag	tcg	gac	ggg	ttc	aag	ctc	gag	gca	240
Leu	Val	Val	Ala	Ser	Phe	Asp	Gln	Ser	Asp	Gly	Phe	Lys	Leu	Glu	Ala	
	65				70				75					80		
tgg	cca	gac	agc	att	tgc	gcg	ttg	aag	gaa	tgg	ccg	gcc	aag	tgg	ctt	288
Trp	Pro	Asp	Ser	Ile	Cys	Ala	Leu	Lys	Glu	Trp	Pro	Ala	Lys	Trp	Leu	
			85					90					95			
gaa	gga	cta	gaa	agg	gaa	gct	gca	gtg	ttt	gag	atg	aaa	gct	ggg	cga	336
Glu	Gly	Leu	Glu	Arg	Glu	Ala	Ala	Val	Phe	Glu	Met	Lys	Ala	Gly	Arg	
			100			105							110			
ttg	gat	ttt	gag	ggg	gac	gag	aat	gat	gaa	gag	ggg	agg	atg	gca	aag	384
Leu	Asp	Phe	Glu	Gly	Asp	Glu	Asn	Asp	Glu	Glu	Gly	Arg	Met	Ala	Lys	
			115			120						125				
cgc	aga	aaa	agg	gat	ctg	gcg	ctg	ggg	gcg	gtg	gta	gag	tgg	gag	aac	432
Arg	Arg	Lys	Arg	Asp	Leu	Ala	Leu	Gly	Ala	Val	Val	Glu	Trp	Glu	Asn	
	130				135						140					
gat	ctc	aag	gtg	gaa	caa	cgg	gcg	acc	aac	tct	ttg	ctc	gtc	ctc	aga	480
Asp	Leu	Lys	Val	Glu	Gln	Arg	Ala	Thr	Asn	Ser	Leu	Leu	Val	Leu	Arg	
	145				150					155					160	

-continued

aac gca tcc ttc aac gca ccc aac gca aag atc ctc tca agc tca agc	528
Asn Ala Ser Phe Asn Ala Pro Asn Ala Lys Ile Leu Ser Ser Ser Ser	
165 170 175	
ttc ctc gct ttt cta gcc gat ttc ttc tct ttg cct cta ccg ttt ctc	576
Phe Leu Ala Phe Leu Ala Asp Phe Phe Ser Leu Pro Leu Pro Phe Leu	
180 185 190	
cag cat ctt tgc ctg aga acc cca gag cct ata cat cat atc ctc atc	624
Gln His Leu Cys Leu Arg Thr Pro Glu Pro Ile His His Ile Leu Ile	
195 200 205	
att gtc cag tcc atc ttc ccc cat ttg cgc gtg gac atg cca ggt atc	672
Ile Val Gln Ser Ile Phe Pro His Leu Arg Val Asp Met Pro Gly Ile	
210 215 220	
gac cgc atc aag cac atc ttt ggc gtc gtc ttc cct cag ctt ttt gtt	720
Asp Arg Ile Lys His Ile Phe Gly Val Val Phe Pro Gln Leu Phe Val	
225 230 235 240	
gat acc cgc gat atc gca atg atg aac aac ctt atc cct ctc atg atg	768
Asp Thr Arg Asp Ile Ala Met Met Asn Asn Leu Ile Pro Leu Met Met	
245 250 255	
atg ggc cag aca atc ccc aat aac cac cct cct ccg cct gaa ctc atc	816
Met Gly Gln Thr Ile Pro Asn Asn His Pro Pro Pro Pro Glu Leu Ile	
260 265 270	
cct cat ctt ctc cag ctt ctc gtt ctc cgt cca gca ggc cca ctt ctc	864
Pro His Leu Leu Gln Leu Leu Val Leu Arg Pro Ala Gly Pro Leu Leu	
275 280 285	
gat ttg act ctt gac atc ctc atc tcc ctc tcc aca aat ccc atc cac	912
Asp Leu Thr Leu Asp Ile Leu Ile Ser Leu Ser Thr Asn Pro Ile His	
290 295 300	
tcc cgt gcc ata ctt tct cat act tct ttc ccg cat cat ctc aaa tcc	960
Ser Arg Ala Ile Leu Ser His Thr Ser Phe Pro His His Leu Lys Ser	
305 310 315 320	
atc aca gcc tta ctc gaa cat caa gct cgt ccg gtg gtg aat gcc ctt	1008
Ile Thr Ala Leu Leu Glu His Gln Ala Arg Pro Val Val Asn Ala Leu	
325 330 335	
gac cca ccg cct tct acg aga ggg aaa atg gtg cgt aac cca gcg gga	1056
Asp Pro Pro Pro Ser Thr Arg Gly Lys Met Val Arg Asn Pro Ala Gly	
340 345 350	
ccg agt tgc aga gca gag gaa ctt aat caa agg ccg acg aag gaa cga	1104
Pro Ser Cys Arg Ala Glu Glu Leu Asn Gln Arg Arg Thr Lys Glu Arg	
355 360 365	
gag gcc gca ttg gga cat atg gat ccc atg gct gga ggt aga ccg gtg	1152
Glu Ala Ala Leu Gly His Met Asp Pro Met Ala Gly Gly Arg Pro Val	
370 375 380	
tac aat gag gta ggg gat aag cca ccg aca ttt agt ccg gcg acg aag	1200
Tyr Asn Glu Val Gly Asp Lys Pro Pro Thr Phe Ser Pro Ala Thr Lys	
385 390 395 400	
aag agg ctt ttc agg atg aaa gaa ccc gaa agg tct atc gag tgg atg	1248
Lys Arg Leu Phe Arg Met Lys Glu Pro Glu Arg Ser Ile Glu Trp Met	
405 410 415	
cac cag gca ttc gtc tac tca tcg aca gcc caa gtc ctt caa gtg aca	1296
His Gln Ala Phe Val Tyr Ser Ser Thr Ala Gln Val Leu Gln Val Thr	
420 425 430	
ttc tgg cac gcc tac cga gat ttc ttc acc aac cca gct tgc gta gaa	1344
Phe Trp His Ala Tyr Arg Asp Phe Phe Thr Asn Pro Ala Cys Val Glu	
435 440 445	
cca atg ttg agt gca tct gat gtg atc aag aat gtc act gca gct ttc	1392
Pro Met Leu Ser Ala Ser Asp Val Ile Lys Asn Val Thr Ala Ala Phe	
450 455 460	

cct Pro 465	gga Gly	gcg Ala	agc Ser	gca Ala	aaa Lys 470	gtt Val	tgg Trp	acc Thr	gat Asp	gcg Ala 475	agt Ser	ggg Gly	gcg Ala	caa Gln	aag Lys 480	1440
ttt Phe	gtg Val	att Ile	gct Ala	ggg Gly 485	gtc Val	ggg Gly	ttc Phe	agg Arg	aag Lys 490	cga Arg	tca Ser	gat Asp	gac Asp	gat Asp 495	gaa Glu	1488
agg Arg	ttt Phe	aca Thr	tgt Cys 500	tac Tyr	tgg Trp	cat His	gca Ala	tgc Cys 505	acc Thr	caa Gln	cgg Arg	tac Tyr	tca Ser	gct Ala	acc Thr	1536
aac Asn	ccc Pro	gtc Val 515	caa Gln	ctg Leu	ctc Leu	gaa Glu	cac His	att Ile	agc Ser	aac Asn	tac Tyr	cat His 525	ctc Leu	caa Gln	acc Thr	1584
ttt Phe	tct Ser 530	gca Ala	ccc Pro	caa Gln	tgc Cys	caa Gln 535	tgg Trp	ggc Gly	tca Ser	tgc Cys 540	gat Asp	cac His	aac Asn	ctc Leu	tgc Cys	1632
acg Thr 545	tac Tyr	tct Ser	cat His	ctc Leu	ctc Leu 550	acc Thr	cat His	atc Ile	ccc Pro	ctc Leu 555	ggc Gly	cag Gln	cct Pro	cca Pro	tcc Ser 560	1680
tcc Ser	atc Ile	tcc Ser	gtc Val	cct Pro 565	gac Asp	gcc Ala	atc Ile	tct Ser	tgc Cys 570	cat His	atc Ile	gca Ala	gac Asp	cat His 575	agt Ser	1728
agc Ser	tcc Ser	gtc Val 580	ttg Gln	cag Gln	cgc Arg	aag Lys	atc Ile	acc Asn 585	aat Arg	cgt Arg	acc Thr	gtc Val 590	cct Pro	cct Pro	tta Leu	1776
tcc Ser	agc Ser	gtt Val 595	cgt Arg	cta Leu	gcc Ala	gtt Val 600	cag Gln	ggg Gly	gca Ala	ttt Phe	acc Thr	cct Pro 605	gtc Val	gac Asp	gct Ala	1824
cgt Arg 610	cga Arg	caa Gln	cct Pro	act Thr	ggc Gly 615	gcc Ala	gcc Ala	ctt Leu	ctc Leu	gcg Ala	gcg Ala	tta Leu 620	ctt Leu	atc Ile	cgt Arg	1872
aac Asn 625	ctc Leu	gcc Ala	cgt Arg	acc Thr	ctc Leu 630	cgt Arg	gcc Ala	gag Glu	atc Ile	tgc Ser 635	ctc Leu	gcc Ala	gtg Val	ccc Pro	gaa Glu 640	1920
ttg Leu	tct Ser	cat His	gct Ala	caa Gln 645	acg Thr	caa Gln	gaa Glu	acg Thr	gca Ala 650	gat Asp	gaa Glu	gct Ala	caa Gln	gcg Ala 655	aga Arg	1968
aaa Lys	aaa Lys	cac His	ctt Leu 660	ctc Leu	gaa Glu	gag Glu	agg Arg	tat Tyr 665	gga Gly	ttg Leu	cca Pro	atc Ile 670	ccg Pro	gat Asp	tcg Ser	2016
gtg Val	ttg Leu	aaa Lys 675	gaa Glu	gaa Glu	gaa Glu	gag Glu 680	gag Glu	cag Gln	gcg Ala	aat Asn	gtg Val	cag Gln 685	caa Gln	ggc Gly	caa Gln	2064
gat Asp 690	tta Leu	gat Asp	atg Met	agt Ser	gag Glu	gaa Glu 695	gag Glu	agg Arg	gag Glu	agg Arg	gcg Ala	aaa Lys	aag Lys	gcg Ala	ttt Phe	2112
gag Glu 705	aat Asn	gtg Val	gag Glu	gag Glu	agg Arg 710	att Ile	atg Met	aag Lys	gtc Val	atg Met 715	ttg Leu	gag Glu	aat Asn	gtt Val	agt Ser 720	2160
ggg Gly	ata Ile	acg Thr	cag Gln	tat Tyr 725	ctt Leu	ggg Gly	gat Asp	gcg Ala	ctt Leu 730	ggg Gly	ctg Leu	tag				2199

```
<210> SEQ ID NO 16
<211> LENGTH: 732
<212> TYPE: PRT
<213> ORGANISM: Cryptococcus neoformans

<400> SEQUENCE: 16
```

-continued

Met	Gln	His	His	Pro	Ala	Val	Ala	Ala	Gln	Pro	Gly	Arg	Thr	Ile	Ala	
1				5					10					15		
Pro	Ile	Pro	His	His	Arg	Pro	Gln	Gln	Pro	Arg	Ile	Thr	Pro	Tyr	Thr	
			20					25					30			
Pro	Asn	Val	Arg	Asp	Leu	Asn	Pro	Gly	Pro	Lys	Asn	Arg	Leu	Ile	Leu	
		35					40					45				
Ala	Leu	Arg	Ser	Asn	Ile	Pro	Phe	Glu	Val	Asp	Trp	Ala	Leu	Pro	Gln	
	50					55					60					
Leu	Val	Val	Ala	Ser	Phe	Asp	Gln	Ser	Asp	Gly	Phe	Lys	Leu	Glu	Ala	
65					70					75					80	
Trp	Pro	Asp	Ser	Ile	Cys	Ala	Leu	Lys	Glu	Trp	Pro	Ala	Lys	Trp	Leu	
			85						90					95		
Glu	Gly	Leu	Glu	Arg	Glu	Ala	Ala	Val	Phe	Glu	Met	Lys	Ala	Gly	Arg	
			100					105					110			
Leu	Asp	Phe	Glu	Gly	Asp	Glu	Asn	Asp	Glu	Glu	Gly	Arg	Met	Ala	Lys	
		115					120					125				
Arg	Arg	Lys	Arg	Asp	Leu	Ala	Leu	Gly	Ala	Val	Val	Glu	Trp	Glu	Asn	
	130					135					140					
Asp	Leu	Lys	Val	Glu	Gln	Arg	Ala	Thr	Asn	Ser	Leu	Leu	Val	Leu	Arg	
145					150					155				160		
Asn	Ala	Ser	Phe	Asn	Ala	Pro	Asn	Ala	Lys	Ile	Leu	Ser	Ser	Ser	Ser	
			165					170						175		
Phe	Leu	Ala	Phe	Leu	Ala	Asp	Phe	Phe	Ser	Leu	Pro	Leu	Pro	Phe	Leu	
		180						185					190			
Gln	His	Leu	Cys	Leu	Arg	Thr	Pro	Glu	Pro	Ile	His	His	Ile	Leu	Ile	
		195					200					205				
Ile	Val	Gln	Ser	Ile	Phe	Pro	His	Leu	Arg	Val	Asp	Met	Pro	Gly	Ile	
	210					215					220					
Asp	Arg	Ile	Lys	His	Ile	Phe	Gly	Val	Val	Phe	Pro	Gln	Leu	Phe	Val	
225				230					235					240		
Asp	Thr	Arg	Asp	Ile	Ala	Met	Met	Asn	Asn	Leu	Ile	Pro	Leu	Met	Met	
			245					250					255			
Met	Gly	Gln	Thr	Ile	Pro	Asn	Asn	His	Pro	Pro	Pro	Pro	Glu	Leu	Ile	
		260					265						270			
Pro	His	Leu	Leu	Gln	Leu	Leu	Val	Leu	Arg	Pro	Ala	Gly	Pro	Leu	Leu	
		275				280					285					
Asp	Leu	Thr	Leu	Asp	Ile	Leu	Ile	Ser	Leu	Ser	Thr	Asn	Pro	Ile	His	
	290				295						300					
Ser	Arg	Ala	Ile	Leu	Ser	His	Thr	Ser	Phe	Pro	His	His	Leu	Lys	Ser	
305					310					315				320		
Ile	Thr	Ala	Leu	Leu	Glu	His	Gln	Ala	Arg	Pro	Val	Val	Asn	Ala	Leu	
			325					330					335			
Asp	Pro	Pro	Pro	Ser	Thr	Arg	Gly	Lys	Met	Val	Arg	Asn	Pro	Ala	Gly	
		340						345					350			
Pro	Ser	Cys	Arg	Ala	Glu	Glu	Leu	Asn	Gln	Arg	Arg	Thr	Lys	Glu	Arg	
		355					360					365				
Glu	Ala	Ala	Leu	Gly	His	Met	Asp	Pro	Met	Ala	Gly	Gly	Arg	Pro	Val	
	370					375					380					
Tyr	Asn	Glu	Val	Gly	Asp	Lys	Pro	Pro	Thr	Phe	Ser	Pro	Ala	Thr	Lys	
385					390					395				400		

-continued

Lys Arg Leu Phe Arg Met Lys Glu Pro Glu Arg Ser Ile Glu Trp Met
 405 410 415
 His Gln Ala Phe Val Tyr Ser Ser Thr Ala Gln Val Leu Gln Val Thr
 420 425 430
 Phe Trp His Ala Tyr Arg Asp Phe Phe Thr Asn Pro Ala Cys Val Glu
 435 440 445
 Pro Met Leu Ser Ala Ser Asp Val Ile Lys Asn Val Thr Ala Ala Phe
 450 455 460
 Pro Gly Ala Ser Ala Lys Val Trp Thr Asp Ala Ser Gly Ala Gln Lys
 465 470 475 480
 Phe Val Ile Ala Gly Val Gly Phe Arg Lys Arg Ser Asp Asp Asp Glu
 485 490 495
 Arg Phe Thr Cys Tyr Trp His Ala Cys Thr Gln Arg Tyr Ser Ala Thr
 500 505 510
 Asn Pro Val Gln Leu Leu Glu His Ile Ser Asn Tyr His Leu Gln Thr
 515 520 525
 Phe Ser Ala Pro Gln Cys Gln Trp Gly Ser Cys Asp His Asn Leu Cys
 530 535 540
 Thr Tyr Ser His Leu Leu Thr His Ile Pro Leu Gly Gln Pro Pro Ser
 545 550 555 560
 Ser Ile Ser Val Pro Asp Ala Ile Ser Cys His Ile Ala Asp His Ser
 565 570 575
 Ser Ser Val Leu Gln Arg Lys Ile Thr Asn Arg Thr Val Pro Pro Leu
 580 585 590
 Ser Ser Val Arg Leu Ala Val Gln Gly Ala Phe Thr Pro Val Asp Ala
 595 600 605
 Arg Arg Gln Pro Thr Gly Ala Ala Leu Leu Ala Ala Leu Leu Ile Arg
 610 615 620
 Asn Leu Ala Arg Thr Leu Arg Ala Glu Ile Ser Leu Ala Val Pro Glu
 625 630 635 640
 Leu Ser His Ala Gln Thr Gln Glu Thr Ala Asp Glu Ala Gln Ala Arg
 645 650 655
 Lys Lys His Leu Leu Glu Glu Arg Tyr Gly Leu Pro Ile Pro Asp Ser
 660 665 670
 Val Leu Lys Glu Glu Glu Glu Glu Gln Ala Asn Val Gln Gln Gly Gln
 675 680 685
 Asp Leu Asp Met Ser Glu Glu Glu Arg Glu Arg Ala Lys Lys Ala Phe
 690 695 700
 Glu Asn Val Glu Glu Arg Ile Met Lys Val Met Leu Glu Asn Val Ser
 705 710 715 720
 Gly Ile Thr Gln Tyr Leu Gly Asp Ala Leu Gly Leu
 725 730

<210> SEQ ID NO 17
 <211> LENGTH: 1305
 <212> TYPE: DNA
 <213> ORGANISM: *Cryptococcus neoformans*
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1)..(1305)

<400> SEQUENCE: 17

atg aga ctc acg att att gcc cca gac tcg gtt cat gag cac gaa gtg
 Met Arg Leu Thr Ile Ile Ala Pro Asp Ser Val His Glu His Glu Val

-continued

1	5	10	15	
tcc cct tcc ttg ctc atc caa gac atc atc aac atc gtt gag gca act				96
Ser Pro Ser Leu Leu Ile Gln Asp Ile Ile Asn Ile Val Glu Ala Thr	20	25	30	
gcc gac ctt ccc ccg gct gtt att gtt ctc aca agt gac gcc ggt aca				144
Ala Asp Leu Pro Pro Ala Val Ile Val Leu Thr Ser Asp Ala Gly Thr	35	40	45	
cca ctc acg gac ccc aca aga act ctc gaa agc tat ggg tta aat gga				192
Pro Leu Thr Asp Pro Thr Arg Thr Leu Glu Ser Tyr Gly Leu Asn Gly	50	55	60	
gag acc gcc acc atc ttc ctt aca cct aca gga cca ccc gtc gct tct				240
Glu Thr Ala Thr Ile Phe Leu Thr Pro Thr Gly Pro Pro Val Ala Ser	65	70	75	80
tcg tct tcc att cca ttc cct gat gca gat gcc gac att gaa agg atg				288
Ser Ser Ser Ile Pro Phe Pro Asp Ala Asp Ala Asp Ile Glu Arg Met	85	90	95	
cgt tta caa gcg ctc gga aat cct tct ttg atg aat gat ttg cgt gag				336
Arg Leu Gln Ala Leu Gly Asn Pro Ser Leu Met Asn Asp Leu Arg Glu	100	105	110	
cgt gat ccg gaa acc ttt gcc gct att caa ggg ggt act caa agc ttc				384
Arg Asp Pro Glu Thr Phe Ala Ala Ile Gln Gly Gly Thr Gln Ser Phe	115	120	125	
aaa aaa gcc ctc caa ctg gcg caa tca aga caa aga gat gcc gaa ttc				432
Lys Lys Ala Leu Gln Leu Ala Gln Ser Arg Gln Arg Asp Ala Glu Phe	130	135	140	
gaa aag caa cgc cag att gaa gca ctc aat gcc gac cct tat gac att				480
Glu Lys Gln Arg Gln Ile Glu Ala Leu Asn Ala Asp Pro Tyr Asp Ile	145	150	155	160
gaa gct cag aaa aag att gag gaa gca att cgg atg gag gcc gtt ttg				528
Glu Ala Gln Lys Lys Ile Glu Glu Ala Ile Arg Met Glu Ala Val Leu	165	170	175	
gag aat atg cag cac gct atg gaa tat tcc cct gag tcg ttt gga aac				576
Glu Asn Met Gln His Ala Met Glu Tyr Ser Pro Glu Ser Phe Gly Asn	180	185	190	
gtg acc atg ctg tat atc aat gtg gaa gta aat ggt cat cct gtt aag				624
Val Thr Met Leu Tyr Ile Asn Val Glu Val Asn Gly His Pro Val Lys	195	200	205	
gca ttc gtt gat tct ggt gca caa aca acg atc att tcc cct gaa tgt				672
Ala Phe Val Asp Ser Gly Ala Gln Thr Thr Ile Ile Ser Pro Glu Cys	210	215	220	
gcc gag caa tgt gga atc atg cgc ctg ctt gat act cgt ttc gcg ggt				720
Ala Glu Gln Cys Gly Ile Met Arg Leu Leu Asp Thr Arg Phe Ala Gly	225	230	235	240
atg gcc gaa gga gta gga aca gct cgt atc ctc ggt cgt atc cac tct				768
Met Ala Glu Gly Val Gly Thr Ala Arg Ile Leu Gly Arg Ile His Ser	245	250	255	
gcc caa att aag ctc ggc tca ctc tac ctc cct tgt gca ttc tcc gtc				816
Ala Gln Ile Lys Leu Gly Ser Leu Tyr Leu Pro Cys Ala Phe Ser Val	260	265	270	
ctc gaa ggc cgt tct gtc gac ctc tta ttt ggt ctt gac atg ctt aaa				864
Leu Glu Gly Arg Ser Val Asp Leu Leu Phe Gly Leu Asp Met Leu Lys	275	280	285	
cgc cat caa tgc tgt atc gac ctc tcc acg aac acg ctc cgg ata aat				912
Arg His Gln Cys Cys Ile Asp Leu Ser Thr Asn Thr Leu Arg Ile Asn	290	295	300	
aac act gaa gta ccc ttt ttg tcg gag cac gag ctg cct gac aag gcg				960
Asn Thr Glu Val Pro Phe Leu Ser Glu His Glu Leu Pro Asp Lys Ala				

-continued

305	310	315	320	
aga aga cgt ggg gag gcg caa gtg gcc ggg gaa atg ggt gat gcg gca				1008
Arg Arg Arg Gly Glu Ala Gln Val Ala Gly Glu Met Gly Asp Ala Ala	325	330	335	
ggg caa ggc gtg aaa gcg ggt gtg gcg agt ccg aag att ggg aag aag				1056
Gly Gln Gly Val Lys Ala Gly Val Ala Ser Pro Lys Ile Gly Lys Lys	340	345	350	
acg ttt ccg gga gag ggg cat gcg ctt ggt gcg ggc agc tcg act gga				1104
Thr Phe Pro Gly Glu Gly His Ala Leu Gly Ala Gly Ser Ser Thr Gly	355	360	365	
cca ggg acg gct acg ggg agt gca agt gcg aca ggt gca agg act ggg				1152
Pro Gly Thr Ala Thr Gly Ser Ala Ser Ala Thr Gly Ala Arg Thr Gly	370	375	380	
ggg act gca agt gtc ccc tcg cct tca aat agg tgg aaa gag gac gat				1200
Gly Thr Ala Ser Val Pro Ser Pro Ser Asn Arg Trp Lys Glu Asp Asp	385	390	395	400
att caa acg ctt gtg aac ctg ggt gcc cct cga gcg caa gct ata cag				1248
Ile Gln Thr Leu Val Asn Leu Gly Ala Pro Arg Ala Gln Ala Ile Gln	405	410	415	
cta ctt gaa gcg tca ggt gga aac gtg gat gtt gct gct tct atg ctc				1296
Leu Leu Glu Ala Ser Gly Gly Asn Val Asp Val Ala Ala Ser Met Leu	420	425	430	
ttt ggt tag				1305
Phe Gly				
<210> SEQ ID NO 18				
<211> LENGTH: 434				
<212> TYPE: PRT				
<213> ORGANISM: Cryptococcus neoformans				
<400> SEQUENCE: 18				
Met Arg Leu Thr Ile Ile Ala Pro Asp Ser Val His Glu His Glu Val	1	5	10	15
Ser Pro Ser Leu Leu Ile Gln Asp Ile Ile Asn Ile Val Glu Ala Thr	20	25	30	
Ala Asp Leu Pro Pro Ala Val Ile Val Leu Thr Ser Asp Ala Gly Thr	35	40	45	
Pro Leu Thr Asp Pro Thr Arg Thr Leu Glu Ser Tyr Gly Leu Asn Gly	50	55	60	
Glu Thr Ala Thr Ile Phe Leu Thr Pro Thr Gly Pro Pro Val Ala Ser	65	70	75	80
Ser Ser Ser Ile Pro Phe Pro Asp Ala Asp Ala Asp Ile Glu Arg Met	85	90	95	
Arg Leu Gln Ala Leu Gly Asn Pro Ser Leu Met Asn Asp Leu Arg Glu	100	105	110	
Arg Asp Pro Glu Thr Phe Ala Ala Ile Gln Gly Gly Thr Gln Ser Phe	115	120	125	
Lys Lys Ala Leu Gln Leu Ala Gln Ser Arg Gln Arg Asp Ala Glu Phe	130	135	140	
Glu Lys Gln Arg Gln Ile Glu Ala Leu Asn Ala Asp Pro Tyr Asp Ile	145	150	155	160
Glu Ala Gln Lys Lys Ile Glu Glu Ala Ile Arg Met Glu Ala Val Leu	165	170	175	
Glu Asn Met Gln His Ala Met Glu Tyr Ser Pro Glu Ser Phe Gly Asn	180	185	190	

-continued

Val	Thr	Met	Leu	Tyr	Ile	Asn	Val	Glu	Val	Asn	Gly	His	Pro	Val	Lys
		195					200					205			
Ala	Phe	Val	Asp	Ser	Gly	Ala	Gln	Thr	Thr	Ile	Ile	Ser	Pro	Glu	Cys
	210					215					220				
Ala	Glu	Gln	Cys	Gly	Ile	Met	Arg	Leu	Leu	Asp	Thr	Arg	Phe	Ala	Gly
	225				230					235					240
Met	Ala	Glu	Gly	Val	Gly	Thr	Ala	Arg	Ile	Leu	Gly	Arg	Ile	His	Ser
				245					250					255	
Ala	Gln	Ile	Lys	Leu	Gly	Ser	Leu	Tyr	Leu	Pro	Cys	Ala	Phe	Ser	Val
			260					265					270		
Leu	Glu	Gly	Arg	Ser	Val	Asp	Leu	Leu	Phe	Gly	Leu	Asp	Met	Leu	Lys
		275					280					285			
Arg	His	Gln	Cys	Cys	Ile	Asp	Leu	Ser	Thr	Asn	Thr	Leu	Arg	Ile	Asn
	290					295					300				
Asn	Thr	Glu	Val	Pro	Phe	Leu	Ser	Glu	His	Glu	Leu	Pro	Asp	Lys	Ala
	305				310					315					320
Arg	Arg	Arg	Gly	Glu	Ala	Gln	Val	Ala	Gly	Glu	Met	Gly	Asp	Ala	Ala
				325					330					335	
Gly	Gln	Gly	Val	Lys	Ala	Gly	Val	Ala	Ser	Pro	Lys	Ile	Gly	Lys	Lys
			340					345					350		
Thr	Phe	Pro	Gly	Glu	Gly	His	Ala	Leu	Gly	Ala	Gly	Ser	Ser	Thr	Gly
		355					360					365			
Pro	Gly	Thr	Ala	Thr	Gly	Ser	Ala	Ser	Ala	Thr	Gly	Ala	Arg	Thr	Gly
	370					375					380				
Gly	Thr	Ala	Ser	Val	Pro	Ser	Pro	Ser	Asn	Arg	Trp	Lys	Glu	Asp	Asp
	385				390					395					400
Ile	Gln	Thr	Leu	Val	Asn	Leu	Gly	Ala	Pro	Arg	Ala	Gln	Ala	Ile	Gln
			405						410					415	
Leu	Leu	Glu	Ala	Ser	Gly	Gly	Asn	Val	Asp	Val	Ala	Ala	Ser	Met	Leu
			420					425					430		

Phe Gly

<210> SEQ ID NO 19
 <211> LENGTH: 3555
 <212> TYPE: DNA
 <213> ORGANISM: Cryptococcus neoformans
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1)..(3555)

<400> SEQUENCE: 19

atg	tct	tcg	cca	gaa	cca	gag	gag	cct	cgc	aga	ggg	gca	agg	gtc	agg	48
Met	Ser	Ser	Pro	Glu	Pro	Glu	Glu	Pro	Arg	Arg	Gly	Ala	Arg	Val	Arg	
1			5						10				15			
aag	cag	gtt	aat	aag	ttt	gat	gct	agc	cag	cag	aac	ggg	agg	ggc	aag	96
Lys	Gln	Val	Asn	Lys	Phe	Asp	Ala	Ser	Gln	Gln	Asn	Gly	Arg	Gly	Lys	
			20					25					30			
aga	aag	cac	att	gaa	gac	agg	gag	gac	gac	gac	cag	gag	ggg	ttg	ata	144
Arg	Lys	His	Ile	Glu	Asp	Arg	Glu	Asp	Asp	Asp	Gln	Glu	Gly	Leu	Ile	
			35				40					45				
cca	gac	ccg	gaa	gac	gag	tct	gat	cac	gaa	cca	act	ccc	aag	aag	aag	192
Pro	Asp	Pro	Glu	Asp	Glu	Ser	Asp	His	Glu	Pro	Thr	Pro	Lys	Lys	Lys	
			50				55				60					
aag	ccg	gcg	gca	cca	cga	aaa	tct	cga	gct	tct	gcg	ggg	act	acc	aag	240
Lys	Pro	Ala	Ala	Pro	Arg	Lys	Ser	Arg	Ala	Ser	Ala	Gly	Thr	Thr	Lys	

-continued

65	70	75	80	
aag gac gga cca aag aca aaa aca aag cct gca gct gaa ggc gtg agc				288
Lys Asp Gly Pro	Lys Thr Lys Thr	Lys Pro Ala Ala	Glu Gly Val Ser	
	85	90	95	
gaa atc gta gaa aag act gat tcg cct tta ttt aat gct ctc cag caa				336
Glu Ile Val Glu Lys Thr Asp Ser Pro Leu Phe Asn Ala Leu Gln Gln				
	100	105	110	
ccc gat atc gcc ctt caa cct ctg att gat gag tgg atc gag acc tac				384
Pro Asp Ile Ala Leu Gln Pro Leu Ile Asp Glu Trp Ile Glu Thr Tyr				
	115	120	125	
caa caa gcc gct ggt gat gaa ata tca gag cag aaa tcc att cac gaa				432
Gln Gln Ala Ala Gly Asp Glu Ile Ser Glu Gln Lys Ser Ile His Glu				
	130	135	140	
ctg gtt gtc ttc ttc att cga tgt tgc ggt atg act acc gag atc gag				480
Leu Val Val Phe Phe Ile Arg Cys Cys Gly Met Thr Thr Glu Ile Glu				
	145	150	155	160
caa gct gaa gca acg gat gac gat ggt atc ccc gat gtc atc gag cga				528
Gln Ala Glu Ala Thr Asp Asp Asp Gly Ile Pro Asp Val Ile Glu Arg				
	165	170	175	
gtg cag gat gaa agc gtt cgc gta gcg ttg gcg act tat ccc tta att				576
Val Gln Asp Glu Ser Val Arg Val Ala Leu Ala Thr Tyr Pro Leu Ile				
	180	185	190	
tcc aaa gca aag aat ttt aag ccc ttc aag tcc aat ttg aac gag ttc				624
Ser Lys Ala Lys Asn Phe Lys Pro Phe Lys Ser Asn Leu Asn Glu Phe				
	195	200	205	
att tca cac ttt att tca tcg ctc gct ctc aca cct atc ctc ttt cac				672
Ile Ser His Phe Ile Ser Ser Leu Ala Leu Thr Pro Ile Leu Phe His				
	210	215	220	
act gcc gac aat act cct cac tca tct ctg ctc atc cca ctt ctc ctc				720
Thr Ala Asp Asn Thr Pro His Ser Ser Leu Leu Ile Pro Leu Leu Leu				
	225	230	235	240
aac tgg ctg atg tgt atg tca tca tca act ctt cga ccc atc cgt cat				768
Asn Trp Leu Met Cys Met Ser Ser Ser Thr Leu Arg Pro Ile Arg His				
	245	250	255	
acc tca aca tac gtg acg ctc agg atg aac tcg gct ttg tgt gac gtt				816
Thr Ser Thr Tyr Val Thr Leu Arg Met Asn Ser Ala Leu Cys Asp Val				
	260	265	270	
gct gcg gat gtg agc aaa gac ctg agc gtt aag caa agg cag cga gat				864
Ala Ala Asp Val Ser Lys Asp Leu Ser Val Lys Gln Arg Gln Arg Asp				
	275	280	285	
gca gaa gtc aga aaa gct gga gct aca aat gca gcg cag aag aga gtg				912
Ala Glu Val Arg Lys Ala Gly Ala Thr Asn Ala Ala Gln Lys Arg Val				
	290	295	300	
aag gct gcc gag gac agg gtc aag gaa gtg caa gaa aga aag caa act				960
Lys Ala Ala Glu Asp Arg Val Lys Glu Val Gln Glu Arg Lys Gln Thr				
	305	310	315	320
tta gaa gag ttg atg cag gag atc ttt gat gtg atg ttc gtc cac cga				1008
Leu Glu Glu Leu Met Gln Glu Ile Phe Asp Val Met Phe Val His Arg				
	325	330	335	
gtt cgc gat gcc gat ccc aac att cga acc gat tgt ctg cgt gaa tta				1056
Val Arg Asp Ala Asp Pro Asn Ile Arg Thr Asp Cys Leu Arg Glu Leu				
	340	345	350	
ggt ctg tgg gcc aaa aaa cac cca gag tac tac gtt tcg act tct tat				1104
Gly Leu Trp Ala Lys Lys His Pro Glu Tyr Tyr Val Ser Thr Ser Tyr				
	355	360	365	
ctc tcc tac ttc acc cgt ggc tgt aac gat acc cac gct cat gcc cga				1152
Leu Ser Tyr Phe Thr Arg Gly Cys Asn Asp Thr His Ala His Ala Arg				

-continued

370				375				380								
ctt Leu 385	gag Glu 385	act Thr 385	gtc Val 385	aag Lys 390	gct Ala 390	ctt Leu 390	gcc Ala 390	aac Asn 390	ctc Leu 395	tac Ile 395	atc Arg 395	cga Glu 400	gaa Thr 400	acc Phe 400	1200	
atc Ile	agt Ser	aac Asn	gct Ala	cga Arg	acc Thr	ttg Leu	acg Thr	atg Met	cgt Arg	tta Leu	gcg Ala	cct Pro	agg Arg	gtg Val	att Ile	1248
gag Glu	atg Met	gcc Ala	acc Thr	agg Arg	gat Asp	gtg Val	gat Asp	ttg Leu	aat Asn	gtg Val	agg Arg	gta Val	gtg Val	gct Ala	ttg Leu	1296
cag Gln	gtg Val	att Ile	aca Thr	ctt Leu	ata Ile	gac Asp	aag Lys	acg Thr	ggg Gly	att Ile	ctg Leu	caa Gln	gac Asp	gag Glu	gag Glu	1344
gac Asp	gag Glu	gaa Glu	aga Arg	gat Asp	aag Lys	gtg Val	gcg Ala	aag Lys	ctt Leu	gtt Val	ttc Phe	gac Asp	cag Gln	gag Glu	cct Pro	1392
cga Arg	att Ile	cga Arg	aaa Lys	gct Ala	gca Ala	ggg Gly	gcg Ala	ttc Phe	atc Ile	ctt Leu	ggg Gly	ttg Leu	tgg Trp	gaa Glu	gag Glu	1440
agg Arg	aaa Lys	gaa Glu	ggc Gly	ctc Leu	aaa Lys	gca Ala	gtc Val	tgg Trp	tcg Ser	ggg Gly	ctg Leu	aga Arg	gcg Ala	aac Asn	aaa Lys	1488
aag Lys	aag Lys	cgt Arg	gca Ala	gca Ala	aac Asn	atc Ile	acc Thr	gaa Glu	gac Asp	gaa Glu	atg Met	tcc Ser	aac Asn	tac Tyr	ctc Leu	1536
aac Asn	tgg Trp	aaa Lys	tcc Ser	ctc Leu	gct Ala	gca Ala	ggt Val	ctc Leu	ctc Leu	tac Tyr	acc Thr	tct Ser	aaa Lys	tcc Ser	ctg Leu	1584
gac Asp	gac Asp	gac Asp	cct Pro	tct Ser	gga Gly	caa Gln	ccc Pro	tct Ser	gcc Ala	ctc Leu	aaa Lys	cca Pro	agc Ser	cta Leu	ctc Leu	1632
att Ile	ccg Pro	tct Ser	tta Leu	ccc Pro	aat Asn	aca Thr	cag Gln	atg Met	aca Thr	agg Arg	gcg Ala	act Thr	gct Ala	gcc Ala	gtc Val	1680
gag Glu	tct Ser	atc Ile	ggg Gly	gct Ala	gag Glu	cat His	gag Glu	ctg Leu	tgg Trp	aaa Lys	gac Asp	tgg Trp	gag Glu	agc Ser	ttg Leu	1728
gtg Val	gac Asp	tat Tyr	ctt Leu	ttg Leu	gtg Val	gat Asp	cac His	tcg Ser	act Thr	aac Asn	gaa Glu	gaa Glu	gat Asp	atg Met	tgg Trp	1776
ctg Leu	ctc Leu	cgt Arg	gaa Glu	gat Asp	gag Glu	gaa Glu	act Phe	ttc Met	atg Met	ttg Leu	cag Gln	gtg Val	ctt Leu	ttg Leu	gct Ala	1824
tgt Cys	att Ile	aag Lys	cgg Arg	gaa Glu	gaa Glu	aat Asn	gaa Glu	gag Glu	gat Asp	gag Glu	ccg Pro	gat Asp	agg Arg	acc Thr	aaa Lys	1872
acg Thr	ttg Leu	ata Ile	aag Lys	ggt Val	ttg Leu	cct Pro	cgg Arg	tta Leu	ttt Phe	gcc Ala	aag Lys	cat His	cag Gln	gct Ala	gat Asp	1920
gtt Val	ggg Gly	cga Arg	atg Met	act Thr	ggg Gly	att Ile	tta Leu	tct Ser	gtt Val	ccc Pro	gga Gly	cac His	atg Met	aag Lys	ctc Leu	1968
agt Ser	ctc Leu	tat Tyr	ctc Leu	gac Asp	atg Met	cgc Arg	atg Met	tcc Ser	tct Ser	gcc Ala	tac Tyr	gag Glu	tcc Ser	ctc Leu	tgg Trp	2016
gat Asp	gac Asp	atc Ile	agc Ser	aaa Lys	cag Gln	ttc Phe	cta Leu	aaa Lys	tac Tyr	act Thr	tcc Ser	cct Pro	acc Thr	atc Ile	ctc Leu	2064

-continued

675					680					685									
aca	gca	tcc	att	tct	gcg	atc	agc	cat	ctc	gtc	ggc	aac	tcg	tcc	ctt	2112			
Thr	Ala	Ser	Ile	Ser	Ala	Ile	Ser	His	Leu	Val	Gly	Asn	Ser	Ser	Leu				
690					695					700									
tca	tcc	atc	aat	gaa	acc	aag	ctt	tct	gag	ctg	cac	gag	tct	ctc	ttc	2160			
Ser	Ser	Ile	Asn	Glu	Thr	Lys	Leu	Ser	Glu	Leu	His	Glu	Ser	Leu	Phe				
705					710					715					720				
gct	tct	cta	aga	gat	gcg	att	ggc	tct	gaa	gat	gtt	gcg	ctt	gtc	act	2208			
Ala	Ser	Leu	Arg	Asp	Ala	Ile	Gly	Ser	Glu	Asp	Val	Ala	Leu	Val	Thr				
					725					730					735				
ttg	gag	gac	gag	cag	atc	agc	cag	ctg	gaa	gca	atc	atg	ctg	agg	ata	2256			
Leu	Glu	Asp	Glu	Gln	Ile	Ser	Gln	Leu	Glu	Ala	Ile	Met	Leu	Arg	Ile				
					740					745					750				
acg	tta	ctg	cag	aga	agt	atg	gat	ttg	gta	gat	gtc	atg	gag	gat	gag	2304			
Thr	Leu	Leu	Gln	Arg	Ser	Met	Asp	Leu	Val	Asp	Val	Met	Glu	Asp	Glu				
					755					760					765				
gaa	ggg	cag	cag	agt	agc	ggc	tgg	gac	att	atc	tgt	gcg	ttt	gct	gat	2352			
Glu	Gly	Gln	Gln	Ser	Ser	Gly	Trp	Asp	Ile	Ile	Cys	Ala	Phe	Ala	Asp				
					770					775					780				
agg	ggc	aaa	ttg	ggg	tac	aag	gag	gaa	gct	act	atg	gta	gac	tat	gct	2400			
Arg	Gly	Lys	Leu	Gly	Tyr	Lys	Glu	Glu	Ala	Thr	Met	Val	Asp	Tyr	Ala				
					785					790					800				
gtt	caa	atc	atc	ttc	ctc	cac	atc	act	tgg	ctc	ttc	aag	cgg	ttc	acc	2448			
Val	Gln	Ile	Ile	Phe	Leu	His	Ile	Thr	Trp	Leu	Phe	Lys	Arg	Phe	Thr				
					805					810					815				
aag	gaa	gat	gcg	caa	gat	gcc	acc	aag	att	gat	ctc	ctt	tcc	acc	cga	2496			
Lys	Glu	Asp	Ala	Gln	Asp	Ala	Thr	Lys	Ile	Asp	Leu	Leu	Ser	Thr	Arg				
					820					825					830				
cgc	gat	acc	gcc	ctt	cag	aca	ttt	aac	cag	ctt	ttc	ctc	gga	gaa	acg	2544			
Arg	Asp	Thr	Ala	Leu	Gln	Thr	Phe	Asn	Gln	Leu	Phe	Leu	Gly	Glu	Thr				
					835					840					845				
acc	aat	acc	gcc	agt	gct	gta	cga	cgt	caa	gcc	ttc	atc	tct	ttc	atc	2592			
Thr	Asn	Thr	Ala	Ser	Ala	Val	Arg	Arg	Gln	Ala	Phe	Ile	Ser	Phe	Ile				
					850					855					860				
aat	acg	tac	gta	ttg	ttc	gcc	aaa	cgt	gca	gag	ggg	agg	gga	gga	gct	2640			
Asn	Thr	Tyr	Val	Leu	Phe	Ala	Lys	Arg	Ala	Glu	Gly	Arg	Gly	Gly	Ala				
					865					870					875		880		
cca	gcg	agc	gac	gtt	tgt	tct	gtg	acg	atg	ccg	gaa	gaa	gta	cag	cat	2688			
Pro	Ala	Ser	Asp	Val	Cys	Ser	Val	Thr	Met	Pro	Glu	Glu	Val	Gln	His				
					885					890					895				
aga	ctg	gga	ggg	gcg	ttc	caa	gcg	gtg	att	gag	agg	tat	gct	tcc	gtc	2736			
Arg	Leu	Gly	Gly	Ala	Phe	Gln	Ala	Val	Ile	Glu	Arg	Tyr	Ala	Ser	Val				
					900					905					910				
gtg	gag	act	aga	tca	gca	gga	cgg	gaa	gag	agt	cag	cag	ccc	ccc	gaa	2784			
Val	Glu	Thr	Arg	Ser	Ala	Gly	Arg	Glu	Glu	Ser	Gln	Gln	Pro	Pro	Glu				
					915					920					925				
ctc	act	cct	gat	gag	atg	cac	gag	gat	ttc	cag	ttt	ttc	caa	ctc	gtt	2832			
Leu	Thr	Pro	Asp	Glu	Met	His	Glu	Asp	Phe	Gln	Phe	Phe	Gln	Leu	Val				
					930					935					940				
tcc	gtt	ttt	gtc	ggt	gcc	atc	cga	tgt	ggt	gtc	ctc	gag	gtt	gaa	cat	2880			
Ser	Val	Phe	Val	Gly	Ala	Ile	Arg	Cys	Gly	Val	Leu	Glu	Val	Glu	His				
					945					950					955		960		
gcc	aag	gaa	cct	ctt	gcc	cat	tac	agt	cgt	ttt	ggg	cca	acg	tac	gat	2928			
Ala	Lys	Glu	Pro	Leu	Ala	His	Tyr	Ser	Arg	Phe	Gly	Pro	Thr	Tyr	Asp				
					965					970					975				
gcg	atc	gtc	aag	aag	ctc	gtt	gat	gta	ctt	cga	gat	gag	ggg	atc	tac	2976			
Ala	Ile	Val	Lys	Lys	Leu	Val	Asp	Val	Leu	Arg	Asp	Glu	Gly	Ile	Tyr				

-continued

980							985				990					
aat	agg	gag	gca	gat	gcg	gtg	cag	cat	gtt	gcg	gga	agc	gcc	ttg	cag	3024
Asn	Arg	Glu	Ala	Asp	Ala	Val	Gln	His	Val	Ala	Gly	Ser	Ala	Leu	Gln	
995							1000				1005					
caa	tcg	ttc	aac	atc	ttc	ctc	gac	tct	gag	gaa	gac	gaa	cca	act		3069
Gln	Ser	Phe	Asn	Ile	Phe	Leu	Asp	Ser	Glu	Glu	Asp	Glu	Pro	Thr		
1010							1015				1020					
gct	cct	ctg	gcc	ctt	gcc	cgt	gtt	att	gca	act	gcg	ttc	gtc	atc		3114
Ala	Pro	Leu	Ala	Leu	Ala	Arg	Val	Ile	Ala	Thr	Ala	Phe	Val	Ile		
1025							1030				1035					
cat	ggt	tcc	caa	ttc	gct	atc	cta	aga	caa	ttg	cat	cca	tct	gat		3159
His	Gly	Ser	Gln	Phe	Ala	Ile	Leu	Arg	Gln	Leu	His	Pro	Ser	Asp		
1040							1045				1050					
gtt	tgc	gat	ttc	cac	ctc	gaa	gcg	ctt	gac	ttt	gtt	tct	ctc	aaa		3204
Val	Cys	Asp	Phe	His	Leu	Glu	Ala	Leu	Asp	Phe	Val	Ser	Leu	Lys		
1055							1060				1065					
gtc	tca	acg	att	gtc	aaa	caa	gaa	gga	aat	gca	agg	aac	aag	gag		3249
Val	Ser	Thr	Ile	Val	Lys	Gln	Glu	Gly	Asn	Ala	Arg	Asn	Lys	Glu		
1070							1075				1080					
caa	aaa	tcc	aga	cta	aca	agg	aaa	aag	tgg	gca	gtg	ctc	aca	ttc		3294
Gln	Lys	Ser	Arg	Leu	Thr	Arg	Lys	Lys	Trp	Ala	Val	Leu	Thr	Phe		
1085							1090				1095					
ttc	aag	gtg	ctc	gtc	cct	ctt	ctc	gcg	cct	gtc	aca	ggt	aga	gat		3339
Phe	Lys	Val	Leu	Val	Pro	Leu	Leu	Ala	Pro	Val	Thr	Gly	Arg	Asp		
1100							1105				1110					
gct	ctc	aag	atc	aag	gct	cat	ctc	gaa	gat	gta	atc	gac	tct	tct		3384
Ala	Leu	Lys	Ile	Lys	Ala	His	Leu	Glu	Asp	Val	Ile	Asp	Ser	Ser		
1115							1120				1125					
ggg	gtg	caa	ctg	aca	acc	aac	aag	ggt	tgg	gat	ggc	tac	cga	gcg		3429
Gly	Val	Gln	Leu	Thr	Thr	Asn	Lys	Gly	Trp	Asp	Gly	Tyr	Arg	Ala		
1130							1135				1140					
tac	gaa	aag	aga	tta	gta	ggg	atc	gca	agc	aag	gac	ccg	aat	gtg		3474
Tyr	Glu	Lys	Arg	Leu	Val	Gly	Ile	Ala	Ser	Lys	Asp	Pro	Asn	Val		
1145							1150				1155					
aaa	atg	atg	gct	agc	aag	aag	gtt	gta	gaa	agg	gag	gat	act	gaa		3519
Lys	Met	Met	Ala	Ser	Lys	Lys	Val	Val	Glu	Arg	Glu	Asp	Thr	Glu		
1160							1165				1170					
cag	ggt	gat	gaa	gac	aat	gtc	ttt	gca	agg	caa	tga					3555
Gln	Gly	Asp	Glu	Asp	Asn	Val	Phe	Ala	Arg	Gln						
1175							1180									

<210> SEQ ID NO 20

<211> LENGTH: 1184

<212> TYPE: PRT

<213> ORGANISM: Cryptococcus neoformans

<400> SEQUENCE: 20

Met Ser Ser Pro Glu Pro Glu Glu Pro Arg Arg Gly Ala Arg Val Arg
1 5 10 15

Lys Gln Val Asn Lys Phe Asp Ala Ser Gln Gln Asn Gly Arg Gly Lys
20 25 30

Arg Lys His Ile Glu Asp Arg Glu Asp Asp Asp Gln Glu Gly Leu Ile
35 40 45

Pro Asp Pro Glu Asp Glu Ser Asp His Glu Pro Thr Pro Lys Lys Lys
50 55 60

Lys Pro Ala Ala Pro Arg Lys Ser Arg Ala Ser Ala Gly Thr Thr Lys
65 70 75 80

-continued

Lys	Asp	Gly	Pro	Lys	Thr	Lys	Thr	Lys	Pro	Ala	Ala	Glu	Gly	Val	Ser		
				85					90					95			
Glu	Ile	Val	Glu	Lys	Thr	Asp	Ser	Pro	Leu	Phe	Asn	Ala	Leu	Gln	Gln		
			100					105					110				
Pro	Asp	Ile	Ala	Leu	Gln	Pro	Leu	Ile	Asp	Glu	Trp	Ile	Glu	Thr	Tyr		
		115					120					125					
Gln	Gln	Ala	Ala	Gly	Asp	Glu	Ile	Ser	Glu	Gln	Lys	Ser	Ile	His	Glu		
		130				135					140						
Leu	Val	Val	Phe	Phe	Ile	Arg	Cys	Cys	Gly	Met	Thr	Thr	Glu	Ile	Glu		
145					150					155					160		
Gln	Ala	Glu	Ala	Thr	Asp	Asp	Asp	Gly	Ile	Pro	Asp	Val	Ile	Glu	Arg		
				165				170						175			
Val	Gln	Asp	Glu	Ser	Val	Arg	Val	Ala	Leu	Ala	Thr	Tyr	Pro	Leu	Ile		
		180						185					190				
Ser	Lys	Ala	Lys	Asn	Phe	Lys	Pro	Phe	Lys	Ser	Asn	Leu	Asn	Glu	Phe		
		195					200					205					
Ile	Ser	His	Phe	Ile	Ser	Ser	Leu	Ala	Leu	Thr	Pro	Ile	Leu	Phe	His		
	210					215					220						
Thr	Ala	Asp	Asn	Thr	Pro	His	Ser	Ser	Leu	Leu	Ile	Pro	Leu	Leu	Leu		
225					230					235				240			
Asn	Trp	Leu	Met	Cys	Met	Ser	Ser	Ser	Thr	Leu	Arg	Pro	Ile	Arg	His		
			245						250					255			
Thr	Ser	Thr	Tyr	Val	Thr	Leu	Arg	Met	Asn	Ser	Ala	Leu	Cys	Asp	Val		
		260						265					270				
Ala	Ala	Asp	Val	Ser	Lys	Asp	Leu	Ser	Val	Lys	Gln	Arg	Gln	Arg	Asp		
		275					280					285					
Ala	Glu	Val	Arg	Lys	Ala	Gly	Ala	Thr	Asn	Ala	Ala	Gln	Lys	Arg	Val		
	290					295					300						
Lys	Ala	Ala	Glu	Asp	Arg	Val	Lys	Glu	Val	Gln	Glu	Arg	Lys	Gln	Thr		
305					310					315				320			
Leu	Glu	Glu	Leu	Met	Gln	Glu	Ile	Phe	Asp	Val	Met	Phe	Val	His	Arg		
			325						330					335			
Val	Arg	Asp	Ala	Asp	Pro	Asn	Ile	Arg	Thr	Asp	Cys	Leu	Arg	Glu	Leu		
		340						345					350				
Gly	Leu	Trp	Ala	Lys	Lys	His	Pro	Glu	Tyr	Tyr	Val	Ser	Thr	Ser	Tyr		
	355					360						365					
Leu	Ser	Tyr	Phe	Thr	Arg	Gly	Cys	Asn	Asp	Thr	His	Ala	His	Ala	Arg		
	370					375					380						
Leu	Glu	Thr	Val	Lys	Ala	Leu	Ala	Asn	Leu	Tyr	Ile	Arg	Glu	Thr	Phe		
385					390					395				400			
Ile	Ser	Asn	Ala	Arg	Thr	Leu	Thr	Met	Arg	Leu	Ala	Pro	Arg	Val	Ile		
			405					410						415			
Glu	Met	Ala	Thr	Arg	Asp	Val	Asp	Leu	Asn	Val	Arg	Val	Val	Ala	Leu		
		420						425					430				
Gln	Val	Ile	Thr	Leu	Ile	Asp	Lys	Thr	Gly	Ile	Leu	Gln	Asp	Glu	Glu		
		435						440				445					
Asp	Glu	Glu	Arg	Asp	Lys	Val	Ala	Lys	Leu	Val	Phe	Asp	Gln	Glu	Pro		
	450					455					460						
Arg	Ile	Arg	Lys	Ala	Ala	Gly	Ala	Phe	Ile	Leu	Gly	Leu	Trp	Glu	Glu		
465					470					475					480		

-continued

Arg	Lys	Glu	Gly	Leu	Lys	Ala	Val	Trp	Ser	Gly	Leu	Arg	Ala	Asn	Lys	485	490	495
Lys	Lys	Arg	Ala	Ala	Asn	Ile	Thr	Glu	Asp	Glu	Met	Ser	Asn	Tyr	Leu	500	505	510
Asn	Trp	Lys	Ser	Leu	Ala	Ala	Val	Leu	Leu	Tyr	Thr	Ser	Lys	Ser	Leu	515	520	525
Asp	Asp	Asp	Pro	Ser	Gly	Gln	Pro	Ser	Ala	Leu	Lys	Pro	Ser	Leu	Leu	530	535	540
Ile	Pro	Ser	Leu	Pro	Asn	Thr	Gln	Met	Thr	Arg	Ala	Thr	Ala	Ala	Val	545	550	555
Glu	Ser	Ile	Gly	Ala	Glu	His	Glu	Leu	Trp	Lys	Asp	Trp	Glu	Ser	Leu	565	570	575
Val	Asp	Tyr	Leu	Leu	Val	Asp	His	Ser	Thr	Asn	Glu	Glu	Asp	Met	Trp	580	585	590
Leu	Leu	Arg	Glu	Asp	Glu	Glu	Thr	Phe	Met	Leu	Gln	Val	Leu	Leu	Ala	595	600	605
Cys	Ile	Lys	Arg	Glu	Glu	Asn	Glu	Glu	Asp	Glu	Pro	Asp	Arg	Thr	Lys	610	615	620
Thr	Leu	Ile	Lys	Val	Leu	Pro	Arg	Leu	Phe	Ala	Lys	His	Gln	Ala	Asp	625	630	635
Val	Gly	Arg	Met	Thr	Gly	Ile	Leu	Ser	Val	Pro	Gly	His	Met	Lys	Leu	645	650	655
Ser	Leu	Tyr	Leu	Asp	Met	Arg	Met	Ser	Ser	Ala	Tyr	Glu	Ser	Leu	Trp	660	665	670
Asp	Asp	Ile	Ser	Lys	Gln	Phe	Leu	Lys	Tyr	Thr	Ser	Pro	Thr	Ile	Leu	675	680	685
Thr	Ala	Ser	Ile	Ser	Ala	Ile	Ser	His	Leu	Val	Gly	Asn	Ser	Ser	Leu	690	695	700
Ser	Ser	Ile	Asn	Glu	Thr	Lys	Leu	Ser	Glu	Leu	His	Glu	Ser	Leu	Phe	705	710	715
Ala	Ser	Leu	Arg	Asp	Ala	Ile	Gly	Ser	Glu	Asp	Val	Ala	Leu	Val	Thr	725	730	735
Leu	Glu	Asp	Glu	Gln	Ile	Ser	Gln	Leu	Glu	Ala	Ile	Met	Leu	Arg	Ile	740	745	750
Thr	Leu	Leu	Gln	Arg	Ser	Met	Asp	Leu	Val	Asp	Val	Met	Glu	Asp	Glu	755	760	765
Glu	Gly	Gln	Gln	Ser	Ser	Gly	Trp	Asp	Ile	Ile	Cys	Ala	Phe	Ala	Asp	770	775	780
Arg	Gly	Lys	Leu	Gly	Tyr	Lys	Glu	Glu	Ala	Thr	Met	Val	Asp	Tyr	Ala	785	790	795
Val	Gln	Ile	Ile	Phe	Leu	His	Ile	Thr	Trp	Leu	Phe	Lys	Arg	Phe	Thr	805	810	815
Lys	Glu	Asp	Ala	Gln	Asp	Ala	Thr	Lys	Ile	Asp	Leu	Leu	Ser	Thr	Arg	820	825	830
Arg	Asp	Thr	Ala	Leu	Gln	Thr	Phe	Asn	Gln	Leu	Phe	Leu	Gly	Glu	Thr	835	840	845
Thr	Asn	Thr	Ala	Ser	Ala	Val	Arg	Arg	Gln	Ala	Phe	Ile	Ser	Phe	Ile	850	855	860
Asn	Thr	Tyr	Val	Leu	Phe	Ala	Lys	Arg	Ala	Glu	Gly	Arg	Gly	Gly	Ala	865	870	875
Pro	Ala	Ser	Asp	Val	Cys	Ser	Val	Thr	Met	Pro	Glu	Glu	Val	Gln	His			

-continued

885					890					895					
Arg	Leu	Gly	Gly	Ala	Phe	Gln	Ala	Val	Ile	Glu	Arg	Tyr	Ala	Ser	Val
		900					905					910			
Val	Glu	Thr	Arg	Ser	Ala	Gly	Arg	Glu	Glu	Ser	Gln	Gln	Pro	Pro	Glu
		915					920					925			
Leu	Thr	Pro	Asp	Glu	Met	His	Glu	Asp	Phe	Gln	Phe	Phe	Gln	Leu	Val
		930					935					940			
Ser	Val	Phe	Val	Gly	Ala	Ile	Arg	Cys	Gly	Val	Leu	Glu	Val	Glu	His
		945					950					955			960
Ala	Lys	Glu	Pro	Leu	Ala	His	Tyr	Ser	Arg	Phe	Gly	Pro	Thr	Tyr	Asp
			965					970						975	
Ala	Ile	Val	Lys	Lys	Leu	Val	Asp	Val	Leu	Arg	Asp	Glu	Gly	Ile	Tyr
			980					985						990	
Asn	Arg	Glu	Ala	Asp	Ala	Val	Gln	His	Val	Ala	Gly	Ser	Ala	Leu	Gln
		995					1000					1005			
Gln	Ser	Phe	Asn	Ile	Phe	Leu	Asp	Ser	Glu	Glu	Asp	Glu	Pro	Thr	
		1010					1015					1020			
Ala	Pro	Leu	Ala	Leu	Ala	Arg	Val	Ile	Ala	Thr	Ala	Phe	Val	Ile	
		1025					1030					1035			
His	Gly	Ser	Gln	Phe	Ala	Ile	Leu	Arg	Gln	Leu	His	Pro	Ser	Asp	
		1040					1045					1050			
Val	Cys	Asp	Phe	His	Leu	Glu	Ala	Leu	Asp	Phe	Val	Ser	Leu	Lys	
		1055					1060					1065			
Val	Ser	Thr	Ile	Val	Lys	Gln	Glu	Gly	Asn	Ala	Arg	Asn	Lys	Glu	
		1070					1075					1080			
Gln	Lys	Ser	Arg	Leu	Thr	Arg	Lys	Lys	Trp	Ala	Val	Leu	Thr	Phe	
		1085					1090					1095			
Phe	Lys	Val	Leu	Val	Pro	Leu	Leu	Ala	Pro	Val	Thr	Gly	Arg	Asp	
		1100					1105					1110			
Ala	Leu	Lys	Ile	Lys	Ala	His	Leu	Glu	Asp	Val	Ile	Asp	Ser	Ser	
		1115					1120					1125			
Gly	Val	Gln	Leu	Thr	Thr	Asn	Lys	Gly	Trp	Asp	Gly	Tyr	Arg	Ala	
		1130					1135					1140			
Tyr	Glu	Lys	Arg	Leu	Val	Gly	Ile	Ala	Ser	Lys	Asp	Pro	Asn	Val	
		1145					1150					1155			
Lys	Met	Met	Ala	Ser	Lys	Lys	Val	Val	Glu	Arg	Glu	Asp	Thr	Glu	
		1160					1165					1170			
Gln	Gly	Asp	Glu	Asp	Asn	Val	Phe	Ala	Arg	Gln					
		1175					1180								

<210> SEQ ID NO 21
 <211> LENGTH: 897
 <212> TYPE: DNA
 <213> ORGANISM: Cryptococcus neoformans
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1)..(897)

<400> SEQUENCE: 21

atg aag tac tct gct acc gca gtc gcc gtt atg ggt gcc ctc gcc att
 Met Lys Tyr Ser Ala Thr Ala Val Ala Val Met Gly Ala Leu Ala Ile
 1 5 10 15

48

caa gcc acc cca atc aag aga gat gct tac acc cca acc gac att gat
 Gln Ala Thr Pro Ile Lys Arg Asp Ala Tyr Thr Pro Thr Asp Ile Asp

96

-continued

20	25	30	
atc cta cag tat gcg ttg act ctc gag cac ctg gag aac aac ttc tac			144
Ile Leu Gln Tyr Ala Leu Thr Leu Glu His Leu Glu Asn Asn Phe Tyr			
35	40	45	
tcc tgc gcc ctc aac aac atg gac gct caa gcg ttc gcc gat gcc gga			192
Ser Cys Ala Leu Asn Asn Met Asp Ala Gln Ala Phe Ala Asp Ala Gly			
50	55	60	
ttc cca gcc tgg gta cgg aac agg ttt gag cag att gcc gct cac gag			240
Phe Pro Ala Trp Val Arg Asn Arg Phe Glu Gln Ile Ala Ala His Glu			
65	70	75	80
gcc tcc cac gtc gcc gtt ctc tcc gat gcc ctc ggc gct gac gcc acc			288
Ala Ser His Val Ala Val Leu Ser Asp Ala Leu Gly Ala Asp Ala Thr			
85	90	95	
aag cca tgc gag tac tcc ttc cca tac acc gac gcc aaa tcg ttc acc			336
Lys Pro Cys Glu Tyr Ser Phe Pro Tyr Thr Asp Ala Lys Ser Phe Thr			
100	105	110	
gct ctc gct cag gtc att gag aat gtt ggt gtt tct gct tac ctc ggt			384
Ala Leu Ala Gln Val Ile Glu Asn Val Gly Val Ser Ala Tyr Leu Gly			
115	120	125	
gcc gcc ggt ttc atc atg gac aag acc tac ttg acc gtt gct ggt tcc			432
Ala Ala Gly Phe Ile Met Asp Lys Thr Tyr Leu Thr Val Ala Gly Ser			
130	135	140	
att ctc acc acc gag gcc cgc cac cag gcc tgg atc gct tcc gcc gtt			480
Ile Leu Thr Thr Glu Ala Arg His Gln Ala Trp Ile Ala Ser Ala Val			
145	150	155	160
aac aag cag aac cca tgg tcc ggc cca tac gac act cct ctc ggt ctc			528
Asn Lys Gln Asn Pro Trp Ser Gly Pro Tyr Asp Thr Pro Leu Gly Leu			
165	170	175	
tcc gat gtc tac tcc att gcc gct gcc ttc atc acc agc tgt cca tcc			576
Ser Asp Val Tyr Ser Ile Ala Ala Phe Ile Thr Ser Cys Pro Ser			
180	185	190	
tcc aac cca act ctc cca gtc aag gca ttc cca gct ctc act ctc tct			624
Ser Asn Pro Thr Leu Pro Val Lys Ala Phe Pro Ala Leu Thr Leu Ser			
195	200	205	
tgc gac tcc gcc ggt tcg act gcc acc ctc aac tat acc ggc gct gat			672
Cys Asp Ser Ala Gly Ser Thr Ala Thr Leu Asn Tyr Thr Gly Ala Asp			
210	215	220	
tca tcc gac acc ctt att ctc tac tct ggc ctc acg acc ctc gct ctc			720
Ser Ser Asp Thr Leu Ile Leu Tyr Ser Gly Leu Thr Thr Leu Ala Leu			
225	230	235	240
ccc atc acc gac atg atg gtc acc atc cca tcc tct ctt cag ggc att			768
Pro Ile Thr Asp Met Met Val Thr Ile Pro Ser Ser Leu Gln Gly Ile			
245	250	255	
gct tac gca gtc gtg tct tca acg tct aac acc acc atg gtt gac gac			816
Ala Tyr Ala Val Val Ser Ser Thr Ser Asn Thr Thr Met Val Asp Asp			
260	265	270	
tct aac acc att gcc ggc cca gcc atc att gac ctt cct ttc gct tct			864
Ser Asn Thr Ile Ala Gly Pro Ala Ile Ile Asp Leu Pro Phe Ala Ser			
275	280	285	
tcc gcc agc aac ccc aac ttc act ggt atg taa			897
Ser Ala Ser Asn Pro Asn Phe Thr Gly Met			
290	295		

<210> SEQ ID NO 22

<211> LENGTH: 298

<212> TYPE: PRT

<213> ORGANISM: Cryptococcus neoformans

-continued

<400> SEQUENCE: 22

```

Met Lys Tyr Ser Ala Thr Ala Val Ala Val Met Gly Ala Leu Ala Ile
1      5      10      15
Gln Ala Thr Pro Ile Lys Arg Asp Ala Tyr Thr Pro Thr Asp Ile Asp
20      25      30
Ile Leu Gln Tyr Ala Leu Thr Leu Glu His Leu Glu Asn Asn Phe Tyr
35      40      45
Ser Cys Ala Leu Asn Asn Met Asp Ala Gln Ala Phe Ala Asp Ala Gly
50      55      60
Phe Pro Ala Trp Val Arg Asn Arg Phe Glu Gln Ile Ala Ala His Glu
65      70      75      80
Ala Ser His Val Ala Val Leu Ser Asp Ala Leu Gly Ala Asp Ala Thr
85      90      95
Lys Pro Cys Glu Tyr Ser Phe Pro Tyr Thr Asp Ala Lys Ser Phe Thr
100     105     110
Ala Leu Ala Gln Val Ile Glu Asn Val Gly Val Ser Ala Tyr Leu Gly
115     120     125
Ala Ala Gly Phe Ile Met Asp Lys Thr Tyr Leu Thr Val Ala Gly Ser
130     135     140
Ile Leu Thr Thr Glu Ala Arg His Gln Ala Trp Ile Ala Ser Ala Val
145     150     155     160
Asn Lys Gln Asn Pro Trp Ser Gly Pro Tyr Asp Thr Pro Leu Gly Leu
165     170     175
Ser Asp Val Tyr Ser Ile Ala Ala Ala Phe Ile Thr Ser Cys Pro Ser
180     185     190
Ser Asn Pro Thr Leu Pro Val Lys Ala Phe Pro Ala Leu Thr Leu Ser
195     200     205
Cys Asp Ser Ala Gly Ser Thr Ala Thr Leu Asn Tyr Thr Gly Ala Asp
210     215     220
Ser Ser Asp Thr Leu Ile Leu Tyr Ser Gly Leu Thr Thr Leu Ala Leu
225     230     235     240
Pro Ile Thr Asp Met Met Val Thr Ile Pro Ser Ser Leu Gln Gly Ile
245     250     255
Ala Tyr Ala Val Val Ser Ser Thr Ser Asn Thr Thr Met Val Asp Asp
260     265     270
Ser Asn Thr Ile Ala Gly Pro Ala Ile Ile Asp Leu Pro Phe Ala Ser
275     280     285
Ser Ala Ser Asn Pro Asn Phe Thr Gly Met
290     295

```

<210> SEQ ID NO 23

<211> LENGTH: 534

<212> TYPE: DNA

<213> ORGANISM: *Cryptococcus neoformans*

<220> FEATURE:

<221> NAME/KEY: CDS

<222> LOCATION: (1)..(534)

<400> SEQUENCE: 23

```

atg tct cta act agt gtc act cgc gtc gta tcc aaa tcc atc ctc ggc      48
Met Ser Leu Thr Ser Val Thr Arg Val Val Ser Lys Ser Ile Leu Gly
1      5      10      15
gct tcc ttt act agc aca act cgc agg ctt acc act acc gtt ccc aga      96
Ala Ser Phe Thr Ser Thr Thr Arg Arg Leu Thr Thr Thr Val Pro Arg

```

-continued

20	25	30	
ttt ggt aga atg cct cct cct gct cac aag atg gcc cac ttc ccg agg			144
Phe Gly Arg Met Pro Pro Pro Ala His Lys Met Ala His Phe Pro Arg			
35	40	45	
atc aca tcc tct ctt ccc tca gaa cac tct gag ttt aga aca gtg atg			192
Ile Thr Ser Ser Leu Pro Ser Glu His Ser Glu Phe Arg Thr Val Met			
50	55	60	
tgg acg ggc gag agc agt caa ctt gtc ctc atg act atc cct gtc gga			240
Trp Thr Gly Glu Ser Ser Gln Leu Val Leu Met Thr Ile Pro Val Gly			
65	70	75	80
gga gaa ata ggg gaa gaa att cac cat gtt gac caa cac ttg gtt ttc			288
Gly Glu Ile Gly Glu Glu Ile His His Val Asp Gln His Leu Val Phe			
85	90	95	
acc tct ggt act gcc aag gcc att gtt gga gga gaa gaa aaa gag atc			336
Thr Ser Gly Thr Ala Lys Ala Ile Val Gly Gly Glu Glu Lys Glu Ile			
100	105	110	
aag gct gga gat ctt gtc atc gtt cct cag ggt acc aag cat aac ttc			384
Lys Ala Gly Asp Leu Val Ile Val Pro Gln Gly Thr Lys His Asn Phe			
115	120	125	
gtc aat acg ggc cct acc cct ctt tgc ctt ttt act gta tat gct ccg			432
Val Asn Thr Gly Pro Thr Pro Leu Cys Leu Phe Thr Val Tyr Ala Pro			
130	135	140	
gcc gag cat gcc gag aca aca gtc aac aaa acg aag gag gaa ggg gat			480
Ala Glu His Ala Glu Thr Thr Val Asn Lys Thr Lys Glu Glu Gly Asp			
145	150	155	160
aaa ttg gaa gac gag ggc aag gat gag cct cca aag tgg gca gtt agg			528
Lys Leu Glu Asp Glu Gly Lys Asp Glu Pro Pro Lys Trp Ala Val Arg			
165	170	175	
aag tag			534
Lys			
<210> SEQ ID NO 24			
<211> LENGTH: 177			
<212> TYPE: PRT			
<213> ORGANISM: Cryptococcus neoformans			
<400> SEQUENCE: 24			
Met Ser Leu Thr Ser Val Thr Arg Val Val Ser Lys Ser Ile Leu Gly			
1	5	10	15
Ala Ser Phe Thr Ser Thr Thr Arg Arg Leu Thr Thr Thr Val Pro Arg			
20	25	30	
Phe Gly Arg Met Pro Pro Pro Ala His Lys Met Ala His Phe Pro Arg			
35	40	45	
Ile Thr Ser Ser Leu Pro Ser Glu His Ser Glu Phe Arg Thr Val Met			
50	55	60	
Trp Thr Gly Glu Ser Ser Gln Leu Val Leu Met Thr Ile Pro Val Gly			
65	70	75	80
Gly Glu Ile Gly Glu Glu Ile His His Val Asp Gln His Leu Val Phe			
85	90	95	
Thr Ser Gly Thr Ala Lys Ala Ile Val Gly Gly Glu Glu Lys Glu Ile			
100	105	110	
Lys Ala Gly Asp Leu Val Ile Val Pro Gln Gly Thr Lys His Asn Phe			
115	120	125	
Val Asn Thr Gly Pro Thr Pro Leu Cys Leu Phe Thr Val Tyr Ala Pro			
130	135	140	
Ala Glu His Ala Glu Thr Thr Val Asn Lys Thr Lys Glu Glu Gly Asp			

-continued

145	150	155	160	
Lys Leu Glu Asp	Glu Gly Lys Asp Glu	Pro Pro Lys Trp Ala	Val Arg	
	165	170	175	
Lys				
<210> SEQ ID NO 25				
<211> LENGTH: 1074				
<212> TYPE: DNA				
<213> ORGANISM: <i>Cryptococcus neoformans</i>				
<220> FEATURE:				
<221> NAME/KEY: CDS				
<222> LOCATION: (1)..(1074)				
<400> SEQUENCE: 25				
atg cca act gta ctc ctc aca ggt atc acg gga ttt ctg tct gcg cac				48
Met Pro Thr Val Leu Leu Thr Gly Ile Thr Gly Phe Leu Ser Ala His				
1	5	10	15	
gtc gcc cat acc ttc ctg aag cat gac tgg ata gtg cac ggc aca ctt				96
Val Ala His Thr Phe Leu Lys His Asp Trp Ile Val His Gly Thr Leu				
	20	25	30	
cgg tcc agc tcg aag gta gcg tta atc gaa gtt att cct gaa tac tct				144
Arg Ser Ser Ser Lys Val Ala Leu Ile Glu Val Ile Pro Glu Tyr Ser				
	35	40	45	
cct tat att tcg tca ggc aaa cta aaa ctc ttc gtt gtc gga cct ctt				192
Pro Tyr Ile Ser Ser Gly Lys Leu Lys Leu Phe Val Val Gly Pro Leu				
	50	55	60	
gag aat gcc gat tac act gaa gcc atg aaa ggc gtt gat gct gtg gtc				240
Glu Asn Ala Asp Tyr Thr Glu Ala Met Lys Gly Val Asp Ala Val Val				
65	70	75	80	
cac act gcg tct ccg gta gag ttt ggt gga gac aat ttt aga gag agc				288
His Thr Ala Ser Pro Val Glu Phe Gly Gly Asp Asn Phe Arg Glu Ser				
	85	90	95	
cat ttg aaa cct gct ttg gaa gga aca agg ggt gtc ctc aga gct gta				336
His Leu Lys Pro Ala Leu Glu Gly Thr Arg Gly Val Leu Arg Ala Val				
	100	105	110	
gcc aaa gag aag aat gta aag tcc gtc gtc tac act agt act ttt gga				384
Ala Lys Glu Lys Asn Val Lys Ser Val Val Tyr Thr Ser Thr Phe Gly				
	115	120	125	
gcc gtt ggt gat cat agg tat cat ccc act gag atc aaa ggc aaa gtt				432
Ala Val Gly Asp His Arg Tyr His Pro Thr Glu Ile Lys Gly Lys Val				
	130	135	140	
atc act gag gat aac tgg aac ccg tat acc ttg gaa gag ctg gat aag				480
Ile Thr Glu Asp Asn Trp Asn Pro Tyr Thr Leu Glu Glu Leu Asp Lys				
145	150	155	160	
atg gtg gaa tct gga gag tca ggc aac ccc aca ttt cct cca gga tat				528
Met Val Glu Ser Gly Glu Ser Gly Asn Pro Thr Phe Pro Pro Gly Tyr				
	165	170	175	
ctg ttc tat aaa gga gcc aag aag tac gcg gaa ctc gct gct tgg gaa				576
Leu Phe Tyr Lys Gly Ala Lys Lys Tyr Ala Glu Leu Ala Ala Trp Glu				
	180	185	190	
tgc cag aaa gaa gcg aga gaa cag ggt gct gaa tgg tct ttg gcc acg				624
Cys Gln Lys Glu Ala Arg Glu Gln Gly Ala Glu Trp Ser Leu Ala Thr				
	195	200	205	
atg aac tgt gtg atg atc tgg ggg cct cca att caa cct ctc aca tca				672
Met Asn Cys Val Met Ile Trp Gly Pro Pro Ile Gln Pro Leu Thr Ser				
	210	215	220	
ctc agt cat ggg gcc atg tcg acc gag ttc ctt tgg atg ctt gca gga				720
Leu Ser His Gly Gly Met Ser Thr Glu Phe Leu Trp Met Leu Ala Gly				

-continued

225	230	235	240	
ggg aaa gat gcc cat atc atg gac agt ctc tat ccc tat tac gtc gat				768
Gly Lys Asp Ala His Ile Met Asp Ser Leu Tyr Pro Tyr Tyr Val Asp				
	245	250	255	
gtt cgg gat gct gct gaa gca cac tat caa gcc acc gtc cgt aga gcg				816
Val Arg Asp Ala Ala Glu Ala His Tyr Gln Ala Thr Val Arg Arg Ala				
	260	265	270	
caa gga agg ttt atc atc tct gcc ggc cct tat gat ttc caa gag ttc				864
Gln Gly Arg Phe Ile Ile Ser Ala Gly Pro Tyr Asp Phe Gln Glu Phe				
	275	280	285	
gca gac atg ctt agg gag ctt tat cct gag caa aaa gaa cga ttc gcc				912
Ala Asp Met Leu Arg Glu Leu Tyr Pro Glu Gln Lys Glu Arg Phe Ala				
	290	295	300	
ctt ggt gct ccc gcc aaa tat atg tac aga gat cca gga gtg tac gtg				960
Leu Gly Ala Pro Gly Lys Tyr Met Tyr Arg Asp Pro Gly Val Tyr Val				
	305	310	315	320
ctc aca aat gaa aag agt caa agg gaa ctt ggt att act tac cgt cca				1008
Leu Thr Asn Glu Lys Ser Gln Arg Glu Leu Gly Ile Thr Tyr Arg Pro				
	325	330	335	
aaa caa gag act ctc aaa gat gca ttt gac agg ttt ttc gct ttg gag				1056
Lys Gln Glu Thr Leu Lys Asp Ala Phe Asp Arg Phe Phe Ala Leu Glu				
	340	345	350	
aaa caa gga ttg aag taa				1074
Lys Gln Gly Leu Lys				
	355			

<210> SEQ ID NO 26

<211> LENGTH: 357

<212> TYPE: PRT

<213> ORGANISM: Cryptococcus neoformans

<400> SEQUENCE: 26

Met Pro Thr Val Leu Leu Thr Gly Ile Thr Gly Phe Leu Ser Ala His
1 5 10 15

Val Ala His Thr Phe Leu Lys His Asp Trp Ile Val His Gly Thr Leu
20 25 30

Arg Ser Ser Ser Lys Val Ala Leu Ile Glu Val Ile Pro Glu Tyr Ser
35 40 45

Pro Tyr Ile Ser Ser Gly Lys Leu Lys Leu Phe Val Val Gly Pro Leu
50 55 60

Glu Asn Ala Asp Tyr Thr Glu Ala Met Lys Gly Val Asp Ala Val Val
65 70 75 80

His Thr Ala Ser Pro Val Glu Phe Gly Gly Asp Asn Phe Arg Glu Ser
85 90 95

His Leu Lys Pro Ala Leu Glu Gly Thr Arg Gly Val Leu Arg Ala Val
100 105 110

Ala Lys Glu Lys Asn Val Lys Ser Val Val Tyr Thr Ser Thr Phe Gly
115 120 125

Ala Val Gly Asp His Arg Tyr His Pro Thr Glu Ile Lys Gly Lys Val
130 135 140

Ile Thr Glu Asp Asn Trp Asn Pro Tyr Thr Leu Glu Glu Leu Asp Lys
145 150 155 160

Met Val Glu Ser Gly Glu Ser Gly Asn Pro Thr Phe Pro Pro Gly Tyr
165 170 175

Leu Phe Tyr Lys Gly Ala Lys Lys Tyr Ala Glu Leu Ala Ala Trp Glu

-continued

180						185						190					
Cys	Gln	Lys	Glu	Ala	Arg	Glu	Gln	Gly	Ala	Glu	Trp	Ser	Leu	Ala	Thr		
195						200						205					
Met	Asn	Cys	Val	Met	Ile	Trp	Gly	Pro	Pro	Ile	Gln	Pro	Leu	Thr	Ser		
210						215						220					
Leu	Ser	His	Gly	Gly	Met	Ser	Thr	Glu	Phe	Leu	Trp	Met	Leu	Ala	Gly		
225			230						235			240					
Gly	Lys	Asp	Ala	His	Ile	Met	Asp	Ser	Leu	Tyr	Pro	Tyr	Tyr	Val	Asp		
			245						250			255					
Val	Arg	Asp	Ala	Ala	Glu	Ala	His	Tyr	Gln	Ala	Thr	Val	Arg	Arg	Ala		
			260			265						270					
Gln	Gly	Arg	Phe	Ile	Ile	Ser	Ala	Gly	Pro	Tyr	Asp	Phe	Gln	Glu	Phe		
			275			280						285					
Ala	Asp	Met	Leu	Arg	Glu	Leu	Tyr	Pro	Glu	Gln	Lys	Glu	Arg	Phe	Ala		
290						295						300					
Leu	Gly	Ala	Pro	Gly	Lys	Tyr	Met	Tyr	Arg	Asp	Pro	Gly	Val	Tyr	Val		
305			310						315			320					
Leu	Thr	Asn	Glu	Lys	Ser	Gln	Arg	Glu	Leu	Gly	Ile	Thr	Tyr	Arg	Pro		
			325						330			335					
Lys	Gln	Glu	Thr	Leu	Lys	Asp	Ala	Phe	Asp	Arg	Phe	Phe	Ala	Leu	Glu		
			340			345						350					
Lys	Gln	Gly	Leu	Lys													
355																	
<210> SEQ ID NO 27																	
<211> LENGTH: 2781																	
<212> TYPE: DNA																	
<213> ORGANISM: Cryptococcus neoformans																	
<220> FEATURE:																	
<221> NAME/KEY: CDS																	
<222> LOCATION: (1)..(2781)																	
<400> SEQUENCE: 27																	
atg	ttt	agg	aag	aga	att	ctt	tat	ctt	tct	tct	ttt	tca	atc	cct	ttg	48	
Met	Phe	Arg	Lys	Arg	Ile	Leu	Tyr	Leu	Ser	Ser	Phe	Ser	Ile	Pro	Leu		
1				5				10				15					
tac	aca	gtc	cca	gcc	cac	agt	tat	tcc	tgt	act	ttt	cag	acc	aac	cag	96	
Tyr	Thr	Val	Pro	Ala	His	Ser	Tyr	Ser	Cys	Thr	Phe	Gln	Thr	Asn	Gln		
			20						25			30					
cgc	cct	tct	act	ctc	ctc	aaa	cgc	gta	cat	tcg	ctc	gct	atg	tcc	ttc	144	
Arg	Pro	Ser	Thr	Leu	Leu	Lys	Arg	Val	His	Ser	Leu	Ala	Met	Ser	Phe		
			35			40						45					
ccg	cca	gtg	cag	ccc	gcc	gac	aat	ggc	atg	gcg	gtc	gtt	gct	ccc	aat	192	
Pro	Pro	Val	Gln	Pro	Ala	Asp	Asn	Gly	Met	Ala	Val	Val	Ala	Pro	Asn		
50						55			60								
ctc	gag	tct	aac	cct	acc	act	gtt	gcg	tcc	cac	gcc	cca	caa	att	gcc	240	
Leu	Glu	Ser	Asn	Pro	Thr	Thr	Val	Ala	Ser	His	Ala	Pro	Gln	Ile	Ala		
65			70						75			80					
gtc	aag	gat	gaa	aat	gat	agt	atg	agc	gag	gat	gag	cag	cct	ttg	gcg	288	
Val	Lys	Asp	Glu	Asn	Asp	Ser	Met	Ser	Glu	Asp	Glu	Gln	Pro	Leu	Ala		
			85			90						95					
aaa	agc	aaa	gcg	aat	gga	gcg	agg	aag	aga	gtc	gaa	aac	agc	agt	gac	336	
Lys	Ser	Lys	Ala	Asn	Gly	Ala	Arg	Lys	Arg	Val	Glu	Asn	Gly	Ser	Asp		
			100			105						110					
gag	gaa	gag	aaa	cct	ctc	agc	aaa	aag	ccc	aga	gcc	aat	ggg	gtc	aac	384	
Glu	Glu	Glu	Lys	Pro	Leu	Ser	Lys	Lys	Pro	Arg	Ala	Asn	Gly	Val	Asn		

-continued

115	120	125	
aag aaa agg gtc gtc gcc agc agt gat gaa gaa agc gat gtt tca cct			432
Lys Lys Arg Val Val Ala Ser Ser Asp Glu Glu Ser Asp Val Ser Pro			
130	135	140	
cct gct aag agg cct gtt tcc aag caa tcc aaa cct gcc acc ccc gat			480
Pro Ala Lys Arg Pro Val Ser Lys Gln Ser Lys Pro Ala Thr Pro Asp			
145	150	155	160
tct gaa tct gat gac gat caa cct ctc gcc aag aag gct aac gga ctg			528
Ser Glu Ser Asp Asp Asp Gln Pro Leu Ala Lys Lys Ala Asn Gly Leu			
165	170	175	
gcc gca tcc aaa cgt cag gct aaa aaa gcg gag gaa tta tca gaa gaa			576
Ala Ala Ser Lys Arg Gln Ala Lys Lys Ala Glu Glu Leu Ser Glu Glu			
180	185	190	
agc tcg gag gaa gaa aag cct ctt gcg aag gtt gcc aag agg gta tca			624
Ser Ser Glu Glu Glu Lys Pro Leu Ala Lys Val Ala Lys Arg Val Ser			
195	200	205	
gca aag aag atg aag agc gag act gag gac tct gag gaa gac cgg cct			672
Ala Lys Lys Met Lys Ser Glu Thr Glu Asp Ser Glu Glu Asp Arg Pro			
210	215	220	
ctt gca aag aag aag gct cct gtt aag cgt gct cca gca aag aaa tcg			720
Leu Ala Lys Lys Lys Ala Pro Val Lys Arg Ala Pro Ala Lys Lys Ser			
225	230	235	240
gcg aag aag gaa cct agt gag agt gaa gag gat gag aag cct tta gcg			768
Ala Lys Lys Glu Pro Ser Glu Ser Glu Glu Asp Glu Lys Pro Leu Ala			
245	250	255	
aag aac gct aga ggg aag gcc aag gcg gcg acg gtg aag gaa gag aaa			816
Lys Asn Ala Arg Gly Lys Ala Lys Ala Ala Thr Val Lys Glu Glu Lys			
260	265	270	
ggt aag aag aca aag aag gag aaa gaa gag gaa gaa gag gag gaa agg			864
Gly Lys Lys Thr Lys Lys Glu Lys Glu Glu Glu Glu Glu Glu Arg			
275	280	285	
tac aag tgg tgg gaa cag gat gct ttg ggt gat ggg tca tcc aag tgg			912
Tyr Lys Trp Trp Glu Gln Asp Ala Leu Gly Asp Gly Ser Ser Lys Trp			
290	295	300	
acg gtc ctt gag cac aac gct gtt ctc ttc cct cct cct tat gtt cct			960
Thr Val Leu Glu His Asn Ala Val Leu Phe Pro Pro Pro Tyr Val Pro			
305	310	315	320
tta ccc aag aac gtg aaa atg aag tac gat ggc gtc tca ctt acc ctc			1008
Leu Pro Lys Asn Val Lys Met Lys Tyr Asp Gly Val Ser Leu Thr Leu			
325	330	335	
cct ccc gag tct gaa gaa gtc gcc ggt ttc ttc ggt gcc ctc ctt gaa			1056
Pro Pro Glu Ser Glu Glu Val Ala Gly Phe Phe Gly Ala Leu Leu Glu			
340	345	350	
acc gac tat gct caa gat gcc aaa ttc cgt gaa aac ttt ttc cga gac			1104
Thr Asp Tyr Ala Gln Asp Ala Lys Phe Arg Glu Asn Phe Phe Arg Asp			
355	360	365	
ttt aag gct atc gtc gaa aaa tat cca ccc aag gag gac gtc aag gtt			1152
Phe Lys Ala Ile Val Glu Lys Tyr Pro Pro Lys Glu Asp Val Lys Val			
370	375	380	
aag aag ttg gaa aag tgc gat ttt aga ccg atg ttt gag tac ttt gaa			1200
Lys Lys Leu Glu Lys Cys Asp Phe Arg Pro Met Phe Glu Tyr Phe Glu			
385	390	395	400
aag gag aag gag aag aag aag gcg ttg act aag gaa gag aaa aag gcg			1248
Lys Glu Lys Glu Lys Lys Lys Ala Leu Thr Lys Glu Glu Lys Lys Ala			
405	410	415	
att aaa gcg gag aag gac aag ctt gaa gca ccg tat ctc tat gcg aat			1296
Ile Lys Ala Glu Lys Asp Lys Leu Glu Ala Pro Tyr Leu Tyr Ala Asn			

-continued

420	425	430	
gtt gat gga agg aag gaa aag gtc ggc aac ttc cgt gca gaa cct cct			1344
Val Asp Gly Arg Lys Glu Lys Val Gly Asn Phe Arg Ala Glu Pro Pro			
435	440	445	
gga ttg ttc aag ggt cgt ggt gaa cat ccc aag aag ggt act gtc aag			1392
Gly Leu Phe Lys Gly Arg Gly Glu His Pro Lys Lys Gly Thr Val Lys			
450	455	460	
aac cgt ctc cga cct gaa gat atc att atc aac att ggc aaa gaa gct			1440
Asn Arg Leu Arg Pro Glu Asp Ile Ile Ile Asn Ile Gly Lys Glu Ala			
465	470	475	480
cct atc cct gtg ccc aac att ccc ggt cag tgg aag ggt atc cag cat			1488
Pro Ile Pro Val Pro Asn Ile Pro Gly Gln Trp Lys Gly Ile Gln His			
485	490	495	
gat aac aca gtg act tgg ctc gct cat tgg aag gag aat gtc aac ggt			1536
Asp Asn Thr Val Thr Trp Leu Ala His Trp Lys Glu Asn Val Asn Gly			
500	505	510	
aac gcc aaa tac gtc ttc ttg agc gct ggt agt gcg tgg aaa ggt caa			1584
Asn Ala Lys Tyr Val Phe Leu Ser Ala Gly Ser Ala Trp Lys Gly Gln			
515	520	525	
agt gat cgt gcc aag ttt gaa aag gcc cgt gag ctt atc aaa cat gtc			1632
Ser Asp Arg Ala Lys Phe Glu Lys Ala Arg Glu Leu Ile Lys His Val			
530	535	540	
gac aaa att cga aaa gac tac act gcc gac ctc aaa tcc aaa gtc atg			1680
Asp Lys Ile Arg Lys Asp Tyr Thr Ala Asp Leu Lys Ser Lys Val Met			
545	550	555	560
gct gac cga caa cgt gcc acc gcc ctg tac ttt atc gat cgt ctg gct			1728
Ala Asp Arg Gln Arg Ala Thr Ala Leu Tyr Phe Ile Asp Arg Leu Ala			
565	570	575	
ctg cga gcg ggt aat gaa aag ggt gaa gat gaa gcg gat act gtc ggc			1776
Leu Arg Ala Gly Asn Glu Lys Gly Glu Asp Glu Ala Asp Thr Val Gly			
580	585	590	
tgt tgt tct ctg cga tac gaa cac gtg acg ctc tct cca ccg aat act			1824
Cys Cys Ser Leu Arg Tyr Glu His Val Thr Leu Ser Pro Pro Asn Thr			
595	600	605	
atc atc ttt gat ttc ctc ggt aag gac tcg atg agg ttc cat cag gaa			1872
Ile Ile Phe Asp Phe Leu Gly Lys Asp Ser Met Arg Phe His Gln Glu			
610	615	620	
gtc gag gtc gat ccg caa gtg ttc aag aac ata aaa ctg ttt aag gct			1920
Val Glu Val Asp Pro Gln Val Phe Lys Asn Ile Lys Leu Phe Lys Ala			
625	630	635	640
gat ccg aag aag aag ggt gac gat atc ttt gac cga ctg acc acc act			1968
Asp Pro Lys Lys Lys Gly Asp Asp Ile Phe Asp Arg Leu Thr Thr Thr			
645	650	655	
ctt ctt aac aag cac ctc aac agc atg atg cct ggt ctt acc gcc aag			2016
Leu Leu Asn Lys His Leu Asn Ser Met Met Pro Gly Leu Thr Ala Lys			
660	665	670	
gtt ttc cgt acc tac aac gcc tca tgg act ttc caa gaa caa ctc aaa			2064
Val Phe Arg Thr Tyr Asn Ala Ser Trp Thr Phe Gln Glu Gln Leu Lys			
675	680	685	
aac aca cct aag aac gga act gta gcc gag aag att gcg gcg tac aac			2112
Asn Thr Pro Lys Asn Gly Thr Val Ala Glu Lys Ile Ala Ala Tyr Asn			
690	695	700	
act gcc aat agg gat gtt gcc atc ttg tgt aat cac caa aag agt gtc			2160
Thr Ala Asn Arg Asp Val Ala Ile Leu Cys Asn His Gln Lys Ser Val			
705	710	715	720
agc aag ggt ttt gag gcc agt ttt gcc aaa gcc gag gat aag att cgt			2208
Ser Lys Gly Phe Glu Gly Ser Phe Ala Lys Ala Glu Asp Lys Ile Arg			

-continued

725	730	735	
gcc ctc aag tat cag cgt ctc aag ctt cgt ctc caa ctt ttt tct ctt Ala Leu Lys Tyr Gln Arg Leu Lys Leu Arg Leu Gln Leu Phe Ser Leu 740 745 750			2256
aac ccc aag att aag aag aag cat ccc gag ctt gcg gag gat gag tct Asn Pro Lys Ile Lys Lys Lys His Pro Glu Leu Ala Glu Asp Glu Ser 755 760 765			2304
gat gtg gat gac gaa ttt atg gag cgc cac gaa gcc gaa tta ctc gaa Asp Val Asp Asp Glu Phe Met Glu Arg His Glu Ala Glu Leu Leu Glu 770 775 780			2352
aaa gct ttg gag aac gca aag aag aaa tgg gat acg gat aat gtc aag Lys Ala Leu Glu Asn Ala Lys Lys Lys Trp Asp Thr Asp Asn Val Lys 785 790 795 800			2400
ctt gaa ggg gat ggg aag aaa aag aag acg aag gga gag ttg gat gag Leu Glu Gly Asp Gly Lys Lys Lys Lys Thr Lys Gly Glu Leu Asp Glu 805 810 815			2448
agg ttg agt gag atc aag gca gag ttt aag gag ttg aag aag gag agg Arg Leu Ser Glu Ile Lys Ala Glu Phe Lys Lys Glu Leu Lys Lys Glu Arg 820 825 830			2496
aag gct aaa aag att gat gcc aag aga gga gcc acg gag gag aaa ctt Lys Ala Lys Lys Ile Asp Ala Lys Arg Gly Ala Thr Glu Glu Lys Leu 835 840 845			2544
ctt gct cag gtc gcc agg atc gac gaa cgt atc gct acc gcc aaa gtc Leu Ala Gln Val Ala Arg Ile Asp Glu Arg Ile Ala Thr Ala Lys Val 850 855 860			2592
cag ctt caa gat cga gac aag ctc aag gat gtt gct ttg ggc aca tcc Gln Leu Gln Asp Arg Asp Lys Leu Lys Asp Val Ala Leu Gly Thr Ser 865 870 875 880			2640
aag att aac tat atc gat cca aga cta act gtc gcg tgg gcg aag aag Lys Ile Asn Tyr Ile Asp Pro Arg Leu Thr Val Ala Trp Ala Lys Lys 885 890 895			2688
ttt gat gtt cct ctc gaa aaa ctg ttc tcc aaa acc ctg cga gaa aag Phe Asp Val Pro Leu Glu Lys Leu Phe Ser Lys Thr Leu Arg Glu Lys 900 905 910			2736
ttc cct tgg gct gag gcg gag gct gga ccg gac tgg gtt ttc tag Phe Pro Trp Ala Glu Ala Glu Ala Gly Pro Asp Trp Val Phe 915 920 925			2781
<210> SEQ ID NO 28			
<211> LENGTH: 926			
<212> TYPE: PRT			
<213> ORGANISM: <i>Cryptococcus neoformans</i>			
<400> SEQUENCE: 28			
Met Phe Arg Lys Arg Ile Leu Tyr Leu Ser Ser Phe Ser Ile Pro Leu 1 5 10 15			
Tyr Thr Val Pro Ala His Ser Tyr Ser Cys Thr Phe Gln Thr Asn Gln 20 25 30			
Arg Pro Ser Thr Leu Leu Lys Arg Val His Ser Leu Ala Met Ser Phe 35 40 45			
Pro Pro Val Gln Pro Ala Asp Asn Gly Met Ala Val Val Ala Pro Asn 50 55 60			
Leu Glu Ser Asn Pro Thr Thr Val Ala Ser His Ala Pro Gln Ile Ala 65 70 75 80			
Val Lys Asp Glu Asn Asp Ser Met Ser Glu Asp Glu Gln Pro Leu Ala 85 90 95			

-continued

Lys	Ser	Lys	Ala	Asn	Gly	Ala	Arg	Lys	Arg	Val	Glu	Asn	Ser	Ser	Asp
			100					105					110		
Glu	Glu	Glu	Lys	Pro	Leu	Ser	Lys	Lys	Pro	Arg	Ala	Asn	Gly	Val	Asn
			115				120					125			
Lys	Lys	Arg	Val	Val	Ala	Ser	Ser	Asp	Glu	Glu	Ser	Asp	Val	Ser	Pro
	130					135					140				
Pro	Ala	Lys	Arg	Pro	Val	Ser	Lys	Gln	Ser	Lys	Pro	Ala	Thr	Pro	Asp
145					150					155					160
Ser	Glu	Ser	Asp	Asp	Asp	Gln	Pro	Leu	Ala	Lys	Lys	Ala	Asn	Gly	Leu
			165						170					175	
Ala	Ala	Ser	Lys	Arg	Gln	Ala	Lys	Lys	Ala	Glu	Glu	Leu	Ser	Glu	Glu
			180				185						190		
Ser	Ser	Glu	Glu	Glu	Lys	Pro	Leu	Ala	Lys	Val	Ala	Lys	Arg	Val	Ser
		195					200					205			
Ala	Lys	Lys	Met	Lys	Ser	Glu	Thr	Glu	Asp	Ser	Glu	Glu	Asp	Arg	Pro
	210					215					220				
Leu	Ala	Lys	Lys	Lys	Ala	Pro	Val	Lys	Arg	Ala	Pro	Ala	Lys	Lys	Ser
225					230					235					240
Ala	Lys	Lys	Glu	Pro	Ser	Glu	Ser	Glu	Glu	Asp	Glu	Lys	Pro	Leu	Ala
			245						250					255	
Lys	Asn	Ala	Arg	Gly	Lys	Ala	Lys	Ala	Ala	Thr	Val	Lys	Glu	Glu	Lys
			260				265						270		
Gly	Lys	Lys	Thr	Lys	Lys	Glu	Lys	Glu	Glu	Glu	Glu	Glu	Glu	Glu	Arg
		275					280					285			
Tyr	Lys	Trp	Trp	Glu	Gln	Asp	Ala	Leu	Gly	Asp	Gly	Ser	Ser	Lys	Trp
	290					295					300				
Thr	Val	Leu	Glu	His	Asn	Ala	Val	Leu	Phe	Pro	Pro	Pro	Tyr	Val	Pro
305					310					315					320
Leu	Pro	Lys	Asn	Val	Lys	Met	Lys	Tyr	Asp	Gly	Val	Ser	Leu	Thr	Leu
			325						330					335	
Pro	Pro	Glu	Ser	Glu	Glu	Val	Ala	Gly	Phe	Phe	Gly	Ala	Leu	Leu	Glu
			340					345					350		
Thr	Asp	Tyr	Ala	Gln	Asp	Ala	Lys	Phe	Arg	Glu	Asn	Phe	Phe	Arg	Asp
		355					360					365			
Phe	Lys	Ala	Ile	Val	Glu	Lys	Tyr	Pro	Pro	Lys	Glu	Asp	Val	Lys	Val
	370					375					380				
Lys	Lys	Leu	Glu	Lys	Cys	Asp	Phe	Arg	Pro	Met	Phe	Glu	Tyr	Phe	Glu
385					390					395					400
Lys	Glu	Lys	Glu	Lys	Lys	Lys	Ala	Leu	Thr	Lys	Glu	Glu	Lys	Lys	Ala
			405						410					415	
Ile	Lys	Ala	Glu	Lys	Asp	Lys	Leu	Glu	Ala	Pro	Tyr	Leu	Tyr	Ala	Asn
			420					425					430		
Val	Asp	Gly	Arg	Lys	Glu	Lys	Val	Gly	Asn	Phe	Arg	Ala	Glu	Pro	Pro
		435					440					445			
Gly	Leu	Phe	Lys	Gly	Arg	Gly	Glu	His	Pro	Lys	Lys	Gly	Thr	Val	Lys
	450					455					460				
Asn	Arg	Leu	Arg	Pro	Glu	Asp	Ile	Ile	Ile	Asn	Ile	Gly	Lys	Glu	Ala
465					470					475					480
Pro	Ile	Pro	Val	Pro	Asn	Ile	Pro	Gly	Gln	Trp	Lys	Gly	Ile	Gln	His
			485					490					495		
Asp	Asn	Thr	Val	Thr	Trp	Leu	Ala	His	Trp	Lys	Glu	Asn	Val	Asn	Gly

-continued

500					505					510				
Asn	Ala	Lys	Tyr	Val	Phe	Leu	Ser	Ala	Gly	Ser	Ala	Trp	Lys	Gln
	515							520				525		
Ser	Asp	Arg	Ala	Lys	Phe	Glu	Lys	Ala	Arg	Glu	Leu	Ile	Lys	His
	530					535					540			Val
Asp	Lys	Ile	Arg	Lys	Asp	Tyr	Thr	Ala	Asp	Leu	Lys	Ser	Lys	Val
	545				550					555				Met
Ala	Asp	Arg	Gln	Arg	Ala	Thr	Ala	Leu	Tyr	Phe	Ile	Asp	Arg	Leu
				565						570				575
Leu	Arg	Ala	Gly	Asn	Glu	Lys	Gly	Glu	Asp	Glu	Ala	Asp	Thr	Val
			580					585					590	Gly
Cys	Cys	Ser	Leu	Arg	Tyr	Glu	His	Val	Thr	Leu	Ser	Pro	Pro	Asn
		595					600					605		Thr
Ile	Ile	Phe	Asp	Phe	Leu	Gly	Lys	Asp	Ser	Met	Arg	Phe	His	Gln
	610					615					620			Glu
Val	Glu	Val	Asp	Pro	Gln	Val	Phe	Lys	Asn	Ile	Lys	Leu	Phe	Lys
	625				630					635				Ala
Asp	Pro	Lys	Lys	Lys	Gly	Asp	Asp	Ile	Phe	Asp	Arg	Leu	Thr	Thr
				645						650				655
Leu	Leu	Asn	Lys	His	Leu	Asn	Ser	Met	Met	Pro	Gly	Leu	Thr	Ala
		660						665					670	Lys
Val	Phe	Arg	Thr	Tyr	Asn	Ala	Ser	Trp	Thr	Phe	Gln	Glu	Gln	Leu
		675					680					685		Lys
Asn	Thr	Pro	Lys	Asn	Gly	Thr	Val	Ala	Glu	Lys	Ile	Ala	Ala	Tyr
	690				695						700			Asn
Thr	Ala	Asn	Arg	Asp	Val	Ala	Ile	Leu	Cys	Asn	His	Gln	Lys	Ser
	705				710					715				Val
Ser	Lys	Gly	Phe	Glu	Gly	Ser	Phe	Ala	Lys	Ala	Glu	Asp	Lys	Ile
			725						730					735
Ala	Leu	Lys	Tyr	Gln	Arg	Leu	Lys	Leu	Arg	Leu	Gln	Leu	Phe	Ser
			740					745					750	Leu
Asn	Pro	Lys	Ile	Lys	Lys	Lys	His	Pro	Glu	Leu	Ala	Glu	Asp	Glu
		755					760					765		Ser
Asp	Val	Asp	Asp	Glu	Phe	Met	Glu	Arg	His	Glu	Ala	Glu	Leu	Glu
	770					775					780			
Lys	Ala	Leu	Glu	Asn	Ala	Lys	Lys	Lys	Trp	Asp	Thr	Asp	Asn	Val
	785				790					795				Lys
Leu	Glu	Gly	Asp	Gly	Lys	Lys	Lys	Lys	Thr	Lys	Gly	Glu	Leu	Asp
			805						810					815
Arg	Leu	Ser	Glu	Ile	Lys	Ala	Glu	Phe	Lys	Glu	Leu	Lys	Lys	Glu
			820					825					830	Arg
Lys	Ala	Lys	Lys	Ile	Asp	Ala	Lys	Arg	Gly	Ala	Thr	Glu	Glu	Lys
		835					840					845		Leu
Leu	Ala	Gln	Val	Ala	Arg	Ile	Asp	Glu	Arg	Ile	Ala	Thr	Ala	Lys
	850					855					860			Val
Gln	Leu	Gln	Asp	Arg	Asp	Lys	Leu	Lys	Asp	Val	Ala	Leu	Gly	Thr
	865				870					875				880
Lys	Ile	Asn	Tyr	Ile	Asp	Pro	Arg	Leu	Thr	Val	Ala	Trp	Ala	Lys
			885						890					895
Phe	Asp	Val	Pro	Leu	Glu	Lys	Leu	Phe	Ser	Lys	Thr	Leu	Arg	Glu
			900					905					910	Lys

-continued

Phe Pro Trp Ala Glu Ala Glu Ala Gly Pro Asp Trp Val Phe
915 920 925

<210> SEQ ID NO 29
<211> LENGTH: 1125
<212> TYPE: DNA
<213> ORGANISM: *Cryptococcus neoformans*
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(1125)

<400> SEQUENCE: 29

atg gcc cac cac cac ttc gta ggc ata aac ccg gca ggc ctc tcc ttc 48
Met Ala His His His Phe Val Gly Ile Asn Pro Ala Gly Leu Ser Phe
1 5 10 15

tcc cat ccc acc ccg cca gca gac cac ccc gcg ccc ccc tcc tcg ggc 96
Ser His Pro Thr Pro Pro Ala Asp His Pro Ala Pro Pro Ser Ser Gly
20 25 30

agc atc cac acc cca gca aac ttc gcc agc att caa gaa ccc atc aca 144
Ser Ile His Thr Pro Ala Asn Phe Ala Ser Ile Gln Glu Pro Ile Thr
35 40 45

gac cca tcc gct gtc gcc gcc cgc cga cgc ggt cgt cct tcc aca agg 192
Asp Pro Ser Ala Val Ala Ala Arg Arg Arg Gly Arg Pro Ser Thr Arg
50 55 60

ggc gaa gct ggc gtc act ccg ccc cca gag atc gga tgg tgg gag gac 240
Gly Glu Ala Gly Val Thr Pro Pro Pro Glu Ile Gly Trp Trp Glu Asp
65 70 75 80

cgt gcg ccc agc tgg cac aag gat gcc atg cag ggc ggc aag tct tct 288
Arg Ala Pro Ser Trp His Lys Asp Ala Met Gln Gly Gly Lys Ser Ser
85 90 95

atg gag ctc ctg atg gaa tgg tca gag gag atg aag aat caa ggc cac 336
Met Glu Leu Leu Met Glu Trp Ser Glu Glu Met Lys Asn Gln Gly His
100 105 110

tac tac tgg atg ggc gtc agg gat ggc ggc aat ctg cat caa ggt gct 384
Tyr Tyr Trp Met Gly Val Arg Asp Gly Gly Asn Leu His Gln Gly Ala
115 120 125

tcg cgt ttt agg gac tac tta tat gcc cag cat ggt cct att agg cgg 432
Ser Arg Phe Arg Asp Tyr Leu Tyr Ala Gln His Gly Pro Ile Arg Arg
130 135 140

tca agt aag gct atc aga aat aaa gtg gag aat att aag caa aag ttc 480
Ser Ser Lys Ala Ile Arg Asn Lys Val Glu Asn Ile Lys Gln Lys Phe
145 150 155 160

ttt gaa gcc cag gaa tgg ctc aag gat ccc aat ggg gac cat acc acc 528
Phe Glu Ala Gln Glu Trp Leu Lys Asp Pro Asn Gly Asp His Thr Thr
165 170 175

atg acc att ccg gac gtc gaa aaa aaa ctc aac aag atc tgt cgc aac 576
Met Thr Ile Pro Asp Val Glu Lys Lys Leu Asn Lys Ile Cys Arg Asn
180 185 190

tac cgc ttc tgg gaa acc atc ttc gta gag ctt cct cca gtt gac cac 624
Tyr Arg Phe Trp Glu Thr Ile Phe Val Glu Leu Pro Pro Val Asp His
195 200 205

gaa gct ggc cag aat gcc gaa ggg tct tca tcc aac cag act ctt cag 672
Glu Ala Gly Gln Asn Ala Glu Gly Ser Ser Ser Asn Gln Thr Leu Gln
210 215 220

tct gct tct caa act gcc gtt cga cag ggt aat ggg ccc ctc atc cgc 720
Ser Ala Ser Gln Thr Ala Val Arg Gln Gly Asn Gly Pro Leu Ile Arg
225 230 235 240

ggc att cct gtt ccg gaa atg gga cag gca gcg gcc gat gat gcg cag 768

-continued

Gly	Ile	Pro	Val	Pro	Glu	Met	Gly	Gln	Ala	Ala	Ala	Asp	Asp	Ala	Gln	
				245					250					255		
cga	aat	gtc	cgc	cga	cgc	ctt	aat	gat	ggc	agc	tct	gcc	act	att	cct	816
Arg	Asn	Val	Arg	Arg	Arg	Leu	Asn	Asp	Gly	Ser	Ser	Ala	Thr	Ile	Pro	
			260					265				270				
tcc	gac	tca	tct	ttg	gtt	ggc	cgc	gtg	ctc	cct	gct	agc	tac	ctc	gaa	864
Ser	Asp	Ser	Ser	Leu	Val	Gly	Arg	Val	Leu	Pro	Ala	Ser	Tyr	Leu	Glu	
			275				280					285				
cgc	acc	cgt	gaa	gaa	cgc	gat	cgc	gaa	aag	cat	gaa	tta	gcg	aaa	aag	912
Arg	Thr	Arg	Glu	Glu	Arg	Asp	Arg	Glu	Lys	His	Glu	Leu	Ala	Lys	Lys	
		290				295				300						
cag	caa	gcc	ctc	aac	agg	gaa	caa	tat	gaa	ctc	gag	cag	aag	aaa	gat	960
Gln	Gln	Ala	Leu	Asn	Arg	Glu	Gln	Tyr	Glu	Leu	Glu	Gln	Lys	Lys	Asp	
				310					315					320		
gag	aga	gat	cag	aag	aga	ttt	gag	tggt	gag	cag	act	aag	cat	ctg	gtg	1008
Glu	Arg	Asp	Gln	Lys	Arg	Phe	Glu	Trp	Glu	Gln	Thr	Lys	His	Leu	Val	
				325				330						335		
gag	acg	gct	tta	aaa	atc	cga	gaa	ttg	gat	atc	att	cgc	ttg	gaa	gcg	1056
Glu	Thr	Ala	Leu	Lys	Ile	Arg	Glu	Leu	Asp	Ile	Ile	Pro	Leu	Glu	Ala	
			340				345					350				
gcg	atg	atc	aaa	gct	aga	gct	ctt	tat	ggc	cag	gcg	cga	gag	gaa	gat	1104
Ala	Met	Ile	Lys	Ala	Arg	Ala	Leu	Tyr	Gly	Gln	Ala	Arg	Glu	Glu	Asp	
			355			360					365					
caa	gct	gaa	gct	act	ctt	taa										1125
Gln	Ala	Glu	Ala	Thr	Leu											
			370													

<210> SEQ ID NO 30

<211> LENGTH: 374

<212> TYPE: PRT

<213> ORGANISM: *Cryptococcus neoformans*

<400> SEQUENCE: 30

Met	Ala	His	His	His	Phe	Val	Gly	Ile	Asn	Pro	Ala	Gly	Leu	Ser	Phe	
1				5					10					15		
Ser	His	Pro	Thr	Pro	Pro	Ala	Asp	His	Pro	Ala	Pro	Pro	Ser	Ser	Gly	
			20					25					30			
Ser	Ile	His	Thr	Pro	Ala	Asn	Phe	Ala	Ser	Ile	Gln	Glu	Pro	Ile	Thr	
			35				40					45				
Asp	Pro	Ser	Ala	Val	Ala	Ala	Arg	Arg	Arg	Gly	Arg	Pro	Ser	Thr	Arg	
		50				55				60						
Gly	Glu	Ala	Gly	Val	Thr	Pro	Pro	Pro	Glu	Ile	Gly	Trp	Trp	Glu	Asp	
				70					75					80		
Arg	Ala	Pro	Ser	Trp	His	Lys	Asp	Ala	Met	Gln	Gly	Gly	Lys	Ser	Ser	
			85					90						95		
Met	Glu	Leu	Leu	Met	Glu	Trp	Ser	Glu	Glu	Met	Lys	Asn	Gln	Gly	His	
			100					105					110			
Tyr	Tyr	Trp	Met	Gly	Val	Arg	Asp	Gly	Gly	Asn	Leu	His	Gln	Gly	Ala	
			115				120					125				
Ser	Arg	Phe	Arg	Asp	Tyr	Leu	Tyr	Ala	Gln	His	Gly	Pro	Ile	Arg	Arg	
			130				135				140					
Ser	Ser	Lys	Ala	Ile	Arg	Asn	Lys	Val	Glu	Asn	Ile	Lys	Gln	Lys	Phe	
			145			150				155					160	
Phe	Glu	Ala	Gln	Glu	Trp	Leu	Lys	Asp	Pro	Asn	Gly	Asp	His	Thr	Thr	
				165				170						175		

-continued

Met	Thr	Ile	Pro	Asp	Val	Glu	Lys	Lys	Leu	Asn	Lys	Ile	Cys	Arg	Asn
			180					185					190		
Tyr	Arg	Phe	Trp	Glu	Thr	Ile	Phe	Val	Glu	Leu	Pro	Pro	Val	Asp	His
		195					200					205			
Glu	Ala	Gly	Gln	Asn	Ala	Glu	Gly	Ser	Ser	Ser	Asn	Gln	Thr	Leu	Gln
	210					215					220				
Ser	Ala	Ser	Gln	Thr	Ala	Val	Arg	Gln	Gly	Asn	Gly	Pro	Leu	Ile	Arg
225				230						235					240
Gly	Ile	Pro	Val	Pro	Glu	Met	Gly	Gln	Ala	Ala	Ala	Asp	Asp	Ala	Gln
				245					250					255	
Arg	Asn	Val	Arg	Arg	Arg	Leu	Asn	Asp	Gly	Ser	Ser	Ala	Thr	Ile	Pro
		260						265					270		
Ser	Asp	Ser	Ser	Leu	Val	Gly	Arg	Val	Leu	Pro	Ala	Ser	Tyr	Leu	Glu
		275					280					285			
Arg	Thr	Arg	Glu	Glu	Arg	Asp	Arg	Glu	Lys	His	Glu	Leu	Ala	Lys	Lys
	290					295					300				
Gln	Gln	Ala	Leu	Asn	Arg	Glu	Gln	Tyr	Glu	Leu	Glu	Gln	Lys	Lys	Asp
305				310						315					320
Glu	Arg	Asp	Gln	Lys	Arg	Phe	Glu	Trp	Glu	Gln	Thr	Lys	His	Leu	Val
			325						330					335	
Glu	Thr	Ala	Leu	Lys	Ile	Arg	Glu	Leu	Asp	Ile	Ile	Pro	Leu	Glu	Ala
		340						345					350		
Ala	Met	Ile	Lys	Ala	Arg	Ala	Leu	Tyr	Gly	Gln	Ala	Arg	Glu	Glu	Asp
		355					360					365			
Gln	Ala	Glu	Ala	Thr	Leu										
		370													

<210> SEQ ID NO 31
 <211> LENGTH: 1251
 <212> TYPE: DNA
 <213> ORGANISM: *Cryptococcus neoformans*
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1) .. (1251)

<400> SEQUENCE: 31

atg gac gcc acc act ctt aca ggg cac gtc aag gag ctc aat gct gca	48
Met Asp Ala Thr Leu Thr Gly His Val Lys Glu Leu Asn Ala Ala	
1 5 10 15	
aac caa gcg gga aaa tca gat gaa gtt atc tct ctg ctc aag aaa ctt	96
Asn Gln Ala Gly Lys Ser Asp Glu Val Ile Ser Leu Leu Lys Lys Leu	
20 25 30	
cag gct gag gtt gtt cct aca gaa gat ctc ctt cga tca tcg aaa gct	144
Gln Ala Glu Val Val Pro Thr Glu Asp Leu Leu Arg Ser Ser Lys Ala	
35 40 45	
ggt gtc gca gtc ggc aag ctt cgt acc cac gcc aca cca tca gtc tca	192
Gly Val Ala Val Gly Lys Leu Arg Thr His Ala Thr Pro Ser Val Ser	
50 55 60	
agt ctt gcc aag gag ata gtt aag aag tgg aga gat gcg gtc gag gag	240
Ser Leu Ala Lys Glu Ile Val Lys Lys Trp Arg Asp Ala Val Glu Glu	
65 70 75 80	
aca aag aag aag aga aaa aga gca gaa ggt gat gaa gga aaa gat gta	288
Thr Lys Lys Lys Arg Lys Arg Ala Glu Gly Asp Glu Gly Lys Asp Val	
85 90 95	
aag aag gag aag gag gaa ggg aac ggg aaa cga gtc aag gcg gaa acg	336
Lys Lys Glu Lys Glu Glu Gly Asn Gly Lys Arg Val Lys Ala Glu Thr	

-continued

100	105	110	
ggg tca tta gcg gcg aca cca tca gct agc aca ccc gcc tcg gcc tct			384
Gly Ser Leu Ala Ala Thr Pro Ser Ala Ser Thr Pro Ala Ser Ala Ser			
115	120	125	
aca ccc gat gtc aaa gcg acc tcc cct cct gtc cgt caa cct ctt tca			432
Thr Pro Asp Val Lys Ala Thr Ser Pro Pro Val Arg Gln Pro Leu Ser			
130	135	140	
acc att gac tca tca cgc act acg cct cga acc gcc aaa agc gat gga			480
Thr Ile Asp Ser Ser Arg Thr Thr Pro Arg Thr Ala Lys Ser Asp Gly			
145	150	155	160
gtg gcc gac agc ctg aga gct gat tcg agc gaa gga ggc agt gta gat			528
Val Ala Asp Ser Leu Arg Ala Asp Ser Ser Glu Gly Gly Ser Val Asp			
165	170	175	
agc gtg agg gac aag tgt gtg atc atg att tat gac gca ttg gcg ttg			576
Ser Val Arg Asp Lys Cys Val Ile Met Ile Tyr Asp Ala Leu Ala Leu			
180	185	190	
gat agc acg gct gaa ata aag att ttg aaa gag cgc gcc att gga att			624
Asp Ser Thr Ala Glu Ile Lys Ile Leu Lys Glu Arg Ala Ile Gly Ile			
195	200	205	
gag cgc gca gcg aat aaa gct atg aac ttc tca aca gga aac gat tat			672
Glu Arg Ala Ala Asn Lys Ala Met Asn Phe Ser Thr Gly Asn Asp Tyr			
210	215	220	
cgc gct aaa atg aga tca cta ttc ctc aac ttg aaa gac aag ggt aat			720
Arg Ala Lys Met Arg Ser Leu Phe Leu Asn Leu Lys Asp Lys Gly Asn			
225	230	235	240
ccc gct ttg aga aac gag att gtc ttg ggc tac gtc agc acc gaa aaa			768
Pro Ala Leu Arg Asn Glu Ile Val Leu Gly Tyr Val Ser Thr Glu Lys			
245	250	255	
gtc gct agc atg tcc aaa gat gaa atg gcc tct gaa agc gtt cga atg			816
Val Ala Ser Met Ser Lys Asp Glu Met Ala Ser Glu Ser Val Arg Met			
260	265	270	
cta aag gag aag att gcg agt gac aac ttg ttc aag gcc aag gct gtc			864
Leu Lys Glu Lys Ile Ala Ser Asp Asn Leu Phe Lys Ala Lys Ala Val			
275	280	285	
gga gtc acc caa gct gag aca gac gcg ttc aag tgc gga cgg tgt cac			912
Gly Val Thr Gln Ala Glu Thr Asp Ala Phe Lys Cys Gly Arg Cys His			
290	295	300	
cag agg aaa tgt act tat tac cag atg cag aca aga agc gcg gat gaa			960
Gln Arg Lys Cys Thr Tyr Tyr Gln Met Gln Thr Arg Ser Ala Asp Glu			
305	310	315	320
cct atg act act ttt gtt acg tat gtg tct gac ctg act cca aaa gaa			1008
Pro Met Thr Thr Phe Val Thr Tyr Val Ser Asp Leu Thr Pro Lys Glu			
325	330	335	
tca ttg ctg act acg tgt acg act tgc tct ttt tat tca gat gta cta			1056
Ser Leu Leu Thr Thr Cys Thr Thr Cys Ser Phe Tyr Ser Asp Val Leu			
340	345	350	
att gta aca aca ggt gga aat tca gct agt ttc gga ttt tgc ctc tgg			1104
Ile Val Thr Thr Gly Gly Asn Ser Ala Ser Phe Gly Phe Cys Leu Trp			
355	360	365	
gga gca ttg tat ctt tcg ggt ttt ttg tca cgt cgt cta tgc agc cag			1152
Gly Ala Leu Tyr Leu Ser Gly Phe Leu Ser Arg Arg Leu Cys Ser Gln			
370	375	380	
tat att tac gag gcg tat cgt tgt gat ttg cgt gtc aat gtc aca aag			1200
Tyr Ile Tyr Glu Ala Tyr Arg Cys Asp Leu Arg Val Asn Val Thr Lys			
385	390	395	400
cca tta agt gcc gta aat atg cct ttt tgc agt gtt ctg aaa ttc aaa			1248
Pro Leu Ser Ala Val Asn Met Pro Phe Cys Ser Val Leu Lys Phe Lys			

-continued

	405	410	415	
tga				1251
<210> SEQ ID NO 32				
<211> LENGTH: 416				
<212> TYPE: PRT				
<213> ORGANISM: Cryptococcus neoformans				
<400> SEQUENCE: 32				
Met Asp Ala Thr Thr Leu Thr Gly His Val Lys Glu Leu Asn Ala Ala				
1	5	10	15	
Asn Gln Ala Gly Lys Ser Asp Glu Val Ile Ser Leu Leu Lys Lys Leu				
	20	25	30	
Gln Ala Glu Val Val Pro Thr Glu Asp Leu Leu Arg Ser Ser Lys Ala				
	35	40	45	
Gly Val Ala Val Gly Lys Leu Arg Thr His Ala Thr Pro Ser Val Ser				
	50	55	60	
Ser Leu Ala Lys Glu Ile Val Lys Lys Trp Arg Asp Ala Val Glu Glu				
	65	70	75	80
Thr Lys Lys Lys Arg Lys Arg Ala Glu Gly Asp Glu Gly Lys Asp Val				
	85	90	95	
Lys Lys Glu Lys Glu Glu Gly Asn Gly Lys Arg Val Lys Ala Glu Thr				
	100	105	110	
Gly Ser Leu Ala Ala Thr Pro Ser Ala Ser Thr Pro Ala Ser Ala Ser				
	115	120	125	
Thr Pro Asp Val Lys Ala Thr Ser Pro Pro Val Arg Gln Pro Leu Ser				
	130	135	140	
Thr Ile Asp Ser Ser Arg Thr Thr Pro Arg Thr Ala Lys Ser Asp Gly				
	145	150	155	160
Val Ala Asp Ser Leu Arg Ala Asp Ser Ser Glu Gly Gly Ser Val Asp				
	165	170	175	
Ser Val Arg Asp Lys Cys Val Ile Met Ile Tyr Asp Ala Leu Ala Leu				
	180	185	190	
Asp Ser Thr Ala Glu Ile Lys Ile Leu Lys Glu Arg Ala Ile Gly Ile				
	195	200	205	
Glu Arg Ala Ala Asn Lys Ala Met Asn Phe Ser Thr Gly Asn Asp Tyr				
	210	215	220	
Arg Ala Lys Met Arg Ser Leu Phe Leu Asn Leu Lys Asp Lys Gly Asn				
	225	230	235	240
Pro Ala Leu Arg Asn Glu Ile Val Leu Gly Tyr Val Ser Thr Glu Lys				
	245	250	255	
Val Ala Ser Met Ser Lys Asp Glu Met Ala Ser Glu Ser Val Arg Met				
	260	265	270	
Leu Lys Glu Lys Ile Ala Ser Asp Asn Leu Phe Lys Ala Lys Ala Val				
	275	280	285	
Gly Val Thr Gln Ala Glu Thr Asp Ala Phe Lys Cys Gly Arg Cys His				
	290	295	300	
Gln Arg Lys Cys Thr Tyr Tyr Gln Met Gln Thr Arg Ser Ala Asp Glu				
	305	310	315	320
Pro Met Thr Thr Phe Val Thr Tyr Val Ser Asp Leu Thr Pro Lys Glu				
	325	330	335	
Ser Leu Leu Thr Thr Cys Thr Thr Cys Ser Phe Tyr Ser Asp Val Leu				
	340	345	350	

```
<210> SEQ ID NO 33
<211> LENGTH: 657
<212> TYPE: DNA
<213> ORGANISM: Cryptococcus neoformans
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(657)
```

<400> SEQUENCE: 33

atg	gat	tac	caa	aat	cga	gca	ggt	gca	aac	aag	ggt	agt	ggt	ggt	gtc	48
Met	Asp	Tyr	Gln	Asn	Arg	Ala	Gly	Ala	Asn	Lys	Gly	Ser	Gly	Gly	Val	
1			5						10					15		
gct	ggt	gca	tcc	gag	aca	gca	gtg	gac	agg	aga	gaa	cgt	ctt	cga	aaa	96
Ala	Gly	Ala	Ser	Glu	Thr	Ala	Val	Asp	Arg	Arg	Glu	Arg	Leu	Arg	Lys	
			20					25					30			
ctt	gct	ttg	gag	act	att	gac	ttg	gcc	aaa	gat	ccc	tat	atc	ctt	agg	144
Leu	Ala	Leu	Glu	Thr	Ile	Asp	Leu	Ala	Lys	Asp	Pro	Tyr	Ile	Leu	Arg	
		35					40				45					
acc	cat	ctc	ggt	aca	tta	gaa	tgc	cgt	ctt	tgt	ctc	act	ctt	cac	gtc	192
Thr	His	Leu	Gly	Thr	Leu	Glu	Cys	Arg	Leu	Cys	Leu	Thr	Leu	His	Val	
	50					55					60					
aac	gag	ggt	tct	tac	ctt	gcc	cac	act	caa	gga	aag	aaa	cat	caa	aca	240
Asn	Glu	Gly	Ser	Tyr	Leu	Ala	His	Thr	Gln	Gly	Lys	Lys	His	Gln	Thr	
65					70					75				80		
aac	ctt	gct	agg	cgt	gca	gcc	aag	gac	aac	aag	gat	cag	aca	tta	atg	288
Asn	Leu	Ala	Arg	Arg	Ala	Ala	Lys	Asp	Asn	Lys	Asp	Gln	Thr	Leu	Met	
			85					90					95			
atc	caa	gct	ccc	aca	gcc	gcg	caa	caa	gtg	aag	aag	aaa	gtg	ttt	gtt	336
Ile	Gln	Ala	Pro	Thr	Ala	Ala	Gln	Gln	Val	Lys	Lys	Lys	Val	Phe	Val	
		100					105					110				
aag	att	gga	aga	cct	gga	tac	aaa	atc	atc	aaa	att	cga	gag	cct	gtc	384
Lys	Ile	Gly	Arg	Pro	Gly	Tyr	Lys	Ile	Ile	Lys	Ile	Arg	Glu	Pro	Val	
	115						120				125					
agt	caa	agg	atg	ggt	tta	tta	ttc	act	gtg	tct	tta	cct	gag	ata	aaa	432
Ser	Gln	Arg	Met	Gly	Leu	Leu	Phe	Thr	Val	Ser	Leu	Pro	Glu	Ile	Lys	
	130					135					140					
gcg	gga	gag	agg	cca	aga	agg	agg	ttc	atg	tct	gct	ttt	gaa	caa	cgg	480
Ala	Gly	Glu	Arg	Pro	Arg	Arg	Arg	Phe	Met	Ser	Ala	Phe	Glu	Gln	Arg	
145					150					155				160		
cga	gag	att	ccc	aat	aaa	gct	ttc	cag	tac	tta	gtt	ttg	gca	gcc	gag	528
Arg	Glu	Ile	Pro	Asn	Lys	Ala	Phe	Gln	Tyr	Leu	Val	Leu	Ala	Ala	Glu	
			165					170					175			
cca	tac	gag	acc	ata	gca	ttt	gcc	atc	ccc	tca	aaa	gag	atg	gtt	gac	576
Pro	Tyr	Glu	Thr	Ile	Ala	Phe	Ala	Ile	Pro	Ser	Lys	Glu	Met	Val	Asp	
		180					185				190					
gtt	gat	gaa	gac	ccg	gag	tcg	aca	tgg	gag	cac	tgg	gat	gcc	gac	gag	624
Val	Asp	Glu	Asp	Pro	Glu	Ser	Thr	Trp	Glu	His	Trp	Asp	Ala	Asp	Glu	
		195				200					205					

-continued

```

aag gtt tac agt tgt caa ttc ttg tat aaa taa      657
Lys Val Tyr Ser Cys Gln Phe Leu Tyr Lys
    210                215

```

```

<210> SEQ ID NO 34
<211> LENGTH: 218
<212> TYPE: PRT
<213> ORGANISM: Cryptococcus neoformans

```

```

<400> SEQUENCE: 34

```

```

Met Asp Tyr Gln Asn Arg Ala Gly Ala Asn Lys Gly Ser Gly Gly Val
 1              5              10              15

Ala Gly Ala Ser Glu Thr Ala Val Asp Arg Arg Glu Arg Leu Arg Lys
    20              25              30

Leu Ala Leu Glu Thr Ile Asp Leu Ala Lys Asp Pro Tyr Ile Leu Arg
    35              40              45

Thr His Leu Gly Thr Leu Glu Cys Arg Leu Cys Leu Thr Leu His Val
 50              55              60

Asn Glu Gly Ser Tyr Leu Ala His Thr Gln Gly Lys Lys His Gln Thr
 65              70              75              80

Asn Leu Ala Arg Arg Ala Ala Lys Asp Asn Lys Asp Gln Thr Leu Met
    85              90              95

Ile Gln Ala Pro Thr Ala Ala Gln Gln Val Lys Lys Lys Val Phe Val
   100              105              110

Lys Ile Gly Arg Pro Gly Tyr Lys Ile Ile Lys Ile Arg Glu Pro Val
   115              120              125

Ser Gln Arg Met Gly Leu Leu Phe Thr Val Ser Leu Pro Glu Ile Lys
   130              135              140

Ala Gly Glu Arg Pro Arg Arg Arg Phe Met Ser Ala Phe Glu Gln Arg
  145              150              155              160

Arg Glu Ile Pro Asn Lys Ala Phe Gln Tyr Leu Val Leu Ala Ala Glu
   165              170              175

Pro Tyr Glu Thr Ile Ala Phe Ala Ile Pro Ser Lys Glu Met Val Asp
   180              185              190

Val Asp Glu Asp Pro Glu Ser Thr Trp Glu His Trp Asp Ala Asp Glu
   195              200              205

Lys Val Tyr Ser Cys Gln Phe Leu Tyr Lys
   210              215

```

```

<210> SEQ ID NO 35
<211> LENGTH: 813
<212> TYPE: DNA
<213> ORGANISM: Cryptococcus neoformans
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1) .. (813)

```

```

<400> SEQUENCE: 35

```

```

atg aca gtc aag gca gag caa gat ctc tat ctt gac ccc tcc att cgg      48
Met Thr Val Lys Ala Glu Gln Asp Leu Tyr Leu Asp Pro Ser Ile Arg
 1              5              10              15

gat tgg gtc ctt atc cct atc acc cta atc atg cta ctc gtc ggt gtg      96
Asp Trp Val Leu Ile Pro Ile Thr Leu Ile Met Leu Val Gly Val
    20              25              30

tta aga cac tac atc acg caa ttc ctt aac tct gca cca aaa aaa caa     144
Leu Arg His Tyr Ile Thr Gln Phe Leu Asn Ser Ala Pro Lys Lys Gln
   35              40              45

```

-continued

```

aca gca gct gcc gtt cgc gaa caa cgc gca ctt ggt cgc tca gct ctg      192
Thr Ala Ala Ala Val Arg Glu Gln Arg Ala Leu Gly Arg Ser Ala Leu
   50                               55                               60

ctt cgg gca act cgc act ctg tcc ccc ctt cgg cct gcc tct tac aag      240
Leu Arg Ala Thr Ala Thr Leu Ser Pro Leu Pro Pro Ala Ser Tyr Lys
   65                               70                               75                               80

gct ctc tcg gga tcc ctt gct gct tca ctt tct act ggt gag tat atc      288
Ala Leu Ser Gly Ser Leu Ala Ala Ser Leu Ser Thr Gly Glu Tyr Ile
                      85                               90                               95

aag ccc gcc cca gag tca aag ggg gat gct tct ccc gcc aat cct ctc      336
Lys Pro Ala Pro Glu Ser Lys Gly Asp Ala Ser Pro Ala Asn Pro Leu
                      100                               105                               110

gaa ggt gct ggg atg gaa aat gcg atg gac ggt atg aaa aag cag gcc      384
Glu Gly Ala Gly Met Glu Asn Ala Met Asp Gly Met Lys Lys Gln Ala
                      115                               120                               125

gta atg atg gta ccc aac atg gtt atc atg cag tat atc aac gtc ttt      432
Val Met Met Val Pro Asn Met Val Ile Met Gln Tyr Ile Asn Val Phe
                      130                               135                               140

ttt tcc gga ttt atc ctt atg cgt ctg cca ttt cct tta acc gca ggc      480
Phe Ser Gly Phe Ile Leu Met Arg Leu Pro Phe Pro Leu Thr Ala Gly
                      145                               150                               155                               160

ttt aag tcg ttg ctg tca agg gat att ccc atg gct gat ctc gat gtg      528
Phe Lys Ser Leu Leu Ser Arg Asp Ile Pro Met Ala Asp Leu Asp Val
                      165                               170                               175

cga tgg gtt tcc gct ttg tcc tgg tat ttt ctc aac ttg ttt ggc ttg      576
Arg Trp Val Ser Ala Leu Ser Trp Tyr Phe Leu Asn Leu Phe Gly Leu
                      180                               185                               190

aac ggt gtt ttc aaa cta att ctt gga gct gag aat gct gct gta gac      624
Asn Gly Val Phe Lys Leu Ile Leu Gly Ala Glu Asn Ala Ala Val Asp
                      195                               200                               205

agc cgt gac ctc acc tcg ctg tct gca ctt tct ggg gca gga ggc cct      672
Ser Arg Asp Leu Thr Ser Leu Ser Ala Leu Ser Gly Ala Gly Gly Pro
                      210                               215                               220

atg ccc ggc ccc ggc ggt cca cca gac atg gtc aag ctt ttc aag gcc      720
Met Pro Gly Pro Gly Gly Pro Pro Asp Met Val Lys Leu Phe Lys Ala
                      225                               230                               235                               240

gag gtt gag aac ttg gca ttg gca gaa agt tca tac aag tgg gtc ggc      768
Glu Val Glu Asn Leu Ala Leu Ala Glu Ser Ser Tyr Lys Trp Val Gly
                      245                               250                               255

gac gga gta gaa gat aga gtt ttg aga gct tgg ggc aaa gtt taa      813
Asp Gly Val Glu Asp Arg Val Leu Arg Ala Trp Gly Lys Val
                      260                               265                               270

```

```

<210> SEQ ID NO 36
<211> LENGTH: 270
<212> TYPE: PRT
<213> ORGANISM: Cryptococcus neoformans

```

```

<400> SEQUENCE: 36

```

```

Met Thr Val Lys Ala Glu Gln Asp Leu Tyr Leu Asp Pro Ser Ile Arg
1           5           10           15

Asp Trp Val Leu Ile Pro Ile Thr Leu Ile Met Leu Leu Val Gly Val
20           25           30

Leu Arg His Tyr Ile Thr Gln Phe Leu Asn Ser Ala Pro Lys Lys Gln
35           40           45

Thr Ala Ala Ala Val Arg Glu Gln Arg Ala Leu Gly Arg Ser Ala Leu
50           55           60

```

-continued

Leu Arg Ala Thr Ala Thr Leu Ser Pro Leu Pro Pro Ala Ser Tyr Lys
 65 70 75 80
 Ala Leu Ser Gly Ser Leu Ala Ala Ser Leu Ser Thr Gly Glu Tyr Ile
 85 90 95
 Lys Pro Ala Pro Glu Ser Lys Gly Asp Ala Ser Pro Ala Asn Pro Leu
 100 105 110
 Glu Gly Ala Gly Met Glu Asn Ala Met Asp Gly Met Lys Lys Gln Ala
 115 120 125
 Val Met Met Val Pro Asn Met Val Ile Met Gln Tyr Ile Asn Val Phe
 130 135 140
 Phe Ser Gly Phe Ile Leu Met Arg Leu Pro Phe Pro Leu Thr Ala Gly
 145 150 155 160
 Phe Lys Ser Leu Leu Ser Arg Asp Ile Pro Met Ala Asp Leu Asp Val
 165 170 175
 Arg Trp Val Ser Ala Leu Ser Trp Tyr Phe Leu Asn Leu Phe Gly Leu
 180 185 190
 Asn Gly Val Phe Lys Leu Ile Leu Gly Ala Glu Asn Ala Ala Val Asp
 195 200 205
 Ser Arg Asp Leu Thr Ser Leu Ser Ala Leu Ser Gly Ala Gly Gly Pro
 210 215 220
 Met Pro Gly Pro Gly Gly Pro Pro Asp Met Val Lys Leu Phe Lys Ala
 225 230 235 240
 Glu Val Glu Asn Leu Ala Leu Ala Glu Ser Ser Tyr Lys Trp Val Gly
 245 250 255
 Asp Gly Val Glu Asp Arg Val Leu Arg Ala Trp Gly Lys Val
 260 265 270

<210> SEQ ID NO 37
 <211> LENGTH: 1365
 <212> TYPE: DNA
 <213> ORGANISM: Cryptococcus neoformans
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1)..(1365)

<400> SEQUENCE: 37

atg acc gcg gtg aac agc aac cag ggc acc ggc aaa ctg agc ggc cgc	48
Met Thr Ala Val Asn Ser Asn Gln Gly Thr Gly Lys Leu Ser Gly Arg	
1 5 10 15	
gtg ggc att gtg ggc acc ggc cat cgc gcg cgc ctg tat acc acc gcg	96
Val Gly Ile Val Gly Thr Gly His Arg Ala Arg Leu Tyr Thr Thr Ala	
20 25 30	
gtg gcg agc cgc gcg aac acc agc ctg gtg gcg ctg tgc gat acc aac	144
Val Ala Ser Arg Ala Asn Thr Ser Leu Val Ala Leu Cys Asp Thr Asn	
35 40 45	
gat gcg cgc atg gat tgg cat aac aaa atg ctg cgc gaa gcg ggc cgc	192
Asp Ala Arg Met Asp Trp His Asn Lys Met Leu Arg Glu Ala Gly Arg	
50 55 60	
ccg gaa gcg aaa aaa tat gcg gcg gaa gat ttt cgc aaa atg ctg gaa	240
Pro Glu Ala Lys Lys Tyr Ala Ala Glu Asp Phe Arg Lys Met Leu Glu	
65 70 75 80	
cag gaa aaa ctg gat gtg ctg gtg gtg acc acc att gat tat acc cat	288
Gln Glu Lys Leu Asp Val Leu Val Val Thr Thr Ile Asp Tyr Thr His	
85 90 95	
gat atg tat att att ccg gcg ctg aaa gcg ggc att aaa gtg ctg agc	336

-continued

Asp	Met	Tyr	Ile	Ile	Pro	Ala	Leu	Lys	Ala	Gly	Ile	Lys	Val	Leu	Ser	
			100					105					110			
gaa	aaa	ccg	atg	acc	acc	aac	gtg	gat	aaa	tgc	aaa	gcg	att	ctg	aac	384
Glu	Lys	Pro	Met	Thr	Thr	Asn	Val	Asp	Lys	Cys	Lys	Ala	Ile	Leu	Asn	
		115					120					125				
gcg	gtg	aac	gaa	agc	aaa	ggc	agc	ctg	acc	gtg	ctg	ttt	aac	tat	cgc	432
Ala	Val	Asn	Glu	Ser	Lys	Gly	Ser	Leu	Thr	Val	Leu	Phe	Asn	Tyr	Arg	
	130					135					140					
tat	aac	ccg	att	cat	tgg	aaa	gtg	gcg	gaa	gtg	att	gcg	aaa	ggc	gaa	480
Tyr	Asn	Pro	Ile	His	Trp	Lys	Val	Ala	Glu	Val	Ile	Ala	Lys	Gly	Glu	
	145				150					155					160	
att	ggc	gaa	gtg	aaa	agc	gtg	cat	ttt	gaa	tgg	ctg	ctg	gat	acc	gtg	528
Ile	Gly	Glu	Val	Lys	Ser	Val	His	Phe	Glu	Trp	Leu	Leu	Asp	Thr	Val	
			165						170					175		
cat	ggc	gcg	gat	tat	ttt	cgc	cgc	tgg	cat	cgc	tat	aaa	gat	cgc	agc	576
His	Gly	Ala	Asp	Tyr	Phe	Arg	Arg	Trp	His	Arg	Tyr	Lys	Asp	Arg	Ser	
			180					185					190			
ggc	ggc	ctg	atg	att	cat	aaa	agc	agc	cat	cat	ttt	gat	ctg	gtg	aac	624
Gly	Gly	Leu	Met	Ile	His	Lys	Ser	Ser	His	His	Phe	Asp	Leu	Val	Asn	
		195					200					205				
ttt	tgg	att	cag	agc	gtg	ccg	cag	agc	gtg	ttt	ggc	atg	ggc	agc	ctg	672
Phe	Trp	Ile	Gln	Ser	Val	Pro	Gln	Ser	Val	Phe	Gly	Met	Gly	Ser	Leu	
	210					215					220					
gcg	ttt	tat	ggc	aaa	gaa	aac	ggc	aaa	aaa	agc	ggc	tgg	ggc	aaa	aac	720
Ala	Phe	Tyr	Gly	Lys	Glu	Asn	Gly	Lys	Lys	Ser	Gly	Trp	Gly	Lys	Asn	
	225				230					235					240	
tat	gaa	cgc	gcg	cgc	gat	gcg	aaa	gaa	gcg	gaa	aac	gat	ccg	ttt	gcg	768
Tyr	Glu	Arg	Ala	Arg	Asp	Ala	Lys	Glu	Ala	Glu	Asn	Asp	Pro	Phe	Ala	
			245						250					255		
att	cat	ctg	ggc	gat	gaa	gaa	ggc	ctg	aaa	ggc	ctg	tat	ttt	gat	gcg	816
Ile	His	Leu	Gly	Asp	Glu	Glu	Gly	Leu	Lys	Gly	Leu	Tyr	Phe	Asp	Ala	
		260					265						270			
gaa	cat	att	gat	ggc	tat	cat	cgc	gat	atg	aac	gtg	ttt	gcg	gat	gat	864
Glu	His	Ile	Asp	Gly	Tyr	His	Arg	Asp	Met	Asn	Val	Phe	Ala	Asp	Asp	
		275					280					285				
att	acc	att	gaa	gat	gat	atg	agc	gtg	ctg	gtg	cat	tat	gaa	agc	ggc	912
Ile	Thr	Ile	Glu	Asp	Asp	Met	Ser	Val	Leu	Val	His	Tyr	Glu	Ser	Gly	
	290					295					300					
gtg	aac	atg	acc	tat	cat	ctg	acc	gcg	tat	agc	ccg	tgg	gaa	ggc	tat	960
Val	Asn	Met	Thr	Tyr	His	Leu	Thr	Ala	Tyr	Ser	Pro	Trp	Glu	Gly	Tyr	
	305				310					315					320	
cgc	gtg	atg	ttt	aac	ggc	acc	cat	ggc	cgc	ctg	gaa	ctg	gaa	gtg	gtg	1008
Arg	Val	Met	Phe	Asn	Gly	Thr	His	Gly	Arg	Leu	Glu	Leu	Glu	Val	Val	
			325						330					335		
gaa	aac	gcg	ttt	cgc	ctg	ccg	att	ccg	aaa	ggc	agc	aac	aac	gcg	agc	1056
Glu	Asn	Ala	Phe	Arg	Leu	Pro	Ile	Pro	Lys	Gly	Ser	Asn	Asn	Ala	Ser	
		340						345					350			
gaa	cat	gtg	cat	ggc	gat	agc	gcg	ctg	ccg	aac	gaa	ggc	cat	agc	aaa	1104
Glu	His	Val	His	Gly	Asp	Ser	Ala	Leu	Pro	Asn	Glu	Gly	His	Ser	Lys	
		355					360					365				
att	acc	ctg	cat	aaa	ctg	tgg	cag	cag	ccg	gtg	aac	gtg	ccg	tat	cag	1152
Ile	Thr	Leu	His	Lys	Leu	Trp	Gln	Gln	Pro	Val	Asn	Val	Pro	Tyr	Gln	
		370				375					380					
gaa	gcg	aaa	ggc	ggc	cat	ggc	ggc	ggc	gat	gaa	gcg	atg	ctg	gat	gaa	1200
Glu	Ala	Lys	Gly	Gly	His	Gly	Gly	Gly	Asp	Glu	Ala	Met	Leu	Asp	Glu	
	385				390				395					400		
att	ttt	ggc	ccg	aaa	gaa	ggc	gaa	gaa	gaa	cgc	aaa	tgc	ccg	gtg	aac	1248

-continued

Ile	Phe	Gly	Pro	Lys	Glu	Gly	Glu	Glu	Glu	Arg	Lys	Cys	Pro	Val	Asn		
				405					410					415			
ggc	ctg	agc	gcg	gat	cag	aaa	gat	ggc	gcg	ctg	gcg	atg	gcg	gtg	ggc	1296	
Gly	Leu	Ser	Ala	Asp	Gln	Lys	Asp	Gly	Ala	Leu	Ala	Met	Ala	Val	Gly		
			420					425					430				
ctg	gcg	gcg	aac	gaa	agc	ttt	aaa	aac	ggc	aaa	cag	gtg	ttt	att	aaa	1344	
Leu	Ala	Ala	Asn	Glu	Ser	Phe	Lys	Asn	Gly	Lys	Gln	Val	Phe	Ile	Lys		
			435				440					445					
gaa	ctg	ctg	ggc	ggc	acc	ctg										1365	
Glu	Leu	Leu	Gly	Gly	Thr	Leu											
			450			455											

<210> SEQ ID NO 38
 <211> LENGTH: 455
 <212> TYPE: PRT
 <213> ORGANISM: Cryptococcus neoformans

<400> SEQUENCE: 38

Met	Thr	Ala	Val	Asn	Ser	Asn	Gln	Gly	Thr	Gly	Lys	Leu	Ser	Gly	Arg		
1				5					10					15			
Val	Gly	Ile	Val	Gly	Thr	Gly	His	Arg	Ala	Arg	Leu	Tyr	Thr	Thr	Ala		
			20				25						30				
Val	Ala	Ser	Arg	Ala	Asn	Thr	Ser	Leu	Val	Ala	Leu	Cys	Asp	Thr	Asn		
			35				40					45					
Asp	Ala	Arg	Met	Asp	Trp	His	Asn	Lys	Met	Leu	Arg	Glu	Ala	Gly	Arg		
			50			55				60							
Pro	Glu	Ala	Lys	Lys	Tyr	Ala	Ala	Glu	Asp	Phe	Arg	Lys	Met	Leu	Glu		
65					70				75					80			
Gln	Glu	Lys	Leu	Asp	Val	Leu	Val	Val	Thr	Thr	Ile	Asp	Tyr	Thr	His		
			85					90						95			
Asp	Met	Tyr	Ile	Ile	Pro	Ala	Leu	Lys	Ala	Gly	Ile	Lys	Val	Leu	Ser		
			100				105						110				
Glu	Lys	Pro	Met	Thr	Thr	Asn	Val	Asp	Lys	Cys	Lys	Ala	Ile	Leu	Asn		
			115			120						125					
Ala	Val	Asn	Glu	Ser	Lys	Gly	Ser	Leu	Thr	Val	Leu	Phe	Asn	Tyr	Arg		
			130			135					140						
Tyr	Asn	Pro	Ile	His	Trp	Lys	Val	Ala	Glu	Val	Ile	Ala	Lys	Gly	Glu		
145				150					155					160			
Ile	Gly	Glu	Val	Lys	Ser	Val	His	Phe	Glu	Trp	Leu	Leu	Asp	Thr	Val		
			165					170						175			
His	Gly	Ala	Asp	Tyr	Phe	Arg	Arg	Trp	His	Arg	Tyr	Lys	Asp	Arg	Ser		
			180				185						190				
Gly	Gly	Leu	Met	Ile	His	Lys	Ser	Ser	His	His	Phe	Asp	Leu	Val	Asn		
		195				200						205					
Phe	Trp	Ile	Gln	Ser	Val	Pro	Gln	Ser	Val	Phe	Gly	Met	Gly	Ser	Leu		
			210			215					220						
Ala	Phe	Tyr	Gly	Lys	Glu	Asn	Gly	Lys	Lys	Ser	Gly	Trp	Gly	Lys	Asn		
225				230						235				240			
Tyr	Glu	Arg	Ala	Arg	Asp	Ala	Lys	Glu	Ala	Glu	Asn	Asp	Pro	Phe	Ala		
			245					250						255			
Ile	His	Leu	Gly	Asp	Glu	Glu	Gly	Leu	Lys	Gly	Leu	Tyr	Phe	Asp	Ala		
			260				265						270				
Glu	His	Ile	Asp	Gly	Tyr	His	Arg	Asp	Met	Asn	Val	Phe	Ala	Asp	Asp		
			275				280					285					

-continued

Ile Thr Ile Glu Asp Asp Met Ser Val Leu Val His Tyr Glu Ser Gly
 290 295 300

Val Asn Met Thr Tyr His Leu Thr Ala Tyr Ser Pro Trp Glu Gly Tyr
 305 310 315 320

Arg Val Met Phe Asn Gly Thr His Gly Arg Leu Glu Leu Glu Val Val
 325 330 335

Glu Asn Ala Phe Arg Leu Pro Ile Pro Lys Gly Ser Asn Asn Ala Ser
 340 345 350

Glu His Val His Gly Asp Ser Ala Leu Pro Asn Glu Gly His Ser Lys
 355 360 365

Ile Thr Leu His Lys Leu Trp Gln Gln Pro Val Asn Val Pro Tyr Gln
 370 375 380

Glu Ala Lys Gly Gly His Gly Gly Gly Asp Glu Ala Met Leu Asp Glu
 385 390 395 400

Ile Phe Gly Pro Lys Glu Gly Glu Glu Glu Arg Lys Cys Pro Val Asn
 405 410 415

Gly Leu Ser Ala Asp Gln Lys Asp Gly Ala Leu Ala Met Ala Val Gly
 420 425 430

Leu Ala Ala Asn Glu Ser Phe Lys Asn Gly Lys Gln Val Phe Ile Lys
 435 440 445

Glu Leu Leu Gly Gly Thr Leu
 450 455

<210> SEQ ID NO 39
 <211> LENGTH: 1338
 <212> TYPE: DNA
 <213> ORGANISM: Cryptococcus neoformans
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1) .. (1338)

<400> SEQUENCE: 39

atg agc gcg att cgc gcg ctg aac atg cgc aaa acc gcg agc gcg ctg Met Ser Ala Ile Arg Ala Leu Asn Met Arg Lys Thr Ala Ser Ala Leu 1 5 10 15	48
aaa gcg ccg gtg gcg ttt aaa cgc acc ctg gcg acc ccg gtg aac agc Lys Ala Pro Val Ala Phe Lys Arg Thr Leu Ala Thr Pro Val Asn Ser 20 25 30	96
ctg tat acc agc gtg ctg ccg gcg aaa att ccg gcg gcg ctg cat ctg Leu Tyr Thr Ser Val Leu Pro Ala Lys Ile Pro Ala Ala Leu His Leu 35 40 45	144
aaa agc ggc cag agc tat ttt ggc agc agc ttt ggc agc gaa aac agc Lys Ser Gly Gln Ser Tyr Phe Gly Ser Ser Phe Gly Ser Glu Asn Ser 50 55 60	192
aaa ttt ggc gaa acc gtg ttt agc acc agc att acc agc tat acc gat Lys Phe Gly Glu Thr Val Phe Ser Thr Ser Ile Thr Ser Tyr Thr Asp 65 70 75 80	240
agc atg acc gat ccg agc tat ctg ggc cag att ctg gtg ttt acc agc Ser Met Thr Asp Pro Ser Tyr Leu Gly Gln Ile Leu Val Phe Thr Ser 85 90 95	288
ccg atg att ggc aac tat ggc gtg ccg agc aac acc agc agc cag ttt Pro Met Ile Gly Asn Tyr Gly Val Pro Ser Asn Thr Ser Ser Gln Phe 100 105 110	336
ccg ggc att ccg ttt ctg gaa agc gaa aaa att cag tgc acc ggc gtg Pro Gly Ile Pro Phe Leu Glu Ser Glu Lys Ile Gln Cys Thr Gly Val 115 120 125	384

-continued

gtg gtg agc gat gtg gcg ctg aaa tat agc cat tat cag gcg gtg gaa Val Val Ser Asp Val Ala Leu Lys Tyr Ser His Tyr Gln Ala Val Glu 130 135 140	432
agc ctg cat gaa tgg tgc aaa cgc tat gat gtg ccg ggc att acc ggc Ser Leu His Glu Trp Cys Lys Arg Tyr Asp Val Pro Gly Ile Thr Gly 145 150 155 160	480
gtg gat acc cgc gcg att acc agc ctg ctg cgc gat cag ggc acc acc Val Asp Thr Arg Ala Ile Thr Ser Leu Leu Arg Asp Gln Gly Thr Thr 165 170 175	528
ctg ggc cgc ctg gcg gtg ggc gat gaa gcg ggc aaa ccg gcg ccg cag Leu Gly Arg Leu Ala Val Gly Asp Glu Ala Gly Lys Pro Ala Pro Gln 180 185 190	576
gaa gcg gaa tat tgg gat ccg agc aaa gaa aac ctg gtg gcg cag gcg Glu Ala Glu Tyr Trp Asp Pro Ser Lys Glu Asn Leu Val Ala Gln Ala 195 200 205	624
agc acc aaa aaa gcg tat gtg ctg aac gaa aaa ggc agc ggc ccg cgc Ser Thr Lys Lys Ala Tyr Val Leu Asn Glu Lys Gly Ser Gly Pro Arg 210 215 220	672
att cgc gtg ctg gat ttt ggc acc aaa gcg aac att ctg cgc agc ctg Ile Ala Val Leu Asp Phe Gly Thr Lys Ala Asn Ile Leu Arg Ser Leu 225 230 235 240	720
att cgc cgc gat cgc gtg gtg acc gtg ctg ccg tgg gat ttt gat ttt Ile Arg Arg Asp Ala Val Val Thr Val Leu Pro Trp Asp Phe Asp Phe 245 250 255	768
aac acc gtg cgc gat cag ttt gat ggc ctg ttt ctg agc aac ggc ccg Asn Thr Val Arg Asp Gln Phe Asp Gly Leu Phe Leu Ser Asn Gly Pro 260 265 270	816
ggc gat ccg aaa atg att atg gat agc gcg atg cgc gtg cgc cag acc Gly Asp Pro Lys Met Ile Met Asp Ser Ala Met Arg Val Arg Gln Thr 275 280 285	864
att aac gaa tgg aac aaa ccg att ttt ggc att tgc atg ggc cat cag Ile Asn Glu Trp Asn Lys Pro Ile Phe Gly Ile Cys Met Gly His Gln 290 295 300	912
gtg ctg ggc ctg gcg gcg ggc ctg gaa gcg tat cgc atg acc ttt ggc Val Leu Gly Leu Ala Ala Gly Leu Glu Ala Tyr Arg Met Thr Phe Gly 305 310 315 320	960
aac cgc ggc cat aac cag ccg gtg ctg gcg ctg gcg agc agc ggc agc Asn Arg Gly His Asn Gln Pro Val Leu Ala Leu Ala Ser Ser Gly Ser 325 330 335	1008
att aaa gcg ggc cgc gtg tat gtg acc agc cag aac cat cag tat gcg Ile Lys Ala Gly Arg Val Tyr Val Thr Ser Gln Asn His Gln Tyr Ala 340 345 350	1056
ctg cgc ctg acc gaa gat ttt ccg gaa ggc tgg gcg ccg ttt ttt att Leu Arg Leu Thr Glu Asp Phe Pro Glu Gly Trp Ala Pro Phe Phe Ile 355 360 365	1104
aac tgc aac gat agc agc gtg gaa ggc att att agc acc ccg gaa agc Asn Cys Asn Asp Ser Ser Val Glu Gly Ile Ile Ser Thr Pro Glu Ser 370 375 380	1152
ggc aaa cgc att tgg ggc gtg cag ttt cat ccg gaa agc gcg ggc ggc Gly Lys Arg Ile Trp Gly Val Gln Phe His Pro Glu Ser Ala Gly Gly 385 390 395 400	1200
ccg ctg gat acc att gaa atg ttt acc gat ttt gtg aac gaa tgc gat Pro Leu Asp Thr Ile Glu Met Phe Thr Asp Phe Val Asn Glu Cys Asp 405 410 415	1248
gtg agc cgc aaa ggc ttt agc ggc agc gcg atg att gcg aac gaa gtg Val Ser Arg Lys Gly Phe Ser Gly Ser Ala Met Ile Ala Asn Glu Val 420 425 430	1296

-continued

```

aaa gtg gat ggc cat gcg gcg aaa gcg gcg agc gtg agc gcg      1338
Lys Val Asp Gly His Ala Ala Lys Ala Ala Ser Val Ser Ala
      435                440                445

```

```

<210> SEQ ID NO 40
<211> LENGTH: 446
<212> TYPE: PRT
<213> ORGANISM: Cryptococcus neoformans

```

```

<400> SEQUENCE: 40

```

```

Met Ser Ala Ile Arg Ala Leu Asn Met Arg Lys Thr Ala Ser Ala Leu
 1          5          10          15

Lys Ala Pro Val Ala Phe Lys Arg Thr Leu Ala Thr Pro Val Asn Ser
      20          25          30

Leu Tyr Thr Ser Val Leu Pro Ala Lys Ile Pro Ala Ala Leu His Leu
      35          40          45

Lys Ser Gly Gln Ser Tyr Phe Gly Ser Ser Phe Gly Ser Glu Asn Ser
      50          55          60

Lys Phe Gly Glu Thr Val Phe Ser Thr Ser Ile Thr Ser Tyr Thr Asp
      65          70          75          80

Ser Met Thr Asp Pro Ser Tyr Leu Gly Gln Ile Leu Val Phe Thr Ser
      85          90          95

Pro Met Ile Gly Asn Tyr Gly Val Pro Ser Asn Thr Ser Ser Gln Phe
      100         105         110

Pro Gly Ile Pro Phe Leu Glu Ser Glu Lys Ile Gln Cys Thr Gly Val
      115         120         125

Val Val Ser Asp Val Ala Leu Lys Tyr Ser His Tyr Gln Ala Val Glu
      130         135         140

Ser Leu His Glu Trp Cys Lys Arg Tyr Asp Val Pro Gly Ile Thr Gly
      145         150         155         160

Val Asp Thr Arg Ala Ile Thr Ser Leu Leu Arg Asp Gln Gly Thr Thr
      165         170         175

Leu Gly Arg Leu Ala Val Gly Asp Glu Ala Gly Lys Pro Ala Pro Gln
      180         185         190

Glu Ala Glu Tyr Trp Asp Pro Ser Lys Glu Asn Leu Val Ala Gln Ala
      195         200         205

Ser Thr Lys Lys Ala Tyr Val Leu Asn Glu Lys Gly Ser Gly Pro Arg
      210         215         220

Ile Ala Val Leu Asp Phe Gly Thr Lys Ala Asn Ile Leu Arg Ser Leu
      225         230         235         240

Ile Arg Arg Asp Ala Val Val Thr Val Leu Pro Trp Asp Phe Asp Phe
      245         250         255

Asn Thr Val Arg Asp Gln Phe Asp Gly Leu Phe Leu Ser Asn Gly Pro
      260         265         270

Gly Asp Pro Lys Met Ile Met Asp Ser Ala Met Arg Val Arg Gln Thr
      275         280         285

Ile Asn Glu Trp Asn Lys Pro Ile Phe Gly Ile Cys Met Gly His Gln
      290         295         300

Val Leu Gly Leu Ala Ala Gly Leu Glu Ala Tyr Arg Met Thr Phe Gly
      305         310         315         320

Asn Arg Gly His Asn Gln Pro Val Leu Ala Leu Ala Ser Ser Gly Ser
      325         330         335

```

-continued

Ile Lys Ala Gly Arg Val Tyr Val Thr Ser Gln Asn His Gln Tyr Ala
340 345 350

Leu Arg Leu Thr Glu Asp Phe Pro Glu Gly Trp Ala Pro Phe Phe Ile
355 360 365

Asn Cys Asn Asp Ser Ser Val Glu Gly Ile Ile Ser Thr Pro Glu Ser
370 375 380

Gly Lys Arg Ile Trp Gly Val Gln Phe His Pro Glu Ser Ala Gly Gly
385 390 395 400

Pro Leu Asp Thr Ile Glu Met Phe Thr Asp Phe Val Asn Glu Cys Asp
405 410 415

Val Ser Arg Lys Gly Phe Ser Gly Ser Ala Met Ile Ala Asn Glu Val
420 425 430

Lys Val Asp Gly His Ala Ala Lys Ala Ala Ser Val Ser Ala
435 440 445

<210> SEQ ID NO 41
 <211> LENGTH: 843
 <212> TYPE: DNA
 <213> ORGANISM: Cryptococcus neoformans
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1)..(843)

<400> SEQUENCE: 41

atg agc gtg ccg agc ctg aaa agc gcg ctg aaa aaa ccg acc aaa agc	48
Met Ser Val Pro Ser Leu Lys Ser Ala Leu Lys Lys Pro Thr Lys Ser	
1 5 10 15	
ttt gat acc ccg ccg gcg ggc ccg agc aaa ctg agc gtg gcg gcg gcg	96
Phe Asp Thr Pro Pro Ala Gly Pro Ser Lys Leu Ser Val Ala Ala Ala	
20 25 30	
gtg ccg gaa aaa agc aaa gcg aaa gcg aaa cag agc gtg agc att gcg	144
Val Pro Glu Lys Ser Lys Ala Lys Ala Lys Gln Ser Val Ser Ile Ala	
35 40 45	
gaa aaa ccg cag cgc ctg cgc ggc ccg gat ctg gaa agc gaa agc gaa	192
Glu Lys Pro Gln Arg Leu Arg Gly Pro Asp Leu Glu Ser Glu Ser Glu	
50 55 60	
ggc aac gcg agc ggc ttt gaa gat gaa agc gcg agc gaa gtg gaa gtg	240
Gly Asn Ala Ser Gly Phe Glu Asp Glu Ser Ala Ser Glu Val Glu Val	
65 70 75 80	
gat gaa gat gaa gaa atg aac acc gat gaa gaa att gaa aaa gcg aaa	288
Asp Glu Asp Glu Glu Met Asn Thr Asp Glu Glu Ile Glu Lys Ala Lys	
85 90 95	
gaa ggc aaa ccg aaa aaa agc acc aaa cgc aaa aaa gcg ccg acc acc	336
Glu Gly Lys Pro Lys Lys Ser Thr Lys Arg Lys Lys Ala Pro Thr Thr	
100 105 110	
gcg gcg gat ttt ggc gcg acc ctg acc agc ctg ctg gcg gat ccg ctg	384
Ala Ala Asp Phe Gly Ala Thr Leu Thr Ser Leu Leu Ala Asp Pro Leu	
115 120 125	
acc aaa agc aac aaa aaa gcg aaa acc gcg gat agc acc aaa aaa gcg	432
Thr Lys Ser Asn Lys Lys Ala Lys Thr Ala Asp Ser Thr Lys Lys Ala	
130 135 140	
gcg gcg gcg ccg att ctg gcg ctg agc gcg cat aaa ctg ccg acc aaa	480
Ala Ala Ala Pro Ile Leu Ala Leu Ser Ala His Lys Leu Pro Thr Lys	
145 150 155 160	
gcg agc gtg agc ctg gaa gcg aaa gcg aaa cgc cag ctg aaa gcg gaa	528
Ala Ser Val Ser Lys Glu Ala Lys Ala Lys Arg Gln Leu Lys Ala Glu	
165 170 175	

-continued

aaa gaa gaa aaa gaa gat cgc gcg cgc gtg cag aac gtg ctg gaa ggc	576
Lys Glu Glu Lys Glu Asp Arg Ala Arg Val Gln Asn Val Leu Glu Gly	
180 185 190	
tggtgg agc ggc gat ggc gtg gtg ggc ggc cag gaa ttt gaa cgc aac ctg	624
Trp Ser Gly Asp Gly Val Val Gly Gly Gln Glu Phe Glu Arg Asn Leu	
195 200 205	
cgccgc aaa acc gcg cag aaa ggc gtg gtg aaa ctg ttt aac gcg att ctg	672
Arg Lys Thr Ala Gln Lys Gly Val Val Lys Leu Phe Asn Ala Ile Leu	
210 215 220	
gtgtgc gcg agc aaa aac gcg gaa gcg gcg cag acc acc ctg agc gaa aaa	720
Val Ala Ser Lys Asn Ala Glu Ala Ala Gln Thr Thr Leu Ser Glu Lys	
225 230 235 240	
gcgcgc ctg aaa ccg gaa gcg gcg aaa aaa gaa aaa gat aac att	768
Ala Arg Leu Lys Pro Glu Ala Ala Lys Lys Lys Glu Lys Asp Asn Ile	
245 250 255	
ctgtggc gcg ggc ggc ggc aaa gaa gat gtg ctg acc aaa gaa agc ttt ctg	816
Leu Gly Arg Gly Lys Glu Asp Val Leu Thr Lys Glu Ser Phe Leu	
260 265 270	
gaa atg gtg cgc aaa ggc agc agc aaa	843
Glu Met Val Arg Lys Gly Ser Ser Lys	
275 280	

<210> SEQ ID NO 42

<211> LENGTH: 281

<212> TYPE: PRT

<213> ORGANISM: Cryptococcus neoformans

<400> SEQUENCE: 42

Met Ser Val Pro Ser Leu Lys Ser Ala Leu Lys Lys Pro Thr Lys Ser	
1 5 10 15	
Phe Asp Thr Pro Pro Ala Gly Pro Ser Lys Leu Ser Val Ala Ala Ala	
20 25 30	
Val Pro Glu Lys Ser Lys Ala Lys Ala Lys Gln Ser Val Ser Ile Ala	
35 40 45	
Glu Lys Pro Gln Arg Leu Arg Gly Pro Asp Leu Glu Ser Glu Ser Glu	
50 55 60	
Gly Asn Ala Ser Gly Phe Glu Asp Glu Ser Ala Ser Glu Val Glu Val	
65 70 75 80	
Asp Glu Asp Glu Glu Met Asn Thr Asp Glu Glu Ile Glu Lys Ala Lys	
85 90 95	
Glu Gly Lys Pro Lys Lys Ser Thr Lys Arg Lys Lys Ala Pro Thr Thr	
100 105 110	
Ala Ala Asp Phe Gly Ala Thr Leu Thr Ser Leu Leu Ala Asp Pro Leu	
115 120 125	
Thr Lys Ser Asn Lys Lys Ala Lys Thr Ala Asp Ser Thr Lys Lys Ala	
130 135 140	
Ala Ala Ala Pro Ile Leu Ala Leu Ser Ala His Lys Leu Pro Thr Lys	
145 150 155 160	
Ala Ser Val Ser Leu Glu Ala Lys Ala Lys Arg Gln Leu Lys Ala Glu	
165 170 175	
Lys Glu Glu Lys Glu Asp Arg Ala Arg Val Gln Asn Val Leu Glu Gly	
180 185 190	
Trp Ser Gly Asp Gly Val Val Gly Gly Gln Glu Phe Glu Arg Asn Leu	
195 200 205	
Arg Lys Thr Ala Gln Lys Gly Val Val Lys Leu Phe Asn Ala Ile Leu	

-continued

210	215	220	
Val Ala Ser Lys Asn Ala Glu Ala Ala Gln Thr Thr Leu Ser Glu Lys			
225	230	235	240
Ala Arg Leu Lys Pro Glu Ala Ala Lys Lys Lys Glu Lys Asp Asn Ile			
	245	250	255
Leu Gly Arg Gly Gly Lys Glu Asp Val Leu Thr Lys Glu Ser Phe Leu			
	260	265	270
Glu Met Val Arg Lys Gly Ser Ser Lys			
	275	280	
<210> SEQ ID NO 43			
<211> LENGTH: 600			
<212> TYPE: DNA			
<213> ORGANISM: Cryptococcus neoformans			
<220> FEATURE:			
<221> NAME/KEY: CDS			
<222> LOCATION: (1)..(600)			
<400> SEQUENCE: 43			
atg acc tgc gcg ctg att ccg ctg ctg cgc aaa agc gat ctg cgc agc			48
Met Thr Cys Ala Leu Ile Pro Leu Leu Arg Lys Ser Asp Leu Arg Ser			
1	5	10	15
gtg gtg att att gcg agc att gcg ggc ctg gcg aac cag cgc gcg acc			96
Val Val Ile Ile Ala Ser Ile Ala Gly Leu Ala Asn Gln Arg Ala Thr			
	20	25	30
ggc agc gtg agc tat ggc gtg agc aaa gcg gcg gcg att cat ctg ggc			144
Gly Ser Val Ser Tyr Gly Val Ser Lys Ala Ala Ala Ile His Leu Gly			
	35	40	45
aaa ctg ctg gcg ggc cgc ctg cat ccg ctg aaa att cgc gtg aac acc			192
Lys Leu Leu Ala Gly Arg Leu His Pro Leu Lys Ile Arg Val Asn Thr			
	50	55	60
att tgc ccg ggc att ttt ccg agc gaa atg acc ggc aaa aac gat gcg			240
Ile Cys Pro Gly Ile Phe Pro Ser Glu Met Thr Gly Lys Asn Asp Ala			
	65	70	75
ggc cag ggc ctg gaa tat gat att ggc gaa att ccg acc aaa gcg gcg			288
Gly Gln Gly Leu Glu Tyr Asp Ile Gly Glu Ile Pro Thr Lys Ala Ala			
	85	90	95
aaa cgc agc acc gtg ggc cgc ccg ggc ctg ccg gaa gaa att gtg ggc			336
Lys Arg Ser Thr Val Gly Arg Pro Gly Leu Pro Glu Glu Ile Val Gly			
	100	105	110
ccg gtg ctg ctg ctg agc agc aaa gcg ggc ggc tat ttt gat ggc gcg			384
Pro Val Leu Leu Ser Ser Lys Ala Gly Gly Tyr Phe Asp Gly Ala			
	115	120	125
atg ctg acc gtg gat ggc ggc cgc ctg atg gtg agc ggc ccg ttt tgc			432
Met Leu Thr Val Asp Gly Gly Arg Leu Met Val Ser Gly Pro Phe Cys			
	130	135	140
ttt gtg ttt agc ccg agc agc ctg ccg gtg gat aac ctg cgc tgc ttt			480
Phe Val Phe Ser Pro Ser Ser Leu Pro Val Asp Asn Leu Arg Cys Phe			
	145	150	155
ctg ctg ctg acc acc gtg ggc aac cgc gtg ccg gcg ttt atg atg gtg			528
Leu Leu Leu Thr Thr Val Gly Asn Arg Val Pro Ala Phe Met Met Val			
	165	170	175
agc gat tgc ctg cgc att cgc att ttt gaa ctg aac gaa cag cgc aaa			576
Ser Asp Cys Leu Arg Ile Arg Ile Phe Glu Leu Asn Glu Gln Arg Lys			
	180	185	190
aac gaa acc gat gtg gaa atg ggc			600
Asn Glu Thr Asp Val Glu Met Gly			
	195	200	

-continued

```

<210> SEQ ID NO 44
<211> LENGTH: 200
<212> TYPE: PRT
<213> ORGANISM: Cryptococcus neoformans

<400> SEQUENCE: 44

Met Thr Cys Ala Leu Ile Pro Leu Leu Arg Lys Ser Asp Leu Arg Ser
1          5          10
Val Val Ile Ile Ala Ser Ile Ala Gly Leu Ala Asn Gln Arg Ala Thr
20        25        30
Gly Ser Val Ser Tyr Gly Val Ser Lys Ala Ala Ala Ile His Leu Gly
35        40        45
Lys Leu Leu Ala Gly Arg Leu His Pro Leu Lys Ile Arg Val Asn Thr
50        55        60
Ile Cys Pro Gly Ile Phe Pro Ser Glu Met Thr Gly Lys Asn Asp Ala
65        70        75        80
Gly Gln Gly Leu Glu Tyr Asp Ile Gly Glu Ile Pro Thr Lys Ala Ala
85        90        95
Lys Arg Ser Thr Val Gly Arg Pro Gly Leu Pro Glu Glu Ile Val Gly
100       105       110
Pro Val Leu Leu Leu Ser Ser Lys Ala Gly Gly Tyr Phe Asp Gly Ala
115       120       125
Met Leu Thr Val Asp Gly Gly Arg Leu Met Val Ser Gly Pro Phe Cys
130       135       140
Phe Val Phe Ser Pro Ser Ser Leu Pro Val Asp Asn Leu Arg Cys Phe
145       150       155       160
Leu Leu Leu Thr Thr Val Gly Asn Arg Val Pro Ala Phe Met Met Val
165       170       175
Ser Asp Cys Leu Arg Ile Arg Ile Phe Glu Leu Asn Glu Gln Arg Lys
180       185       190
Asn Glu Thr Asp Val Glu Met Gly
195       200

```

```

<210> SEQ ID NO 45
<211> LENGTH: 1440
<212> TYPE: DNA
<213> ORGANISM: Cryptococcus neoformans
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1) .. (1440)

<400> SEQUENCE: 45

atg ctg gtg aac agc agc agc atg ctg gtg acc cgc acc cat ggc ctg      48
Met Leu Val Asn Ser Ser Ser Met Leu Val Thr Arg Thr His Gly Leu
1          5          10          15

atg ggc gat gaa gcg tgg aaa gaa ctg gcg aaa tat ggc ctg acc cgc      96
Met Gly Asp Glu Ala Trp Lys Glu Leu Ala Lys Tyr Gly Leu Thr Arg
20        25        30

tgg agc gat gat ggc gcg ttt ctg acc gtg ccg gcg cgc ggc tgc agc     144
Trp Ser Asp Asp Gly Ala Phe Leu Thr Val Pro Ala Arg Gly Cys Ser
35        40        45

atg tgc gaa gtg gat ccg gtg ctg tgc gaa gaa att ggc gaa gat aac     192
Met Cys Glu Val Asp Pro Val Leu Cys Glu Glu Ile Gly Glu Asp Asn
50        55        60

ctg aaa cgc agc ctg gcg ttt agc ggc acc aac cgc cgc ctg aaa cgc     240

```

-continued

Leu 65	Lys	Arg	Ser	Leu 70	Ala	Phe	Ser	Gly	Thr	Asn 75	Arg	Arg	Leu	Lys	Arg 80	
gtg	ctg	gcg	aaa	ctg	cg	cg	ggc	gaa	acc	att	aac	gtg	ggc	gcg	att	288
Val	Leu	Ala	Lys	Leu	Arg	Arg	Gly	Glu	Thr	Ile	Asn	Val	Gly	Ala	Ile	
				85					90					95		
ggc	ggc	agc	gtg	acc	aaa	ggc	tat	ggc	ctg	aac	cg	tat	aac	gaa	ccg	336
Gly	Gly	Ser	Val	Thr	Lys	Gly	Tyr	Gly	Leu	Asn	Arg	Tyr	Asn	Glu	Pro	
			100					105					110			
tat	tat	ccg	gat	acc	ccg	acc	aac	ctg	cat	cg	att	att	ttt	gat	cat	384
Tyr	Tyr	Pro	Asp	Thr	Pro	Thr	Asn	Leu	His	Arg	Ile	Ile	Phe	Asp	His	
		115					120					125				
ctg	gtg	agc	ctg	tat	ccg	cg	ccg	aac	ggc	gtg	aaa	acc	gat	gat	agc	432
Leu	Val	Ser	Leu	Tyr	Pro	Ala	Pro	Asn	Gly	Val	Lys	Thr	Asp	Asp	Ser	
	130					135					140					
ggc	cg	aaa	gaa	ggc	aaa	cat	ggc	tat	att	aac	ggc	ggc	cag	ggc	gcg	480
Gly	Arg	Lys	Glu	Gly	Lys	His	Gly	Tyr	Ile	Asn	Gly	Gly	Gln	Gly	Ala	
145					150					155				160		
acc	ggc	acc	ggc	tat	ttt	agc	tat	tgc	tgg	gaa	gaa	cat	gtg	ccg	gcg	528
Thr	Gly	Thr	Gly	Tyr	Phe	Ser	Tyr	Cys	Trp	Glu	Glu	His	Val	Pro	Ala	
			165					170					175			
gat	ctg	gat	ctg	att	ttt	ctg	gaa	cag	cg	att	aac	gat	gaa	ctg	ctg	576
Asp	Leu	Asp	Leu	Ile	Phe	Leu	Glu	Gln	Ala	Ile	Asn	Asp	Glu	Leu	Leu	
			180					185					190			
ctg	cg	aac	att	gat	agc	tat	gaa	ctg	ctg	gtg	cg	agc	ctg	ctg	gat	624
Leu	Arg	Asn	Ile	Asp	Ser	Tyr	Glu	Leu	Leu	Val	Arg	Ser	Leu	Leu	Asp	
		195					200					205				
ctg	ccg	acc	agc	ccg	ggc	att	gtg	aac	ctg	cat	gtg	ttt	gcg	ctg	atg	672
Leu	Pro	Thr	Ser	Pro	Ala	Ile	Val	Asn	Leu	His	Val	Phe	Ala	Leu	Met	
	210					215					220					
ttt	aac	agc	att	acc	ctg	ggc	ggc	gat	ctg	cat	cag	agc	att	gcg	cag	720
Phe	Asn	Ser	Ile	Thr	Leu	Gly	Gly	Asp	Leu	His	Gln	Ser	Ile	Ala	Gln	
225				230						235				240		
ttt	tat	gat	ctg	ccg	gtg	ctg	agc	ctg	cg	aac	gcg	ctg	ctg	aac	gat	768
Phe	Tyr	Asp	Leu	Pro	Val	Leu	Ser	Leu	Arg	Asn	Ala	Leu	Leu	Asn	Asp	
			245					250					255			
atg	ctg	aaa	aac	gaa	agc	ctg	att	agc	gaa	tat	ttt	ttt	gtg	cat	ccg	816
Met	Leu	Lys	Asn	Glu	Ser	Leu	Ile	Ser	Glu	Tyr	Phe	Phe	Val	His	Pro	
		260					265						270			
gaa	ggc	gat	att	gat	ctg	cg	cat	att	agc	cg	aaa	ggc	cat	aac	gtg	864
Glu	Gly	Asp	Ile	Asp	Leu	Arg	His	Ile	Ser	Arg	Lys	Gly	His	Asn	Val	
		275					280					285				
atg	ggc	cg	att	ggc	gcg	gcg	tat	atg	gat	agc	cag	att	tgc	gaa	atg	912
Met	Gly	Arg	Ile	Gly	Ala	Ala	Tyr	Met	Asp	Ser	Gln	Ile	Cys	Glu	Met	
	290				295						300					
gat	aaa	tat	gaa	cag	ggc	att	ccg	ggc	gcg	gat	agc	atg	agc	att	gat	960
Asp	Lys	Tyr	Glu	Gln	Gly	Ile	Pro	Gly	Ala	Asp	Ser	Met	Ser	Ile	Asp	
	305				310					315				320		
cag	ctg	tat	ccg	gtg	gaa	ccg	att	ccg	cg	atg	cag	att	aac	atg	aaa	1008
Gln	Leu	Tyr	Pro	Val	Glu	Pro	Ile	Pro	Arg	Met	Gln	Ile	Asn	Met	Lys	
			325					330					335			
tat	gat	aaa	gat	ctg	gtg	ctg	ccg	acc	att	aaa	ccg	cag	tgc	ttt	agc	1056
Tyr	Asp	Lys	Asp	Leu	Val	Leu	Pro	Thr	Ile	Lys	Pro	Gln	Cys	Phe	Ser	
		340						345					350			
gcg	aac	agc	gaa	aaa	cat	ccg	ctg	gtg	ccg	gtg	gaa	aac	aac	ggc	tgg	1104
Ala	Asn	Ser	Glu	Lys	His	Pro	Leu	Val	Pro	Val	Glu	Asn	Asn	Gly	Trp	
		355				360						365				
cg	aaa	tgg	aac	tgg	aaa	gaa	aaa	cat	tat	ctg	gtg	gcg	gat	gtg	ccg	1152

-continued

Arg	Lys	Trp	Asn	Trp	Lys	Glu	Lys	His	Tyr	Leu	Val	Ala	Asp	Val	Pro		
370						375					380						
ggc	agc	cgc	gtg	agc	ttt	aaa	ctg	aaa	acc	aac	atg	ggc	aaa	att	gaa	1200	
Gly	Ser	Arg	Val	Ser	Phe	Lys	Leu	Lys	Thr	Asn	Met	Gly	Lys	Ile	Glu		
385					390					395					400		
gtg	cag	tat	ctg	cgc	agc	tat	cag	tat	cat	cag	ggc	agc	gcg	aaa	tgc	1248	
Val	Gln	Tyr	Leu	Arg	Ser	Tyr	Gln	Tyr	His	Gln	Gly	Ser	Ala	Lys	Cys		
				405					410					415			
tgg	gtg	gat	gaa	gaa	gtg	gaa	aaa	gcg	att	aaa	ctg	gat	ggc	tat	tgg	1296	
Trp	Val	Asp	Glu	Glu	Val	Glu	Lys	Ala	Ile	Lys	Leu	Asp	Gly	Tyr	Trp		
				420				425					430				
aaa	gaa	ccg	tat	aac	att	ggc	cgc	gcg	gtg	acc	att	cgc	gaa	ggc	ctg	1344	
Lys	Glu	Pro	Tyr	Asn	Ile	Gly	Arg	Ala	Val	Thr	Ile	Arg	Glu	Gly	Leu		
		435					440					445					
gaa	ccg	ggc	gaa	cat	acc	ctg	acc	tgc	gaa	ctg	ctg	aaa	cag	acc	gcg	1392	
Glu	Pro	Gly	Glu	His	Thr	Leu	Thr	Cys	Glu	Leu	Leu	Lys	Gln	Thr	Ala		
		450				455				460							
gat	ccg	gaa	ggc	ggc	ctg	gaa	ttt	cgc	ctg	att	agc	att	atg	agc	att	1440	
Asp	Pro	Glu	Gly	Gly	Leu	Glu	Phe	Arg	Leu	Ile	Ser	Ile	Met	Ser	Ile		
465					470				475						480		

<210> SEQ ID NO 46

<211> LENGTH: 480

<212> TYPE: PRT

<213> ORGANISM: Cryptococcus neoformans

<400> SEQUENCE: 46

Met	Leu	Val	Asn	Ser	Ser	Ser	Met	Leu	Val	Thr	Arg	Thr	His	Gly	Leu		
1			5						10					15			
Met	Gly	Asp	Glu	Ala	Trp	Lys	Glu	Leu	Ala	Lys	Tyr	Gly	Leu	Thr	Arg		
		20						25					30				
Trp	Ser	Asp	Asp	Gly	Ala	Phe	Leu	Thr	Val	Pro	Ala	Arg	Gly	Cys	Ser		
		35				40						45					
Met	Cys	Glu	Val	Asp	Pro	Val	Leu	Cys	Glu	Glu	Ile	Gly	Glu	Asp	Asn		
	50					55					60						
Leu	Lys	Arg	Ser	Leu	Ala	Phe	Ser	Gly	Thr	Asn	Arg	Arg	Leu	Lys	Arg		
65				70						75				80			
Val	Leu	Ala	Lys	Leu	Arg	Arg	Gly	Glu	Thr	Ile	Asn	Val	Gly	Ala	Ile		
			85					90						95			
Gly	Gly	Ser	Val	Thr	Lys	Gly	Tyr	Gly	Leu	Asn	Arg	Tyr	Asn	Glu	Pro		
		100						105					110				
Tyr	Tyr	Pro	Asp	Thr	Pro	Thr	Asn	Leu	His	Arg	Ile	Ile	Phe	Asp	His		
		115					120						125				
Leu	Val	Ser	Leu	Tyr	Pro	Ala	Pro	Asn	Gly	Val	Lys	Thr	Asp	Asp	Ser		
	130					135					140						
Gly	Arg	Lys	Glu	Gly	Lys	His	Gly	Tyr	Ile	Asn	Gly	Gly	Gln	Gly	Ala		
145					150					155					160		
Thr	Gly	Thr	Gly	Tyr	Phe	Ser	Tyr	Cys	Trp	Glu	Glu	His	Val	Pro	Ala		
			165					170						175			
Asp	Leu	Asp	Leu	Ile	Phe	Leu	Glu	Gln	Ala	Ile	Asn	Asp	Glu	Leu	Leu		
			180					185					190				
Leu	Arg	Asn	Ile	Asp	Ser	Tyr	Glu	Leu	Leu	Val	Arg	Ser	Leu	Leu	Asp		
		195					200					205					
Leu	Pro	Thr	Ser	Pro	Ala	Ile	Val	Asn	Leu	His	Val	Phe	Ala	Leu	Met		
	210					215					220						

-continued

Phe Asn Ser Ile Thr Leu Gly Gly Asp Leu His Gln Ser Ile Ala Gln
 225 230 235 240
 Phe Tyr Asp Leu Pro Val Leu Ser Leu Arg Asn Ala Leu Leu Asn Asp
 245 250 255
 Met Leu Lys Asn Glu Ser Leu Ile Ser Glu Tyr Phe Phe Val His Pro
 260 265 270
 Glu Gly Asp Ile Asp Leu Arg His Ile Ser Arg Lys Gly His Asn Val
 275 280 285
 Met Gly Arg Ile Gly Ala Ala Tyr Met Asp Ser Gln Ile Cys Glu Met
 290 295 300
 Asp Lys Tyr Glu Gln Gly Ile Pro Gly Ala Asp Ser Met Ser Ile Asp
 305 310 315 320
 Gln Leu Tyr Pro Val Glu Pro Ile Pro Arg Met Gln Ile Asn Met Lys
 325 330 335
 Tyr Asp Lys Asp Leu Val Leu Pro Thr Ile Lys Pro Gln Cys Phe Ser
 340 345 350
 Ala Asn Ser Glu Lys His Pro Leu Val Pro Val Glu Asn Asn Gly Trp
 355 360 365
 Arg Lys Trp Asn Trp Lys Glu Lys His Tyr Leu Val Ala Asp Val Pro
 370 375 380
 Gly Ser Arg Val Ser Phe Lys Leu Lys Thr Asn Met Gly Lys Ile Glu
 385 390 395 400
 Val Gln Tyr Leu Arg Ser Tyr Gln Tyr His Gln Gly Ser Ala Lys Cys
 405 410 415
 Trp Val Asp Glu Glu Val Glu Lys Ala Ile Lys Leu Asp Gly Tyr Trp
 420 425 430
 Lys Glu Pro Tyr Asn Ile Gly Arg Ala Val Thr Ile Arg Glu Gly Leu
 435 440 445
 Glu Pro Gly Glu His Thr Leu Thr Cys Glu Leu Leu Lys Gln Thr Ala
 450 455 460
 Asp Pro Glu Gly Gly Leu Glu Phe Arg Leu Ile Ser Ile Met Ser Ile
 465 470 475 480

<210> SEQ ID NO 47
 <211> LENGTH: 1176
 <212> TYPE: DNA
 <213> ORGANISM: *Cryptococcus neoformans*
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1)..(1176)

<400> SEQUENCE: 47

atg agc ttt gat gcg gtg gtg att ggc agc ggc gtg att ggc ctg agc	48
Met Ser Phe Asp Ala Val Val Ile Gly Ser Gly Val Ile Gly Leu Ser	
1 5 10 15	
att gcg cgc gaa ctg cat aac cgc ggc ctg aaa gtg gcg att gtg gcg	96
Ile Ala Arg Glu Leu His Asn Arg Gly Leu Lys Val Ala Ile Val Ala	
20 25 30	
cgc gat ctg gcg gaa gat agc att agc gtg ggc ttt gcg agc ccg tgg	144
Arg Asp Leu Ala Glu Asp Ser Ile Ser Val Gly Phe Ala Ser Pro Trp	
35 40 45	
gcg ggc tgc aac tgg ttt agc ttt gcg gaa ggc ggc acc ccg gcg gcg	192
Ala Gly Cys Asn Trp Phe Ser Phe Ala Glu Gly Gly Thr Pro Ala Ala	
50 55 60	

-continued

gaa tgg gat acc att acc ttt ggc aaa ctg gcg aaa ctg gcg aaa gat Glu Trp Asp Thr Ile Thr Phe Gly Lys Leu Ala Lys Leu Ala Lys Asp 65 70 75 80	240
cat ccg cat att tgc cag aaa att ccg ttt tgc agc gtg tgg gat ctg His Pro His Ile Cys Gln Lys Ile Pro Phe Cys Ser Val Trp Asp Leu 85 90 95	288
ccg aaa agc gat gcg gaa agc gaa ccg tgg ttt aaa gat ctg gtg ttt Pro Lys Ser Asp Ala Glu Ser Glu Pro Trp Phe Lys Asp Leu Val Phe 100 105 110	336
gat tat aaa aac ctg aaa agc acc ccg ggc cag ccg ctg ccg ggc ggc Asp Tyr Lys Asn Leu Lys Ser Thr Pro Gly Gln Pro Leu Pro Gly Gly 115 120 125	384
aaa aaa ttt ggc cat agc ttt gcg agc tat gtg ctg cat gcg ccg aac Lys Lys Phe Gly His Ser Phe Ala Ser Tyr Val Leu His Ala Pro Asn 130 135 140	432
tat att cgc cat ctg agc agc gaa acc ccg gcg ctg ggc att ccg gtg Tyr Ile Arg His Leu Ser Ser Glu Thr Arg Ala Leu Gly Ile Pro Val 145 150 155 160	480
cat cgc tat cgc ctg agc agc ctg gat gaa gcg tat aac ctg agc ggc His Arg Tyr Arg Leu Ser Ser Leu Asp Glu Ala Tyr Asn Leu Ser Gly 165 170 175	528
att ggc aaa gtg agc ctg gtg gtg aac gcg agc ggc ctg ggc gcg aaa Ile Gly Lys Val Ser Leu Val Val Asn Ala Ser Gly Leu Gly Ala Lys 180 185 190	576
gcg ctg att ggc gtg gaa gat gaa aaa gtg tat ccg ggc cgc ggc cag Ala Leu Ile Gly Val Glu Asp Glu Lys Val Tyr Pro Gly Arg Gly Gln 195 200 205	624
acc gtg ctg gtg cgc gcg ccg ggc ttt aaa gcg tgc att atg cat acc Thr Val Leu Val Arg Ala Pro Gly Phe Lys Ala Cys Ile Met His Thr 210 215 220	672
gaa ggc ttt tat gcg gat ctg gat gaa agc ggc cgc gaa gtg acc ccg Glu Gly Phe Tyr Ala Asp Leu Asp Glu Ser Gly Arg Glu Val Thr Pro 225 230 235 240	720
ccg ccg ccg gcg tat att att ccg cgc ccg ggc ccg gaa ggc cat gtg Pro Pro Pro Ala Tyr Ile Ile Pro Arg Pro Gly Pro Glu Gly His Val 245 250 255	768
gtg ctg ggc ggc gtg tat cag cgc gat aac tgg agc acc ctg ccg gat Val Leu Gly Gly Val Tyr Gln Arg Asp Asn Trp Ser Thr Leu Pro Asp 260 265 270	816
ctg aaa gaa gcg gaa cgc att ctg aaa gat tgc tat aac ctg gcg ccg Leu Lys Glu Ala Glu Arg Ile Leu Lys Asp Cys Tyr Asn Leu Ala Pro 275 280 285	864
gaa ctg gcg ggc ccg aac ggc aaa acc tgg aaa gat att gaa att att Glu Leu Ala Gly Pro Asn Gly Lys Thr Trp Lys Asp Ile Glu Ile Ile 290 295 300	912
agc cat aac gtg ggc ctg cgc ccg gcg cgc gaa ggc ggc ccg cgc ctg Ser His Asn Val Gly Leu Arg Pro Ala Arg Glu Gly Gly Pro Arg Leu 305 310 315 320	960
gaa att gaa gaa cgc gaa gtg ggc acc ggc gcg aac gaa ggc aac gcg Glu Ile Glu Glu Arg Glu Val Gly Thr Gly Ala Asn Glu Gly Asn Ala 325 330 335	1008
tat gat gtg gcg ccg atg att ggc cgc att ggc gaa cgc cgc aaa gtg Tyr Asp Val Ala Pro Met Ile Gly Arg Ile Gly Glu Arg Arg Lys Val 340 345 350	1056
gcg gtg gtg cat gcg tat ggc att ggc agc gcg ggc ttt cag gcg agc Ala Val Val His Ala Tyr Gly Ile Gly Ser Ala Gly Phe Gln Ala Ser 355 360 365	1104

-continued

```

ctg ggc atg gcg gaa aaa gcg agc gat ctg acc gtg aaa tat ctg agc      1152
Leu Gly Met Ala Glu Lys Ala Ser Asp Leu Thr Val Lys Tyr Leu Ser
    370                375                380

```

```

ggc aaa cgc agc ccg gcg cgc ctg      1176
Gly Lys Arg Ser Pro Ala Arg Leu
385                390

```

```

<210> SEQ ID NO 48
<211> LENGTH: 392
<212> TYPE: PRT
<213> ORGANISM: Cryptococcus neoformans

```

```

<400> SEQUENCE: 48

```

```

Met Ser Phe Asp Ala Val Val Ile Gly Ser Gly Val Ile Gly Leu Ser
1      5      10      15

Ile Ala Arg Glu Leu His Asn Arg Gly Leu Lys Val Ala Ile Val Ala
20     25     30

Arg Asp Leu Ala Glu Asp Ser Ile Ser Val Gly Phe Ala Ser Pro Trp
35     40     45

Ala Gly Cys Asn Trp Phe Ser Phe Ala Glu Gly Gly Thr Pro Ala Ala
50     55     60

Glu Trp Asp Thr Ile Thr Phe Gly Lys Leu Ala Lys Leu Ala Lys Asp
65     70     75     80

His Pro His Ile Cys Gln Lys Ile Pro Phe Cys Ser Val Trp Asp Leu
85     90     95

Pro Lys Ser Asp Ala Glu Ser Glu Pro Trp Phe Lys Asp Leu Val Phe
100    105    110

Asp Tyr Lys Asn Leu Lys Ser Thr Pro Gly Gln Pro Leu Pro Gly Gly
115    120    125

Lys Lys Phe Gly His Ser Phe Ala Ser Tyr Val Leu His Ala Pro Asn
130    135    140

Tyr Ile Arg His Leu Ser Ser Glu Thr Arg Ala Leu Gly Ile Pro Val
145    150    155    160

His Arg Tyr Arg Leu Ser Ser Leu Asp Glu Ala Tyr Asn Leu Ser Gly
165    170    175

Ile Gly Lys Val Ser Leu Val Val Asn Ala Ser Gly Leu Gly Ala Lys
180    185    190

Ala Leu Ile Gly Val Glu Asp Glu Lys Val Tyr Pro Gly Arg Gly Gln
195    200    205

Thr Val Leu Val Arg Ala Pro Gly Phe Lys Ala Cys Ile Met His Thr
210    215    220

Glu Gly Phe Tyr Ala Asp Leu Asp Glu Ser Gly Arg Glu Val Thr Pro
225    230    235    240

Pro Pro Pro Ala Tyr Ile Ile Pro Arg Pro Gly Pro Glu Gly His Val
245    250    255

Val Leu Gly Gly Val Tyr Gln Arg Asp Asn Trp Ser Thr Leu Pro Asp
260    265    270

Leu Lys Glu Ala Glu Arg Ile Leu Lys Asp Cys Tyr Asn Leu Ala Pro
275    280    285

Glu Leu Ala Gly Pro Asn Gly Lys Thr Trp Lys Asp Ile Glu Ile Ile
290    295    300

Ser His Asn Val Gly Leu Arg Pro Ala Arg Glu Gly Gly Pro Arg Leu
305    310    315    320

```

```
<210> SEQ ID NO 49
<211> LENGTH: 198
<212> TYPE: DNA
<213> ORGANISM: Cryptococcus neoformans
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(198)
```

<400> SEQUENCE: 49

atg ccg ggc ttt cag gat gtg att tat aac acc ttt ttt cgc cgc aac 48
Met Pro Gly Phe Gln Asp Val Ile Tyr Asn Thr Phe Phe Arg Arg Asn
1 5 10 15

agc gtg ttt gtg gcg acc acc ttt att gcg gcg ttt agc ttt agc atg 96
 Ser Val Phe Val Ala Thr Thr Phe Ile Ala Ala Phe Ser Phe Ser Met
 20 25 30

ggc ttt gat ctg gcg acc acc gcg ttt tgg gat agc cat aac cgc ggc 144
Gly Phe Asp Leu Ala Thr Thr Ala Phe Trp Asp Ser His Asn Arg Gly
35 40 45

aaa cag tgg aaa gat att cgc cat aaa tat att gaa gcg gcg ggc gat 192
Lys Gln Trp Lys Asp Ile Arg His Lys Tyr Ile Glu Ala Ala Gly Asp
50 55 60

gat gaa 198
Asp Glu
65

```
<210> SEQ ID NO 50
<211> LENGTH: 66
<212> TYPE: PRT
<213> ORGANISM: Cryptococcus neoformans
```

<400> SEQUENCE: 50

Met Pro Gly Phe Gln Asp Val Ile Tyr Asn Thr Phe Phe Arg Arg Asn
1 5 10 15

Ser Val Phe Val Ala Thr Thr Phe Ile Ala Ala Phe Ser Phe Ser Met
20 25 30

Gly Phe Asp Leu Ala Thr Thr Ala Phe Trp Asp Ser His Asn Arg Gly
35 40 45

Lys Gln Trp Lys Asp Ile Arg His Lys Tyr Ile Glu Ala Ala Gly Asp
50 55 60

Asp Glu
65

```
<210> SEQ ID NO 51
<211> LENGTH: 1368
<212> TYPE: DNA
<213> ORGANISM: Cryptococcus neoformans
<220> FEATURE:
<221> NAME/KEY: CDS
```

-continued

<222> LOCATION: (1) .. (1368)

<400> SEQUENCE: 51

atg agc agc ggc aac gtg ccg aaa att gaa cgc ctg agc tgc gtg ccg	48
Met Ser Ser Gly Asn Val Pro Lys Ile Glu Arg Leu Ser Cys Val Pro	
1 5 10 15	
aac gat tat ccg tgg ggc gaa gtg ggc aac gat agc ctg gcg gcg ccg	96
Asn Asp Tyr Pro Trp Gly Glu Val Gly Asn Asp Ser Leu Ala Ala Arg	
20 25 30	
ctg gcg agc aaa aac ggc gcg gtg agc ttt gat ctg aaa ccg gaa cag	144
Leu Ala Ser Lys Asn Gly Ala Val Ser Phe Asp Leu Lys Pro Glu Gln	
35 40 45	
gcg tat gcg gaa ctg tgg atg ggc acc cat ccg aac aac ccg gcg cat	192
Ala Tyr Ala Glu Leu Trp Met Gly Thr His Pro Asn Asn Pro Ala His	
50 55 60	
ctg ttt agc agc ccg gat acc ctg ctg agc acc cat ctg aaa aaa aac	240
Leu Phe Ser Ser Pro Asp Thr Leu Leu Ser Thr His Leu Lys Lys Asn	
65 70 75 80	
ccg agc ctg ctg ggc gcg gcg aac cgc ttt agc ccg ccg ttt acc ggc	288
Pro Ser Leu Leu Gly Ala Ala Asn Arg Phe Ser Pro Pro Phe Thr Gly	
85 90 95	
gcg aaa ggc agc ggc gcg gaa ggc cag gaa gaa ggc cat gtg ccg ttt	336
Ala Lys Gly Ser Gly Ala Glu Gly Gln Glu Glu Gly His Val Pro Phe	
100 105 110	
ctg ttt aaa gtg ctg acc tgc aaa cag gcg ctg ccg ctg cag att cat	384
Leu Phe Lys Val Leu Thr Cys Lys Gln Ala Leu Pro Leu Gln Ile His	
115 120 125	
ccg gat aaa gcg ctg gcg aaa aaa ctg cat gaa gaa aac ccg aaa cag	432
Pro Asp Lys Ala Leu Ala Lys Lys Leu His Glu Glu Asn Pro Lys Gln	
130 135 140	
ttt ggc gat att aac cat aaa ccg gaa att gcg gtg tgc ctg agc gat	480
Phe Gly Asp Ile Asn His Lys Pro Glu Ile Ala Val Cys Leu Ser Asp	
145 150 155 160	
cgc ttt ctg ggc ttt gcg agc ttt cgc ccg tat gat aaa att gcg agc	528
Arg Phe Leu Gly Phe Ala Ser Phe Arg Pro Tyr Asp Lys Ile Ala Ser	
165 170 175	
ctg ctg aaa agc gtg cag gaa att agc ctg ctg ccg agc ctg ctg cag	576
Leu Leu Lys Ser Val Gln Glu Ile Ser Leu Leu Pro Ser Leu Leu Gln	
180 185 190	
aaa agc att aaa agc ttt att agc gcg ccg agc gcg gaa acc ctg cag	624
Lys Ser Ile Lys Ser Phe Ile Ser Ala Pro Ser Ala Glu Thr Leu Gln	
195 200 205	
ccg acc tgg gaa ggc ttt att aaa ctg ggc gat aac gaa gaa agc gtg	672
Pro Thr Trp Glu Gly Phe Ile Lys Leu Gly Asp Asn Glu Glu Ser Val	
210 215 220	
aaa aaa ttt agc gat cgc gtg ctg agc cag ggc ctg aaa gcg ttt gat	720
Lys Lys Phe Ser Asp Arg Val Leu Ser Gln Gly Leu Lys Ala Phe Asp	
225 230 235 240	
agc gtg gat att gaa gat gaa gat aaa aac cgc ctg gtg cgc gcg gtg	768
Ser Val Asp Ile Glu Asp Glu Asp Lys Asn Arg Leu Val Arg Ala Val	
245 250 255	
gaa ctg ggc aaa aaa tat aac ccg ggc gat gcg ggc ctg ttt agc agc	816
Glu Leu Gly Lys Lys Tyr Asn Pro Gly Asp Ala Gly Leu Phe Ser Ser	
260 265 270	
ctg ctg ttt ctg aac ctg att gaa ctg aaa aaa gat cag ggc atg tat	864
Leu Leu Phe Leu Asn Leu Ile Glu Leu Lys Lys Asp Gln Gly Met Tyr	
275 280 285	

-continued

gtg ggc gcg gat ggc ccg cat gcg tgg ctg gaa ggc gaa att gtg gaa	912
Val Gly Ala Asp Gly Pro His Ala Trp Leu Glu Gly Glu Ile Val Glu	
290 295 300	
ctg atg gcg att agc gat aac gtg ctg aac gtg ggc ttt acc agc gat	960
Leu Met Ala Ile Ser Asp Asn Val Leu Asn Val Gly Phe Thr Ser Asp	
305 310 315 320	
gat agc aaa gat gat ccg agc ctg gtg gcg aaa gcg gtg acc tgc acc	1008
Asp Ser Lys Asp Asp Pro Ser Leu Val Ala Lys Ala Val Thr Cys Thr	
325 330 335	
ccg aaa gcg att aaa gat ctg ctg ctg gat gcg agc aaa tat agc aaa	1056
Pro Lys Ala Ile Lys Asp Leu Leu Leu Asp Ala Ser Lys Tyr Ser Lys	
340 345 350	
agc cag aac gcg cgc acc acc gtg tat agc acc ccg ttt gaa gaa ttt	1104
Ser Gln Asn Gly Arg Thr Thr Val Tyr Ser Thr Pro Phe Glu Glu Phe	
355 360 365	
agc att atg aaa att gcg ggc gat gaa att ctg agc ccg ctg gat ggc	1152
Ser Ile Met Lys Ile Ala Gly Asp Glu Ile Leu Ser Pro Leu Asp Gly	
370 375 380	
gcg ggc gtg gcg gtg gtg ctg gaa ggc gaa tgg acc gtg gaa gat cag	1200
Ala Gly Val Ala Val Val Leu Glu Gly Glu Trp Thr Val Glu Asp Gln	
385 390 395 400	
gaa ggc acc aaa cgc ggc ggc gaa ggc acc gat ggc gaa ggc ggc gaa	1248
Glu Gly Thr Lys Arg Gly Gly Glu Gly Thr Asp Gly Glu Gly Gly Glu	
405 410 415	
ggc acc att tgg ttt att ggc agc gcg acc gaa acc aaa tgg acc gcg	1296
Gly Thr Ile Trp Phe Ile Gly Ser Ala Thr Glu Thr Lys Trp Thr Ala	
420 425 430	
aaa ggc ggc aaa ggc cag att tgg att gcg ttt tat gat aaa acc gcg	1344
Lys Gly Gly Lys Gly Gln Ile Trp Ile Ala Phe Tyr Asp Lys Thr Ala	
435 440 445	
aaa aaa gat gat gtg ggc aaa aaa	1368
Lys Lys Asp Asp Val Gly Lys Lys	
450 455	

<210> SEQ ID NO 52

<211> LENGTH: 456

<212> TYPE: PRT

<213> ORGANISM: *Cryptococcus neoformans*

<400> SEQUENCE: 52

Met Ser Ser Gly Asn Val Pro Lys Ile Glu Arg Leu Ser Cys Val Pro	
1 5 10 15	
Asn Asp Tyr Pro Trp Gly Glu Val Gly Asn Asp Ser Leu Ala Ala Arg	
20 25 30	
Leu Ala Ser Lys Asn Gly Ala Val Ser Phe Asp Leu Lys Pro Glu Gln	
35 40 45	
Ala Tyr Ala Glu Leu Trp Met Gly Thr His Pro Asn Asn Pro Ala His	
50 55 60	
Leu Phe Ser Ser Pro Asp Thr Leu Leu Ser Thr His Leu Lys Lys Asn	
65 70 75 80	
Pro Ser Leu Leu Gly Ala Ala Asn Arg Phe Ser Pro Pro Phe Thr Gly	
85 90 95	
Ala Lys Gly Ser Gly Ala Glu Gly Gln Glu Glu Gly His Val Pro Phe	
100 105 110	
Leu Phe Lys Val Leu Thr Cys Lys Gln Ala Leu Pro Leu Gln Ile His	
115 120 125	

-continued

Pro	Asp	Lys	Ala	Leu	Ala	Lys	Lys	Leu	His	Glu	Glu	Asn	Pro	Lys	Gln
130						135					140				
Phe	Gly	Asp	Ile	Asn	His	Lys	Pro	Glu	Ile	Ala	Val	Cys	Leu	Ser	Asp
145				150						155					160
Arg	Phe	Leu	Gly	Phe	Ala	Ser	Phe	Arg	Pro	Tyr	Asp	Lys	Ile	Ala	Ser
			165						170					175	
Leu	Leu	Lys	Ser	Val	Gln	Glu	Ile	Ser	Leu	Leu	Pro	Ser	Leu	Leu	Gln
		180						185					190		
Lys	Ser	Ile	Lys	Ser	Phe	Ile	Ser	Ala	Pro	Ser	Ala	Glu	Thr	Leu	Gln
		195					200					205			
Pro	Thr	Trp	Glu	Gly	Phe	Ile	Lys	Leu	Gly	Asp	Asn	Glu	Glu	Ser	Val
	210					215					220				
Lys	Lys	Phe	Ser	Asp	Arg	Val	Leu	Ser	Gln	Gly	Leu	Lys	Ala	Phe	Asp
225					230					235					240
Ser	Val	Asp	Ile	Glu	Asp	Glu	Asp	Lys	Asn	Arg	Leu	Val	Arg	Ala	Val
			245						250					255	
Glu	Leu	Gly	Lys	Lys	Tyr	Asn	Pro	Gly	Asp	Ala	Gly	Leu	Phe	Ser	Ser
		260						265					270		
Leu	Leu	Phe	Leu	Asn	Leu	Ile	Glu	Leu	Lys	Lys	Asp	Gln	Gly	Met	Tyr
		275					280					285			
Val	Gly	Ala	Asp	Gly	Pro	His	Ala	Trp	Leu	Glu	Gly	Glu	Ile	Val	Glu
	290					295					300				
Leu	Met	Ala	Ile	Ser	Asp	Asn	Val	Leu	Asn	Val	Gly	Phe	Thr	Ser	Asp
305					310					315					320
Asp	Ser	Lys	Asp	Asp	Pro	Ser	Leu	Val	Ala	Lys	Ala	Val	Thr	Cys	Thr
			325						330					335	
Pro	Lys	Ala	Ile	Lys	Asp	Leu	Leu	Leu	Asp	Ala	Ser	Lys	Tyr	Ser	Lys
		340						345					350		
Ser	Gln	Asn	Gly	Arg	Thr	Thr	Val	Tyr	Ser	Thr	Pro	Phe	Glu	Glu	Phe
		355					360					365			
Ser	Ile	Met	Lys	Ile	Ala	Gly	Asp	Glu	Ile	Leu	Ser	Pro	Leu	Asp	Gly
	370					375					380				
Ala	Gly	Val	Ala	Val	Val	Leu	Glu	Gly	Glu	Trp	Thr	Val	Glu	Asp	Gln
385					390					395					400
Glu	Gly	Thr	Lys	Arg	Gly	Gly	Glu	Gly	Thr	Asp	Gly	Glu	Gly	Gly	Glu
			405						410					415	
Gly	Thr	Ile	Trp	Phe	Ile	Gly	Ser	Ala	Thr	Glu	Thr	Lys	Trp	Thr	Ala
		420						425					430		
Lys	Gly	Gly	Lys	Gly	Gln	Ile	Trp	Ile	Ala	Phe	Tyr	Asp	Lys	Thr	Ala
		435					440					445			
Lys	Lys	Asp	Asp	Val	Gly	Lys	Lys								
450						455									

<210> SEQ ID NO 53

<211> LENGTH: 1962

<212> TYPE: DNA

<213> ORGANISM: Cryptococcus neoformans

<220> FEATURE:

<221> NAME/KEY: CDS

<222> LOCATION: (1) .. (1962)

<400> SEQUENCE: 53

atg acc cgc gat ttt gat agc ctg ttt ttt acc ggc ccg att ttt gtg
Met Thr Arg Asp Phe Asp Ser Leu Phe Phe Thr Gly Pro Ile Phe Val

48

-continued

1	5	10	15	
gat tat agc ttt acc gcg cgc cat ctg gaa agc ttt ctg agc agc ttt				96
Asp Tyr Ser Phe Thr Ala Arg His Leu Glu Ser Phe Leu Ser Ser Phe	20	25	30	
ccg ccg cag gtg agc cat gcg atg agc agc gcg agc acc ccg acc gcg				144
Pro Pro Gln Val Ser His Ala Met Ser Ser Ala Ser Thr Pro Thr Ala	35	40	45	
ccg tat ctg gaa gat ctg gtg cgc aac agc ctg gat cag acc ctg ccg				192
Pro Tyr Leu Glu Asp Leu Val Arg Asn Ser Leu Asp Gln Thr Leu Pro	50	55	60	
tgg gtg gtg cag aaa tat ggc ggc acc agc gtg ggc aaa agc ctg gat				240
Trp Val Val Gln Lys Tyr Gly Gly Thr Ser Val Gly Lys Ser Leu Asp	65	70	75	80
aac att acc aaa att gtg ggc agc tat att gat aac ggc agc aaa gtg				288
Asn Ile Thr Lys Ile Val Gly Ser Tyr Ile Asp Asn Gly Ser Lys Val	85	90	95	
gcg att gtg tgc agc gcg cgc agc acc cag acc aaa agc ctg ggc acc				336
Ala Ile Val Cys Ser Ala Arg Ser Thr Gln Thr Lys Ser Leu Gly Thr	100	105	110	
acc aac ctg ctg ctg cag gcg agc cgc gaa gcg ctg cag ccg gcg ctg				384
Thr Asn Leu Leu Gln Ala Ser Arg Glu Ala Leu Gln Pro Ala Leu	115	120	125	
agc agc agc ggc gat ggc cgc agc ggc agc atg agc ggc acc gcg acc				432
Ser Ser Ser Gly Asp Gly Arg Ser Gly Ser Met Ser Gly Thr Ala Thr	130	135	140	
ccg ttt tat ccg aaa cgc gtg ggc agc ggc ttt ttt ggc aaa gat cag				480
Pro Phe Tyr Pro Lys Arg Val Gly Ser Gly Phe Phe Gly Lys Asp Gln	145	150	155	160
agc acc agc atg gtg agc agc gtg agc agc ctg agc cag ctg gaa ccg				528
Ser Thr Ser Met Val Ser Ser Val Ser Leu Ser Gln Leu Glu Pro	165	170	175	
cag ctg ggc cgc agc ggc agc ccg agc ccg ttt cag agc agc agc agc				576
Gln Leu Gly Arg Ser Gly Ser Pro Ser Pro Phe Gln Ser Ser Ser Ser	180	185	190	
cgc agc ccg ccg cgc agc ccg ggc acc ccg agc cag gat agc agc gtg				624
Arg Ser Pro Pro Arg Ser Pro Ala Thr Pro Ser Gln Asp Ser Ser Val	195	200	205	
agc cag gaa ccg ggc ttt cat gcg acc gtg gat ctg att aaa aaa ggc				672
Ser Gln Glu Pro Ala Phe His Ala Thr Val Asp Leu Ile Lys Lys Gly	210	215	220	
cat ctg gaa gcg gcg cgc gcg agc ctg aaa gaa ggc ccg ctg cgc gat				720
His Leu Glu Ala Ala Arg Ala Ser Leu Lys Glu Gly Pro Leu Arg Asp	225	230	235	240
gaa ctg gaa gaa gaa att gaa cgc gat tgc gaa agc ctg cgc agc ttt				768
Glu Leu Glu Glu Ile Glu Arg Asp Cys Glu Ser Leu Arg Ser Phe	245	250	255	
ctg tat gcg gcg cag att att gat gaa att agc ccg cgc agc cag gat				816
Leu Tyr Ala Ala Gln Ile Ile Asp Glu Ile Ser Pro Arg Ser Gln Asp	260	265	270	
agc att gtg ggc acc ggc gaa cgc ctg gcg tgc aaa att gtg gcg gcg				864
Ser Ile Val Gly Thr Gly Glu Arg Leu Ala Cys Lys Ile Val Ala Ala	275	280	285	
gcg ctg cgc gat cgc ggc gtg gat agc gaa ctg gtg gtg ctg gat aac				912
Ala Leu Arg Asp Arg Gly Val Asp Ser Glu Leu Val Val Leu Asp Asn	290	295	300	
att gtg gat gcg agc atg agc gcg gcg agc gaa gcg att agc gtg gat				960
Ile Val Asp Ala Ser Met Ser Ala Ala Ser Glu Ala Ile Ser Val Asp				

-continued

305	310	315	320	
gcg ggc gat cag ggc gtg gcg cag ctg ggc cag gaa ttt tat gat cag Ala Gly Asp Gln Gly Val Ala Gln Leu Gly Gln Glu Phe Tyr Asp Gln 325 330 335				1008
ctg agc ttt cgc ctg ggc gaa cgc ctg cgc gaa tgc ggc cag cgc gtg Leu Ser Phe Arg Leu Gly Glu Arg Leu Arg Glu Cys Gly Gln Arg Val 340 345 350				1056
ccg gtg gtg acc ggc tat ttt ggc ccg gtg ccg ggc agc ctg ctg gcg Pro Val Val Thr Gly Tyr Phe Gly Pro Val Pro Gly Ser Leu Leu Ala 355 360 365				1104
cag att ggc cgc ggc tat acc gat ctg tgc gcg gcg ctg tgc gcg gtg Gln Ile Gly Arg Gly Tyr Thr Asp Leu Cys Ala Ala Leu Cys Ala Val 370 375 380				1152
ggc ctg aaa gcg agc gaa ctg cag gtg tgg aaa gaa gtg gat ggc att Gly Leu Lys Ala Ser Glu Leu Gln Val Trp Lys Glu Val Asp Gly Ile 385 390 395 400				1200
ttt acc gcg gat ccg cgc aaa gtg ccg agc gcg cgc ctg gtg ccg att Phe Thr Ala Asp Pro Arg Lys Val Pro Ser Ala Arg Leu Val Pro Ile 405 410 415				1248
att acc ccg gat gaa gcg gcg gaa ctg acc tat tat ggc agc gaa gtg Ile Thr Pro Asp Glu Ala Ala Glu Leu Thr Tyr Tyr Gly Ser Glu Val 420 425 430				1296
att cat ccg ttt acc atg gaa cag gtg att cgc gcg cgc att ccg att Ile His Pro Phe Thr Met Glu Gln Val Ile Arg Ala Arg Ile Pro Ile 435 440 445				1344
cgc att aaa aac gtg gaa aac ccg agc ggc gcg ggc acc gtg att tat Arg Ile Lys Asn Val Glu Asn Pro Ser Gly Ala Gly Thr Val Ile Tyr 450 455 460				1392
ccg gat ctg ggc ttt ccg cgc ggc ctg gat acc gaa ccg ccg aaa gcg Pro Asp Leu Gly Phe Pro Arg Gly Leu Asp Thr Glu Pro Pro Lys Ala 465 470 475 480				1440
gaa cgc att gtg gaa ggc gtg gat gaa cgc atg ccg acc gcg gtg acc Glu Arg Ile Val Glu Gly Val Asp Glu Arg Met Pro Thr Ala Val Thr 485 490 495				1488
att aaa gat gaa att att gtg ctg aac att cat agc aac cgc aaa acc Ile Lys Asp Glu Ile Ile Val Leu Asn Ile His Ser Asn Arg Lys Thr 500 505 510				1536
ctg agc cat ggc ttt ctg gcg cgc att ttt ggc acc ctg gat cgc gcg Leu Ser His Gly Phe Leu Ala Arg Ile Phe Gly Thr Leu Asp Arg Ala 515 520 525				1584
ggc gtg gtg gtg gat ctg att agc acc agc gaa gtg cat gtg agc atg Gly Val Val Val Asp Leu Ile Ser Thr Ser Glu Val His Val Ser Met 530 535 540				1632
gcg atg cag gat ttt ctg aac cgc aaa cgc ctg gaa cgc ctg gtg aaa Ala Met Gln Asp Phe Leu Asn Arg Lys Arg Leu Glu Arg Leu Val Lys 545 550 555 560				1680
gat ctg gaa aaa att ggc gaa gtg acc gtg agc aaa gat atg gcg att Asp Leu Glu Lys Ile Gly Glu Val Thr Val Ser Lys Asp Met Ala Ile 565 570 575				1728
ctg agc ctg gtg ggc cgc aac atg cgc aac gcg att ggc agc gcg ggc Leu Ser Leu Val Gly Arg Asn Met Arg Asn Ala Ile Gly Ser Ala Gly 580 585 590				1776
ctg atg ttt gcg agc ctg gcg cgc gcg atg att aac att gaa atg att Leu Met Phe Ala Ser Leu Ala Arg Ala Met Ile Asn Ile Glu Met Ile 595 600 605				1824
agc cag ggc gcg agc gaa att aac att agc tgc gtg att gaa aac aaa Ser Gln Gly Ala Ser Glu Ile Asn Ile Ser Cys Val Ile Glu Asn Lys				1872

-continued

610	615	620	
gat gcg att aaa gcg ctg aac gtg att cat gaa agc tgc ctg agc tat			1920
Asp Ala Ile Lys Ala Leu Asn Val Ile His Glu Ser Cys Leu Ser Tyr			
625	630	635	640
ccg cgc agc ccg gcg acc gaa atg gcg ggc ctg cag ctg cag			1962
Pro Arg Ser Pro Ala Thr Glu Met Ala Gly Leu Gln Leu Gln			
645	650		

<210> SEQ ID NO 54

<211> LENGTH: 654

<212> TYPE: PRT

<213> ORGANISM: *Cryptococcus neoformans*

<400> SEQUENCE: 54

Met Thr Arg Asp Phe Asp Ser Leu Phe Phe Thr Gly Pro Ile Phe Val			
1	5	10	15
Asp Tyr Ser Phe Thr Ala Arg His Leu Glu Ser Phe Leu Ser Ser Phe			
20	25	30	
Pro Pro Gln Val Ser His Ala Met Ser Ser Ala Ser Thr Pro Thr Ala			
35	40	45	
Pro Tyr Leu Glu Asp Leu Val Arg Asn Ser Leu Asp Gln Thr Leu Pro			
50	55	60	
Trp Val Val Gln Lys Tyr Gly Gly Thr Ser Val Gly Lys Ser Leu Asp			
65	70	75	80
Asn Ile Thr Lys Ile Val Gly Ser Tyr Ile Asp Asn Gly Ser Lys Val			
85	90	95	
Ala Ile Val Cys Ser Ala Arg Ser Thr Gln Thr Lys Ser Leu Gly Thr			
100	105	110	
Thr Asn Leu Leu Leu Gln Ala Ser Arg Glu Ala Leu Gln Pro Ala Leu			
115	120	125	
Ser Ser Ser Gly Asp Gly Arg Ser Gly Ser Met Ser Gly Thr Ala Thr			
130	135	140	
Pro Phe Tyr Pro Lys Arg Val Gly Ser Gly Phe Phe Gly Lys Asp Gln			
145	150	155	160
Ser Thr Ser Met Val Ser Ser Val Ser Ser Leu Ser Gln Leu Glu Pro			
165	170	175	
Gln Leu Gly Arg Ser Gly Ser Pro Ser Pro Phe Gln Ser Ser Ser Ser			
180	185	190	
Arg Ser Pro Pro Arg Ser Pro Ala Thr Pro Ser Gln Asp Ser Ser Val			
195	200	205	
Ser Gln Glu Pro Ala Phe His Ala Thr Val Asp Leu Ile Lys Lys Gly			
210	215	220	
His Leu Glu Ala Ala Arg Ala Ser Leu Lys Glu Gly Pro Leu Arg Asp			
225	230	235	240
Glu Leu Glu Glu Glu Ile Glu Arg Asp Cys Glu Ser Leu Arg Ser Phe			
245	250	255	
Leu Tyr Ala Ala Gln Ile Ile Asp Glu Ile Ser Pro Arg Ser Gln Asp			
260	265	270	
Ser Ile Val Gly Thr Gly Glu Arg Leu Ala Cys Lys Ile Val Ala Ala			
275	280	285	
Ala Leu Arg Asp Arg Gly Val Asp Ser Glu Leu Val Val Leu Asp Asn			
290	295	300	
Ile Val Asp Ala Ser Met Ser Ala Ala Ser Glu Ala Ile Ser Val Asp			

-continued

305	310	315	320
Ala Gly Asp Gln Gly Val Ala Gln Leu Gly Gln Glu Phe Tyr Asp Gln	325	330	335
Leu Ser Phe Arg Leu Gly Glu Arg Leu Arg Glu Cys Gly Gln Arg Val	340	345	350
Pro Val Val Thr Gly Tyr Phe Gly Pro Val Pro Gly Ser Leu Leu Ala	355	360	365
Gln Ile Gly Arg Gly Tyr Thr Asp Leu Cys Ala Ala Leu Cys Ala Val	370	375	380
Gly Leu Lys Ala Ser Glu Leu Gln Val Trp Lys Glu Val Asp Gly Ile	385	390	395
Phe Thr Ala Asp Pro Arg Lys Val Pro Ser Ala Arg Leu Val Pro Ile	405	410	415
Ile Thr Pro Asp Glu Ala Ala Glu Leu Thr Tyr Tyr Gly Ser Glu Val	420	425	430
Ile His Pro Phe Thr Met Glu Gln Val Ile Arg Ala Arg Ile Pro Ile	435	440	445
Arg Ile Lys Asn Val Glu Asn Pro Ser Gly Ala Gly Thr Val Ile Tyr	450	455	460
Pro Asp Leu Gly Phe Pro Arg Gly Leu Asp Thr Glu Pro Pro Lys Ala	465	470	475
Glu Arg Ile Val Glu Gly Val Asp Glu Arg Met Pro Thr Ala Val Thr	485	490	495
Ile Lys Asp Glu Ile Ile Val Leu Asn Ile His Ser Asn Arg Lys Thr	500	505	510
Leu Ser His Gly Phe Leu Ala Arg Ile Phe Gly Thr Leu Asp Arg Ala	515	520	525
Gly Val Val Val Asp Leu Ile Ser Thr Ser Glu Val His Val Ser Met	530	535	540
Ala Met Gln Asp Phe Leu Asn Arg Lys Arg Leu Glu Arg Leu Val Lys	545	550	555
Asp Leu Glu Lys Ile Gly Glu Val Thr Val Ser Lys Asp Met Ala Ile	565	570	575
Leu Ser Leu Val Gly Arg Asn Met Arg Asn Ala Ile Gly Ser Ala Gly	580	585	590
Leu Met Phe Ala Ser Leu Ala Arg Ala Met Ile Asn Ile Glu Met Ile	595	600	605
Ser Gln Gly Ala Ser Glu Ile Asn Ile Ser Cys Val Ile Glu Asn Lys	610	615	620
Asp Ala Ile Lys Ala Leu Asn Val Ile His Glu Ser Cys Leu Ser Tyr	625	630	635
Pro Arg Ser Pro Ala Thr Glu Met Ala Gly Leu Gln Leu Gln	645	650	

<210> SEQ ID NO 55

<211> LENGTH: 1269

<212> TYPE: DNA

<213> ORGANISM: Cryptococcus neoformans

<220> FEATURE:

<221> NAME/KEY: CDS

<222> LOCATION: (1) .. (1269)

<400> SEQUENCE: 55

-continued

atg	ccg	aaa	cag	tgg	ccg	acc	att	gtg	aaa	ctg	gaa	acc	ttt	att	ccg	48
Met	Pro	Lys	Gln	Trp	Pro	Thr	Ile	Val	Lys	Leu	Glu	Thr	Phe	Ile	Pro	
1			5					10					15			
agc	gcg	cat	ggc	agc	ggc	ggc	gat	tat	cat	cgc	cag	ggc	ggc	gat	cat	96
Ser	Ala	His	Gly	Ser	Gly	Gly	Asp	Tyr	His	Arg	Gln	Gly	Gly	Asp	His	
			20				25					30				
tgg	att	gtg	cag	ggc	aac	att	agc	tgc	ccg	atg	cat	aaa	tat	gaa	gaa	144
Trp	Ile	Val	Gln	Gly	Asn	Ile	Ser	Cys	Pro	Met	His	Lys	Tyr	Glu	Glu	
		35				40					45					
tat	aaa	gtg	agc	cgc	acc	agc	tgg	ggc	att	ggc	gtg	ctg	ggc	agc	att	192
Tyr	Lys	Val	Ser	Arg	Thr	Ser	Trp	Gly	Ile	Gly	Val	Leu	Gly	Ser	Ile	
	50					55				60						
ttt	gtg	aaa	gtg	cat	gcg	agc	gat	ggc	acc	gtg	ggc	tat	gcg	acc	ggc	240
Phe	Val	Lys	Val	His	Ala	Ser	Asp	Gly	Thr	Val	Gly	Tyr	Ala	Thr	Gly	
65				70				75						80		
ttt	ggc	ggc	ccg	ccg	gcg	tgc	tgg	ctg	att	gaa	gaa	cat	ttt	aaa	cgc	288
Phe	Gly	Gly	Pro	Pro	Ala	Cys	Trp	Leu	Ile	Glu	Glu	His	Phe	Lys	Arg	
			85					90					95			
ttt	att	gtg	ggc	cag	gat	ccg	cgc	gat	acc	aac	aaa	atg	tgg	gat	cag	336
Phe	Ile	Val	Gly	Gln	Asp	Pro	Arg	Asp	Thr	Asn	Lys	Met	Trp	Asp	Gln	
		100					105					110				
atg	ttt	cgc	gcg	agc	atg	ttt	tat	ggc	cgc	aaa	ggc	ctg	ccg	ctg	gcg	384
Met	Phe	Arg	Ala	Ser	Met	Phe	Tyr	Gly	Arg	Lys	Gly	Leu	Pro	Leu	Ala	
		115				120				125						
gcg	att	agc	gtg	gtg	gat	ctg	gcg	att	tgg	gat	ctg	ctg	ggc	aaa	att	432
Ala	Ile	Ser	Val	Val	Asp	Leu	Ala	Ile	Trp	Asp	Leu	Leu	Gly	Lys	Ile	
	130				135					140						
cgc	ggc	gaa	ccg	att	tat	aaa	atg	att	ggc	ggc	cgc	acc	aaa	aaa	gat	480
Arg	Gly	Glu	Pro	Ile	Tyr	Lys	Met	Ile	Gly	Gly	Arg	Thr	Lys	Lys	Asp	
	145			150					155					160		
att	ccg	ctg	tat	ctg	acc	ggc	ccg	cgc	ccg	gaa	gtg	gcg	aaa	aaa	ctg	528
Ile	Pro	Leu	Tyr	Leu	Thr	Gly	Pro	Arg	Pro	Glu	Val	Ala	Lys	Lys	Leu	
		165					170						175			
ggc	ttt	tgg	ggc	agc	aaa	gtg	gcg	ctg	ccg	cat	ggc	ccg	ccg	gat	ggc	576
Gly	Phe	Trp	Gly	Ser	Lys	Val	Ala	Leu	Pro	His	Gly	Pro	Pro	Asp	Gly	
		180				185						190				
cat	gaa	ggc	att	cgc	aaa	aac	gtg	gaa	tat	ctg	aaa	gcg	tgc	aaa	gaa	624
His	Glu	Gly	Ile	Arg	Lys	Asn	Val	Glu	Tyr	Leu	Lys	Ala	Cys	Lys	Glu	
	195					200					205					
gcg	gtg	ggc	ccg	gat	tat	ccg	gtg	cag	gtg	gat	tgc	tat	atg	agc	ctg	672
Ala	Val	Gly	Pro	Asp	Tyr	Pro	Val	Gln	Val	Asp	Cys	Tyr	Met	Ser	Leu	
	210				215					220						
gat	gtg	ccg	tat	acc	att	gcg	ctg	gtg	aaa	gcg	tgc	gaa	aaa	gcg	ggc	720
Asp	Val	Pro	Tyr	Thr	Ile	Ala	Leu	Val	Lys	Ala	Cys	Glu	Lys	Ala	Gly	
	225			230					235					240		
gtg	gaa	att	aac	tgg	tgg	gaa	gaa	gtg	ctg	cat	ccg	gat	gat	ttt	gat	768
Val	Glu	Ile	Asn	Trp	Trp	Glu	Glu	Val	Leu	His	Pro	Asp	Asp	Phe	Asp	
		245				250							255			
ggc	cat	att	aaa	ctg	aaa	gaa	gcg	ctg	ccg	tat	gtg	aaa	ttt	acc	acc	816
Gly	His	Ile	Lys	Leu	Lys	Glu	Ala	Leu	Pro	Tyr	Val	Lys	Phe	Thr	Thr	
		260				265						270				
ggc	gaa	cat	gaa	tat	agc	aaa	tat	ggc	ttt	cgc	aaa	ctg	att	gaa	aac	864
Gly	Glu	His	Glu	Tyr	Ser	Lys	Tyr	Gly	Phe	Arg	Lys	Leu	Ile	Glu	Asn	
	275					280					285					
cgc	gcg	gtg	gat	att	att	cag	ccg	gat	gtg	atg	tgg	ctg	ggc	ggc	ctg	912
Arg	Ala	Val	Asp	Ile	Ile	Gln	Pro	Asp	Val	Met	Trp	Leu	Gly	Gly	Leu	
	290					295				300						

-continued

acc gaa ctg att aaa gtg gcg gcg atg gcg gcg gcg tat gat att ccg	960
Thr Glu Leu Ile Lys Val Ala Ala Met Ala Ala Ala Tyr Asp Ile Pro	
305 310 315 320	
gtg gtg ccg cat ggc agc ggc ccg tat agc ttt cag gcg att atg agc	1008
Val Val Pro His Gly Ser Gly Pro Tyr Ser Phe Gln Ala Ile Met Ser	
325 330 335	
ttt ccg aac agc gat ttt tgc gaa tat att gcg aac agc ccg gat ggc	1056
Phe Pro Asn Ser Asp Phe Cys Glu Tyr Ile Ala Asn Ser Pro Asp Gly	
340 345 350	
aaa agc att gaa ccg agc ttt ggc aac ctg ttt ctg aac gaa gtg ctg	1104
Lys Ser Ile Glu Pro Ser Phe Gly Asn Leu Phe Leu Asn Glu Val Leu	
355 360 365	
ccg cgc aac ggc cgc gtg gat ctg acc gat gaa ccg ggc ttt ggc ctg	1152
Pro Arg Asn Gly Arg Val Asp Leu Thr Asp Glu Pro Gly Phe Gly Leu	
370 375 380	
gaa ctg aac ccg agc gcg gaa ctg gtg ccg tat aaa agc ttt ttt acc	1200
Glu Leu Asn Pro Ser Ala Glu Leu Val Pro Tyr Lys Ser Phe Phe Thr	
385 390 395 400	
ccg agc aaa agc ctg ggc gcg gcg ggc gaa gtg gaa gat gat ggc aaa	1248
Pro Ser Lys Ser Leu Gly Ala Ala Gly Glu Val Glu Asp Asp Gly Lys	
405 410 415	
gcg aaa gtg aac ggc aaa cat	1269
Ala Lys Val Asn Gly Lys His	
420	
<210> SEQ ID NO 56	
<211> LENGTH: 423	
<212> TYPE: PRT	
<213> ORGANISM: Cryptococcus neoformans	
<400> SEQUENCE: 56	
Met Pro Lys Gln Trp Pro Thr Ile Val Lys Leu Glu Thr Phe Ile Pro	
1 5 10 15	
Ser Ala His Gly Ser Gly Gly Asp Tyr His Arg Gln Gly Gly Asp His	
20 25 30	
Trp Ile Val Gln Gly Asn Ile Ser Cys Pro Met His Lys Tyr Glu Glu	
35 40 45	
Tyr Lys Val Ser Arg Thr Ser Trp Gly Ile Gly Val Leu Gly Ser Ile	
50 55 60	
Phe Val Lys Val His Ala Ser Asp Gly Thr Val Gly Tyr Ala Thr Gly	
65 70 75 80	
Phe Gly Gly Pro Pro Ala Cys Trp Leu Ile Glu Glu His Phe Lys Arg	
85 90 95	
Phe Ile Val Gly Gln Asp Pro Arg Asp Thr Asn Lys Met Trp Asp Gln	
100 105 110	
Met Phe Arg Ala Ser Met Phe Tyr Gly Arg Lys Gly Leu Pro Leu Ala	
115 120 125	
Ala Ile Ser Val Val Asp Leu Ala Ile Trp Asp Leu Leu Gly Lys Ile	
130 135 140	
Arg Gly Glu Pro Ile Tyr Lys Met Ile Gly Gly Arg Thr Lys Lys Asp	
145 150 155 160	
Ile Pro Leu Tyr Leu Thr Gly Pro Arg Pro Glu Val Ala Lys Lys Leu	
165 170 175	
Gly Phe Trp Gly Ser Lys Val Ala Leu Pro His Gly Pro Pro Asp Gly	
180 185 190	

-continued

His	Glu	Gly	Ile	Arg	Lys	Asn	Val	Glu	Tyr	Leu	Lys	Ala	Cys	Lys	Glu
		195					200					205			
Ala	Val	Gly	Pro	Asp	Tyr	Pro	Val	Gln	Val	Asp	Cys	Tyr	Met	Ser	Leu
	210					215					220				
Asp	Val	Pro	Tyr	Thr	Ile	Ala	Leu	Val	Lys	Ala	Cys	Glu	Lys	Ala	Gly
225					230					235					240
Val	Glu	Ile	Asn	Trp	Trp	Glu	Glu	Val	Leu	His	Pro	Asp	Asp	Phe	Asp
			245						250					255	
Gly	His	Ile	Lys	Leu	Lys	Glu	Ala	Leu	Pro	Tyr	Val	Lys	Phe	Thr	Thr
		260						265					270		
Gly	Glu	His	Glu	Tyr	Ser	Lys	Tyr	Gly	Phe	Arg	Lys	Leu	Ile	Glu	Asn
		275					280					285			
Arg	Ala	Val	Asp	Ile	Ile	Gln	Pro	Asp	Val	Met	Trp	Leu	Gly	Gly	Leu
	290					295					300				
Thr	Glu	Leu	Ile	Lys	Val	Ala	Ala	Met	Ala	Ala	Ala	Tyr	Asp	Ile	Pro
305					310					315					320
Val	Val	Pro	His	Gly	Ser	Gly	Pro	Tyr	Ser	Phe	Gln	Ala	Ile	Met	Ser
			325						330					335	
Phe	Pro	Asn	Ser	Asp	Phe	Cys	Glu	Tyr	Ile	Ala	Asn	Ser	Pro	Asp	Gly
		340						345					350		
Lys	Ser	Ile	Glu	Pro	Ser	Phe	Gly	Asn	Leu	Phe	Leu	Asn	Glu	Val	Leu
		355					360					365			
Pro	Arg	Asn	Gly	Arg	Val	Asp	Leu	Thr	Asp	Glu	Pro	Gly	Phe	Gly	Leu
	370					375					380				
Glu	Leu	Asn	Pro	Ser	Ala	Glu	Leu	Val	Pro	Tyr	Lys	Ser	Phe	Phe	Thr
385					390					395					400
Pro	Ser	Lys	Ser	Leu	Gly	Ala	Ala	Gly	Glu	Val	Glu	Asp	Asp	Gly	Lys
			405						410					415	
Ala	Lys	Val	Asn	Gly	Lys	His									
			420												

<210> SEQ ID NO 57
 <211> LENGTH: 1743
 <212> TYPE: DNA
 <213> ORGANISM: Cryptococcus neoformans
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1) .. (1743)

<400> SEQUENCE: 57

atg	gcg	aac	gcg	ccg	cat	ggc	ggc	gtg	ctg	aaa	gat	ctg	ctg	gtg	cgc	48
Met	Ala	Asn	Ala	Pro	His	Gly	Gly	Val	Leu	Lys	Asp	Leu	Leu	Val	Arg	
1			5					10					15			
gat	gcg	gcg	ctg	cat	gat	agc	ctg	ctg	cag	gaa	gcg	cgc	agc	ctg	aac	96
Asp	Ala	Ala	Leu	His	Asp	Ser	Leu	Leu	Gln	Glu	Ala	Arg	Ser	Leu	Asn	
			20					25				30				
gat	att	ttt	ctg	acc	gaa	cgc	cag	ctg	tgc	gat	ctg	gaa	ctg	att	ctg	144
Asp	Ile	Phe	Leu	Thr	Glu	Arg	Gln	Leu	Cys	Asp	Leu	Glu	Leu	Ile	Leu	
			35				40					45				
aac	ggc	ggc	ttt	agc	ccg	ctg	gaa	ggc	ttt	atg	aac	gaa	cgc	gat	tat	192
Asn	Gly	Gly	Phe	Ser	Pro	Leu	Glu	Gly	Phe	Met	Asn	Glu	Arg	Asp	Tyr	
	50					55				60						
acc	agc	gtg	gtg	gaa	acc	ctg	cgc	ctg	gcg	ccg	tat	aac	ggc	cag	aaa	240
Thr	Ser	Val	Val	Glu	Thr	Leu	Arg	Leu	Ala	Pro	Tyr	Asn	Gly	Gln	Lys	
65					70					75				80		

-continued

cat ggc gat gtg ttt ccg att ccg att acc ctg gat gtg agc cag gaa	288
His Gly Asp Val Phe Pro Ile Pro Ile Thr Leu Asp Val Ser Gln Glu	
85 90 95	
gat att aac acc ctg ggc ctg aaa cag ggc ggc cgc gtg gcg ctg cgc	336
Asp Ile Asn Thr Leu Gly Leu Lys Gln Gly Gly Arg Val Ala Leu Arg	
100 105 110	
gat ccg cgc gat gat gcg gcg ctg gcg att ctg acc gtg agc gat att	384
Asp Pro Arg Asp Asp Ala Ala Leu Ala Ile Leu Thr Val Ser Asp Ile	
115 120 125	
tat cgc ccg aac aaa gcg att gaa gcg gaa aaa gtg atg ggc gcg gat	432
Tyr Arg Pro Asn Lys Ala Ile Glu Ala Glu Lys Val Met Gly Ala Asp	
130 135 140	
gat att gcg cat ccg agc gtg gcg tat ctg cgc aac aac gtg aaa gaa	480
Asp Ile Ala His Pro Ser Val Ala Tyr Leu Arg Asn Asn Val Lys Glu	
145 150 155 160	
ttt tat gtg ggc ggc aaa gtg cag gcg att cag gcg ccg acc cat ttt	528
Phe Tyr Val Gly Lys Val Gln Ala Ile Gln Ala Pro Thr His Phe	
165 170 175	
gat tat gtg ccg ctg cgc ttt acc ccg gcg gaa ctg cgc gcg cat ttt	576
Asp Tyr Val Pro Leu Arg Phe Thr Pro Ala Glu Leu Arg Ala His Phe	
180 185 190	
cat aaa ctg gcg tgg cgc aaa gtg gtg gcg ttt cag acc cgc aac ccg	624
His Lys Leu Ala Trp Arg Lys Val Val Ala Phe Gln Thr Arg Asn Pro	
195 200 205	
atg cat cgc gcg cat cgc gaa ctg acc gtg cgc gcg gcg cgc cag cgc	672
Met His Arg Ala His Arg Glu Leu Thr Val Arg Ala Ala Arg Gln Arg	
210 215 220	
cgc gcg aac gtg ctg att cat ccg gtg gtg ggc ctg acc aaa ccg ggc	720
Arg Ala Asn Val Leu Ile His Pro Val Val Gly Leu Thr Lys Pro Gly	
225 230 235 240	
gat gtg gat cat tat acc cgc gtg cgc gcg tat cag gcg ctg atg ccg	768
Asp Val Asp His Tyr Thr Arg Val Arg Ala Tyr Gln Ala Leu Met Pro	
245 250 255	
agc tat ccg gaa ggc atg gcg cat ctg gcg ctg ctg ccg ctg gcg atg	816
Ser Tyr Pro Glu Gly Met Ala His Leu Ala Leu Leu Pro Leu Ala Met	
260 265 270	
cgc atg gcg ggc ccg cgc gaa gcg gtg tgg cat gcg gtg att cgc aaa	864
Arg Met Ala Gly Pro Arg Glu Ala Val Trp His Ala Val Ile Arg Lys	
275 280 285	
aac ttt ggc gcg acc cat ttt att gtg ggc cgc gat cat gcg ggc ccg	912
Asn Phe Gly Ala Thr His Phe Ile Val Gly Arg Asp His Ala Gly Pro	
290 295 300	
ggc aaa aac agc cag ggc cag gat ttt tat ggc ccg tat gat gcg cag	960
Gly Lys Asn Ser Gln Gly Gln Asp Phe Tyr Gly Pro Tyr Asp Ala Gln	
305 310 315 320	
gaa ctg gtg acc cag ttt aaa gat gaa ctg cag att gaa atg gtg ccg	1008
Glu Leu Val Thr Gln Phe Lys Asp Glu Leu Gln Ile Glu Met Val Pro	
325 330 335	
ttt cag gcg atg acc tat ctg ccg ggc agc gat gaa tat cag ccg gtg	1056
Phe Gln Ala Met Thr Tyr Leu Pro Gly Ser Asp Glu Tyr Gln Pro Val	
340 345 350	
gat gaa gtg ccg aaa ggc acc ccg acc gcg gat att agc ggc acc gaa	1104
Asp Glu Val Pro Lys Gly Thr Pro Thr Ala Asp Ile Ser Gly Thr Glu	
355 360 365	
ctg cgc aaa cgc ctg cgc acc ggc gcg agc att ccg gat tgg ttt agc	1152
Leu Arg Lys Arg Leu Arg Thr Gly Ala Ser Ile Pro Asp Trp Phe Ser	
370 375 380	

-continued

tat acc ggc gtg gtg aaa gtg ctg cgc gaa agc tat ccg ccg cgc ccg	1200
Tyr Thr Gly Val Val Lys Val Leu Arg Glu Ser Tyr Pro Pro Arg Pro	
385 390 395 400	
cag cag ggc ttt acc att ctg ctg acc ggc ctg cat aac agc ggc aaa	1248
Gln Gln Gly Phe Thr Ile Leu Leu Thr Gly Leu His Asn Ser Gly Lys	
405 410 415	
gat acc att gcg cgc gcg ctg cag gtg acc ctg cag cag cag ggc agc	1296
Asp Thr Ile Ala Arg Ala Leu Gln Val Thr Leu Gln Gln Gln Gly Ser	
420 425 430	
cgc agc gtg agc ctg ctg ctg ggc gaa gaa ctg cgc agc gat ctg gat	1344
Arg Ser Val Ser Leu Leu Leu Gly Glu Glu Leu Arg Ser Asp Leu Asp	
435 440 445	
ccg cag att ggc cgc gcg att acc ccg gaa cag aaa cat att aac ctg	1392
Pro Gln Ile Gly Arg Ala Ile Thr Pro Glu Gln Lys His Ile Asn Leu	
450 455 460	
gaa cgc att ggc ttt gtg gcg ggc gaa ctg acc aaa gcg ggc gcg gcg	1440
Glu Arg Ile Gly Phe Val Ala Gly Glu Leu Thr Lys Ala Gly Ala Ala	
465 470 475 480	
gtg att gcg gcg ccg acc gcg ccg tat gaa cgc agc cgc cag gcg ttt	1488
Val Ile Ala Ala Pro Thr Ala Pro Tyr Glu Arg Ser Arg Gln Ala Phe	
485 490 495	
aaa aaa cag gtg gtg ggc agc ggc ggc ggc aac tat ttt ctg gtg cat	1536
Lys Lys Gln Val Val Gly Ser Gly Gly Gly Asn Tyr Phe Leu Val His	
500 505 510	
gtg gcg acc ccg ctg gaa tgg tgc gaa aaa gtg gat cgc cgc ggc ctg	1584
Val Ala Thr Pro Leu Glu Trp Cys Glu Lys Val Asp Arg Arg Gly Leu	
515 520 525	
tat aaa gcg gcg cgc gcg ggc gaa att aaa aac ctg acc ggc gtg gat	1632
Tyr Lys Ala Ala Arg Ala Gly Glu Ile Lys Asn Leu Thr Gly Val Asp	
530 535 540	
gat gtg tat gaa gcg ccg gaa gat gcg gat ctg gtg tgc gat ctg cgc	1680
Asp Val Tyr Glu Ala Pro Glu Asp Ala Asp Leu Val Cys Asp Leu Arg	
545 550 555 560	
aac gat acc gtg ccg gaa att gtg cat agc att att atg att ctg gaa	1728
Asn Asp Thr Val Pro Glu Ile Val His Ser Ile Ile Met Ile Leu Glu	
565 570 575	
agc cag aac ctg gtg	1743
Ser Gln Asn Leu Val	
580	

<210> SEQ ID NO 58

<211> LENGTH: 581

<212> TYPE: PRT

<213> ORGANISM: Cryptococcus neoformans

<400> SEQUENCE: 58

Met Ala Asn Ala Pro His Gly Gly Val Leu Lys Asp Leu Leu Val Arg
1 5 10 15

Asp Ala Ala Leu His Asp Ser Leu Leu Gln Glu Ala Arg Ser Leu Asn
20 25 30

Asp Ile Phe Leu Thr Glu Arg Gln Leu Cys Asp Leu Glu Leu Ile Leu
35 40 45

Asn Gly Gly Phe Ser Pro Leu Glu Gly Phe Met Asn Glu Arg Asp Tyr
50 55 60

Thr Ser Val Val Glu Thr Leu Arg Leu Ala Pro Tyr Asn Gly Gln Lys
65 70 75 80

His Gly Asp Val Phe Pro Ile Pro Ile Thr Leu Asp Val Ser Gln Glu

-continued

85								90					95				
Asp	Ile	Asn	Thr	Leu	Gly	Leu	Lys	Gln	Gly	Gly	Arg	Val	Ala	Leu	Arg		
100								105					110				
Asp	Pro	Arg	Asp	Asp	Ala	Ala	Leu	Ala	Ile	Leu	Thr	Val	Ser	Asp	Ile		
115								120					125				
Tyr	Arg	Pro	Asn	Lys	Ala	Ile	Glu	Ala	Glu	Lys	Val	Met	Gly	Ala	Asp		
130								135					140				
Asp	Ile	Ala	His	Pro	Ser	Val	Ala	Tyr	Leu	Arg	Asn	Asn	Val	Lys	Glu		
145								150					155				
Phe	Tyr	Val	Gly	Gly	Lys	Val	Gln	Ala	Ile	Gln	Ala	Pro	Thr	His	Phe		
165								170					175				
Asp	Tyr	Val	Pro	Leu	Arg	Phe	Thr	Pro	Ala	Glu	Leu	Arg	Ala	His	Phe		
180								185					190				
His	Lys	Leu	Ala	Trp	Arg	Lys	Val	Val	Ala	Phe	Gln	Thr	Arg	Asn	Pro		
195								200					205				
Met	His	Arg	Ala	His	Arg	Glu	Leu	Thr	Val	Arg	Ala	Ala	Arg	Gln	Arg		
210								215					220				
Arg	Ala	Asn	Val	Leu	Ile	His	Pro	Val	Val	Gly	Leu	Thr	Lys	Pro	Gly		
225								230					235				
Asp	Val	Asp	His	Tyr	Thr	Arg	Val	Arg	Ala	Tyr	Gln	Ala	Leu	Met	Pro		
245								250					255				
Ser	Tyr	Pro	Glu	Gly	Met	Ala	His	Leu	Ala	Leu	Leu	Pro	Leu	Ala	Met		
260								265					270				
Arg	Met	Ala	Gly	Pro	Arg	Glu	Ala	Val	Trp	His	Ala	Val	Ile	Arg	Lys		
275								280					285				
Asn	Phe	Gly	Ala	Thr	His	Phe	Ile	Val	Gly	Arg	Asp	His	Ala	Gly	Pro		
290								295					300				
Gly	Lys	Asn	Ser	Gln	Gly	Gln	Asp	Phe	Tyr	Gly	Pro	Tyr	Asp	Ala	Gln		
305								310					315				
Glu	Leu	Val	Thr	Gln	Phe	Lys	Asp	Glu	Leu	Gln	Ile	Glu	Met	Val	Pro		
325								330					335				
Phe	Gln	Ala	Met	Thr	Tyr	Leu	Pro	Gly	Ser	Asp	Glu	Tyr	Gln	Pro	Val		
340								345					350				
Asp	Glu	Val	Pro	Lys	Gly	Thr	Pro	Thr	Ala	Asp	Ile	Ser	Gly	Thr	Glu		
355								360					365				
Leu	Arg	Lys	Arg	Leu	Arg	Thr	Gly	Ala	Ser	Ile	Pro	Asp	Trp	Phe	Ser		
370								375					380				
Tyr	Thr	Gly	Val	Val	Lys	Val	Leu	Arg	Glu	Ser	Tyr	Pro	Pro	Arg	Pro		
385								390					395				
Gln	Gln	Gly	Phe	Thr	Ile	Leu	Leu	Thr	Gly	Leu	His	Asn	Ser	Gly	Lys		
405								410					415				
Asp	Thr	Ile	Ala	Arg	Ala	Leu	Gln	Val	Thr	Leu	Gln	Gln	Gln	Gly	Ser		
420								425					430				
Arg	Ser	Val	Ser	Leu	Leu	Leu	Gly	Glu	Glu	Leu	Arg	Ser	Asp	Leu	Asp		
435								440					445				
Pro	Gln	Ile	Gly	Arg	Ala	Ile	Thr	Pro	Glu	Gln	Lys	His	Ile	Asn	Leu		
450								455					460				
Glu	Arg	Ile	Gly	Phe	Val	Ala	Gly	Glu	Leu	Thr	Lys	Ala	Gly	Ala	Ala		
465								470					475				
Val	Ile	Ala	Ala	Pro	Thr	Ala	Pro	Tyr	Glu	Arg	Ser	Arg	Gln	Ala	Phe		
485								490					495				

-continued

Lys Lys Gln Val Val Gly Ser Gly Gly Gly Asn Tyr Phe Leu Val His
500 505 510

Val Ala Thr Pro Leu Glu Trp Cys Glu Lys Val Asp Arg Arg Gly Leu
515 520 525

Tyr Lys Ala Ala Arg Ala Gly Glu Ile Lys Asn Leu Thr Gly Val Asp
530 535 540

Asp Val Tyr Glu Ala Pro Glu Asp Ala Asp Leu Val Cys Asp Leu Arg
545 550 555 560

Asn Asp Thr Val Pro Glu Ile Val His Ser Ile Ile Met Ile Leu Glu
565 570 575

Ser Gln Asn Leu Val
580

<210> SEQ ID NO 59
<211> LENGTH: 1716
<212> TYPE: DNA
<213> ORGANISM: Cryptococcus neoformans
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1) .. (1716)

<400> SEQUENCE: 59

atg cac atc gca tac att ctc ggc ctc gta ccc ctc gct ttc gcc ggt	48
Met His Ile Ala Tyr Ile Leu Gly Leu Val Pro Leu Ala Phe Ala Gly	
1 5 10 15	
gtc atc aag cac gac cct ccc aag ttc cag cct att cag tct acc agg	96
Val Ile Lys His Asp Pro Pro Lys Phe Gln Pro Ile Gln Ser Thr Arg	
20 25 30	
att gtg cgg ctg cac cca aac ggg gac aaa agc aag tgc gtt gac ctc	144
Ile Val Arg Leu His Pro Asn Gly Asp Lys Ser Lys Cys Val Asp Leu	
35 40 45	
ctg ggt aat act cgc cag gat ggt cag ccc gtg cag att tgc gac tgc	192
Leu Gly Asn Thr Arg Gln Asp Gly Gln Pro Val Gln Ile Cys Asp Cys	
50 55 60	
gac ggt acc ccg gct cag gac tgg gtc ctc aat gcc gcc cgc ggt cag	240
Asp Gly Thr Pro Ala Gln Asp Trp Val Leu Asn Ala Gly Arg Gly Gln	
65 70 75 80	
acc aag gtc cag ctc gcc ggc acc agt ttc tgt ctc gat gcc acc cac	288
Thr Lys Val Gln Leu Ala Gly Thr Ser Phe Cys Leu Asp Ala Thr His	
85 90 95	
cct tac gca gcc gac ggg acc aac atg aag atc tgg aag tgc ttg gac	336
Pro Tyr Ala Ala Asp Gly Thr Asn Met Lys Ile Trp Lys Cys Leu Asp	
100 105 110	
gtc caa cag caa gac tgg tat tgg acg agt gat aac aga atc gtt ctc	384
Val Gln Gln Gln Asp Trp Tyr Trp Thr Ser Asp Asn Arg Ile Val Leu	
115 120 125	
cgc gac cag ggc aag tgc ctc gac tgg gcc act ggg gat cgg tct gat	432
Arg Asp Gln Gly Lys Cys Leu Asp Trp Ala Thr Gly Asp Arg Ser Asp	
130 135 140	
ttc aac cag ctg cag gtc tgg cgg tgc agc acg gat aac aac aat cag	480
Phe Asn Gln Leu Gln Val Trp Arg Cys Ser Thr Asp Asn Asn Asn Gln	
145 150 155 160	
gtc tgg aca acg gga ccg gac tac ggt ggg aac cat ggg ggt gat gct	528
Val Trp Thr Thr Gly Pro Asp Tyr Gly Gly Asn His Gly Gly Asp Ala	
165 170 175	
ggg ggg aac ccc gga ggt aat caa gcc gat gat tca aga gcc aaa acc	576
Gly Gly Asn Pro Gly Gly Asn Gln Gly Asp Asp Ser Arg Gly Lys Thr	

-continued

180						185						190						
aat	act	ggt	gga	aac	ccc	gga	ggt	aat	caa	ggt	ggt	gat	tca	gga	ggg	624		
Asn	Thr	Gly	Gly	Asn	Pro	Gly	Gly	Asn	Gln	Gly	Gly	Asp	Ser	Gly	Gly			
		195					200					205						
aaa	acc	aat	cac	atc	att	ccc	gac	ccc	cca	ggg	cca	gac	ccc	aac	agc	672		
Lys	Thr	Asn	His	Ile	Ile	Pro	Asp	Pro	Pro	Gly	Pro	Asp	Pro	Asn	Ser			
		210					215					220						
gag	ccc	ctc	aac	ccc	gcc	ctt	gaa	gcc	att	gtt	aac	gtc	acc	gag	gca	720		
Glu	Pro	Leu	Asn	Pro	Ala	Leu	Glu	Ala	Ile	Val	Asn	Val	Thr	Glu	Ala			
		225			230					235					240			
gct	gga	ccc	tgg	ccg	ccc	atg	atc	aac	ttc	gac	ggc	gat	tac	agc	aat	768		
Ala	Gly	Pro	Trp	Pro	Pro	Met	Ile	Asn	Phe	Asp	Gly	Asp	Tyr	Ser	Asn			
			245						250					255				
gac	gac	gtg	acc	gta	tcg	gac	caa	gta	ccg	ttc	gac	tac	tgt	atc	ggg	816		
Asp	Asp	Val	Thr	Val	Ser	Asp	Gln	Val	Pro	Phe	Asp	Tyr	Cys	Ile	Gly			
			260					265					270					
gag	ggg	tct	ggt	aac	ccg	acg	gat	gat	gaa	gga	cag	cag	caa	gga	caa	864		
Glu	Gly	Ser	Gly	Asn	Pro	Thr	Asp	Asp	Glu	Gly	Gln	Gln	Gln	Gly	Gln			
		275					280					285						
aac	ttc	aca	gca	aat	gta	gct	ggg	ata	ggg	aga	gac	ttc	tgc	ctg	gac	912		
Asn	Phe	Thr	Ala	Asn	Val	Ala	Gly	Ile	Gly	Arg	Asp	Phe	Cys	Leu	Asp			
		290				295					300							
aat	ttt	ggc	aat	cct	gac	att	cgg	aac	acc	att	tct	ttc	gac	aac	aac	960		
Asn	Phe	Gly	Asn	Pro	Asp	Ile	Arg	Asn	Thr	Ile	Ser	Phe	Asp	Asn	Asn			
		305			310					315					320			
acc	agc	att	ggg	aac	gga	gcg	gac	act	ggg	cga	gcc	ctt	cac	aag	cgg	1008		
Thr	Ser	Ile	Gly	Asn	Gly	Ala	Asp	Thr	Gly	Arg	Ala	Leu	His	Lys	Arg			
			325					330					335					
aca	ttt	gcg	gat	tca	ggg	gcg	acg	ggt	acg	ccc	aac	cgg	tgg	aga	cga	1056		
Thr	Phe	Ala	Asp	Ser	Gly	Ala	Thr	Gly	Thr	Pro	Asn	Arg	Trp	Arg	Arg			
			340				345						350					
ggg	tcg	gtg	att	tcc	att	tgc	gtc	gag	agg	aac	aac	aat	tat	ctg	gtt	1104		
Gly	Ser	Val	Ile	Ser	Ile	Cys	Val	Glu	Arg	Asn	Asn	Asn	Tyr	Leu	Val			
		355				360						365						
cca	tat	gcg	tcc	tcc	ccc	gtt	ccc	atc	cga	gca	tcg	gct	atc	gtc	gca	1152		
Pro	Tyr	Ala	Ser	Ser	Pro	Val	Pro	Ile	Arg	Ala	Ser	Ala	Ile	Val	Ala			
		370				375					380							
tcc	gcc	atg	gta	cgt	gca	atc	aac	ttc	tgg	aac	gca	ggt	ctg	aac	aag	1200		
Ser	Ala	Met	Val	Arg	Ala	Ile	Asn	Phe	Trp	Asn	Ala	Gly	Leu	Asn	Lys			
		385			390					395					400			
cga	ttc	gtc	tcg	ttc	gag	ttt	gtg	gag	aac	tgc	aac	gac	gcc	gtg	ttc	1248		
Arg	Phe	Val	Ser	Phe	Glu	Phe	Val	Glu	Asn	Cys	Asn	Asp	Ala	Val	Phe			
			405					410					415					
cat	act	ctt	gct	gtt	gac	cag	atc	aag	tct	gcc	aaa	gag	cct	act	gtg	1296		
His	Thr	Leu	Ala	Val	Asp	Gln	Ile	Lys	Ser	Ala	Lys	Glu	Pro	Thr	Val			
			420				425						430					
ctc	gcg	act	gcc	ccc	ttc	cct	cct	cgg	ggt	gaa	gag	ggt	gct	agg	aac	1344		
Leu	Ala	Thr	Ala	Pro	Phe	Pro	Pro	Arg	Gly	Glu	Glu	Gly	Ala	Arg	Asn			
		435				440						445						
cgc	aac	atc	ttc	gtg	tgg	aat	acg	gct	ttc	gag	gcc	aac	ttt	cag	aac	1392		
Arg	Asn	Ile	Phe	Val	Trp	Asn	Thr	Ala	Phe	Glu	Ala	Asn	Phe	Gln	Asn			
		450				455				460								
gtc	ctt	acc	ttt	atc	atg	tca	cat	gag	ctg	ggg	cac	act	ctt	ggc	ctg	1440		
Val	Leu	Thr	Phe	Ile	Met	Ser	His	Glu	Leu	Gly	His	Thr	Leu	Gly	Leu			
		465			470				475					480				
gcg	cat	gag	gac	tgc	aaa	tcc	aga	gac	caa	cct	tgc	gaa	gtt	atc	act	1488		
Ala	His	Glu	Asp	Cys	Lys	Ser	Arg	Asp	Gln	Pro	Cys	Glu	Val	Ile	Thr			

-continued

485	490	495	
gac aag gtg gct ggg tca gtc gtg gaa agc cgt atc tcc ggc agc acc			1536
Asp Lys Val Ala Gly Ser Val Val Glu Ser Arg Ile Ser Gly Ser Thr			
500	505	510	
aca cag ctg ttc aat ggc ccc acc ccg ctt gac ata gca ggg gcg aac			1584
Thr Gln Leu Phe Asn Gly Pro Thr Pro Leu Asp Ile Ala Gly Ala Asn			
515	520	525	
gag tac tac tca ctt gca gcg gga ccc aac acc ccg gag aac atc gta			1632
Glu Tyr Tyr Ser Leu Ala Ala Gly Pro Asn Thr Pro Glu Asn Ile Val			
530	535	540	
ctc tgg cct gcg acg agg ggt ccg ttt atc aac tac ccg ccg cta ccg			1680
Leu Trp Pro Ala Thr Arg Gly Pro Phe Ile Asn Tyr Pro Pro Leu Pro			
545	550	555	560
aaa tgc aag tgg ttc ctc ggt att tgc tat tac tag			1716
Lys Cys Lys Trp Phe Leu Gly Ile Cys Tyr Tyr			
565	570		

<210> SEQ ID NO 60

<211> LENGTH: 571

<212> TYPE: PRT

<213> ORGANISM: Cryptococcus neoformans

<400> SEQUENCE: 60

Met His Ile Ala Tyr Ile Leu Gly Leu Val Pro Leu Ala Phe Ala Gly			
1	5	10	15
Val Ile Lys His Asp Pro Pro Lys Phe Gln Pro Ile Gln Ser Thr Arg			
20	25	30	
Ile Val Arg Leu His Pro Asn Gly Asp Lys Ser Lys Cys Val Asp Leu			
35	40	45	
Leu Gly Asn Thr Arg Gln Asp Gly Gln Pro Val Gln Ile Cys Asp Cys			
50	55	60	
Asp Gly Thr Pro Ala Gln Asp Trp Val Leu Asn Ala Gly Arg Gly Gln			
65	70	75	80
Thr Lys Val Gln Leu Ala Gly Thr Ser Phe Cys Leu Asp Ala Thr His			
85	90	95	
Pro Tyr Ala Ala Asp Gly Thr Asn Met Lys Ile Trp Lys Cys Leu Asp			
100	105	110	
Val Gln Gln Gln Asp Trp Tyr Trp Thr Ser Asp Asn Arg Ile Val Leu			
115	120	125	
Arg Asp Gln Gly Lys Cys Leu Asp Trp Ala Thr Gly Asp Arg Ser Asp			
130	135	140	
Phe Asn Gln Leu Gln Val Trp Arg Cys Ser Thr Asp Asn Asn Asn Gln			
145	150	155	160
Val Trp Thr Thr Gly Pro Asp Tyr Gly Gly Asn His Gly Gly Asp Ala			
165	170	175	
Gly Gly Asn Pro Gly Gly Asn Gln Gly Asp Asp Ser Arg Gly Lys Thr			
180	185	190	
Asn Thr Gly Gly Asn Pro Gly Gly Asn Gln Gly Gly Asp Ser Gly Gly			
195	200	205	
Lys Thr Asn His Ile Ile Pro Asp Pro Pro Gly Pro Asp Pro Asn Ser			
210	215	220	
Glu Pro Leu Asn Pro Ala Leu Glu Ala Ile Val Asn Val Thr Glu Ala			
225	230	235	240
Ala Gly Pro Trp Pro Pro Met Ile Asn Phe Asp Gly Asp Tyr Ser Asn			

-continued

245				250				255							
Asp	Asp	Val	Thr	Val	Ser	Asp	Gln	Val	Pro	Phe	Asp	Tyr	Cys	Ile	Gly
		260					265						270		
Glu	Gly	Ser	Gly	Asn	Pro	Thr	Asp	Asp	Glu	Gly	Gln	Gln	Gln	Gly	Gln
		275					280					285			
Asn	Phe	Thr	Ala	Asn	Val	Ala	Gly	Ile	Gly	Arg	Asp	Phe	Cys	Leu	Asp
		290				295					300				
Asn	Phe	Gly	Asn	Pro	Asp	Ile	Arg	Asn	Thr	Ile	Ser	Phe	Asp	Asn	Asn
		305			310					315				320	
Thr	Ser	Ile	Gly	Asn	Gly	Ala	Asp	Thr	Gly	Arg	Ala	Leu	His	Lys	Arg
			325						330					335	
Thr	Phe	Ala	Asp	Ser	Gly	Ala	Thr	Gly	Thr	Pro	Asn	Arg	Trp	Arg	Arg
		340							345				350		
Gly	Ser	Val	Ile	Ser	Ile	Cys	Val	Glu	Arg	Asn	Asn	Asn	Tyr	Leu	Val
		355					360					365			
Pro	Tyr	Ala	Ser	Ser	Pro	Val	Pro	Ile	Arg	Ala	Ser	Ala	Ile	Val	Ala
		370				375					380				
Ser	Ala	Met	Val	Arg	Ala	Ile	Asn	Phe	Trp	Asn	Ala	Gly	Leu	Asn	Lys
		385			390					395				400	
Arg	Phe	Val	Ser	Phe	Glu	Phe	Val	Glu	Asn	Cys	Asn	Asp	Ala	Val	Phe
			405						410					415	
His	Thr	Leu	Ala	Val	Asp	Gln	Ile	Lys	Ser	Ala	Lys	Glu	Pro	Thr	Val
		420						425					430		
Leu	Ala	Thr	Ala	Pro	Phe	Pro	Pro	Arg	Gly	Glu	Glu	Gly	Ala	Arg	Asn
		435					440					445			
Arg	Asn	Ile	Phe	Val	Trp	Asn	Thr	Ala	Phe	Glu	Ala	Asn	Phe	Gln	Asn
		450				455					460				
Val	Leu	Thr	Phe	Ile	Met	Ser	His	Glu	Leu	Gly	His	Thr	Leu	Gly	Leu
		465			470					475				480	
Ala	His	Glu	Asp	Cys	Lys	Ser	Arg	Asp	Gln	Pro	Cys	Glu	Val	Ile	Thr
			485						490					495	
Asp	Lys	Val	Ala	Gly	Ser	Val	Val	Glu	Ser	Arg	Ile	Ser	Gly	Ser	Thr
		500						505					510		
Thr	Gln	Leu	Phe	Asn	Gly	Pro	Thr	Pro	Leu	Asp	Ile	Ala	Gly	Ala	Asn
		515					520					525			
Glu	Tyr	Tyr	Ser	Leu	Ala	Ala	Gly	Pro	Asn	Thr	Pro	Glu	Asn	Ile	Val
		530				535					540				
Leu	Trp	Pro	Ala	Thr	Arg	Gly	Pro	Phe	Ile	Asn	Tyr	Pro	Pro	Leu	Pro
		545			550					555				560	
Lys	Cys	Lys	Trp	Phe	Leu	Gly	Ile	Cys	Tyr	Tyr					
			565						570						

<210> SEQ ID NO 61
 <211> LENGTH: 1500
 <212> TYPE: DNA
 <213> ORGANISM: Cryptococcus neoformans
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1)..(1500)

<400> SEQUENCE: 61

atg ccg agc ctg acc cag acc aaa gat ctg gcg agc ctg ctg agc gat
 Met Pro Ser Leu Thr Gln Thr Lys Asp Leu Ala Ser Leu Leu Ser Asp
 1 5 10 15

-continued

gcg agc cat ttt aaa cag aaa ggc tat att aac ggc gaa tgg gtg agc Ala Ser His Phe Lys Gln Lys Gly Tyr Ile Asn Gly Glu Trp Val Ser 20 25 30	96
gcg agc gat ggc gcg acc ttt ccg ctg tat aac ccg gcg acc ggc gcg Ala Ser Asp Gly Ala Thr Phe Pro Leu Tyr Asn Pro Ala Thr Gly Ala 35 40 45	144
aaa ctg gcg gat atg ccg cat atg ccg cgc agc cag gtg gcg gaa gcg Lys Leu Ala Asp Met Pro His Met Pro Arg Ser Gln Val Ala Glu Ala 50 55 60	192
att aac gcg gcg aaa gcg gcg ttt ccg gcg tgg gcg gcg ctg acc gcg Ile Asn Ala Ala Lys Ala Ala Phe Pro Ala Trp Ala Ala Leu Thr Ala 65 70 75 80	240
tat cag cgc cag aac tat ctg ctg aaa ctg ttt aaa gaa atg gaa gaa Tyr Gln Arg Gln Asn Tyr Leu Leu Lys Leu Phe Lys Glu Met Glu Glu 85 90 95	288
cat agc gaa gat ctg gcg att att ctg tgc acc gaa aac ggc aaa ccg His Ser Glu Asp Leu Ala Ile Ile Leu Cys Thr Glu Asn Gly Lys Pro 100 105 110	336
ctg gcg gaa agc cgc gtg gaa att agc tat ggc gcg agc ttt ctg acc Leu Ala Glu Ser Arg Val Glu Ile Ser Tyr Gly Ala Ser Phe Leu Thr 115 120 125	384
tgg aac gcg gcg gaa gcg ctg cgc acc tat ggc cag acc att ccg agc Trp Asn Ala Ala Glu Ala Leu Arg Thr Tyr Gly Gln Thr Ile Pro Ser 130 135 140	432
ccg ttt ccg ggc acc cgc aac acc gtg att aaa cag ccg att ggc gtg Pro Phe Pro Gly Thr Arg Asn Thr Val Ile Lys Gln Pro Ile Gly Val 145 150 155 160	480
tgc ggc ctg att acc ccg tgg aac ttt ccg aac gcg atg att acc cgc Cys Gly Leu Ile Thr Pro Trp Asn Phe Pro Asn Ala Met Ile Thr Arg 165 170 175	528
aaa atg gcg ccg gcg ctg gcg gcg ggc tgc acc gtg gtg att aaa gcg Lys Met Ala Pro Ala Leu Ala Ala Gly Cys Thr Val Val Ile Lys Ala 180 185 190	576
ccg gcg gaa acc ccg ctg agc gcg ctg gcg atg tgc gtg ctg tgc gaa Pro Ala Glu Thr Pro Leu Ser Ala Leu Ala Met Cys Val Leu Cys Glu 195 200 205	624
cgc gtg ggc att ccg ccg ggc gtg gtg aac gtg gtg acc atg gat aaa Arg Val Gly Ile Pro Pro Gly Val Val Asn Val Val Thr Met Asp Lys 210 215 220	672
ggc cag cgc gaa atg gcg gcg ggc ctg gaa ctg tgc gaa aac gtg aaa Gly Gln Arg Glu Met Ala Ala Gly Leu Glu Cys Glu Asn Val Lys 225 230 235 240	720
gtg agc aaa att agc ttt acc ggc agc acc ccg gtg ggc cgc ctg ctg Val Ser Lys Ile Ser Phe Thr Gly Ser Thr Pro Val Gly Arg Leu Leu 245 250 255	768
atg aaa cag agc agc ggc acc ctg aaa aaa ctg agc ttt gaa ctg ggc Met Lys Gln Ser Ser Gly Thr Leu Lys Lys Leu Ser Phe Glu Leu Gly 260 265 270	816
ggc aac gcg gcg ttt att att ttt gat gat gcg gat ctg gat ctg gcg Gly Asn Ala Ala Phe Ile Ile Phe Asp Asp Ala Asp Leu Asp Leu Ala 275 280 285	864
gtg aac ggc gtg att ctg agc aaa ttt cgc gcg gcg ggc cag acc tgc Val Asn Gly Val Ile Leu Ser Lys Phe Arg Ala Ala Gly Gln Thr Cys 290 295 300	912
att tgc gcg aac cgc att ttt gtg cat agc aaa att tat gat gat ttt Ile Cys Ala Asn Arg Ile Phe Val His Ser Lys Ile Tyr Asp Asp Phe 305 310 315 320	960

-continued

gcg cgc cgc ctg gtg gaa cgc gtg aaa gcg ttt aaa gtg ggc aac ggc Ala Arg Arg Leu Val Glu Arg Val Lys Ala Phe Lys Val Gly Asn Gly 325 330 335	1008
att gaa gaa ggc gtg acc att ggc ccg ctg gtg agc cag cgc ggc gtg Ile Glu Glu Gly Val Thr Ile Gly Pro Leu Val Ser Gln Arg Gly Val 340 345 350	1056
gaa aaa gtg gaa cgc cat gtg cag gat gcg gtg ggc ctg ggc gcg aaa Glu Lys Val Glu Arg His Val Gln Asp Ala Val Gly Leu Gly Ala Lys 355 360 365	1104
gtg ctg gtg ggc ggc aaa cgc att gat aaa ggc gaa ggc agc tgc ttt Val Leu Val Gly Gly Lys Arg Ile Asp Lys Gly Glu Gly Ser Cys Phe 370 375 380	1152
tat gaa ccg acc gtg ctg gtg gat gtg ccg cgc cag tgc gcg gtg agc Tyr Glu Pro Thr Val Leu Val Asp Val Pro Arg Gln Cys Ala Val Ser 385 390 395 400	1200
aac gaa gaa acc ttt ggc ccg ctg gcg ccg ctg ttt aaa ttt gat gat Asn Glu Glu Thr Phe Gly Pro Leu Ala Pro Leu Phe Lys Phe Asp Asp 405 410 415	1248
gaa gat gat gtg gtg gaa cgc gcg aac agc agc gaa gtg ggc ctg gcg Glu Asp Asp Val Val Glu Arg Ala Asn Ser Ser Glu Val Gly Leu Ala 420 425 430	1296
gcg tat ttt ttt acc aaa gat ctg gcg cgc acc cat cgc gtg gcg gaa Ala Tyr Phe Phe Thr Lys Asp Leu Ala Arg Thr His Arg Val Ala Glu 435 440 445	1344
aaa ctg gaa gtg ggc atg gtg gcg gtg aac acc ggc gcg att gcg cag Lys Leu Glu Val Gly Met Val Ala Val Asn Thr Gly Ala Ile Ala Gln 450 455 460	1392
agc tgc gtg ccg ttt ggc ggc gtg aaa cag agc ggc ttt ggc cgc gaa Ser Cys Val Pro Phe Gly Gly Val Lys Gln Ser Gly Phe Gly Arg Glu 465 470 475 480	1440
ggc ggc ccg agc ggc att gat gaa ttt atg gtg gaa aaa ctg att acc Gly Gly Pro Ser Gly Ile Asp Glu Phe Met Val Glu Lys Leu Ile Thr 485 490 495	1488
att ggc ggc ctg Ile Gly Gly Leu 500	1500

<210> SEQ ID NO 62

<211> LENGTH: 500

<212> TYPE: PRT

<213> ORGANISM: Cryptococcus neoformans

<400> SEQUENCE: 62

Met Pro Ser Leu Thr Gln Thr Lys Asp Leu Ala Ser Leu Leu Ser Asp
1 5 10 15

Ala Ser His Phe Lys Gln Lys Gly Tyr Ile Asn Gly Glu Trp Val Ser
20 25 30

Ala Ser Asp Gly Ala Thr Phe Pro Leu Tyr Asn Pro Ala Thr Gly Ala
35 40 45

Lys Leu Ala Asp Met Pro His Met Pro Arg Ser Gln Val Ala Glu Ala
50 55 60

Ile Asn Ala Ala Lys Ala Ala Phe Pro Ala Trp Ala Ala Leu Thr Ala
65 70 75 80

Tyr Gln Arg Gln Asn Tyr Leu Leu Lys Leu Phe Lys Glu Met Glu Glu
85 90 95

His Ser Glu Asp Leu Ala Ile Ile Leu Cys Thr Glu Asn Gly Lys Pro

[illegible]

-continued

```

<210> SEQ ID NO 63
<211> LENGTH: 1200
<212> TYPE: DNA
<213> ORGANISM: Cryptococcus neoformans
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(1200)

<400> SEQUENCE: 63

atg tgc agc agc cat gcg acc gcg gtg gaa agc gtg agc ccg gcg ccg      48
Met Cys Ser Ser His Ala Thr Ala Val Glu Ser Val Ser Pro Ala Pro
1          5          10          15

cgc aaa agc cag tat gaa gtg aaa tat gat ccg gat ctg gtg ctg aaa      96
Arg Lys Ser Gln Tyr Glu Val Lys Tyr Asp Pro Asp Leu Val Leu Lys
          20          25          30

agc gcg gaa ttt aaa gaa ctg aaa cag gcc gat aaa gaa ctg gaa gat      144
Ser Ala Glu Phe Lys Glu Leu Lys Gln Gly Asp Lys Glu Leu Glu Asp
          35          40          45

ccg aaa gcg aac ctg gcg tgc gcg tat gat gaa aaa cat aac gtg aaa      192
Pro Lys Ala Asn Leu Ala Cys Ala Tyr Asp Glu Lys His Asn Val Lys
          50          55          60

atg att aac aaa ccg att ccg aaa gcg cgc cag gat gaa gtg gtg gtg      240
Met Ile Asn Lys Pro Ile Pro Lys Ala Arg Gln Asp Glu Val Val Val
65          70          75          80

cat att aaa gcg acc gcc att tgc gcc agc gat gtg cat ttt tgg aaa      288
His Ile Lys Ala Thr Gly Ile Cys Gly Ser Asp Val His Phe Trp Lys
          85          90          95

cat gcc cag att gcc ccg acc atg att gtg acc gat acc tgc gcc gcg      336
His Gly Gln Ile Gly Pro Thr Met Ile Val Thr Asp Thr Cys Gly Ala
          100          105          110

gcc cat gaa agc gcg gcc gaa gtg gtg gaa gtg gcc ccg gcc gtg gaa      384
Gly His Glu Ser Ala Gly Glu Val Val Glu Val Gly Pro Gly Val Glu
          115          120          125

cag tgg aaa gtg gcc gat cgc gtg gcg att gaa tgc gcc gtg ccg tgc      432
Gln Trp Lys Val Gly Asp Arg Val Ala Ile Glu Cys Gly Val Pro Cys
          130          135          140

gcc cag gcg agc tgc gcc ccg tgc gtg acc gcc cgc tat aac gcg tgc      480
Gly Gln Ala Ser Cys Gly Pro Cys Val Thr Gly Arg Tyr Asn Ala Cys
          145          150          155          160

ccg cag gtg gtg ttt ttt agc acc ccg ccg tat cat gcc acc ctg acc      528
Pro Gln Val Val Phe Phe Ser Thr Pro Pro Tyr His Gly Thr Leu Thr
          165          170          175

cgc tat cat gcg cat ccg gcg agc tgg ctg cat cgc ctg ccg gat aac      576
Arg Tyr His Ala His Pro Ala Ser Trp Leu His Arg Leu Pro Asp Asn
          180          185          190

ctg agc tat gaa gaa gcc gcg ctg tgc gaa ccg ttt gcg gtg gcg ctg      624
Leu Ser Tyr Glu Glu Gly Ala Leu Cys Glu Pro Phe Ala Val Ala Leu
          195          200          205

gcg gcg ctg gaa cgc gcg gcc aac cgc ctg gcc gat ccg gtg ctg att      672
Ala Ala Leu Glu Arg Ala Gly Asn Arg Leu Gly Asp Pro Val Leu Ile
          210          215          220

tgc gcc gcg gcc ccg att gcc ctg gtg acc ctg ctg gcg agc cat gcg      720
Cys Gly Ala Gly Pro Ile Gly Leu Val Thr Leu Leu Ala Ser His Ala
          225          230          235          240

gcg gcc tgc acc ccg att gtg att acc gat ctg cag gcg agc cgc ctg      768
Ala Gly Cys Thr Pro Ile Val Ile Thr Asp Leu Gln Ala Ser Arg Leu
          245          250          255

```

-continued

gaa gtc gcg aaa aaa ctg att ccg acc gtc aaa acc gtc cag att gaa	816
Glu Val Ala Lys Lys Leu Ile Pro Thr Val Lys Thr Val Gln Ile Glu	
260 265 270	
cgc agc tgg acc agc aaa gaa acc agc gaa gcg att aaa gaa gcg gcg	864
Arg Ser Trp Thr Ser Lys Glu Thr Ser Glu Ala Ile Lys Glu Ala Ala	
275 280 285	
ggc acc ggc att cgc gtc gcg att gat gcg acc ggc ttt gaa agc agc	912
Gly Thr Gly Ile Arg Val Ala Ile Asp Ala Thr Gly Phe Glu Ser Ser	
290 295 300	
att acc gcg gcg att tat agc gtc gtc ttt ggc ggc aaa gtc ttt gtc	960
Ile Thr Ala Ala Ile Tyr Ser Val Val Phe Gly Gly Lys Val Phe Val	
305 310 315 320	
att ggc gcg ggc ccg agc gaa cag aaa tat ccg ttt ggc tat tgc agc	1008
Ile Gly Ala Gly Pro Ser Glu Gln Lys Tyr Pro Phe Gly Tyr Cys Ser	
325 330 335	
gcg aac gaa att gat ctg cag ttt cag tat cgc tat gcg cat cag tat	1056
Ala Asn Glu Ile Asp Leu Gln Phe Gln Tyr Arg Tyr Ala His Gln Tyr	
340 345 350	
ccg aaa gcg ctg cgc att gtc agc ggc ggc ctg att aac ctg aaa ccg	1104
Pro Lys Ala Leu Arg Ile Val Ser Gly Gly Leu Ile Asn Leu Lys Pro	
355 360 365	
ctg ctg acc cat acc ttt ccg ctg aac aaa gcg gtc gaa gcg ttt cat	1152
Leu Leu Thr His Thr Phe Pro Leu Asn Lys Ala Val Glu Ala Phe His	
370 375 380	
gtg gcg gcg gat ccg acc aaa ggc gcg att aaa gtc cag att att gat	1200
Val Ala Ala Asp Pro Thr Lys Gly Ala Ile Lys Val Gln Ile Ile Asp	
385 390 395 400	

<210> SEQ ID NO 64

<211> LENGTH: 400

<212> TYPE: PRT

<213> ORGANISM: *Cryptococcus neoformans*

<400> SEQUENCE: 64

Met Cys Ser Ser His Ala Thr Ala Val Glu Ser Val Ser Pro Ala Pro	
1 5 10 15	
Arg Lys Ser Gln Tyr Glu Val Lys Tyr Asp Pro Asp Leu Val Leu Lys	
20 25 30	
Ser Ala Glu Phe Lys Glu Leu Lys Gln Gly Asp Lys Glu Leu Glu Asp	
35 40 45	
Pro Lys Ala Asn Leu Ala Cys Ala Tyr Asp Glu Lys His Asn Val Lys	
50 55 60	
Met Ile Asn Lys Pro Ile Pro Lys Ala Arg Gln Asp Glu Val Val Val	
65 70 75 80	
His Ile Lys Ala Thr Gly Ile Cys Gly Ser Asp Val His Phe Trp Lys	
85 90 95	
His Gly Gln Ile Gly Pro Thr Met Ile Val Thr Asp Thr Cys Gly Ala	
100 105 110	
Gly His Glu Ser Ala Gly Glu Val Val Glu Val Gly Pro Gly Val Glu	
115 120 125	
Gln Trp Lys Val Gly Asp Arg Val Ala Ile Glu Cys Gly Val Pro Cys	
130 135 140	
Gly Gln Ala Ser Cys Gly Pro Cys Val Thr Gly Arg Tyr Asn Ala Cys	
145 150 155 160	
Pro Gln Val Val Phe Phe Ser Thr Pro Pro Tyr His Gly Thr Leu Thr	
165 170 175	

-continued

Arg Tyr His Ala His Pro Ala Ser Trp Leu His Arg Leu Pro Asp Asn
 180 185 190
 Leu Ser Tyr Glu Glu Gly Ala Leu Cys Glu Pro Phe Ala Val Ala Leu
 195 200 205
 Ala Ala Leu Glu Arg Ala Gly Asn Arg Leu Gly Asp Pro Val Leu Ile
 210 215 220
 Cys Gly Ala Gly Pro Ile Gly Leu Val Thr Leu Leu Ala Ser His Ala
 225 230 235 240
 Ala Gly Cys Thr Pro Ile Val Ile Thr Asp Leu Gln Ala Ser Arg Leu
 245 250 255
 Glu Val Ala Lys Lys Leu Ile Pro Thr Val Lys Thr Val Gln Ile Glu
 260 265 270
 Arg Ser Trp Thr Ser Lys Glu Thr Ser Glu Ala Ile Lys Glu Ala Ala
 275 280 285
 Gly Thr Gly Ile Arg Val Ala Ile Asp Ala Thr Gly Phe Glu Ser Ser
 290 295 300
 Ile Thr Ala Ala Ile Tyr Ser Val Val Phe Gly Gly Lys Val Phe Val
 305 310 315 320
 Ile Gly Ala Gly Pro Ser Glu Gln Lys Tyr Pro Phe Gly Tyr Cys Ser
 325 330 335
 Ala Asn Glu Ile Asp Leu Gln Phe Gln Tyr Arg Tyr Ala His Gln Tyr
 340 345 350
 Pro Lys Ala Leu Arg Ile Val Ser Gly Gly Leu Ile Asn Leu Lys Pro
 355 360 365
 Leu Leu Thr His Thr Phe Pro Leu Asn Lys Ala Val Glu Ala Phe His
 370 375 380
 Val Ala Ala Asp Pro Thr Lys Gly Ala Ile Lys Val Gln Ile Ile Asp
 385 390 395 400

<210> SEQ ID NO 65
 <211> LENGTH: 1689
 <212> TYPE: DNA
 <213> ORGANISM: Cryptococcus neoformans
 <220> FEATURE:
 <221> NAME/KEY: CDS
 <222> LOCATION: (1)..(1689)

<400> SEQUENCE: 65

atg gtg tgc gtg att agc gat ccg gat tgg tgg cgc cag gcg gtg gtg	48
Met Val Cys Val Ile Ser Asp Pro Asp Trp Trp Arg Gln Ala Val Val	
1 5 10 15	
tat cag att tat ccg cgc agc ttt gcg gat gcg aac ggc gat ggc att	96
Tyr Gln Ile Tyr Pro Arg Ser Phe Ala Asp Ala Asn Gly Asp Gly Ile	
20 25 30	
ggc gat ctg aaa ggc att acc gcg cgc gtg ccg tat ctg aaa gcg ctg	144
Gly Asp Leu Lys Gly Ile Thr Ala Arg Val Pro Tyr Leu Lys Ala Leu	
35 40 45	
ggc gtg gat gcg att tgg ctg agc ccg ttt tat ccg agc gcg ctg cgc	192
Gly Val Asp Ala Ile Trp Leu Ser Pro Phe Tyr Pro Ser Ala Leu Arg	
50 55 60	
gat ggc ggc tat gat gtg gcg gat tat cgc gat gtg gat ccg aaa att	240
Asp Gly Gly Tyr Asp Val Ala Asp Tyr Arg Asp Val Asp Pro Lys Ile	
65 70 75 80	
ggc acc ctg gaa gaa ttt gat gaa atg acc gcg gcg ttt cag aaa gtg	288
Gly Thr Leu Glu Glu Phe Asp Glu Met Thr Ala Ala Phe Gln Lys Val	

																85																	90																	95																
ggc	att	cgc	gtg	att	gtg	gat	att	gtg	cgc	aac	cat	agc	agc	gat	gat	336																																																		
Gly	Ile	Arg	Val	Ile	Val	Asp	Ile	Val	Pro	Asn	His	Ser	Ser	Asp	Asp																																																			
			100						105			110																																																						
cat	gaa	tgg	ttt	cag	gcg	gcg	ctg	aaa	gcg	ggc	aaa	ggc	agc	ccg	gaa	384																																																		
His	Glu	Trp	Phe	Gln	Ala	Ala	Leu	Lys	Ala	Gly	Lys	Gly	Ser	Pro	Glu																																																			
			115						120			125																																																						
cgc	gaa	cgc	tat	att	ttt	cgc	gat	ggc	ctg	ggc	cgc	aac	aaa	gat	cag	432																																																		
Arg	Glu	Arg	Tyr	Ile	Phe	Arg	Asp	Gly	Leu	Gly	Pro	Asn	Lys	Asp	Gln																																																			
			130			135						140																																																						
ccg	ccg	acc	gat	tgg	att	tgc	agc	ttt	ggc	ggc	agc	gcg	tgg	agc	ccg	480																																																		
Pro	Pro	Thr	Asp	Trp	Ile	Cys	Ser	Phe	Gly	Gly	Ser	Ala	Trp	Ser	Pro																																																			
145						150			155			160																																																						
agc	ggc	atg	aac	gat	ggc	cag	tgg	tat	ttt	cat	tgg	ttt	gat	agc	agc	528																																																		
Ser	Gly	Met	Asn	Asp	Gly	Gln	Trp	Tyr	Phe	His	Trp	Phe	Asp	Ser	Ser																																																			
			165						170			175																																																						
cag	ccg	gat	tgg	aac	tgg	gaa	aac	ccg	gat	gtg	aaa	gcg	gat	ttt	ctg	576																																																		
Gln	Pro	Asp	Trp	Asn	Trp	Glu	Asn	Pro	Asp	Val	Lys	Ala	Asp	Phe	Leu																																																			
			180			185						190																																																						
aaa	acc	ctg	aaa	ttt	tgg	ggc	gat	cgc	ggc	gtg	agc	ggc	ttt	cgc	att	624																																																		
Lys	Thr	Leu	Lys	Phe	Trp	Gly	Asp	Arg	Gly	Val	Ser	Gly	Phe	Arg	Ile																																																			
195						200			205																																																									
gat	gtg	gcg	cat	ggc	ctg	gcg	aaa	gat	atg	agc	gaa	ccg	ctg	ccg	aac	672																																																		
Asp	Val	Ala	His	Gly	Leu	Ala	Lys	Asp	Met	Ser	Glu	Pro	Leu	Pro	Asn																																																			
210						215			220																																																									
tgg	gaa	cag	ctg	acc	aaa	ctg	acc	cat	cag	aaa	ctg	acc	aac	ggc	aac	720																																																		
Trp	Glu	Gln	Leu	Thr	Lys	Leu	Thr	His	Gln	Lys	Leu	Thr	Asn	Gly	Asn																																																			
225			230						235			240																																																						
agc	gaa	ctg	gat	cat	ccg	ctg	ctg	gat	cgc	aaa	gaa	gtg	cat	gat	att	768																																																		
Ser	Glu	Leu	Asp	His	Pro	Leu	Leu	Asp	Arg	Lys	Glu	Val	His	Asp	Ile																																																			
			245						250			255																																																						
tat	cgc	agc	tgg	cgc	gaa	gtg	ttt	aac	cag	ttt	aac	ccg	ccg	ctg	atg	816																																																		
Tyr	Arg	Ser	Trp	Arg	Glu	Val	Phe	Asn	Gln	Phe	Asn	Pro	Pro	Leu	Met																																																			
			260			265						270																																																						
gcg	gtg	gcg	gaa	gcg	tgg	gtg	gcg	ccg	gat	cag	aaa	ccg	ctg	tat	gcg	864																																																		
Ala	Val	Ala	Glu	Ala	Trp	Val	Ala	Pro	Asp	Gln	Lys	Pro	Leu	Tyr	Ala																																																			
275						280						285																																																						
agc	agc	gaa	ggc	ctg	ggc	cag	acc	ttt	agc	ttt	gat	att	ctg	ctg	tgc	912																																																		
Ser	Ser	Glu	Gly	Leu	Gly	Gln	Thr	Phe	Ser	Phe	Asp	Ile	Leu	Leu	Cys																																																			
290						295			300																																																									
aac	ttt	gat	gcg	gaa	gaa	tat	cgc	cag	tgc	att	aaa	agc	agc	ctg	gcg	960																																																		
Asn	Phe	Asp	Ala	Glu	Glu	Tyr	Arg	Gln	Cys	Ile	Lys	Ser	Ser	Leu	Ala																																																			
305			310						315			320																																																						
ggc	agc	aaa	aaa	agc	gat	agc	acc	acc	acc	tgg	gtg	ctg	agc	aac	cat	1008																																																		
Gly	Ser	Lys	Lys	Ser	Asp	Ser	Thr	Thr	Thr	Trp	Val	Leu	Ser	Asn	His																																																			
			325						330			335																																																						
gat	gtg	atg	cgc	cat	ccg	acc	cgc	ttt	ggc	ctg	ccg	aac	gtg	ccg	aac	1056																																																		
Asp	Val	Met	Arg	His	Pro	Thr	Arg	Phe	Gly	Leu	Pro	Asn	Val	Pro	Asn																																																			
			340						345			350																																																						
gcg	aac	cat	gcg	atg	acc	acc	gat	acc	tat	aac	aaa	ttt	ctg	aaa	acc	1104																																																		
Ala	Asn	His	Ala	Met	Thr	Thr	Asp	Thr	Tyr	Asn	Lys	Phe	Leu	Lys	Thr																																																			
355						360						365																																																						
aaa	ctg	acc	gat	ccg	aaa	gtg	gat	att	gaa	cag	ggc	ctg	cgc	cgc	gcg	1152																																																		
Lys	Leu	Thr	Asp	Pro	Lys	Val	Asp	Ile	Glu	Gln	Gly	Leu	Arg	Arg	Ala																																																			
370						375			380																																																									
aaa	gcg	gcg	acc	ctg	atg	att	ctg	gcg	ctg	ccg	ggc	agc	acc	tat	ctg	1200																																																		
Lys	Ala	Ala	Thr	Leu	Met	Ile	Leu	Ala	Leu	Pro	Gly	Ser	Thr	Tyr	Leu																																																			

-continued

385	390	395	400	
tat cag ggc gaa gaa ctg ggc ctg cag gaa gtg gtg gaa att ccg gat				1248
Tyr Gln Gly Glu Glu Leu Gly Leu Gln Glu Val Val Glu Ile Pro Asp				
	405	410	415	
gaa gaa cgc cag gat ccg att ttt att cgc acc aaa ggc gaa gaa gtg				1296
Glu Glu Arg Gln Asp Pro Ile Phe Ile Arg Thr Lys Gly Glu Glu Val				
	420	425	430	
ggc cgc gat ggc tgc cgc gtg ccg att ccg tgg gtg gcg gat gaa aaa				1344
Gly Arg Asp Gly Cys Arg Val Pro Ile Pro Trp Val Ala Asp Glu Lys				
	435	440	445	
aac ttt ggc tat ggc ccg ggc aaa cgc gcg cat ctg ccg cag ccg gcg				1392
Asn Phe Gly Tyr Gly Pro Gly Lys Arg Ala His Leu Pro Gln Pro Ala				
	450	455	460	
tgg ttt aaa gat tat gcg gtg gat gtg gaa gaa aaa gat gcg aac agc				1440
Trp Phe Lys Asp Tyr Ala Val Asp Val Glu Glu Lys Asp Ala Asn Ser				
	465	470	475	480
gtg ctg agc ctg tat cgc cgc gcg ctg ggc ctg cgc aaa ggc ctg cag				1488
Val Leu Ser Leu Tyr Arg Arg Ala Leu Gly Leu Arg Lys Gly Leu Gln				
	485	490	495	
agc gcg gaa gaa ctg gaa tgg gtg gaa aac ccg aac aaa gaa gtg ctg				1536
Ser Ala Glu Glu Leu Glu Trp Val Glu Asn Pro Asn Lys Glu Val Leu				
	500	505	510	
cat ttt cgc cgc ccg ggc ggc tgg gaa gtg gtg gtg aac att ggc aaa				1584
His Phe Arg Arg Pro Gly Gly Trp Glu Val Val Val Asn Ile Gly Lys				
	515	520	525	
gat agc gtg gat ctg ccg aaa ggc agc gtg ctg att agc agc agc aac				1632
Asp Ser Val Asp Leu Pro Lys Gly Ser Val Leu Ile Ser Ser Ser Asn				
	530	535	540	
aac gcg ctg aaa ggc ggc agc att ccg ggc gaa acc acc gtg tgg ctg				1680
Asn Ala Leu Lys Gly Gly Ser Ile Pro Gly Glu Thr Thr Val Trp Leu				
	545	550	555	560
aaa agc gcg				1689
Lys Ser Ala				
<210> SEQ ID NO 66				
<211> LENGTH: 563				
<212> TYPE: PRT				
<213> ORGANISM: Cryptococcus neoformans				
<400> SEQUENCE: 66				
Met Val Cys Val Ile Ser Asp Pro Asp Trp Trp Arg Gln Ala Val Val				
1	5	10	15	
Tyr Gln Ile Tyr Pro Arg Ser Phe Ala Asp Ala Asn Gly Asp Gly Ile				
	20	25	30	
Gly Asp Leu Lys Gly Ile Thr Ala Arg Val Pro Tyr Leu Lys Ala Leu				
	35	40	45	
Gly Val Asp Ala Ile Trp Leu Ser Pro Phe Tyr Pro Ser Ala Leu Arg				
	50	55	60	
Asp Gly Gly Tyr Asp Val Ala Asp Tyr Arg Asp Val Asp Pro Lys Ile				
	65	70	75	80
Gly Thr Leu Glu Glu Phe Asp Glu Met Thr Ala Ala Phe Gln Lys Val				
	85	90	95	
Gly Ile Arg Val Ile Val Asp Ile Val Pro Asn His Ser Ser Asp Asp				
	100	105	110	
His Glu Trp Phe Gln Ala Ala Leu Lys Ala Gly Lys Gly Ser Pro Glu				
	115	120	125	

-continued

Arg	Glu	Arg	Tyr	Ile	Phe	Arg	Asp	Gly	Leu	Gly	Pro	Asn	Lys	Asp	Gln
130						135					140				
Pro	Pro	Thr	Asp	Trp	Ile	Cys	Ser	Phe	Gly	Gly	Ser	Ala	Trp	Ser	Pro
145					150					155					160
Ser	Gly	Met	Asn	Asp	Gly	Gln	Trp	Tyr	Phe	His	Trp	Phe	Asp	Ser	Ser
				165					170					175	
Gln	Pro	Asp	Trp	Asn	Trp	Glu	Asn	Pro	Asp	Val	Lys	Ala	Asp	Phe	Leu
			180					185					190		
Lys	Thr	Leu	Lys	Phe	Trp	Gly	Asp	Arg	Gly	Val	Ser	Gly	Phe	Arg	Ile
		195					200					205			
Asp	Val	Ala	His	Gly	Leu	Ala	Lys	Asp	Met	Ser	Glu	Pro	Leu	Pro	Asn
	210					215					220				
Trp	Glu	Gln	Leu	Thr	Lys	Leu	Thr	His	Gln	Lys	Leu	Thr	Asn	Gly	Asn
225					230					235					240
Ser	Glu	Leu	Asp	His	Pro	Leu	Leu	Asp	Arg	Lys	Glu	Val	His	Asp	Ile
				245					250					255	
Tyr	Arg	Ser	Trp	Arg	Glu	Val	Phe	Asn	Gln	Phe	Asn	Pro	Pro	Leu	Met
			260					265					270		
Ala	Val	Ala	Glu	Ala	Trp	Val	Ala	Pro	Asp	Gln	Lys	Pro	Leu	Tyr	Ala
		275					280					285			
Ser	Ser	Glu	Gly	Leu	Gly	Gln	Thr	Phe	Ser	Phe	Asp	Ile	Leu	Leu	Cys
	290					295					300				
Asn	Phe	Asp	Ala	Glu	Glu	Tyr	Arg	Gln	Cys	Ile	Lys	Ser	Ser	Leu	Ala
305					310					315					320
Gly	Ser	Lys	Lys	Ser	Asp	Ser	Thr	Thr	Thr	Trp	Val	Leu	Ser	Asn	His
				325					330					335	
Asp	Val	Met	Arg	His	Pro	Thr	Arg	Phe	Gly	Leu	Pro	Asn	Val	Pro	Asn
			340					345					350		
Ala	Asn	His	Ala	Met	Thr	Thr	Asp	Thr	Tyr	Asn	Lys	Phe	Leu	Lys	Thr
		355					360					365			
Lys	Leu	Thr	Asp	Pro	Lys	Val	Asp	Ile	Glu	Gln	Gly	Leu	Arg	Arg	Ala
	370					375					380				
Lys	Ala	Ala	Thr	Leu	Met	Ile	Leu	Ala	Leu	Pro	Gly	Ser	Thr	Tyr	Leu
385					390					395					400
Tyr	Gln	Gly	Glu	Glu	Leu	Gly	Leu	Gln	Glu	Val	Val	Glu	Ile	Pro	Asp
				405					410					415	
Glu	Glu	Arg	Gln	Asp	Pro	Ile	Phe	Ile	Arg	Thr	Lys	Gly	Glu	Glu	Val
			420					425					430		
Gly	Arg	Asp	Gly	Cys	Arg	Val	Pro	Ile	Pro	Trp	Val	Ala	Asp	Glu	Lys
		435					440					445			
Asn	Phe	Gly	Tyr	Gly	Pro	Gly	Lys	Arg	Ala	His	Leu	Pro	Gln	Pro	Ala
	450					455					460				
Trp	Phe	Lys	Asp	Tyr	Ala	Val	Asp	Val	Glu	Glu	Lys	Asp	Ala	Asn	Ser
465					470					475					480
Val	Leu	Ser	Leu	Tyr	Arg	Arg	Ala	Leu	Gly	Leu	Arg	Lys	Gly	Leu	Gln
				485					490					495	
Ser	Ala	Glu	Glu	Leu	Glu	Trp	Val	Glu	Asn	Pro	Asn	Lys	Glu	Val	Leu
			500					505					510		
His	Phe	Arg	Arg	Pro	Gly	Gly	Trp	Glu	Val	Val	Val	Asn	Ile	Gly	Lys
		515					520					525			
Asp	Ser	Val	Asp	Leu	Pro	Lys	Gly	Ser	Val	Leu	Ile	Ser	Ser	Ser	Asn

-continued

530	535	540	
Asn Ala Leu Lys Gly Gly Ser Ile Pro Gly Glu Thr Thr Val Trp Leu			
545	550	555	560
Lys Ser Ala			
<210> SEQ ID NO 67			
<211> LENGTH: 729			
<212> TYPE: DNA			
<213> ORGANISM: <i>Cryptococcus neoformans</i>			
<220> FEATURE:			
<221> NAME/KEY: CDS			
<222> LOCATION: (1) .. (729)			
<400> SEQUENCE: 67			
atg ccg agc gtg gtg ttt gat gtg gtg ggc acc tgc ttt agc tat gat			48
Met Pro Ser Val Val Phe Asp Val Val Gly Thr Cys Phe Ser Tyr Asp			
1 5 10 15			
aac ggc gcg gaa gcg ctg cag gcg cgc ctg ggc ccg aaa ctg gcg aaa			96
Asn Gly Ala Glu Ala Leu Gln Ala Arg Leu Gly Pro Lys Leu Ala Lys			
20 25 30			
tat ggc att ccg agc aaa ctg ctg ttt tat agc tgg gtg tgc agc acc			144
Tyr Gly Ile Pro Ser Lys Leu Leu Phe Tyr Ser Trp Val Cys Ser Thr			
35 40 45			
gaa cgc gat tat agc tat ctg agc cag att aaa cag tat aaa gcg ttt			192
Glu Arg Asp Tyr Ser Tyr Leu Ser Gln Ile Lys Gln Tyr Lys Ala Phe			
50 55 60			
ttt gcg att ctg agc aac acc ctg acc cgc gtg ctg ttt cag gcg ggc			240
Phe Ala Ile Leu Ser Asn Thr Leu Thr Arg Val Leu Phe Gln Ala Gly			
65 70 75 80			
gtg ccg gtg gaa gcg ctg gat gat ttt ttt acc gcg gat gat gtg gat			288
Val Pro Val Glu Ala Leu Asp Asp Phe Phe Thr Ala Asp Asp Val Asp			
85 90 95			
tat att atg aac gaa tat aaa aaa ctg aaa gcg cgc ccg ggc ctg gcg			336
Tyr Ile Met Asn Glu Tyr Lys Lys Leu Lys Ala Arg Pro Gly Leu Ala			
100 105 110			
gaa atg atg cag acc ctg cgc gat ggc ggc ttt gaa gtg tgg tgc tgc			384
Glu Met Met Gln Thr Leu Arg Asp Gly Gly Phe Glu Val Trp Cys Cys			
115 120 125			
agc gat gcg aac gtg gat cgc gtg aaa ggc tat ttt gat aac gcg ggc			432
Ser Asp Ala Asn Val Asp Arg Val Lys Gly Tyr Phe Asp Asn Ala Gly			
130 135 140			
gtg gaa atg ccg ctg gat cat att ctg agc gcg gat atg gtg aaa gcg			480
Val Glu Met Pro Leu Asp His Ile Leu Ser Ala Asp Met Val Lys Ala			
145 150 155 160			
ggc aaa ccg gaa gcg gcg gtg tat aaa ttt gcg cgc gaa aaa gcg ggc			528
Gly Lys Pro Glu Ala Ala Val Tyr Lys Phe Ala Arg Glu Lys Ala Gly			
165 170 175			
agc gat cag ccg ggc gaa gtg agc gtg ttt gcg gcg agc cat gcg tgg			576
Ser Asp Gln Pro Gly Glu Val Ser Val Phe Ala Ala Ser His Ala Trp			
180 185 190			
gat tgc gcg gcg gcg aaa gcg gcg ggc ttt ctg acc gcg tat acc acc			624
Asp Cys Ala Ala Ala Lys Ala Ala Gly Phe Leu Thr Ala Tyr Thr Thr			
195 200 205			
acc tat gaa tat gat gaa tgc gaa gtg att ttt ggc aaa agc gat ctg			672
Thr Tyr Glu Tyr Asp Glu Cys Glu Val Ile Phe Gly Lys Ser Asp Leu			
210 215 220			
gtg gcg ccg gat ctg gtg agc ctg ggc aaa ggc att gtg gaa aaa tgg			720
Val Ala Pro Asp Leu Val Ser Leu Gly Lys Gly Ile Val Glu Lys Trp			

-continued

```

225                230                235                240
ggc aaa aaa
Gly Lys Lys
729

<210> SEQ ID NO 68
<211> LENGTH: 243
<212> TYPE: PRT
<213> ORGANISM: Cryptococcus neoformans

<400> SEQUENCE: 68

Met Pro Ser Val Val Phe Asp Val Val Gly Thr Cys Phe Ser Tyr Asp
1                5                10                15
Asn Gly Ala Glu Ala Leu Gln Ala Arg Leu Gly Pro Lys Leu Ala Lys
20                25                30
Tyr Gly Ile Pro Ser Lys Leu Leu Phe Tyr Ser Trp Val Cys Ser Thr
35                40                45
Glu Arg Asp Tyr Ser Tyr Leu Ser Gln Ile Lys Gln Tyr Lys Ala Phe
50                55                60
Phe Ala Ile Leu Ser Asn Thr Leu Thr Arg Val Leu Phe Gln Ala Gly
65                70                75                80
Val Pro Val Glu Ala Leu Asp Asp Phe Phe Thr Ala Asp Asp Val Asp
85                90                95
Tyr Ile Met Asn Glu Tyr Lys Lys Leu Lys Ala Arg Pro Gly Leu Ala
100               105               110
Glu Met Met Gln Thr Leu Arg Asp Gly Gly Phe Glu Val Trp Cys Cys
115               120               125
Ser Asp Ala Asn Val Asp Arg Val Lys Gly Tyr Phe Asp Asn Ala Gly
130               135               140
Val Glu Met Pro Leu Asp His Ile Leu Ser Ala Asp Met Val Lys Ala
145               150               155               160
Gly Lys Pro Glu Ala Ala Val Tyr Lys Phe Ala Arg Glu Lys Ala Gly
165               170               175
Ser Asp Gln Pro Gly Glu Val Ser Val Phe Ala Ala Ser His Ala Trp
180               185               190
Asp Cys Ala Ala Ala Lys Ala Ala Gly Phe Leu Thr Ala Tyr Thr Thr
195               200               205
Thr Tyr Glu Tyr Asp Glu Cys Glu Val Ile Phe Gly Lys Ser Asp Leu
210               215               220
Val Ala Pro Asp Leu Val Ser Leu Gly Lys Gly Ile Val Glu Lys Trp
225               230               235               240
Gly Lys Lys

```

What is claimed is:

1. A method of testing compounds for activity to inhibit germination of spores, the method comprising:

- (a) providing bacterial, fungal, or plant spores transformed to contain and express a detectable marker, wherein the marker when expressed, is operationally linked to a spore-specific or yeast-specific protein, in a medium and under environmental conditions in which the spores will germinate, and measuring a first signal output generated by the marker prior to the spores initiating germination;
- (b) contacting the spores of step (a) with a compound whose activity to inhibit germination of spores is to be measured;

- (c) incubating the spores of step (b) under environmental conditions and for a time wherein spores not treated with the compound will germinate; and

- (d) determining extent of germination of the spores by measuring a second signal output generated by the marker, wherein a difference between the first signal output and the second signal output is proportional to the extent of germination of the spores.

2. The method of claim 1, wherein the marker is operationally linked to a gene encoding a spore-specific protein selected from the group consisting of XP_567740.1 (SEQ. ID. NO: 2), XP_566791.1 (SEQ. ID. NO: 4), XP_570303.1 (SEQ. ID. NO: 6), XP_571089.1 (SEQ. ID. NO: 8),

XP_571997.1 (SEQ. ID. NO: 10), XP_569295.1 (SEQ. ID. NO: 12), XP_569173.1 (SEQ. ID. NO: 14), XP_569068.1 (SEQ. ID. NO: 16), XP_569336.1 (SEQ. ID. NO: 18), XP_567136.1 (SEQ. ID. NO: 20), XP_568990.1 (SEQ. ID. NO: 22), XP_570610.1 (SEQ. ID. NO: 24), XP_571921.1 (SEQ. ID. NO: 26), XP_572925.1 (SEQ. ID. NO: 28), XP_570796.1 (SEQ. ID. NO: 30), XP_571548.1 (SEQ. ID. NO: 32), XP_570447.1 (SEQ. ID. NO: 34), and XP_571343.1 (SEQ. ID. NO: 36).

3. The method of claim 1, wherein the marker is operationally connected to a gene selected from the group consisting of SEQ. ID. NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 30, 31, 33, and 35.

4. The method of claim 1, wherein the marker, when expressed, is operationally connected to a protein encoded by gene CNK01510 (SEQ. ID. NO: 1).

5. The method of claim 1, wherein the spores of step (a) are of a genus selected from the group consisting of *Histoplasma*, *Blastomyces*, *Aspergillus*, *Coccidioides*, *Sporothrix*, *Penicillium*, and *Cryptococcus*.

6. The method of claim 1, wherein the spores of step (a) are a species selected from the group consisting of *Histoplasma capsulatum*, *Blastomyces dermatitidis*, *Aspergillus fumigatus*, *Coccidioides immitis*, *Sporothrix schenckii*, *Penicillium marneffei*, and *Cryptococcus neoformans*.

7. The method of claim 1, wherein the detectable marker, when expressed, is a fluorophore or a chemiluminescent marker.

8. The method of claim 1, wherein the detectable marker, when expressed, is luciferase.

9. A method of testing compounds for activity to inhibit germination of spores, the method comprising:

- providing bacterial, fungal, or plant spores transformed to contain and express a detectable marker, wherein the marker is operationally linked to a spore-specific or yeast-specific protein, in a medium and under environmental conditions in which the spores will germinate, and measuring a first signal output generated by the marker prior to the spores initiating germination;
- contacting the spores of step (a) with a compound whose activity to inhibit germination of spores is to be measured;
- incubating the spores of step (b) under environmental conditions and for a time wherein spores not treated with the compound will germinate;
- determining extent of germination of the spores by measuring a second signal output generated by the marker, wherein a difference between the first signal output and the second signal output is proportional to the extent of germination of the spores, and
- plotting area and aspect ratio of the spores and any germinated cells after the incubation of step (c).

10. The method of claim 7, wherein the marker is operationally linked to a gene encoding a spore-specific protein selected from the group consisting of XP_567740.1 (SEQ. ID. NO: 2), XP_566791.1 (SEQ. ID. NO: 4), XP_570303.1 (SEQ. ID. NO: 6), XP_571089.1 (SEQ. ID. NO: 8), XP_571997.1 (SEQ. ID. NO: 10), XP_569295.1 (SEQ. ID. NO: 12), XP_569173.1 (SEQ. ID. NO: 14), XP_569068.1 (SEQ. ID. NO: 16), XP_569336.1 (SEQ. ID. NO: 18), XP_567136.1 (SEQ. ID. NO: 20), XP_568990.1 (SEQ. ID. NO: 22), XP_570610.1 (SEQ. ID. NO: 24), XP_571921.1 (SEQ. ID. NO: 26), XP_572925.1 (SEQ. ID. NO: 28),

XP_570796.1 (SEQ. ID. NO: 30), XP_571548.1 (SEQ. ID. NO: 32), XP_570447.1 (SEQ. ID. NO: 34), and XP_571343.1 (SEQ. ID. NO: 36).

11. The method of claim 7, wherein the marker is operationally connected to a gene selected from the group consisting of SEQ. ID. NOS: 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25, 27, 29, 30, 31, 33, and 35.

12. The method of claim 7, wherein the marker, when expressed, is operationally connected to a protein encoded by gene CNK01510 (SEQ. ID. NO: 1).


13. The method of claim 7, wherein the spores of step (a) are of a genus selected from the group consisting of *Histoplasma*, *Blastomyces*, *Aspergillus*, *Coccidioides*, *Sporothrix*, *Penicillium*, and *Cryptococcus*.

14. The method of claim 7, wherein the spores of step (a) are a species selected from the group consisting of *Histoplasma capsulatum*, *Blastomyces dermatitidis*, *Aspergillus fumigatus*, *Coccidioides immitis*, *Sporothrix schenckii*, *Penicillium marneffei*, and *Cryptococcus neoformans*.

15. The method of claim 1, wherein the detectable marker, when expressed, is a fluorophore or a chemiluminescent marker.


16. The method of claim 1, wherein the detectable marker, when expressed, is luciferase.

17. A composition of matter for inhibiting germination of fungal spores, the composition comprising a spore germination-inhibiting concentration of a compound selected from the group consisting of



and salts thereof, in combination with a vehicle.

18. A pharmaceutical composition for inhibiting fungal infection in mammals, the composition comprising a spore germination-inhibiting amount of a compound selected from the group consisting of:



wherein R is linear or branched C₁₋₁₂ alkyl and “x” is an integer of from 1 to 12, and salts thereof, in combination with a pharmaceutically suitable vehicle.

* * * * *